WorldWideScience

Sample records for abilify aripiprazole metabolic

  1. Aripiprazole

    Science.gov (United States)

    ... bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot ... difficulty communicating and interacting with others). Aripiprazole may ...

  2. Aripiprazole: a review of its use in the management of schizophrenia in adults.

    Science.gov (United States)

    Croxtall, Jamie D

    2012-02-01

    Oral aripiprazole (Abilify®) is an atypical antipsychotic agent that is approved worldwide for use in adult patients with schizophrenia. It is a quinolinone derivative that has a unique receptor binding profile as it exhibits both partial agonist activity at dopamine D(2) receptors and serotonin 5-HT(1A) receptors and antagonist activity at 5-HT(2A) receptors. In several well designed, randomized, clinical trials of 4-6 weeks duration, aripiprazole provided symptomatic control for patients with acute, relapsing schizophrenia or schizoaffective disorder. Furthermore, following 26 weeks' treatment, the time to relapse was significantly longer for patients with chronic, stabilized schizophrenia receiving aripiprazole compared with those receiving placebo. Using a variety of efficacy outcomes, aripiprazole showed a mixed response when evaluated against other antipsychotic agents in randomized clinical trials. Longer-term data showed that improvements in remission rates and response rates favoured aripiprazole over haloperidol, although, the time to failure to maintain a response was not significantly different between the treatment arms. On the other hand, improvements in positive and negative symptom scores mostly favoured olanzapine over aripiprazole, although, the time to all-cause treatment discontinuation was not significantly different between the two treatments. Several open-label, switching trials showed that aripiprazole provided continued control of symptoms in patients with schizophrenia or schizoaffective disorder. Using a variety of efficacy outcomes or quality-of-life scores, longer-term treatment generally favoured patients switched to receive aripiprazole compared with standard-of-care oral antipsychotics. Aripiprazole was generally well tolerated in patients with schizophrenia. In particular, its use seems to be associated with a lower incidence of extrapyramidal symptoms than haloperidol and fewer weight-gain issues than olanzapine. Aripiprazole also

  3. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study

    Directory of Open Access Journals (Sweden)

    Wani RA

    2015-03-01

    Full Text Available Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad MallaDepartment of Psychiatry, Government Medical College, Srinagar, Jammu and Kashmir, IndiaBackground: Patients with schizophrenia suffer high rates of metabolic derangements on some antipsychotic medications that predispose them to cardiovascular diseases. Keeping this fact in mind, we planned this open-label study to see the effect on various metabolic parameters after switching stable schizophrenia subjects, who had developed metabolic syndrome on olanzapine, to aripiprazole.Methods: Sixty-two patients with schizophrenia who were stable on olanzapine and were fulfilling modified National Cholesterol Education Program (NCEP Adult Treatment Panel III (ATP-III criteria for the presence of metabolic syndrome were enrolled on the study. Patients were randomly assigned either to switch to aripiprazole or to stay on olanzapine, on a 1:1 basis. Cross-tapering over a period of 1 month was done while switching patients to aripiprazole. Laboratory assessment for metabolic parameters was done at baseline, 8 weeks, and 24 weeks after enrollment; efficacy assessment was done using the Positive and Negative Syndrome Scale (PANSS at baseline and 24 weeks, the Clinical Global Impressions severity subscale (CGI-S at baseline, and the Clinical Global Impressions improvement subscale (CGI-I at 24 weeks.Results: All parameters of metabolic syndrome (waist circumference, blood pressure, triglyceride level, fasting blood glucose, and high-density lipoprotein cholesterol kept deteriorating in the stay group, compared with a continuous improvement in the switch group over time. At the end of the study, 26 patients (100% from the stay group and 15 patients (42.8% from switch group met the modified NCEP ATP-III criteria for presence of metabolic syndrome (P<0.001. There were no statistically significant differences between groups in

  4. Studies of phase transitions in the aripiprazole solid dosage form.

    Science.gov (United States)

    Łaszcz, Marta; Witkowska, Anna

    2016-01-05

    Studies of the phase transitions in an active substance contained in a solid dosage form are very complicated but essential, especially if an active substance is classified as a BCS Class IV drug. The purpose of this work was the development of sensitive methods for the detection of the phase transitions in the aripiprazole tablets containing initially its form III. Aripiprazole exhibits polymorphism and pseudopolymorphism. Powder diffraction, Raman spectroscopy and differential scanning calorimetry methods were developed for the detection of the polymorphic transition between forms III and I as well as the phase transition of form III into aripiprazole monohydrate in tablets. The study involved the initial 10 mg and 30 mg tablets, as well as those stored in Al/Al blisters, a triplex blister pack and HDPE bottles (with and without desiccant) under accelerated and long term conditions. The polymorphic transition was not observed in the initial and stored tablets but it was visible on the DSC curve of the Abilify(®) 10 mg reference tablets. The formation of the monohydrate was observed in the diffractograms and Raman spectra in the tablets stored under accelerated conditions. The monohydrate phase was not detected in the tablets stored in the Al/Al blisters under long term conditions. The results showed that the Al/Al blisters can be recommended as the packaging of the aripiprazole tablets containing form III.

  5. Aripiprazole salts. II. Aripiprazole perchlorate.

    Science.gov (United States)

    Freire, Eleonora; Polla, Griselda; Baggio, Ricardo

    2012-06-01

    The molecular structure of aripiprazole perchlorate (systematic name: 4-(2,3-dichlorophenyl)-1-{4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl}piperazin-1-ium perchlorate), C(23)H(28)Cl(2)N(3)O(2)(+)·ClO(4)(-), does not differ substantially from the recently published structure of aripiprazole nitrate [Freire, Polla & Baggio (2012). Acta Cryst. C68, o170-o173]. Both compounds have almost identical bond distances, bond angles and torsion angles. The two different counter-ions occupy equivalent places in the two structures, giving rise to very similar first-order `packing motifs'. However, these elemental arrangements interact with each other in different ways in the two structures, leading to two-dimensional arrays with quite different organizations.

  6. Aripiprazole-montmorillonite: a new organic-inorganic nanohybrid material for biomedical applications.

    Science.gov (United States)

    Oh, Yeon-Ji; Choi, Goeun; Choy, Young Bin; Park, Je Won; Park, Jung Hyun; Lee, Hwa Jeong; Yoon, Yeo Joon; Chang, Hee Chul; Choy, Jin-Ho

    2013-04-08

    Poor aqueous solubility and the unpleasant taste of aripiprazole (APZ) have been recurring problems, owing to its low bioavailability and low patient tolerance, respectively. Herein, we prepared a nanohybrid system that was based on a bentonite clay material, montmorillonite (MMT), which could both mask the taste and enhance the solubility of APZ (i.e., APZ-MMT). To further improve the efficacy of this taste masking and drug solubility, APZ-MMT was also coated with a cationic polymer, polyvinylacetal diethylamino acetate (AEA). In vitro dissolution tests at neutral pH showed that the amount of drug that was released from the AEA-coated APZ-MMT was greatly suppressed (<1%) for the first 3 min, thus suggesting that AEA-coated APZ-MMT has strong potential for the taste masking of APZ. Notably, in simulated gastric juice at pH 1.2, the total percentage of APZ that was released within the first 2 h increased up to 95% for AEA-coated APZ-MMT. Furthermore, this in vitro release profile was also similar to that of Abilify®, a commercially available medication. In vivo experiments by using Sprague-Dawley rats were also performed to compare the pharmacokinetics of AEA-coated APZ-MMT and Abilify®. AEA-coated APZ-MMT exhibited about 20% higher systemic exposure of APZ and its metabolite, dehydro-APZ, compared with Abilify®. Therefore, a new MMT-based nanovehicle, which is coated with a cationic polymer, can act as a promising delivery system for both taste masking and for enhancing the bioavailability of APZ. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

  7. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder.

    Science.gov (United States)

    McKeage, Kate

    2014-02-01

    Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors, which may explain differences in tolerability profiles. Recently in the EU, oral aripiprazole 10 mg once daily for 12 weeks was approved for the treatment of moderate to severe manic episodes in adolescents (aged ≥13 years) with bipolar I disorder. Approval was based on a phase 3, 30-week US trial in children and adolescents with bipolar I disorder experiencing manic or mixed episodes. Using trial data together with ancillary analyses, the European Medicines Agency concluded that aripiprazole 10 mg once daily for 12 weeks was effective in reducing symptoms of mania, but because of the high drop-out rate, efficacy over 30 weeks of treatment was not proven. Aripiprazole was generally well tolerated in the phase 3 trial. Ancillary analyses indicated that tolerability was less favourable in younger (10-12 years) than in older (≥13 years) subjects, and less favourable with the higher (30 mg/day) than the lower dosage (10 mg/day). The drug is associated with sedation, weight gain and extrapyramidal symptoms (EPS), although the incidence of EPS over 12 weeks was not significantly different between aripiprazole 10 mg/day and placebo. Data comparing the use of atypical antipsychotics in the treatment of mania in adolescents with bipolar I disorder are limited, but evidence shows that aripiprazole provides a valuable additional therapeutic option for use in this population.

  8. Aripiprazole (Otsuka Pharmaceutical Co).

    Science.gov (United States)

    Ozdemir, Vural; Fourie, Jeanne; Ozdener, Fatih

    2002-01-01

    Otsuka Pharmaceuticals in collaboration with Bristol-Myers Squibb is developing aripiprazole, a dual dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist, for the potential treatment of psychoses including schizophrenia [281327], [340364]. A regulatory filing for schizophrenia in the US was submitted at the end of 2001 [340364]. The compound entered phase III trials in Japan in 1995 [192966]. Although presynaptic dopamine autoreceptor agonists may be efficacious in the treatment of schizophrenia, they may also potentially increase the risk for exacerbation of psychosis through stimulation of postsynaptic dopaminergic receptors [245791], [350478], [350479]. However, earlier neuropharmacology studies have shown that aripiprazole can act as a presynaptic D2 agonist while displaying an antagonistic effect at the postsynaptic D2 receptors [281327], [337126], [350479], [424587], [424588]. In animal models, aripiprazole inhibits the apomorphine-induced stereotypy, without causing catalepsy [281327], [337126]. Moreover, in contrast to classical antipsychotics that produce disabling movement disorders, aripiprazole does not cause an upregulation of D2 receptors or an increase in expression of the c-fos mRNA in the striatum, in agreement with the low risk for extrapyramidal side effects (EPS) during aripiprazole treatment [245781], [262096], [350481], [350483]. Collectively, aripiprazole is an important atypical antipsychotic candidate with a favorable safety profile. Moreover, the mechanism of action of aripiprazole differentiates it from both typical and atypical antipsychotics and hence, may provide important leads for pharmacotherapy of schizophrenia and other psychotic disorders. In January 2000, Lehman Brothers predicted peak sales of aripiprazole could reach US $500 million [357788]. In February 2001, Credit Suisse First Boston predicted sales of US $403 million in 2005 [399484].

  9. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.

    Science.gov (United States)

    Turncliff, Ryan; Hard, Marjie; Du, Yangchun; Risinger, Robert; Ehrich, Elliot W

    2014-11-01

    Aripiprazole lauroxil is a linker lipid ester of aripiprazole for extended-release intramuscular (IM) injection. This multicenter, randomized, open-label study evaluated the pharmacokinetics (PK), relative bioavailability, and tolerability of a single IM deltoid or gluteal injection of aripiprazole lauroxil in adult subjects with chronic stable schizophrenia or schizoaffective disorder. Forty-six subjects were randomized 1:1 to aripiprazole lauroxil 441 mg IM in the deltoid or gluteal muscle. Samples were collected through 89 days post-dose to measure levels of aripiprazole lauroxil, N-hydroxymethyl aripiprazole, aripiprazole, and dehydro-aripiprazole. Forty-three (93.5%) subjects completed all study assessments; most were CYP2D6 extensive or immediate metabolizers (96%); two (4%) were poor metabolizers. The PK of aripiprazole following aripiprazole lauroxil was characterized by a steady rise in plasma concentrations (Tmax 44-50 days), a broad peak, and prolonged exposure attributable to the dissolution of aripiprazole lauroxil and formation rate-limited elimination of aripiprazole (t1/2=15.4-19.2 days). Deltoid vs. gluteal administration resulted in slightly higher Cmax aripiprazole concentrations [1.31 (1.02, 1.67); GMR 90% CI]; total exposure (AUCinf) was similar between sites of administration [0.84 (0.57, 1.24)]. N-hydroxymethyl-aripiprazole and dehydro-aripiprazole exposures were 10% and 33-36%, respectively, of aripiprazole exposure following aripiprazole lauroxil. The most common adverse events were injection site pain in 20 subjects (43.5%) and headache in 6 subjects (13.0%) of mild intensity occurring at a similar rate with deltoid and gluteal administration. Exposure ranges with deltoid and gluteal administration overlapped, suggesting that these sites may be used interchangeably. Despite a higher incidence of adverse events, deltoid muscle provides a more accessible injection site and could facilitate patient acceptance.

  10. Delusional Infestation in a Patient with Renal Failure, Metabolic Syndrome, and Chronic Cerebrovascular Disease Treated with Aripiprazole: A Case Report

    Science.gov (United States)

    Carpiniello, Bernardo; Pinna, Federica; Tuveri, Raffaella

    2011-01-01

    Delusional infestation is an aspecific psychiatric condition manifested either as a primary psychotic disorder or a secondary disorder induced by a wide range of very different medical conditions. Both primary and secondary delusional infestations seem to respond to typical and atypical antipsychotics. The latter are considered the first-line treatment although the use of second-generation antipsychotics featuring a higher metabolic, cardiovascular, and renal tolerability is preferable in secondary cases, which often occur in patients with multiple, severe medical conditions. We report a case of a 72-year-old patient affected by delusional infestation associated with severe renal failure, metabolic syndrome, hypertensive cardiopathy, and chronic cerebrovascular disease. PMID:22174718

  11. Delusional Infestation in a Patient with Renal Failure, Metabolic Syndrome, and Chronic Cerebrovascular Disease Treated with Aripiprazole: A Case Report

    Directory of Open Access Journals (Sweden)

    Bernardo Carpiniello

    2011-01-01

    Full Text Available Delusional infestation is an aspecific psychiatric condition manifested either as a primary psychotic disorder or a secondary disorder induced by a wide range of very different medical conditions. Both primary and secondary delusional infestations seem to respond to typical and atypical antipsychotics. The latter are considered the first-line treatment although the use of second-generation antipsychotics featuring a higher metabolic, cardiovascular, and renal tolerability is preferable in secondary cases, which often occur in patients with multiple, severe medical conditions. We report a case of a 72-year-old patient affected by delusional infestation associated with severe renal failure, metabolic syndrome, hypertensive cardiopathy, and chronic cerebrovascular disease.

  12. Role of aripiprazole in treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Mossaheb N

    2012-05-01

    Full Text Available Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed “treatment-resistant”. Clozapine is still the gold standard in these cases. However, 40%–70% of patients do not improve sufficiently on clozapine either. In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia. The evidence for aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than clozapine is scant, and no recommendation can be made on the basis of the currently available data. More effort has been made in describing combinations of aripiprazole and clozapine. Most of the open-label and case studies as well as case reports have shown positive effects of this combination on overall psychopathology and to some extent on negative symptoms. Several reports describe the possibility of dose reduction for clozapine in combination with aripiprazole, a strategy that might help so-called “treatment-intolerant” patients. The findings of four randomized controlled trials with respect to changes in psychopathology seem less conclusive. The most commonly found beneficial effects are better metabolic outcomes and indicators of the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are repeatedly reported. Further, none of the studies report longer-term outcomes. In the absence of alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole with clozapine in

  13. Aripiprazole-induced priapism

    Directory of Open Access Journals (Sweden)

    Satya K Trivedi

    2016-01-01

    Full Text Available Priapism is a urologic emergency representing a true disorder of penile erection that persists beyond or is unrelated to sexual interest or stimulation. A variety of psychotropic drugs are known to produce priapism, albeit rarely, through their antagonistic action on alpha-1 adrenergic receptors. We report such a case of priapism induced by a single oral dose of 10 mg aripiprazole, a drug with the least affinity to adrenergic receptors among all atypical antipsychotics. Polymorphism of alpha-2A adrenergic receptor gene in schizophrenia patients is known to be associated with sialorrhea while on clozapine treatment. Probably, similar polymorphism of alpha-1 adrenergic receptor gene could contribute to its altered sensitivity and resultant priapism. In future, pharmacogenomics-based approach may help in personalizing the treatment and effectively prevent the emergence of such side effects.

  14. Study on metabolic risk of first-episode acute schizophrenia patients treated with aripiprazole%阿立哌唑对首发急性精神分裂症患者代谢风险的探讨

    Institute of Scientific and Technical Information of China (English)

    吴小立; 文飞; 钟智勇; 韩自力

    2011-01-01

    目的:探讨阿立哌唑对首发急性期精神分裂症患者的代谢影响.方法:31例首发急性期精神分裂症患者入选病例组接受阿立哌唑治疗,治疗前后各测量一次体重、腰围、腰臀比、血清TC、TG、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A1(Apo-A1)、载脂蛋白B(Apo B100)、脂蛋白a(LPa)、空腹血糖(FBS)、空腹胰岛素(INS)、C肽(C-P),并分别计算出BMI、胰岛素抵抗指数(HOMA-IR).另设健康对照组44例,同法测量上述指标.将病例组与健康对照组、病例组治疗前后各项指标进行比较分析.结果:病例组INS、C-P及HOMA-IR均高于正常对照组,差异有统计学意义(P<0.05);病例组治疗后体重、BMI、腰围、腰臀比均较治疗前增加,差异有统计学意义(P<0.05);治疗后:病例组TG、INS、C-P、HOMA-IR均高于对照组,差异有统计学意义(P<0.05);且aPOA1低于对照组,差异有统计学意义(P<0.05).结论:精神分裂症患者本身可能存在有代谢异常;非典型抗精神病药物(APS)阿立哌唑对患者血糖、血脂代谢相对影响较小.%AIM: To study the metabolic risk of first-episode acute schizophrenia patients trea ted with aripiprazole.METHODS: 31 first-episode acute patients with schizophrenic were enrolled into case group and 44 healthy subjects were enrolled into controle group, all cases accepted treatment with oral aripiprazole.At the baseline and at the end, all patients were checked or tested for weight, waist circumference, waist-to-hipratio(WHR), TC, TG, high density lipoprotein(HDL), low density lipoprotein(LDL), apolipoprotein A1 ( Apo Al), apolipoprotein B (Apo-B100), lipoprotein a (LPa),fasting blood glucose (FBS), fasting insulin (INS)and c-peptide(C-P),respectively.The BMI and insulin resistance index (HOMA-IR) were calculated.All indexes were compared and analysed between the case group and controle group,pre and post treatment in the case group.RESULTS:The INS, C-P and HOMA

  15. 非水反相高效液相色谱法测定阿立哌唑的含量%Determination of Aripiprazole by Nonaqueous Reversed-Phase High Performance Liquid Chromatography

    Institute of Scientific and Technical Information of China (English)

    刘红菊; 蒋晔; 郝晓花

    2005-01-01

    阿立哌唑(aripiprazole, 7-[4-[4-(2,3-二氯苯基)-1-哌嗪基]丁氧基]-3,4-二氢化喹喏啉酮)是日本Otsuka公司于1988年开发的第二代非典型性抗精神病药,于2002年由美国食品药品管理局(FDA)批准上市,商品名为Abilify,用于精神分裂症的治疗.阿立哌唑的含量测定方法尚未见报道.

  16. Worsened hypertension control induced by aripiprazole

    Directory of Open Access Journals (Sweden)

    Yasui-Furukori N

    2013-04-01

    Full Text Available Norio Yasui-Furukori, Akira Fujii Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Aripiprazole is widely used in the treatment of schizophrenia and bipolar disorders. Although antipsychotics generally have hypotensive effects, two cases were identified that demonstrated hypertension during the switch from other antipsychotics to aripiprazole. The hypertensive state of these patients recovered after switching back to other antipsychotics, and these cases suggest that aripiprazole may lead to hypertension. Keywords: hypertension, aripiprazole, dopamine antagonist, 5-HT1a

  17. Aripiprazole-induced oculogyric crisis (acute dystonia

    Directory of Open Access Journals (Sweden)

    Jyotik T Bhachech

    2012-01-01

    Full Text Available Aripiprazole is the third generation atypical antipsychotic and a dopamine serotonin system stabilizer (DSS effective against positive and negative symptoms of schizophrenia. It has a low propensity for extrapyramidal side effects, causes minimal weight gain or sedation, produces no elevation in serum prolactin levels, and does not cause prolongation of QTc interval. This case report is of a patient suffering from schizophrenia (paranoid. The patient developed oculogyric crisis (acute dystonia with aripiprazole dose uptitration. Dystonic reaction resolved with promethazine administration. Naranjo′s causality assessment reveals probable association of aripiprazole with oculogyric crisis. A thorough workup and vigilance is required prior to initiation of aripiprazole in the case of schizophrenia.

  18. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

    Directory of Open Access Journals (Sweden)

    Izchak Kohen

    2010-03-01

    Full Text Available Izchak Kohen1, Paula E Lester2, Sum Lam31Division of Geriatric Psychiatry, Zucker-Hillside Hospital, Glen Oaks, NY, USA; 2Division of Geriatric Medicine, Winthrop University Hospital, Mineola, NY, USA; 3Division of Pharmacy and Geriatrics, St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY, USAAbstract: Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.Keywords: aripiprazole, antipsychotics, elderly, adverse drug reaction

  19. The effects of aripiprazole,risperidone and clozapine administrated for schizophrenia treatment on glucose and lipid metabolism%阿立哌唑、利培酮和氯氮平治疗精神分裂症对糖脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    马达休; 李永华; 冉庆国; 陈大坤; 周琳钧

    2011-01-01

    Objective To compare the effects of aripiprazole, risperidone and clozapine used for treating schizophrenia on serum glucose and lipids of patients. Methods 270 patients with schizophrenia were divided randomly into 3 groups of 90 patients each; aripiprazole group, risperidone group and clozapine group, and aripiprazole, risperidone and clozapine were administrated for 12 weeks,respectively. Levels of fast blood glucose (FBG) ,total cholesterol (TC) ,triglycericle(TG) and body mass index (BMX) before and after treatment were compared. Results FBG levels of patients in 3 groups after treatment were increased as compared to those before treatment(P0. 05) ,all those in risperidone and clozapine groups increased after treatment as compared with treatment before(P<0. 05) ,and those in clozapine group increased greater than in risperidone group(P<0. 05). Conclusion Aripiprazole,risperidone and clozapine used for schizophrenia treatment can lead to adverse effects of glucose and lipid metabolism which are relatively milder for aripiprazole.%目的 比较阿立哌唑、利培酮和氯氮平治疗精神分裂症对患者血糖、血脂影响.方法 将270例精神分裂症患者随机分为3组:阿立哌唑组、利培酮组及氯氮平组(各90例),分别给予口服阿立哌唑、利培酮及氯氮平治疗12周.比较治疗前后空腹血糖(FBG)、总胆固醇(TC)、三酰甘油(TG),体质量指数(BMI)的变化.结果 3组患者治疗后,FBG较治疗前增高(P<0.05),氯氮平组增高最明显;阿立哌唑组治疗后TC、TG,BMI值较治疗前差异无统计学意义(P>0.05);利培酮及氯氮平组治疗后TC、TG、BMI较治疗前均有升高(P<0.05),且氯氮平组增高大于利培酮组(P<0.05).结论 阿立哌唑、利培酮及氯氮平治疗精神分裂症均可导致糖脂代谢异常的不良反应,阿立哌唑的不良反应相对较小.

  20. Worsened hypertension control induced by aripiprazole

    OpenAIRE

    Yasui-Furukori N; Fujii A

    2013-01-01

    Norio Yasui-Furukori, Akira Fujii Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Aripiprazole is widely used in the treatment of schizophrenia and bipolar disorders. Although antipsychotics generally have hypotensive effects, two cases were identified that demonstrated hypertension during the switch from other antipsychotics to aripiprazole. The hypertensive state of these patients recovered after switching back to other antipsychot...

  1. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  2. Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study

    Science.gov (United States)

    Benedetti, Alessandra; Di Paolo, Antonello; Lastella, Marianna; Casamassima, Francesco; Candiracci, Chiara; Litta, Antonella; Ciofi, Laura; Danesi, Romano; Lattanzi, Lorenzo; Del Tacca, Mario; Cassano, Giovanni Battista

    2010-01-01

    Aim: To evaluate the efficacy and safety of the augmentation of clozapine with aripiprazole in patients with treatment-resistant schizoaffective and psychotic bipolar disorders in a retrospective manner. Pharmacodynamic and pharmacokinetic interactions between the two drugs were also investigated. Patients: Three men and 4 women (median age 36 and 40 years, respectively) who had mean scores at BPRS and CGI-Severity of 59.1±12.0 and 5.4±0.5, respectively, were treated with clozapine (mean dose 292.9±220.7 mg/day). Patients received an adjunctive treatment with aripiprazole (mean dose 6.8 ± 3.7 mg/day). Clozapine, norclozapine and aripiprazole plasma levels were measured by means of a high performance liquid chromatograpy with UV detection. Results: Total scores at BPRS decreased significantly (from 59.1±12.0 to 51.1±15.6, p=0.007) after aripirazole augmentation. In particular, the factors “thought disorder” (from 10.4±4.4 to 9.0±4.5, p=.047) and “anergia” (from 10.0±2.7 to 8.0±2.4, p=.018) significantly improved. Concomitant administration of aripiprazole and clozapine did not result in an increase in side effects over the period of treatment. Dose-normalized plasma levels of both clozapine and norclozapine and the clozapine/norclozapine metabolic ratio in all patients did not vary as well. Conclusion: The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and bipolar disorders which failed to respond to atypical antipsychotics. A possible pharmacokinetic interaction between clozapine and aripiprazole does not account for the improved clinical benefit obtained after aripiprazole augmentation. PMID:20648219

  3. Aripiprazole Can Improve Apraxia of Eyelid Opening in Parkinson's Disease.

    Science.gov (United States)

    Tokisato, Kaori; Fukunaga, Kimiko; Tokunaga, Makoto; Watanabe, Susumu; Nakanishi, Ryoji; Yamanaga, Hiroaki

    2015-01-01

    We herein report three cases of Parkinson's disease associated with difficulty in eyelid opening, referred to as apraxia of eyelid opening (AEO), which improved after aripiprazole treatment. In case 1, aripiprazole was administered as a psychiatric treatment. It proved to be effective in AEO with blepharospasm. In case 2 and case 3, the patients experienced AEO without blepharospasm, and a significant improvement was observed after aripiprazole treatment. In this study, the aripiprazole dosage ranged between 3 and 9 mg/day. This is the first report of aripiprazole as a potentially effective treatment for AEO in Parkinson's disease.

  4. Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series.

    Science.gov (United States)

    Patra, Suravi

    2016-01-01

    Aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. Tardive dyskinesia is rarely caused by Aripiprazole and has only been documented in high risk patients i.e., female gender, advanced age, affective illness, coexisting neurological disorders. Here the author describes two atypical cases of tardive dyskinesia associated with Aripiprazole. First case of tardive dyskinesia was observed in a neuroleptic naïve young adult male with paranoid illness after six months of treatment with Aripiprazole upon addition of Fluoxetine and the second case was a middle aged female with affective illness where dyskinetic movements appeared after stopping Aripiprazole. The role of Fluoxetine in causing tardive dyskinesia with Aripiprazole and covert dyskinesia due to Aripiprazole with appropriate management is discussed.

  5. 3D printed orodispersible films with Aripiprazole.

    Science.gov (United States)

    Jamróz, Witold; Kurek, Mateusz; Łyszczarz, Ewelina; Szafraniec, Joanna; Knapik-Kowalczuk, Justyna; Syrek, Karolina; Paluch, Marian; Jachowicz, Renata

    2017-05-24

    Three dimensional printing technology is gaining in importance because of its increasing availability and wide applications. One of the three dimensional printing techniques is Fused Deposition Modelling (FDM) which works on the basis of hot melt extrusion-well known in the pharmaceutical technology. Combination of fused deposition modelling with preparation of the orodispersible film with poorly water soluble substance such as aripiprazole seems to be extra advantageous in terms of dissolution rate. 3D printed as well as casted films were compared in terms of physicochemical and mechanical properties. Moreover, drug-free films were prepared to evaluate the impact of the extrusion process and aripiprazole presence on the film properties. X-ray diffractometry and thermal analyses confirmed transition of aripiprazole into amorphous state during film preparation using 3D printing technique. Amorphization of the aripiprazole and porous structure of printed film led to increased dissolution rate in comparison to casted films, which, however have slightly better mechanical properties due to their continuous structure. It can be concluded that fused deposition modelling is suitable technique and polyvinyl alcohol is applicable polymer for orodispersible films preparation. Copyright © 2017 Elsevier B.V. All rights reserved.

  6. Two Cases of Hypersexuality Probably Associated with Aripiprazole

    OpenAIRE

    Cheon, EunJin; Koo, Bon-Hoon; Seo, Sang Soo; Lee, Jun-Yeob

    2013-01-01

    Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological pr...

  7. Effect of lower dose clozapine plus aripiprazole on body weight, glucose and lipid metabolism in patients with schizophrenia%较低剂量氯氮平合并阿立哌唑对精神分裂症患者体质量及糖脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    王小红; 王艳婷; 周云云; 兰润林; 侯春兰; 侯凌峰; 董继学; 李俊福

    2013-01-01

    目的:探讨较低剂量氯氮平合并阿立哌唑对精神分裂症患者体质量及糖脂代谢的影响.方法:选取2008年3月至2010年3月我院住院精神分裂症患者92例,随机分为研究组和对照组,研究组给予较低剂量氯氮平合并阿立哌唑治疗,对照组给予单纯氯氮平治疗.两组观察疗程24周.两组患者分别在治疗前、治疗12周及24周对其体质量、身高、血糖、餐后2h血糖、三酰甘油及胆固醇进行测定,并做统计分析. 结果:与对照组相比,研究组治疗前后体质量及糖脂代谢变化显著较小(P均<0.01).研究组体质量、血糖及三酰甘油异常率明显低于对照组(P均<0.01). 结论:较低剂量氯氮平合并阿立哌唑治疗与单用较高剂量氯氮平相比,对精神分裂症患者体质量及糖脂代谢影响较小.%Objective: To investigate effect of the lower dose of clozapine plus aripiprazole on body weight,glucose and lipid metabolism in patients with schizophrenia. Method:92 schizophrenic patients from our hospital March,2008 to March,2010 were randomly divided into study group and control group,the study group was given a low dose clozapine combined with aripiprazole and the control group was given clozapine treatment for 24 weeks. The body mass, height, blood glucose, postprandial 2 hour blood glucose, cholesterol and tri-glyceride were measured before treatment, week 12 and 24. Results: Compared with the control group, the study group showed fewer changes on body weight and metabolism of glucose and lipid between before and after the treatment (all P<0.01), and abnormal rates of body mass, glucose and triglyceride (all P<0.01). Conclusion: Lower dose clozapine plus aripiprazole have less impact on the body mass and glucose metabolism than only high doses clozapine in the treatment of schizophrenia.

  8. Comparison of Short-term Metabolic Risk in First-episode Young-adult Schizophrenia Treated with Aripiprazole and Olanzapine%阿立哌唑与奥氮平对首发年轻成人精神分裂症患者短期内代谢风险的比较

    Institute of Scientific and Technical Information of China (English)

    吴小立; 魏钦令; 钟智勇; 张晋碚

    2011-01-01

    摘要:[目的]比较阿立哌唑与奥氮平对首发年轻成人精神分裂症患者短期内的代谢风险.[方法]采用开放对照的临床观察方法,对符合美国精神障碍诊断与统计手册第4版(DSM-Ⅳ)精神分裂症诊断标准的首发住院精神分裂症患者,分别使用阿立哌唑(21例)和奥氮平(42例)治疗,自然观察时间不低于2周,不大于4周,于治疗前后各检测一次体质量、腰围、空腹血脂血糖及胰岛素、C肽.[结果]观察结束时:阿立哌唑组的体质量、体质量指数(BMI)、腰围、腰臀比均有增高(P<0.05),糖脂改变无统计学差异,男女患者间各项代谢指标的变化无统计学差异(P>0.05);奥氮平组的体质量、体质量指数(BMI)、腰围、腰臀比、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白AI和B100及脂蛋白LPa较治疗前增高(P<0.0l),且胰岛素(INS)水平和胰岛素抵抗指数(IR)增高(P<0.05),多元逐步回归分析显示胰岛素抵抗与甘油三脂的增高有关(R2 =0.107,P=0.007);奥氛平组男性患者的空腹胰岛素和C肽、胰岛素抵抗指数均增高(P<0.05),女性患者则没有.[结论]阿立哌唑和奥氮平对首发年轻成人精神分裂症患者短期内的代谢风险即有差异,性别差异可能影响着非典型抗精神病药物的代谢风险.%[Objective] To compare the short-term metabolic risk in the first-episode young-adult schizophrenia treated with Aripiprazole and Olanzapine. [ Methods] The open-lable, natural observed, compared method was designed for this study. All of these cases were diagnosed as first-episode schizophrenia in accordance with the DSM-IV diagnosis criteria and respectively allocated into two groups for either Aripiprazole or Olanzapine treatment. The natural observed period was from two weeks to four weeks. Weight, waist circumference, fasting glucose, and lipid concentration, fasting insulin and C peptide

  9. Aripiprazole for autism spectrum disorders (ASD).

    Science.gov (United States)

    Hirsch, Lauren E; Pringsheim, Tamara

    2016-06-26

    Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011). To assess the safety and efficacy of aripiprazole as medication treatment for individuals with ASD. In October 2015, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and seven other databases as well as two trial registers. We searched for records published in 1990 or later, as this was the year aripiprazole became available. Randomised controlled trials (RCTs) of aripiprazole (administered orally and at any dosage) versus placebo for treatment of individuals with a diagnosis of ASD. Two review authors independently collected, evaluated and analysed data. We performed meta-analysis for primary and secondary outcomes, when possible. We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach to rate the overall quality of the evidence. We included three trials in this review. Two were included in the previous published review, and the results of one, placebo-controlled discontinuation study were added to this review. Although we searched for studies across age groups, we found only studies conducted in children and youth. Included trials had low risk of bias across most domains. High risk of bias was seen in only one trial with incomplete outcome data. We judged the overall quality of the evidence for most outcomes to be moderate.Two RCTs with similar methods evaluated

  10. Postmortem Femoral Blood Reference Concentrations of Aripiprazole, Chlorprothixene, and Quetiapine

    DEFF Research Database (Denmark)

    Skov, Louise; Johansen, Sys Stybe; Linnet, Kristian

    2015-01-01

    Postmortem femoral blood concentrations of the antipsychotic drugs aripiprazole, chlorprothixene and its metabolite, and quetiapine were determined by LC-MS-MS in 25 cases for aripiprazole and 60 cases each for chlorprothixene and quetiapine. For cases where the cause of death was not related to ...

  11. Aripiprazole: the evidence of its therapeutic impact in schizophrenia

    Directory of Open Access Journals (Sweden)

    William Winlow

    2006-06-01

    Full Text Available William Winlow, Louise Profit, Paul ChrispCore Medical Publishing, Knutsford, UKIntroduction: An ideal antipsychotic would rapidly stabilize acute psychotic symptoms and maintain the patient, without relapse, for prolonged periods in the absence of extrapyramidal, endocrine, diabetic, or cardiovascular side effects, and without weight gain. The dopamine partial agonist aripiprazole is compared with this ideal and with conventional antipsychotics, such as haloperidol, and with atypical antipsychotics.Aims: To review the evidence for the clinical impact of aripiprazole in the treatment of patients with schizophrenia.Evidence review: There is clear evidence that aripiprazole is as effective as haloperidol in reducing the positive and negative symptoms of schizophrenia and schizoaffective disorder. In patients with schizophrenia, aripiprazole has been shown to stabilize acute psychotic symptoms, prevent relapse in stabilized patients, and maintain patients with schizophrenia following acute relapse. Furthermore, in common with other atypical antipsychotics, aripiprazole appears to be associated with a lower incidence of side effects than typical antipsychotics and may reduce discontinuation of drug therapy. Evidence also suggests that aripiprazole may be associated with a lower incidence of extrapyramidal symptoms than conventional antipsychotics, but further long-term studies concerning tardive dyskinesia are required. Studies on the cost effectiveness of aripiprazole, as well as the quality of life and general functioning of patients taking the drug are still required, although there is some evidence of improved quality of life. Further evidence comparing aripiprazole with other atypical antipsychotics would be welcome.Clinical value: In conclusion, aripiprazole is an atypical antipsychotic suitable for first-line use in patients with schizophrenia. Its clinical value in relation to other atypical antipsychotics remains to be elucidated.Key words

  12. Behandling af Tourettes syndrom med aripiprazol

    DEFF Research Database (Denmark)

    Stenstrøm, Anne Dorte; Sindø, Ingrid

    2008-01-01

    Tourette's syndrome (TS) is a motoric disorder characterised by multiple motor and vocal tics. The treatment for patients with moderate to severe TS includes antipsychotic medication. A case report is described in which a 20 year-old male had taken antipsychotic medication since the age of five......, due to TS. The initial treatment consisted of pimozide and risperidone, both of which had an unsatisfactorily efficacy on tics and side effects in the form of weight gain and sedation. The patient is now treated with aripiprazole and there is a marked reduction of tics and no side effects...

  13. Two cases of hypersexuality probably associated with aripiprazole.

    Science.gov (United States)

    Cheon, Eunjin; Koo, Bon-Hoon; Seo, Sang Soo; Lee, Jun-Yeob

    2013-06-01

    Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological profile, partial agonism with high affinity at dopamine D2-receptor, may have contributed to the development of these symptoms.

  14. The prescribing pattern of a new antipsychotic: A descriptive study of aripiprazole for psychiatric in-patients

    DEFF Research Database (Denmark)

    Johansson, M.; Manniche, C.; Andersen, Stig Ejdrup

    2008-01-01

    -naive. In 25% aripiprazole, monotherapy was commenced whereas aripiprazole-antipsychotic combinations were initially prescribed in 75%. Overall, 85% of the patients received periods of antipsychotic polypharmacy and aripiprazole was combined with 17 different antipsychotics. Each patient received median three...... (range 0-8) psychoactive drugs parallel with aripiprazole. This study demonstrates reality in psychopharmacology and quote aripiprazole as example. In day-to-day practice, aripiprazole is used as part of highly individualized regimens comprising polypharmacy and excessive dosing. Although theoretically...

  15. Aripiprazole induced non-cardiogenic pulmonary edema: a case report.

    Science.gov (United States)

    Cetin, Mustafa; Celik, Mustafa; Cakıcı, Musa; Polat, Mustafa; Suner, Arif

    2014-01-01

    Aripiprazole is a second-generation antipsychotic drug with partial dopamine agonistic activity. Although the adverse cardiovascular effects of both typical and atypical antipsychotics are well known, similar data on aripiprazole, which was recently introduced, are scarce. Herein we report a 35-year-old female that presented to our emergency department with non-cardiogenic pulmonary edema. Chest X-ray and thoracic CT showed pulmonary edema and bilateral pleural effusion. Anamnesis showed that she had been taking sertraline 200 mg d-1 for obsessive-compulsive disorder for a long time and that aripiprazole10 mg d-1 was added for augmentation 2 months prior to presentation. We think that the CYP 2D6 inhibitor sertraline might have played a role in increasing the plasma concentration and toxicity of aripiprazole in the presented patient.

  16. Treatment of refractory catatonic schizophrenia with low dose aripiprazole

    Directory of Open Access Journals (Sweden)

    Sasaki Tsuyoshi

    2012-05-01

    Full Text Available Abstract This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, the treatment with low-dose aripiprazole dramatically improved the patient’s psychotic symptoms and extrapyramidal symptoms. The mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics, aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous advantages, especially in cases of stuporous catatonia and a defective general status.

  17. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.

    Science.gov (United States)

    Fleischhacker, W Wolfgang; Sanchez, Raymond; Johnson, Brian; Jin, Na; Forbes, Robert A; McQuade, Robert; Baker, Ross A; Carson, William; Kane, John M

    2013-07-01

    The aim of this study was to evaluate the safety and tolerability of aripiprazole once-monthly (ARI-OM) for the maintenance treatment of schizophrenia. This long-term, pivotal study had four phases: oral conversion (phase 1, 4-6 weeks); oral stabilization (phase 2, 4-12 weeks); ARI-OM stabilization with coadministration of oral aripiprazole in the first 2 weeks (phase 3, 12-36 weeks); and a 52-week, randomized [phase 4, ARI-OM vs. placebo (2 : 1)], double-blind, maintenance phase. Safety was assessed across study phases by the time of first onset of adverse events, as were objective measures of extrapyramidal symptoms, fasting metabolic parameters, and body weight. Patient enrollment was phase 1=633; phase 2=710, of whom 210 entered phase 2 directly; phase 3=576; and phase 4=403 (ARI-OM, n=269; placebo, n=134). Adverse events (>5%) in any phase were insomnia, headache, anxiety, akathisia, increase in weight, injection-site pain, and tremor. Headache, somnolence, and nausea had a peak first onset within 4 weeks of treatment initiation. The incidence of extrapyramidal symptoms was similar in all phases. There were no unexpected changes in weight or shifts in fasting metabolic parameters across all study phases. ARI-OM had a safety and tolerability profile comparable with oral aripiprazole in maintenance treatment of schizophrenia.

  18. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination. PMID:26221370

  19. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats.

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination.

  20. The cardiac safety of aripiprazole treatment in patients at high risk for torsade

    DEFF Research Database (Denmark)

    Polcwiartek, Christoffer; Sneider, Benjamin; Graff, Claus;

    2015-01-01

    prolongation risk was lower compared with placebo and active controls. Epidemiological studies linked aripiprazole to weak/moderate torsadogenicity. No studies were found associating aripiprazole with BrS suggesting low affinity for the fast sodium current. CONCLUSIONS: Aripiprazole is a low-risk antipsychotic...

  1. [Hypersexuality associated with aripiprazole: a new case and review of the literature].

    Science.gov (United States)

    Vrignaud, Laura; Aouille, Jerémie; Mallaret, Michel; Durrieu, Geneviève; Jonville-Béra, Annie-Pierre

    2014-01-01

    We report the case of a patient with hypersexuality while he was treated with aripiprazole since 6 months. Clinical manifestations were an increased libido, unusual frequent masturbation and sexual instincts. All have resolved upon discontinuation of aripiprazole, and recurred after it was restarted. The partial dopaminergic agonist effect of aripiprazole could probably explain the occurrence of this compulsive behaviour.

  2. 阿立哌唑%AbilifyTM

    Institute of Scientific and Technical Information of China (English)

    孙爱风; 吴范宏

    2003-01-01

    @@ [化学名称] [4-[4-(2,3-二氯苯基)-1-哌嗪基]丁氧基]-3,4-二氢-2-(1H)-喹喏啉酮 [药理作用] 本品为非典型抗精神病药,对多巴胺D2,D3,5-HT1A受体和5-HT2A受体的亲和性均很强(Ki值分别为0.34,0.8,1.7和3.4nmol);对多巴胺D4,5-HT1C和5-HT7以及α1-肾上腺受体和组胺H1受体的亲和性中等(Ki值分别为44,15,39,57和61nmol);对胆碱能受体无明显亲和力(IC50>1 000nmol*L-1).

  3. Aripiprazole Augmentation in Childhood Obsessive-Compulsive Disorder: Three Case Reports

    Directory of Open Access Journals (Sweden)

    Murat Yuce

    2013-08-01

    Full Text Available Aripiprazole is a third generation antipsychotic that has a partial dopamine agonistic activity. There is an increasing usage of aripiprazole in children and adolescents with schizophrenia, pervasive developmental disorders, and bipolar disorders. In these presentation, we aimed to present three pediatric obsessive%u2013compulsive disorder (OCD cases who were resistant to two different selective serotonin reuptake inhibitor treatments and prescribed aripiprazole for augmentation therapy. The results of these three cases suggest that aripiprazole is an effective and safe alternative as augmentation for childhood OCD treatment. However, to investigate the efficacy and safety of aripiprazole in childhood OCD, randomized controlled treatment studies are needed.

  4. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    Science.gov (United States)

    Bakker, Ilse C A; Schubart, Chris D

    2016-01-01

    Summary In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs. Learning points Prolactinoma coinciding with psychosis can represent a therapeutic challenge. In contrast to many other antipsychotic drugs, aripiprazole is associated with a decrease in prolactin levels. Aripiprazole can be a valuable pharmaceutical tool to treat both prolactinoma and psychosis. PMID:27284453

  5. Biological conversion of aripiprazole lauroxil − An N-acyloxymethyl aripiprazole prodrug

    Directory of Open Access Journals (Sweden)

    Morten Rohde

    2014-01-01

    Full Text Available N-acyloxyalkylation of NH-acidic compounds can be a prodrug approach for e.g. tertiary or some N-heterocyclic amines and secondary amides and have the potential to modify the properties of the parent drug for specific uses, for example its physicochemical, pharmacokinetic or biopharmaceutical properties. Aripiprazole lauroxil was prepared as a model compound for such prodrugs and its bioconversion was investigated both in vitro and in vivo. Theoretically, N-acyloxyalkyl derivates of NH-acid compounds undergo a two-step bioconversion into the parent NH-acidic drug through an N-hydroxyalkyl intermediate. However, to our knowledge no published studies have investigated the formation of an intermediate in vivo. In the present study, it was demonstrated that the assumed N-hydroxymethyl intermediate was readily observed both in vitro and in vivo. In vivo, the observed plasma concentration of the intermediate was at the same level as the drug (aripiprazole. When prodrug intermediates are formed, it is important to make a proper pharmacological, pharmacokinetic and toxicological evaluation of the intermediates to ensure patient safety; however, several challenges were identified when testing an N-acyloxyalkyl prodrug. These included the development of a suitable bioanalytical method, the accurate prediction of prodrug bioconversion and thereby the related pharmacokinetics in humans and the toxicological potential of the intermediate.

  6. 阿立哌唑联合氯氮平对精神分裂症患者糖脂代谢与睡眠及体重的影响%Effect of aripiprazole combined with clozapine on glucolipid metabolism, sleep and body mass in patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    肖鹏; 孙晓花

    2016-01-01

    Objective To investigate the clinical effect of aripiprazole combined with clozapine on glucolipid metabolism , sleep quality and body mass in patients with schizophrenia .Methods Seventy -six pa-tients with schizophrenia were divided into treatment group and control group , each group 38 cases.Control group was given clozapine 400-500 mg・ d -1 .Treatment group was given aripiprazole 30 mg・ d-1 combined clozapine 200-300 mg・ d-1 .The course of treatment was 6 months. The changes of blood glucose and lipid levels , sleep quality , body mass and clinical symptoms were compared in two groups before and after treatment.The clinical efficacy and adverse drug reactions in two groups were observed.Results After treatment, the self-rating scale of sleep ( SRSS ) and pittsburgh sleep quality index ( PSQI ) in treatment group were (15.74 ±3.21), (2.42 ±0.45), significantly lower than (20.45 ±4.67) ,(6.43 ±0.78) in control group(P<0.05).The levels of fasting blood glucose , postprandial 2 h blood glucose, triacylglycerol and cholesterol levels in control group were (5.64 ±0.57), (9.75 ±0.66), (1.57 ±0.18), (5.67 ±0.53) mmol・ L-1, signifi-cantly higher than (4.57 ±0.45), (7.89 ±0.55), (1.03 ±0.13),(4.54 ±0.46) mmol・ L-1 in treatment group ( P <0.05 ) .Body mass and body mass index in control group were ( 68.32 ±4.12 ) kg and ( 26.17 ±4.05 ) kg・ m-2 , significantly higher than (57.56 ±3.63 ) kg and (22.07 ±3.44 ) kg・ m-2 in treatment group ( P<0.05 ) . The total effective rate of treatment group was 92.11%, significantly higher than 76.32%in control group ( P<0.05 ) . The incidence rate of adverse drug reactions in treatment group was 15.79%, obviously lower than 39.47%in control group (P<0.05).Conclusion Aripiprazole combined with clozapine can be beneficial to glucose metabolism and body mass of patients in a stable state in the treatment of patients with schizophrenia , and can improve sleep condition and clinical symptoms of patients , and had

  7. Efficacy of aripiprazole in sulpiride-induced tardive oromandibular dystonia.

    Science.gov (United States)

    Imai, Noboru; Ikawa, Masako

    2011-01-01

    Tardive dystonia is a side effect of dopamine receptor-blocking agents, which are mainly used as antipsychotic drugs. The treatment of tardive dystonia is difficult and often unsuccessful. An 82-year-old woman experienced mandibular deviation to the left due to spasm of the masticatory muscles with involuntary chewing movement and Parkinsonism. She had been treated with sulpiride for motility disorder for 5 years. Parkinsonism almost disappeared after the withdrawal of sulpiride, but tardive oromandibular dystonia showed no improvement. Aripiprazole treatment at 3 mg/day improved tardive oromandibular dystonia without worsening Parkinsonism. Low-dosage aripiprazole may be effective for tardive oromandibular dystonia in patients with no other psychiatric disorder.

  8. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    NARCIS (Netherlands)

    Bakker, Ilse C A; Schubart, Chris D; Zelissen, Pierre M J

    2016-01-01

    In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and

  9. Cognitive-enhancing effects of aripiprazole: a case report

    Directory of Open Access Journals (Sweden)

    Galderisi Silvana

    2008-10-01

    Full Text Available Abstract Patients with schizophrenia often present mild to severe cognitive deficits which contribute to their social disability. Second-generation antipsychotics have shown only mild to moderate beneficial effects on cognition. The present case report suggests cognitive enhancing effects of aripiprazole, a dopamine partial agonist, shown to increase dopamine release in prefrontal cortex in animal studies. The patient was in his first-episode of schizophrenia, and had no previous exposure to first-generation antipsychotics. Before schizophrenia onset his cognitive functioning was poor and he could not attend regular courses to reach his high school degree; he started but was not able to attend the University courses for several years. After schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole. During treatment with the first two second-generation antipsychotics, positive symptoms markedly improved while cognitive functioning remained poor. During treatment with aripiprazole, clinical remission was obtained and the patient was able to attend university courses and pass several examinations. Social functioning was markedly improved. Aripiprazole demonstrated cognitive enhancing effects in this patient. These effects were long-lasting and paralleled by a positive impact on social functioning.

  10. Effect of aripiprazole on mismatch negativity (MMN in schizophrenia.

    Directory of Open Access Journals (Sweden)

    Zhenhe Zhou

    Full Text Available BACKGROUND: Cognitive deficits are considered core symptoms of the schizophrenia. Cognitive function has been found to be a better predictor of functional outcome than symptom levels. Changed mismatch negativity (MMN reflects abnormalities of early auditory processing in schizophrenia. Up to now, no studies for the effects of aripiprazole on MMN in schizophrenia have been reported. METHODOLOGY/PRINCIPAL FINDINGS: Subjects included 26 patients with schizophrenia, and 26 controls. Psychopathology was rated in patients with the Positive and Negative Syndrome Scale (PANSS at baseline, after 4- and 8-week treatments with aripiprazole. Auditory stimuli for ERP consisted of 100 millisecond/1000 Hz standards, intermixed with 100 millisecond/1500 Hz frequency deviants and 250 millisecond/1000 Hz duration deviants. EEG was recorded at Fz. BESA 5.1.8 was used to perform data analysis. MMN waveforms were obtained by subtracting waveforms elicited by standards from waveforms elicited by frequency- or duration-deviant stimuli. Aripiprazole decreased all PANSS. Patients showed smaller mean amplitudes of frequency and duration MMN at baseline than did controls. A repeated measure ANOVA with sessions (i.e., baseline, 4- and 8-week treatments and MMN type (frequency vs. duration as within-subject factors revealed no significant MMN type or MMN type × session main effect for MMN amplitudes. Session main effect was significant. LSD tests demonstrated significant differences between MMN amplitudes at 8 weeks and those at both baseline and 4 weeks. There was significant negative correlation between changes in amplitudes of frequency and duration MMN and changes in PANSS total scores at baseline and follow-up periods. CONCLUSIONS: Aripiprazole improved the amplitudes of MMN. MMN offers objective evidence that treatment with the aripiprazole may ameliorate preattentive deficits in schizophrenia.

  11. Development and validation of a high-performance liquid chromatography method using diode array detection for the simultaneous quantification of aripiprazole and dehydro-aripiprazole in human plasma.

    Science.gov (United States)

    Lancelin, Frédérique; Djebrani, Kayssa; Tabaouti, Khalid; Kraoul, Linda; Brovedani, Sophie; Paubel, Pascal; Piketty, Marie-Liesse

    2008-05-01

    A high-performance liquid chromatography method with diode array detection (HPLC-DAD) was developed for quantification of aripiprazole and dehydro-aripiprazole, in human plasma. After a simple liquid-liquid extraction, chromatographic separation was carried out on a C18 reversed-phase column, using an ammonium buffer-acetonitrile mobile phase (40:60, v/v). The total run time was only 7 min at a flow-rate of 1.0 ml/min. The precision values were less than 12% and the accuracy values were ranging from 98 to 113% and the lower limit of quantification was 2 ng/ml for both compounds. Calibration curves were linear over a range of 2-1000 ng/ml. The mean trough plasma concentrations in patients treated with aripiprazole were 157 and 29 ng/ml for aripiprazole and dehydro-aripiprazole, respectively.

  12. Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder.

    Science.gov (United States)

    Joseph, Sam Padamadan

    2016-01-01

    Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolactinemia while on aripiprazole treatment. Dopamine acts as a tonic inhibitor of prolactin secretion through the tubero-infundibular dopaminergic system. Aripiprazole being a partial agonist has a lower intrinsic activity at the D2 receptor than dopamine, allowing it to act as both, a functional agonist and antagonist, depending on the surrounding levels of dopamine. Hence, in the absence of a competing D2 antagonist and the presence of dopamine (the natural agonist), aripiprazole could act as a functional antagonist and thus elevate prolactin levels.

  13. Use of aripiprazole in clozapine induced enuresis: report of two cases.

    Science.gov (United States)

    Lee, Myung-Ji; Kim, Chul-Eung

    2010-02-01

    This report describes the efficacy of combined use of aripiprazole in the treatment of a patient with clozapine induced enuresis. Aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis. We speculate that aripiprazole functioned as a D2 agonist in hypodopaminergic state of basal ganglia caused by clozapine and maintained dopamine level that would improve enuresis ultimately.

  14. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

    National Research Council Canada - National Science Library

    Kirino, Eiji

    2014-01-01

    .... Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes...

  15. Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.

    Science.gov (United States)

    Darwish, M; Bond, M; Yang, R; Hellriegel, E T; Robertson, P

    2015-07-01

    Armodafinil, a moderate inducer of cytochrome P450 (CYP) 3A4, has been studied as adjunctive therapy to maintenance medications for major depressive episodes associated with bipolar I disorder. We evaluated the effect of daily dosing with armodafinil on the pharmacokinetics and safety of the CYP3A4 substrate aripiprazole, an atypical antipsychotic used to treat bipolar I disorder. Healthy adults received 15 mg aripiprazole alone and after armodafinil (250 mg/day) pretreatment. Pharmacokinetic parameters were derived from plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole, obtained over 16 days after each aripiprazole administration. Steady-state pharmacokinetics of armodafinil and its 2 circulating metabolites was assessed. Of 36 subjects enrolled, 24 were evaluable for pharmacokinetic analysis. Armodafinil reduced systemic exposure to aripiprazole (Cmax, - 8%; AUC0-∞, -34%) and dehydro-aripiprazole, which is both formed and eliminated in part via CYP3A4 (Cmax, - 10%; AUC0-∞, - 32%). Adverse events were generally consistent with known safety profiles of each agent. Systemic exposure to aripiprazole and dehydro-aripiprazole was moderately reduced following armodafinil pretreatment. The combination was generally well tolerated under the conditions studied. © Georg Thieme Verlag KG Stuttgart · New York.

  16. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

    OpenAIRE

    Katsumasa Muneoka; Nobuhisa Kanahara; Shou Kimura

    2017-01-01

    Objectives: The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. Methods: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. Results: In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in ...

  17. Aripiprazole-induced writer’s cramp: a case report

    Directory of Open Access Journals (Sweden)

    Priyajyoti Chakma

    2016-07-01

    Full Text Available Dystonia is a movement disorder, which causes sustained muscle contractions, twisting movements, and abnormal postures. Writer’s cramp is the most commonly identified tasks-specific focal dystonia of writing, characterised by abnormal muscle spasm of hand and arm. Even in the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10, writer’s cramp is classified under idiopathic nonfamilial dystonias. Our case was a 20 years, Hindu, unmarried, literate of middle socioeconomic status, from urban part of Tripura. He presented with history of difficulty to write because of a stiffening of his right hand and also he noticed that prolonged period of writing caused cramping pain. He was a diagnosed case of paranoid schizophrenia (F20.0 as per ICD-10 for last three years and was on tablet aripiprazole. Diagnosis of writer’s cramp was made which developed after six months of treatment with aripiprazole 15 mg.

  18. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice

    Institute of Scientific and Technical Information of China (English)

    Jaqueline Nascimento PICADA; Viviane Minuzzo PONTES; Patrícia PEREIRA; Bruna de Jesus Neto DOS SANTOS; Franciele CELSO; Jéssica Dias MONTEIRO; Kelly Morais DA ROSA; Leandro Rosa CAMACHO; Luciana Rodrigues VIEIRA; Taís Madelon FREITAS; Tatiana Grasiela DASILVA

    2011-01-01

    Aim:Aripiprazole is an antipsychotic agent to treat schizophrenia,which acts through dopamine D2 partial agonism,serotonin 5-HT1A partial agonism and 5-HT2A antagonism.This study was designed to evaluate the neurobehavioral effects and genotoxic/mutagenic activities of the agent,as well as its effects on lipoperoxidation.Methods:Open field and inhibitory avoidance tasks were used.Thirty min before performing the behavioral tasks,adult male CF-1 mice were administered aripiprazole (1,3 or 10 mg/kg,ip) once for the acute treatment,or the same doses for 5 d for the subchronic treatment.Genotoxic effects were assessed using comet assay in the blood and brain tissues.Mutagenic effects were evaluated using bone marrow micronucleus test.Lipoperoxidation was assessed with thiobarbituric acid reactive substances (TBARS).Results:Acute and subchronic treatments significantly decreased the number of crossing and rearing in the open field task.Acute treatment significantly increased the step-down latency for both the short- and long-term memory in the inhibitory avoidance task.Subchronic treatments with aripiprazole (3 and 10 mg/kg) caused significant DNA strain-break damage in peripheral blood but not in the brain.Mutagenic effect was not detected in the acute and subchronic treatments.Nor TBARS levels in the liver were affected.Conclusion:Aripiprazole improved memory,but could impair motor activities in mice.The drug increased DNA damage in blood,but did not show mutagenic effects,suggesting that it might affect long-term genomic stability.

  19. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    Directory of Open Access Journals (Sweden)

    Ilse C A Bakker

    2016-06-01

    Full Text Available In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs.

  20. Aripiprazole for acute mania in an elderly person

    Directory of Open Access Journals (Sweden)

    Balaji Bharadwaj

    2011-01-01

    Full Text Available New-onset bipolar disorder is rare in the elderly. Symptom profile is similar to that in young adults but the elderly are more likely to have neurological co-morbidities. There are no case reports of elderly mania being treated with aripiprazole, an atypical antipsychotic. A 78-year-old gentleman presented to us with symptoms suggestive of mania of 1 month′s duration. He had similar history 3 years ago and a family history of postpartum psychosis in his mother. There were no neurological signs on examination and work-up for an organic etiology was negative except for age-related cerebral atrophy. He improved with aripiprazole and tolerated the medications well. The use of psychotropic medications in the elderly is associated with side-effects of sedation, increased cardiovascular risk, and greater risk of extra-pyramidal side-effects. The use of partial dopaminergic antagonists like aripiprazole may be useful in the balancing of effects and side-effects.

  1. Augmentation treatment in major depressive disorder: focus on aripiprazole

    Directory of Open Access Journals (Sweden)

    J Craig Nelson

    2008-08-01

    Full Text Available J Craig Nelson1, Andrei Pikalov2, Robert M Berman31University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USAAbstract: Major depressive disorder (MDD is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.Keywords: major depression, antipsychotic, mood disorder, aripiprazole

  2. Aripiprazole-associated tic in a schizophrenia patient

    Directory of Open Access Journals (Sweden)

    Guo X

    2015-03-01

    Full Text Available Xieli Guo,1,2,* Dali Lu,3,* Yugang Jiang1 1Department of Neurosurgery, Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Neurosurgery, Jinjiang Hospital of Quanzhou Medical College, Jinjiang, Fujian, People’s Republic of China; 3Department of Psychiatry, Xiamen Xianyue Hospital, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Abstract: Tic disorder, characterized by the presence of both motor and vocal tics is common in adolescents and adults. Antipsychotics including typical antipsychotics and atypical antipsychotics are generally recognized by experts as the most effective pharmacological treatment for tics. However, previous studies suggest that tic-like symptoms might manifest during treatment with atypical antipsychotics such as clo­zapine, quetiapine, but not aripiprazole. We present the first case, to our knowledge, of an adult schizophrenia patient who developed tics during treatment with aripiprazole. Keywords: aripiprazole, antipsychotics, tic, schizophrenia, side effect

  3. Use of aripiprazole for delirium in the elderly: a short review.

    Science.gov (United States)

    Kirino, Eiji

    2015-03-01

    The effects and tolerability of antipsychotics in delirium treatment remain controversial. Compared to other antipsychotics, aripiprazole differs in pharmacological activity because it exerts its effect as a dopamine D2 partial agonist. The guidelines of the American Psychiatric Association rank aripiprazole highly among antipsychotics with regard to safety, and this drug is likely to be useful for delirium treatment. Here, we reviewed the efficacy and safety of aripiprazole for delirium. The results of our literature review on the efficacy and safety of delirium treatments suggest that aripiprazole is an effective treatment option for delirium in the elderly. Aripiprazole is as effective as other antipsychotics in improving delirium symptoms, and it is safer because it is less likely to cause extrapyramidal symptoms, excessive sedation, and weight gain. However, these findings are based on only a few clinical studies of elderly patients with delirium. Therefore, further investigations are necessary.

  4. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases.

    Science.gov (United States)

    Muneoka, Katsumasa; Kanahara, Nobuhisa; Kimura, Shou

    2017-01-01

    The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case. We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis.

  5. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

    Directory of Open Access Journals (Sweden)

    Katsumasa Muneoka

    2017-02-01

    Full Text Available Objectives: The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. Methods: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. Results: In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case. Conclusions: We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis.

  6. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

    Science.gov (United States)

    Muneoka, Katsumasa; Kanahara, Nobuhisa; Kimura, Shou

    2017-01-01

    Objectives: The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. Methods: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. Results: In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case. Conclusions: We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis. PMID:28255444

  7. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

    Directory of Open Access Journals (Sweden)

    Berman R

    2011-05-01

    discontinuation. Mean weight change was 4.4 kg; 36.6% experienced ≥7% increase in weight from baseline (observed case analysis, n = 303. No clinically relevant changes in other metabolic parameters were seen. At the end of open-label treatment, 221 patients (69.7% had a Clinical Global Impression-Severity of Illness score of 1 (not at all ill or 2 (borderline ill.Conclusion: Long-term adjunctive aripiprazole therapy was well tolerated with an acceptable long-term safety and tolerability profile in patients with major depressive disorder who had not responded to treatment with one or more antidepressant therapies. Clinically significant weight gain was observed in about one-third of patients. Overall, the adverse event profile was consistent with that reported in the short-term trials and readily managed clinically.Keywords: adjunctive aripiprazole, antidepressant therapy, major depressive disorder, long-term safety and tolerability

  8. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

    Directory of Open Access Journals (Sweden)

    Xianbin Li

    Full Text Available OBJECTIVE: To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. METHODS: POPULATION: adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms. INTERVENTIONS: adjunctive aripiprazole vs. adjunctive placebo. OUTCOME MEASURES: adverse events and efficacy of treatment. STUDIES: randomized controlled trials. RESULTS: Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158 prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed -0.05 to 0.04 (95% confidence interval -0.13 to 0.16; I(2 =0% to 68%, P=0.20 to 0.70. However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random 0.76 (95% confidence interval 0.67 to 0.85; I(2 =43%, P<0.00001. The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. No significant differences between groups in discontinuation and improvements of psychiatric symptoms. CONCLUSION: Adjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day.

  9. Peripheral Antinociception Induced by Aripiprazole Is Mediated by the Opioid System

    Directory of Open Access Journals (Sweden)

    Renata Cristina Mendes Ferreira

    2017-01-01

    Full Text Available Background. Aripiprazole is an antipsychotic drug used to treat schizophrenia and related disorders. Our previous study showed that this compound also induces antinociceptive effects. The present study aimed to assess the participation of the opioid system in this effect. Methods. Male Swiss mice were submitted to paw pressure test and hyperalgesia was induced by intraplantar injection of prostaglandin E2 (PGE2, 2 μg. Aripiprazole was injected 10 min before the measurement. Naloxone, clocinnamox, naltrindole, nor-binaltorphimine, and bestatin were given 30 min before aripiprazole. Nociceptive thresholds were measured in the 3rd hour after PGE2 injection. Results. Aripiprazole (100 μg/paw injected locally into the right hind paw induced an antinociceptive effect that was blocked by naloxone (50 μg/paw, a nonselective opioid receptor antagonist. The role of μ-, δ-, and κ-opioid receptors was investigated using the selective antagonists, clocinnamox (40 μg/paw, naltrindole (15, 30, and 60 μg/paw, and nor-binaltorphimine (200 μg/paw, respectively. The data indicated that only the δ-opioid receptor antagonist inhibited the peripheral antinociception induced by aripiprazole. Bestatin (400 μg, an aminopeptidase-N inhibitor, significantly enhanced low-dose (25 μg/paw aripiprazole-induced peripheral antinociception. Conclusion. The results suggest the participation of the opioid system via δ-opioid receptor in the peripheral antinociceptive effect induced by aripiprazole.

  10. Waterborne aripiprazole blunts the stress response in zebrafish

    Science.gov (United States)

    Barcellos, Heloísa Helena De Alcantara; Kalichak, Fabiana; da Rosa, João Gabriel Santos; Oliveira, Thiago Acosta; Koakoski, Gessi; Idalencio, Renan; de Abreu, Murilo Sander; Giacomini, Ana Cristina Varrone; Fagundes, Michele; Variani, Cristiane; Rossini, Mainara; Piato, Angelo L.; Barcellos, Leonardo José Gil

    2016-11-01

    Here we provide, at least to our knowledge, the first evidence that aripiprazole (APPZ) in the water blunts the stress response of exposed fish in a concentration ten times lower than the concentration detected in the environment. Although the mechanism of APPZ in the neuroendocrine axis is not yet determined, our results highlight that the presence of APPZ residues in the environment may interfere with the stress responses in fish. Since an adequate stress response is crucial to restore fish homeostasis after stressors, fish with impaired stress response may have trouble to cope with natural and/or imposed stressors with consequences to their welfare and survival.

  11. Metabolism

    Science.gov (United States)

    ... Surgery? Choosing the Right Sport for You Shyness Metabolism KidsHealth > For Teens > Metabolism Print A A A ... food through a process called metabolism. What Is Metabolism? Metabolism (pronounced: meh-TAB-uh-lih-zem) is ...

  12. Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum.

    Science.gov (United States)

    Batista, Luara A; Viana, Thércia G; Silveira, Vívian T; Aguiar, Daniele C; Moreira, Fabrício A

    2016-01-01

    Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. In addition to its antipsychotic activity, this compound blocks the effects of some psychostimulant drugs. It has not been verified, however, if aripiprazole interferes with the effects of caffeine. Hence, this study tested the hypothesis that aripiprazole prevents caffeine-induced hyperlocomotion and investigated the effects of these drugs on neural activity in the striatum. Male Swiss mice received injections of vehicle or antipsychotic drugs followed by vehicle or caffeine. Locomotion was analyzed in a circular arena and c-Fos protein expression was quantified in the dorsolateral, dorsomedial, and ventrolateral striatum, and in the core and shell regions of nucleus accumbens. Aripiprazole (0.1, 1, and 10 mg/kg) prevented caffeine (10 mg/kg)-induced hyperlocomotion at doses that do not change basal locomotion. Haloperidol (0.01, 0.03, and 0.1 mg/kg) also decreased caffeine-induced hyperlocomotion at all doses, although at the two higher doses, this compound reduced basal locomotion. Immunohistochemistry analysis showed that aripiprazole increases c-Fos protein expression in all regions studied, whereas caffeine did not alter c-Fos protein expression. Combined treatment of aripiprazole and caffeine resulted in a decrease in the number of c-Fos positive cells as compared to the group receiving aripiprazole alone. In conclusion, aripiprazole prevents caffeine-induced hyperlocomotion and increases neural activation in the striatum. This latter effect is reduced by subsequent administration of caffeine. These results advance our understanding on the pharmacological profile of aripiprazole.

  13. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.

    Science.gov (United States)

    Shiokawa, Mitsuru; Narita, Minoru; Nakamura, Atsushi; Kurokawa, Kazuhiro; Inoue, Tadao; Suzuki, Tsutomu

    2007-09-10

    In the management of pain, nausea and vomiting are some of the most distressing adverse effects induced by opioids. In the present study, we investigated the effect of the dopamine system-stabilizer aripiprazole on morphine-induced emesis. Morphine induced retching and vomiting in a dose-dependent manner in ferrets. The emetic effect of morphine was significantly suppressed by pretreatment with either the dopamine receptor antagonist haloperidol or aripiprazole. These results suggest that the co-administration of aripiprazole may be useful for reducing the severity of morphine-induced emesis.

  14. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

    Science.gov (United States)

    Heitzmann, Edwige; Weiner, Luisa; Michel, Bruno

    2016-01-01

    Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly. PMID:27818825

  15. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

    Directory of Open Access Journals (Sweden)

    Edwige Heitzmann

    2016-01-01

    Full Text Available Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly.

  16. Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

    Directory of Open Access Journals (Sweden)

    David J Muzina

    2009-05-01

    Full Text Available David J MuzinaCenter for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Institute, Cleveland, Ohio, USAAbstract: Aripiprazole is a second-generation antipsychotic with a unique pharmacologic receptor profile that has efficacy in the treatment and prevention of mania in bipolar I disorder. This article reviews the evidence supporting treatment of adults with bipolar I disorder using aripiprazole as monotherapy or adjunctively during acute mania and its utility as an intramuscular agent for agitation in manic patients. Results from one of the longest bipolar maintenance trials which support aripiprazole as a prophylactic mood stabilizer, specifically against manic relapses, will be discussed as well as a post-hoc analysis that suggests efficacy for rapid cycling bipolar disorder. Safety and tolerability issues, patient-focused perspectives and aripiprazole’s place in therapy for bipolar mania will be covered.Keywords: bipolar disorder, mania, prevention, aripiprazole, rapid cycling

  17. Aripiprazole for treating irritability in children & adolescents with autism: A systematic review

    OpenAIRE

    Ahmad Ghanizadeh; Sylvie Tordjman; Nematollah Jaafari

    2015-01-01

    Background & objectives: No clear therapeutic benefits of antipsychotics have been reported for the treatment of behavioural symptoms in autism. This systematic review provides an assessment of evidence for treating irritability in autism by aripiprazole. Methods: The databases of MEDLINE/PubMed and Google Scholar were searched for relevant articles about the effect of aripiprazole in children with autism. The articles were searched according to the inclusion and exclusion criteria speci...

  18. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

    OpenAIRE

    Edwige Heitzmann; Hervé Javelot; Luisa Weiner; Bruno Michel

    2016-01-01

    Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsi...

  19. Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.

    Science.gov (United States)

    Douglas-Hall, Petrina; Curran, Sarah; Bird, Victoria; Taylor, David

    2011-01-01

    A systematic review and meta-analysis were performed examining the efficacy of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents. Aripiprazole was found to be more effective in reducing irritability compared with placebo at 8 weeks, SMD -0.64 [-0.90 to -0.39, P autism. Long-term studies are required to determine the efficacy and safety of aripiprazole in autistic disorder in children.

  20. Aripiprazole for treating irritability in children & adolescents with autism: A systematic review

    Directory of Open Access Journals (Sweden)

    Ahmad Ghanizadeh

    2015-01-01

    Full Text Available Background & objectives: No clear therapeutic benefits of antipsychotics have been reported for the treatment of behavioural symptoms in autism. This systematic review provides an assessment of evidence for treating irritability in autism by aripiprazole. Methods: The databases of MEDLINE/PubMed and Google Scholar were searched for relevant articles about the effect of aripiprazole in children with autism. The articles were searched according to the inclusion and exclusion criteria specifed for this review. All the double-blind, controlled, randomized, clinical trials examining the efficacy of aripiprazole for treating children and adolescents with autism were included. Results: From the 93 titles identified, 26 were irrelevant and 58 were evaluated for more details. Only five articles met the inclusive criteria. The evidence from precise randomized double blind clinical trials of aripiprazole for the treatment of autism in children and adolescents was convincing enough to recommend aripiprazole. Adverse effects were not very common and were usually mild. Interpretation & conclusions: Current evidence suggests that aripiprazole is as effective and safe as risperidone for treating irritability in autism. However, further studies with larger sample size and longer duration are required.

  1. Clinical Effectiveness of Aripiprazole in Short-term Treatment of Tic Disorder in Children and Adolescents: A Naturalistic Study

    Directory of Open Access Journals (Sweden)

    Che-Sheng Ho

    2014-02-01

    Conclusion: Aripiprazole is effective for short-term treatment of TD, especially vocal tics, in children and adolescents with mild adverse effects. However, further double-blind trials against placebo or other medications are needed to verify the efficacy of aripiprazole in the pharmacotherapy of TD.

  2. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents.

    Science.gov (United States)

    Kirino, Eiji

    2014-01-01

    Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs) and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies.

  3. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders.

    Science.gov (United States)

    Kishi, Taro; Matsuda, Yuki; Matsunaga, Shinji; Mukai, Tomohiko; Moriwaki, Masatsugu; Tabuse, Hideaki; Fujita, Kiyoshi; Iwata, Nakao

    2016-01-01

    There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events. Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups. Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia.

  4. Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

    Science.gov (United States)

    Hsu, Yi-Chien; Chou, Yu-Ching; Chang, Hsin-An; Kao, Yu-Chen; Huang, San-Yuan; Tzeng, Nian-Sheng

    2015-01-01

    Objectives Refractory major depressive disorder (MDD) is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy. Design Descriptive study. Outcome measures Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole. Intervention We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic. Results Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%). The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%), followed by insurance official policy audit and deletion in the claims review system (30.1%). Conclusion The prescribing behavior of Taiwanese psychiatrists for augmentation antipsy-chotics is affected by health insurance policy. PMID:25657586

  5. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first......-trimester exposure and pregnancy outcome with respect to congenital malformations. Cumulated data for olanzapine were 1090 first-trimester-exposed pregnancies with 38 malformations resulting in a malformation rate of 3.5%. The corresponding numbers for quetiapine, risperidone and aripiprazole were 443/16 (3.6%), 432...... of congenital malformation. Data for quetiapine and risperidone do not suggest a substantially increased risk, while the risk estimate for aripiprazole remains imprecise owing to a low amount of data....

  6. Add-on treatment of aripiprazole in an adult onychophagia patient

    Directory of Open Access Journals (Sweden)

    Mehmet Cemal Kaya

    2012-12-01

    Full Text Available Nail biting (onychophagia is a common disorder whichhas not been investigated yet. There are different opinionsabout to classify onychophagia, but according toDSM-IV-TR it is classified as impulse control disorder nototherwise specified. The knowledge about treatment ofonychophagia is limited. There are a few studies abouttreatment of onychophagia with psychotherapy and astudy with pharmacotherapy. Some studies suggest thatan atypical antipsychotic aripiprazole may have beneficialeffects in the treatment of impulse control disorders. Inthis study we report a case of onychophagia which hassuccessfully treated with aripiprazole add-on to escitalopramtreatment that has never reported before. J Clin ExpInvest 2012; 3(4: 545-547Key words: Onychophagia, aripiprazole, add-on treatment

  7. Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs

    Directory of Open Access Journals (Sweden)

    Albino Petrone

    2013-09-01

    Full Text Available Aripiprazole is a 2nd generation antipsychotic medication, atypical neuroleptic used for treatment of schizophrenia improving symptoms such as hallucinations, delusions, and disorganized thinking. A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS has been reported in association with administration of antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during aripiprazole treatment in the worldwide clinical database. The disease is characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia. We report on a 63-year old woman with depression syndrome who developed neuroleptic malignant syndrome after twelve days of aripripazole 5 mg per day. Our case is added to the small number already described and suggests the need for caution when aripripazole is added to increase the effect of other antipsychotics.

  8. Covert dyskinesia associated with aripiprazole: a case report and review of the literature.

    Science.gov (United States)

    Moseley, Carrie N; Simpson-Khanna, Heather A; Catalano, Glenn; Catalano, Maria C

    2013-01-01

    The atypical antipsychotic agents are felt by many to have a lower risk of inducing the development of dyskinetic movements than the conventional antipsychotic agents agents such as haloperidol and fluphenazine. However, that does not mean that treatment with the atypical antipsychotic agents carries no risk of developing dyskinesias. To the contrary, all of the atypical antipsychotic agents, including aripiprazole, have been associated with the induction of dyskinetic movements. We will present the case of a patient who developed a covert dyskinesia that manifested shortly after the discontinuation of aripiprazole. We will review the use of aripiprazole and the adverse effects most commonly associated with its use. We will also discuss the risk factors associated with the development of tardive dyskinesia and review the different clinical variations (withdrawal dyskinesia, covert dyskinesia, tardive diskinesia) of medication-induced dyskinesias.

  9. Aripiprazole in the acute and maintenance phase of bipolar I disorder

    Directory of Open Access Journals (Sweden)

    Zupancic M

    2012-01-01

    Full Text Available Melanie Zupancic1, Misty L Gonzalez2,31Southern Illinois University School of Medicine, 2Division of Medicine Psychiatry, Southern Illinois University School of Medicine, 3Southern Illinois University Edwardsville School of Pharmacy, Southern Illinois University Edwardsville, Springfield, IL, USAAbstract: Bipolar affective disorder is a disabling illness with substantial morbidity and many management challenges. Traditional mood stabilizers such as lithium, valproate, and carbamazepine are often inadequate in controlling symptoms both during the acute and maintenance phase of treatment. Aripiprazole is a second-generation antipsychotic with a unique mechanism of action. Evidence suggests that it is effective in acute manic and mixed states. There are limited data to suggest its efficacy as a maintenance agent. Future studies will be needed to better define the role of aripiprazole relative to other traditional pharmacologic agents.Keywords: aripiprazole, bipolar disorder, acute treatment, maintenance treatment

  10. Metabolism

    Science.gov (United States)

    ... Are More Common in People With Type 1 Diabetes Metabolic Syndrome Your Child's Weight Healthy Eating Endocrine System Blood Test: Basic Metabolic Panel (BMP) Activity: Endocrine System Growth Disorders Diabetes Center Thyroid Disorders Your Endocrine System Movie: Endocrine ...

  11. Metabolism

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    2008255 Serum adiponectin level declines in the elderly with metabolic syndrome.WU Xiaoyan(吴晓琰),et al.Dept Geriatr,Huashan Hosp,Fudan UnivShanghai200040.Chin J Geriatr2008;27(3):164-167.Objective To investigate the correlation between ser-um adiponectin level and metabolic syndrome in the elderly·Methods Sixty-one subjects with metabolic syndrome and140age matched subjects without metabolic

  12. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

    Directory of Open Access Journals (Sweden)

    Kishi T

    2016-11-01

    Full Text Available Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Tomohiko Mukai,1,2 Masatsugu Moriwaki,1,2 Hideaki Tabuse,3 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, 3Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d vs blonanserin (4-24 mg/d in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194.Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21 score, response rate, discontinuation rate, and individual adverse events.Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups.Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia. Keywords: aripiprazole, blonanserin, schizophrenia

  13. Aripiprazole in the acute and maintenance phase of bipolar I disorder.

    Science.gov (United States)

    Zupancic, Melanie; Gonzalez, Misty L

    2012-01-01

    Bipolar affective disorder is a disabling illness with substantial morbidity and many management challenges. Traditional mood stabilizers such as lithium, valproate, and carbamazepine are often inadequate in controlling symptoms both during the acute and maintenance phase of treatment. Aripiprazole is a second-generation antipsychotic with a unique mechanism of action. Evidence suggests that it is effective in acute manic and mixed states. There are limited data to suggest its efficacy as a maintenance agent. Future studies will be needed to better define the role of aripiprazole relative to other traditional pharmacologic agents.

  14. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.

    Science.gov (United States)

    Ghanizadeh, Ahmad; Haghighi, Alireza

    2014-10-01

    There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder. Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was the score of Yale Global Tic Severity Scale. In addition, health related quality of life and adverse events were assessed. Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score. Both aripiprazole and risperidone were tolerated well. Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day]. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients' social functioning more than aripiprazole in short term.

  15. TSH and PRL, side-effect markers in aripiprazole treatment: adjunctive aripiprazole-induced thyrotropin oversuppression in a young man with schizophrenia.

    Science.gov (United States)

    Ohta, Hidenobu; Inoue, Satoru; Hara, Koichiro; Watanabe, Akihiko

    2017-08-22

    A 26-year-old Japanese man was admitted to our unit with exacerbated paranoid schizophrenia. Prior to his admission, daily administration of olanzapine had been sufficient to maintain a partial remission of his schizophrenia, but due to an exacerbation of his delusions, he had then also been prescribed aripiprazole, which had been followed by no improvement in symptoms and a gradual further exacerbation of auditory delusions. Physical examinations, brain MRI and neurophysiological assessment were unremarkable. Blood analysis, however, revealed extremely low thyroid-stimulating hormone (TSH) and prolactin-releasing hormone (PRL) concentration. Interestingly, after aripiprazole discontinuation, he returned to partial remission with an increase in plasma TSH and PRL concentration. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

  16. Aripiprazole in the treatment of Huntington’s disease: a case series

    Directory of Open Access Journals (Sweden)

    Andrea Ciammola

    2008-11-01

    Full Text Available Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani11Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS, ItalyObjectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD.Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.Keywords: Huntington’s disease, aripiprazole, treatment, chorea

  17. Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®: a case report

    Directory of Open Access Journals (Sweden)

    Shao Q

    2015-12-01

    Full Text Available Qing Shao,1,2,* Wei Quan,1,2,* Xiaoni Jia,1 Jianbo Chen,1 Shanbo Ma,3 Xiaohong Zhang11Xi’an Mental Health Center, Institute of Mental Health, Xi’an Medical University, Xi’an, Shaanxi, People’s Republic of China; 2Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China; 3Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China*These authors contributed equally to this workAbstract: Psychotropic medications have been known to cause cardiac conduction disturbances. Not much is known about the cardiovascular side effects of newer atypical antipsychotics such as aripiprazole. A case of a 13-year-old girl with schizophrenia is presented. An analysis of the presented patient’s clinical history indicates the need for a detailed analysis of the severe arrhythmia induced by aripiprazole. This presented case report contains valuable guidelines that can be of assistance in the treatment of patients with aripiprazole.Keywords: schizophrenia, aripiprazole, arrhythmia, antipsychotics

  18. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice

    DEFF Research Database (Denmark)

    Sørensen, Gunnar; Sager, Thomas N; Petersen, Jørgen H

    2008-01-01

    doses (0.03, 0.1, and 0.3 mg/kg/infusion) even caused significant decreases in nose-poking activity, possibly due to extrapyramidal side effects. CONCLUSIONS: These data are consistent with a potential role for aripiprazole in treatment of cocaine addiction without abuse potential per se....

  19. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.

    Science.gov (United States)

    Miura, Itaru; Shiga, Tetsuya; Katsumi, Akihiko; Kanno-Nozaki, Keiko; Mashiko, Hirobumi; Niwa, Shin-Ichi; Yabe, Hirooki

    2014-03-01

    Blonanserin is a novel atypical antipsychotic drug that has efficacy equal to risperidone. We investigated the effects of aripiprazole and blonanserin on clinical symptoms and plasma levels of homovanillic acid (pHVA) and 3-methoxy-4hydroxyphenylglycol in the switching strategy of schizophrenia. Twenty two Japanese patients with schizophrenia were enrolled into this open study. The antipsychotics of all patients were switched to aripiprazole or blonanserin for the improvement of clinical symptoms or side effects. Plasma monoamine metabolites levels were analyzed with high-performance liquid chromatography. There were no significant effects for time (p = 0.346) or time × group interaction (p = 0.27) on the changes of positive and negative syndrome scale (PANSS) total score, although blonanserin decreased PANSS scores. We observed negative correlation between pHVA at baseline and the change in PANSS total score (rs = -0.450, p = 0.046). We also found positive correlation between the changes in pHVA and the changes in PANSS total (rs = 0.536, p = 0.015) and positive (rs = 0.572, p = 0.008) scores. There were no differences between blonanserin and aripiprazole in the improvement of clinical symptoms. Our results suggest that pHVA may be useful indicator for the switching strategy to aripiprazole or blonanserin in schizophrenia. Copyright © 2014 John Wiley & Sons, Ltd.

  20. Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study.

    Science.gov (United States)

    Fujioi, J; Iwamoto, K; Banno, M; Kikuchi, T; Aleksic, B; Ozaki, N

    2017-03-01

    Introduction: Although adjunctive aripiprazole improves hyperprolactinemia, sufficient evidence for its effects on sexual dysfunction has not been obtained. We assessed the usefulness of adjunctive aripiprazole for schizophrenia with sexual dysfunction. Methods: 22 Japanese schizophrenia patients with antipsychotic-induced hyperprolactinemia and sexual dysfunction were enrolled, and 19 of them completed the study. Aripiprazole was administrated in a flexible titration schedule to participants according to the judgment of each doctor, and patients were followed for 24 weeks. Serum prolactin, Clinical Global Impression Scales-Severity (CGI-S), and Nagoya Sexual Function Questionnaire (NSFQ) were measured at baseline and at 4, 8, 12, and 24 weeks. Results: Prolactin at week 4 and later was significantly lower than that at baseline. Compared to baseline, we observed a significant improvement in total sexual dysfunction as measured by NSFQ at week 8 and later. In males, erectile dysfunction was significantly reduced at week 24. In females, menstrual irregularity and galactorrhea were significantly reduced at week 24. CGI-S did not significantly change. Discussion: Although the small sample size is a limitation in this study, adjunctive aripiprazole may be useful treatment for sexual dysfunction including hyperprolactinemia in schizophrenia. © Georg Thieme Verlag KG Stuttgart · New York.

  1. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

    Directory of Open Access Journals (Sweden)

    Kirino E

    2014-11-01

    Full Text Available Eiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies. Keywords: child, mania, mixed state

  2. Case Reports of Aripiprazole Causing False-Positive Urine Amphetamine Drug Screens in Children.

    Science.gov (United States)

    Kaplan, Justin; Shah, Pooja; Faley, Brian; Siegel, Mark E

    2015-12-01

    Urine drug screens (UDSs) are used to identify the presence of certain medications. One limitation of UDSs is the potential for false-positive results caused by cross-reactivity with other substances. Amphetamines have an extensive list of cross-reacting medications. The literature contains reports of false-positive amphetamine UDSs with multiple antidepressants and antipsychotics. We present 2 cases of presumed false-positive UDSs for amphetamines after ingestion of aripiprazole. Case 1 was a 16-month-old girl who accidently ingested 15 to 45 mg of aripiprazole. She was lethargic and ataxic at home with 1 episode of vomiting containing no identifiable tablets. She remained sluggish with periods of irritability and was admitted for observation. UDS on 2 consecutive days came back positive for amphetamines. Case 2 was of a 20-month-old girl who was brought into the hospital after accidental ingestion of an unknown quantity of her father's medications which included aripiprazole. UDS on the first day of admission came back positive only for amphetamines. Confirmatory testing with gas chromatography-mass spectrometry (GC-MS) on the blood and urine samples were also performed for both patients on presentation to detect amphetamines and were subsequently negative. Both patients returned to baseline and were discharged from the hospital. To our knowledge, these cases represent the first reports of false-positive amphetamine urine drug tests with aripiprazole. In both cases, aripiprazole was the drug with the highest likelihood of causing the positive amphetamine screen. The implications of these false-positives include the possibility of unnecessary treatment and monitoring of patients.

  3. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

    Directory of Open Access Journals (Sweden)

    Chiara Cecchelli

    2010-01-01

    Full Text Available Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram. Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.

  4. Variations of Aripiprazole-Induced Dyskinesia Existing with Concurrent Use of Amantadine and an Anticholinergic Agent in an Elderly Patient

    Directory of Open Access Journals (Sweden)

    I-Wen Sun

    2012-06-01

    Full Text Available Elderly patients are vulnerable to the adverse neurological effects of antipsychotics, particularly Parkinsonian symptoms and tardive dyskinesia. This vulnerability in the elderly becomes complex and unpredictable when aripiprazole is prescribed to replace other second-generation or first-generation antipsychotics. This report describes a 69-year-old female schizophrenic patient, who received aripiprazole after using a few antipsychotics, including the first- and second-generation ones. The tardive dyskinesia developed 6 weeks after switching to aripiprazole but subsided 4 weeks later when stopping the concurrent amantadine and decreasing the dosage of trihexyphenidyl. However, Parkinsonian symptoms developed insidiously thereafter, which remitted after the dosage of trihexyphenidyl was increased again. The possible mechanisms of the alternated adverse neurological events after a switch to aripiprazole in the chronic elderly psychosis are discussed.

  5. Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice

    Science.gov (United States)

    Han, Changsu; Wang, Sheng-Min; Lee, Soo-Jung; Jun, Tae-Youn

    2015-01-01

    Major depressive disorder (MDD) is a recurrent, chronic, and devastating disorder leading to serious impairment in functional capacity as well as increasing public health care costs. In the previous decade, switching therapy and dose adjustment of ongoing antidepressants was the most frequently chosen subsequent treatment option for MDD. However, such recommendations were not based on firmly proven efficacy data from well-designed, placebo-controlled, randomized clinical trials (RCTs) but on practical grounds and clinical reasoning. Aripiprazole augmentation has been dramatically increasing in clinical practice owing to its unique action mechanisms as well as proven efficacy and safety from adequately powered and well-controlled RCTs. Despite the increased use of aripiprazole in depression, limited clinical information and knowledge interfere with proper and efficient use of aripiprazole augmentation for MDD. The objective of the present review was to enhance clinicians' current understanding of aripiprazole augmentation and how to optimize the use of this therapy in the treatment of MDD. PMID:26306301

  6. Metabolism

    Science.gov (United States)

    ... a particular food provides to the body. A chocolate bar has more calories than an apple, so ... acid phenylalanine, needed for normal growth and protein production). Inborn errors of metabolism can sometimes lead to ...

  7. Low-dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome).

    Science.gov (United States)

    Chen, Cheng-Che; Liu, Hsing-Cheng

    2011-06-01

    We reported a patient who suffered from complex visual hallucinations with left homonymous hemianopsia. Brain imaging showed an acute haemorrhage infarct at the right occipital lobe. Charles Bonnet syndrome (CBS) was suspected and aripiprazole was prescribed at 5 mg daily. After 3 weeks, the symptoms of hallucinations and anxiety were relieved. Although some CBS patients might be self-limited without discomfort, low-dose aripiprazole can be considered as a safe medication for significantly anxious patients with CBS.

  8. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol

    Directory of Open Access Journals (Sweden)

    Ingeborg eBolstad

    2015-05-01

    Full Text Available Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning.Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD functional magnetic resonance imaging (fMRI was carried out. Results: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference. Conclusion: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons.This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14; https://clinicaltrials.gov/.

  9. TARDIVE DYSKINESIA AND OTHER EXTRAPYRAMIDAL SYMPTOMS ASSOCIATED WITH ARIPIPRAZOLE: A CASE SERIES

    Directory of Open Access Journals (Sweden)

    Nayana Sanjay

    2016-06-01

    Full Text Available BACKGROUND Aripiprazole is a third generation antipsychotic introduced in 2004 for treatment of Schizophrenia and bipolar disorders. It has partial agonist activity at dopamine D2 receptor and D2 antagonist activity under hyperdopaminergic condition. In addition, it is a partial agonist at serotonin 5HT1A receptor and antagonist at 5HT2A receptor. Because its pharmacological profile differs from other atypical antipsychotics, it was initially thought to produce lesser side effects and movement disorders. But over the years, there is a growing body of evidence in the form of case reports and case series of Aripiprazole induced movement disorders like Tardive dyskinesia, Parkinsonism, akathisia and dystonia. Of late it has been advocated for irritability associated with autism and as an augmenter for depressive disorder. It has lower potential for weight gain and sedation, as it has relatively low affinity for H1 [Histamine] receptor compared to clozapine, olanzapine and quetiapine. Based on this unique mechanism, it is claimed to have minimal or non-significant motor side effects like Tardive dyskinesia. We document a case series of 8 patients who developed Tardive dyskinesia, Parkinsonism and akathisia following treatment with Aripiprazole (ARP. METHODS This is both retrospective and observational study. Patients from outpatient and inpatient department of a tertiary psychiatric teaching hospital with an ICD-10 diagnosis of psychiatric disorder, who has experienced movement disorder while on treatment with Aripiprazole are included in this report. All these patients were under the care of authors as treating Psychiatrists. Rating scales like Abnormal Involuntary Movement Scale (AIMS, Naranjo’s Causality Scale, Barnes Akathisia Rating Scale (BARS and Simpson Angus extrapyramidal Scale (SAS were used. RESULTS Total of eight patients presented with various movement disorders associated with Aripiprazole, out of which three patients with tardive

  10. METABOLISM

    Institute of Scientific and Technical Information of China (English)

    1999-01-01

    Objective: To determine the allele frequencies of genetic variants 373 Ala→Pro and 451 Arg→Gln of cholesteryl ester transfer protein (CETP) and to explore their potential impacts on serum lipid metabolism. Methods: The genotypes in CETP codon 373 and 451 in 91 German healthy students and 409 an-

  11. A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

    Directory of Open Access Journals (Sweden)

    Sugawara H

    2016-05-01

    Full Text Available Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Arakawa-ku, 4Department of Research, Medical Research Institute, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan Background: Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD. Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population.  Methods: Eighty-five depressed Japanese patients who underwent aripiprazole augmentation therapy after failing to respond satisfactorily to antidepressant monotherapy were included in the study. Treatment responses were evaluated based on Clinical Global Impression Improvement scores assessed 8 weeks after initiation of aripiprazole administration. We compared demographic and diagnostic variables, psychiatric medication variables, and clinical variables between remission and nonremission groups.  Results: The aripiprazole augmentation remission rate was 36.5%. Multiple logistic regression analysis indicated that aripiprazole augmentation was significantly more effective for bipolar depression than for major depressive disorder, and both absence of comorbid anxiety disorders and current episode duration >3 months were significantly associated with the efficacy of aripiprazole augmentation.  Conclusion: Polarity of depression, comorbidity of anxiety disorders, and current episode duration may predict the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and

  12. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome.

    Science.gov (United States)

    Gerasch, Sarah; Kanaan, Ahmad Seif; Jakubovski, Ewgeni; Müller-Vahl, Kirsten R

    2016-01-01

    Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  13. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.

    Science.gov (United States)

    Ozaki, Norio; Otsubo, Tempei; Kato, Masaki; Higuchi, Teruhiko; Ono, Hiroaki; Kamijima, Kunitoshi

    2015-01-01

    Results from this randomized, placebo-controlled study of aripiprazole augmentation to antidepressant therapy (ADT) in Japanese patients with major depressive disorder (MDD) (the Aripiprazole Depression Multicenter Efficacy [ADMIRE] study) revealed that aripiprazole augmentation was superior to ADT alone and was well tolerated. In subgroup analyses, we investigated the influence of demographic- and disease-related factors on the observed responses. We also examined how individual symptom improvement was related to overall improvement in MDD. Data from the ADMIRE study were analyzed. Subgroup analyses were performed on the primary outcome measures: the mean change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from the end of selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) treatment to the end of the randomized treatment. Changes in the MADRS total scores were consistently greater with aripiprazole than placebo in each of the subgroups. Efficacy was not related to sex, age, number of adequate ADT trials in the current episode, MDD diagnosis, number of depressive episodes, duration of the current episode, age at first depressive episode, time since the first depressive episode, type of SSRI/SNRI, or severity at the end of SSRI/SNRI treatment phase. Compared to placebo, aripiprazole resulted in significant and rapid improvement on seven of the 10 MADRS items, including sadness. These post-hoc analyses indicated that aripiprazole was effective for a variety of Japanese patients with MDD who had exhibited inadequate responses to ADT. Additionally, we suggest that aripiprazole significantly and rapidly improved the core depressive symptoms. © 2014 The Authors. Psychiatry and Clinical Neurosciences © 2014 Japanese Society of Psychiatry and Neurology.

  14. 合用与换用阿立哌唑对已绝经女性精神分裂症患者催乳素水平影响的对照研究%Control Study of Combined with Aripiprazole or Switching to Aripiprazole on Prolactin Levels in Postmenopausal Women with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    倪静; 戴兴海; 朱欣彦; 沈涛; 周颖; 田良辉; 咸晶; 徐颺

    2015-01-01

    Objective: To investigate the role of aripiprazole in prolactin ( PRL ) metabolism through comparing the PRL levels of the postmenopausal women with schizophrenia and hyperprolactinemia .Method:90 women with schizophrenia and hyperprolactinemia were randomly divided into 2 groups:group A with 45 cases, former drugs plus aripiprazole 5mg once a day for 12 weeks) and group B with 45 cases, Aripiprazole 14.78±4.76mg once a day for 12 weeks).Then examined the PRL levels at 5 time points:prior treatment, 2 weeks, 4 weeks, 8 weeks, 12 weeks and accomplished the PANSS scales at the time points stated above as well.Result:According to the result of repeated measures ANOVA , the PRL levels of the 2 groups had no significant differences ( F=3.507,P=0.064) and had interaction between the groups and time points ( P=0. 002), suggesting that PRL was influenced by different treatment of aripiprazole and time .The score of PAN-SS scales had no significant differences (F=0.145,P=0.705).Conclusion:Aripiprazole may down-regulate the expression of the PRL levels of women with schizophrenia and hyperprolactinemia .%目的:探讨已绝经女性精神分裂症合并高催乳素血症患者在合用与换用阿立哌唑时对其催乳素水平影响的对照研究。方法:对90例已绝经女性精神分裂症同时合并高催乳素血症的患者随机分为两组,合用组:45例,为原有药物联合阿立哌唑5mg/d治疗12周,换用组:45例,为原有药物更换为治疗剂量阿立哌唑(14.78±4.76mg/d)12周,治疗前和治疗后2、4、8、12周末分别测定催乳素水平并予以阳性和阴性量表(PANSS)和副反应量表(TESS)评定病情并进行比较。结果:根据重复测量结果,两组间PRL水平尚无统计学差异( F=3.507,P=0.064),但组间检验提示时间、研究组别有交互作用(P=0.002),即PRL的值受到时间和组别的共同影响。 PRL随着时间的推移逐渐下降,且

  15. Successful treatment of catatonic syndrome in bipolar I disorder adding aripiprazole to ECT: A case report

    Directory of Open Access Journals (Sweden)

    Diego Hidalgo, MD

    2012-09-01

    Full Text Available Background and Objectives: Catatonic syndrome is a condition presenting in multiple ways, sharing many of them with the neuroleptic malignant syndrome and other diseases. This diagnostic challenge is the main cause of keep treating catatonic syndromes without neuroleptics. Methods: Review of the literature and a case report. Results: We present the case of a 19 years old bipolar I patient with a severe catatonic syndrome, with a torpid clinical evolution, partial response to benzodiazepines and ECT, which successfully resolved with intramuscular aripiprazole. We found through a systematic review (PubMed 2005-2010 that there are few but significant case reports of catatonic syndromes treated with new second generation antipsychotics for different reasons with good outcomes as ours. The pharmacological profile of aripiprazole and the low incidence of NMS reported make it a suitable option in treating this syndrome. Conclusions: We think that this case report could contribute to add more evidence for aripiprazole to be considered a good third-line option in the treatment of catatonic syndrome. However, this would require randomized controlled trials to confirm its effectiveness and safety.

  16. Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia

    Directory of Open Access Journals (Sweden)

    Hikaru Hori

    2017-03-01

    Full Text Available Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia. Therefore, in the present study, we evaluated biological markers, clinical data, and psychiatric symptoms in order to identify factors that influence cognitive function in patients with schizophrenia undergoing aripiprazole treatment. We evaluated cognitive function in 51 patients with schizophrenia using Brief Assessment of Cognition in Schizophrenia (BACS, as well as background information, psychiatric symptoms, plasma catecholamine metabolites—homovanillic acid (HVA, 3-methoxy-4-hydroxyphenylglycol (MHPG—, and serum brain-derived neurotrophic factor (BDNF. Multivariate analyses were performed in order to identify factors independently associated with cognitive function. Brain-derived neurotrophic factor levels, number of hospitalizations, and MHPG levels were associated with verbal memory and learning. Total hospitalization period and MHPG levels were associated with working memory. Age at first hospitalization and education were associated with motor speed. The number of hospital admissions, Positive and Negative Syndrome Scale negative subscale scores (PANSS-N, MHPG levels, BDNF levels, and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS scores were associated with verbal fluency. Homovanillic acid and MHPG levels, duration of illness, and PANSS-N scores were associated with attention and processing speed. Brain-derived neurotrophic factor and MHPG levels were associated with executive function. These results suggest that treatment of psychiatric symptoms and cognitive dysfunction may be improved in patients treated with aripiprazole by controlling for these contributing factors.

  17. Aripiprazole once-monthly as treatment for psychosis in Turner syndrome: literature review and case report.

    Science.gov (United States)

    Carlone, Cristiano; Pompili, Enrico; Silvestrini, Cristiana; Nicolò, Giuseppe

    2016-01-01

    Turner syndrome (TS) is a neurogenetic disorder characterized by partial or complete monosomy-X, usually resulting of a sporadic chromosomal nondisjunction. It is one of the most common sex chromosome abnormalities, affecting approximately 1 in 2,000 live born females. There are sporadic few case reports of concomitant TS with schizophrenia worldwide. No defined psychiatric condition has been traditionally related to TS, and it is not mentioned in DSM-IV. Although it is not associated with any psychiatric syndrome, several case reports in the literature describe a similar constellation of symptoms in TS that may represent a biologically-based entity. Aripiprazole once-monthly is a second generation antipsychotic recently developed. Its efficacy and non-inferiority to oral aripiprazole have been demonstrated in preventing relapse in patients with schizophrenia. Experience with oral aripiprazole and the current availability of the long-acting formulation suggest a potential benefit in a variety of clinical scenarios and therefore consideration as a treatment option in the treatment of schizophrenia and psychotic symptoms in several disease like TS.

  18. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.

    Science.gov (United States)

    den Boon, F S; Body, S; Hampson, C L; Bradshaw, C M; Szabadi, E; de Bruin, N

    2012-09-01

    Clozapine and some other atypical antipsychotics (e.g. quetiapine, olanzapine) have been found to exert a characteristic profile of action on operant behaviour maintained by progressive-ratio schedules, as revealed by Killeen's Mathematical Principles of Reinforcement model of schedule-controlled behaviour. These drugs increase the value of a parameter that expresses the 'incentive value' of the reinforcer (a) and a parameter that is inversely related to the organism's 'motor capacity' (δ). This experiment examined the effects of two further atypical antipsychotics, aripiprazole and amisulpride, on progressive-ratio schedule performance in rats; the effects of clozapine and a conventional antipsychotic, haloperidol, were also examined. In agreement with previous findings, clozapine (4, 8 mg kg⁻¹) increased a and δ, whereas haloperidol (0.05, 0.1 mg kg⁻¹) reduced a and increased δ. Aripiprazole (3,30 mg kg⁻¹) increased δ but did not affect a. Amisulpride (5, 50 mg kg⁻¹) had a delayed and protracted effect: δ was increased 3-6 hours after treatment; a was increased 1.5 hours, and reduced 12-24 hours after treatment. Interpretation based on Killeen's model suggests that aripiprazole does not share clozapine's ability to enhance reinforcer value. Amisulpride produced a short-lived enhancement, followed by a long-lasting reduction, of reinforcer value. Both drugs impaired motor performance.

  19. Aripiprazole improves associated comorbid Conditions in addition to Tics in adult Patients with Gilles de la Tourette Syndrome

    Directory of Open Access Journals (Sweden)

    Sarah Gerasch

    2016-09-01

    Full Text Available Gilles de la Tourette Syndrome (GTS is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD, attention deficit/hyperactivity disorder (ADHD, depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU, and quality of life (QoL. Moreover we were interested in the factors that influence a patient’s decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. 18 out of 44 patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1 aripiprazole resulted in significant reduction of tics, but did not affect PU; (2 aripiprazole significantly improved OCD and showed a trend towards improvement of other comorbidities including depression, anxiety and ADHD; (3 neither severity of tics, nor PU or QoL influenced patients’ decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4 most frequently reported adverse effects were sleeping problems; (5 patients’ QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  20. Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: a retrospective chart review

    Directory of Open Access Journals (Sweden)

    Fikretoglu Deniz

    2011-05-01

    Full Text Available Abstract Background In this chart review, we attempted to evaluate the benefits of adding aripiprazole in veterans with military-related PTSD and comorbid depression, who had been minimally or partially responsive to their existing medications. Methods A retrospective chart review of patients who received an open-label, flexible-dose, 12- week course of adjunctive aripiprazole was conducted in 27 military veterans meeting DSM-IV criteria for PTSD and comorbid major depression. Concomitant psychiatric medications continued unchanged, except for other antipsychotics which were discontinued prior to initiating aripiprazole. The primary outcome variable was a change from baseline in the PTSD checklist-military version (PCL-M and the Beck Depression Inventory (BDI-II. Results PTSD severity (Total PCL scores decreased from 56.11 at baseline to 46.85 at 12-weeks (p Conclusions The addition of aripiprazole contributed to a reduction in both PTSD and depression symptomatology in a population that has traditionally demonstrated poor pharmacological response. Further investigations, including double-blind, placebo-controlled studies, are essential to confirm and further demonstrate the benefit of aripiprazole augmentation in the treatment of military related PTSD.

  1. Combination of omega-3 Fatty acids, lithium, and aripiprazole reduces oxidative stress in brain of mice with mania.

    Science.gov (United States)

    Arunagiri, Pandiyan; Rajeshwaran, Krishnamoorthy; Shanthakumar, Janakiraman; Tamilselvan, Thangavel; Balamurugan, Elumalai

    2014-09-01

    Manic episode in bipolar disorder (BD) was evaluated in the present study with supplementation of omega-3 fatty acids in combination with aripiprazole and lithium on methylphenidate (MPD)-induced manic mice model. Administration of MPD 5 mg/kg bw intraperitoneally (i.p.) caused increase in oxidative stress in mice brain. To retract this effect, supplementation of omega-3 fatty acids 1.5 ml/kg (p.o.), aripiprazole 1.5 mg/kg bw (i.p.), and lithium 50 mg/kg bw (p.o) were given to mice. Omega-3 fatty acids alone and in combination with aripiprazole- and lithium-treated groups significantly reduced the levels of superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation products (thiobarbituric acid reactive substances) in the brain. MPD treatment significantly decreased the reduced glutathione (GSH) level and glutathione peroxidase (GPx) activity, and they were restored by supplementation of omega-3 fatty acids with aripiprazole and lithium. There is no remarkable difference in the effect of creatine kinase (CK) activity between MPD-induced manic model and the treatment groups. Therefore, our results demonstrate that oxidative stress imbalance and mild insignificant CK alterations induced by administration of MPD can be restored back to normal physiological levels through omega-3 fatty acids combined with lithium and aripiprazole that attributes to effective prevention against mania in adult male Swiss albino mice.

  2. Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats.

    Science.gov (United States)

    De Santis, Michael; Pan, Bo; Lian, Jiamei; Huang, Xu-Feng; Deng, Chao

    2014-09-01

    Following on the success of Aripiprazole with its high clinical efficacy and minimal side effects, further antipsychotic drugs (such as Bifeprunox) have been developed based on the same dopamine D2 partial agonist pharmacological profile as Aripiprazole. However clinical trials of Bifeprunox have found differing results to that of its predecessor, without the same significant clinical efficacy. This study has therefore investigated the different effects of 10 week treatment with Aripiprazole (0.75 mg/kg, 3 times per day), Bifeprunox (0.8 mg/kg, 3 times per day) and Haloperidol (0.1mg/kg, 3 times per day) on body weight gain, food and water intake, white fat mass, and 8 week treatment on locomotor activity. Treatment with Bifeprunox was found to significantly reduce all of the measured parameters except white fat mass compared to the control group. However, Aripiprazole and Haloperidol treatment reduced water intake compared to the control, without any significant effects on the other measured parameters. These findings further demonstrate the potential pharmacological differences between Aripiprazole and Bifeprunox, and identify potential weight loss side effects and increased anxiety behaviour with Bifeprunox treatment. Copyright © 2014 Elsevier Inc. All rights reserved.

  3. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats

    DEFF Research Database (Denmark)

    Thomsen, Morgane; Fink-Jensen, Anders; Woldbye, David

    2008-01-01

    RATIONALE: Dopamine D2-like partial agonists such as aripiprazole have received some attention as potential pharmacotherapies for the treatment of psychostimulant addiction. However, the preclinical evaluations so far have focused on acute effects of aripiprazole. OBJECTIVES: We tested the hypoth......RATIONALE: Dopamine D2-like partial agonists such as aripiprazole have received some attention as potential pharmacotherapies for the treatment of psychostimulant addiction. However, the preclinical evaluations so far have focused on acute effects of aripiprazole. OBJECTIVES: We tested......, chronic treatment with aripiprazole does not show much promise as a potential pharmacotherapy for cocaine addiction. Both acute and chronic treatment data are in agreement with published clinical findings, suggesting that the concurrent choice procedure in rats has predictive validity of efficacy...

  4. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.

    Science.gov (United States)

    Tramontina, Silzá; Zeni, Cristian P; Ketzer, Carla R; Pheula, Gabriel F; Narvaez, Joana; Rohde, Luis Augusto

    2009-04-21

    To assess response to treatment with aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder (ADHD). Children and adolescents were extensively assessed according to DSM-IV criteria for bipolar disorder comorbid with ADHD (n = 710). Those with this comorbidity who were acutely manic or in mixed states were randomly assigned in a 6-week double-blind, placebo-controlled trial to aripiprazole (n = 18) or placebo (n = 25). Primary outcome measures were assessed weekly and included the Young Mania Rating Scale; the Swanson, Nolan, and Pelham Scale-Version IV; and weight. Secondary outcome measures were the Clinical Global Impressions-Severity of Illness scale, the Child Mania Rating Scale-Parental Version (CMRS-P), the Children's Depression Rating Scale-Revised, the Kutcher Adolescent Depression Scale, and adverse events. The trial was conducted at the Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil, from January 2005 to November 2007. The group receiving aripiprazole showed a significantly greater reduction in YMRS scores (P = .02, effect size [ES] = 0.80), CMRS-P scores (P = .02; ES = 0.54), and CGI-S scores (P = .04; ES = 0.28) from baseline to endpoint than the placebo group. In addition, higher rates of response (P = .02) and remission (P = .01) were found for the aripiprazole group. No significant between-group differences were found in weight, ADHD symptoms, and depressive symptoms. Adverse events significantly more frequent in the aripiprazole group were somnolence and sialorrhea. Aripiprazole was effective in reducing manic symptoms and improving global functioning without promoting severe adverse events or weight gain. No significant treatment effect in ADHD symptoms was observed. Studies are needed to assess psychopharmacologic interventions for improving ADHD symptoms in juvenile bipolar disorder comorbid with ADHD. clinicaltrials.gov Identifier: NCT00116259. Copyright 2009

  5. Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis.

    Science.gov (United States)

    Lee, Seung-Yup; Min, Jung-Ah; Lee, In Goo; Kim, Jung Jin

    2016-08-31

    Tuberous sclerosis is not as rare as once thought and has high psychiatric comorbidities. However, bipolar or psychotic features associated with tuberous sclerosis have been rarely reported. This report first presents a tuberous sclerosis patient, resembling a schizoaffective disorder of bipolar type. A patient with known tuberous sclerosis displayed mood fluctuation and psychotic features. Her symptoms did not remit along with several psychiatric medications. After hospitalization, the patient responded well with lamotrigine and aripiprazole without exacerbation. As demonstrated in this case, tuberous sclerosis may also encompass bipolar affective or psychotic features. We would like to point out the necessity to consider bipolarity in evaluating and treating tuberous sclerosis.

  6. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

    DEFF Research Database (Denmark)

    Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine

    2016-01-01

    with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic...

  7. Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.

    Science.gov (United States)

    Uttley, Lesley; Kearns, Ben; Ren, Shijie; Stevenson, Matt

    2013-11-01

    As part of its single technology process, the National Institute for Health and Care Excellence (NICE) invited the manufacturers of aripiprazole (Otsuka Pharmaceutical Co. and Bristol Myers Squibb) to submit evidence of the clinical and cost effectiveness of aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cost effectiveness of the technology, based upon the manufacturers' submission to NICE. The evidence, which was derived mainly from a double-blind, phase III, placebo-controlled trial of aripiprazole in patients aged 10-17 years, showed that aripiprazole performed significantly better than placebo in reducing mania according to the primary outcome measurement (the Young Mania Rating Scale at 4 weeks). Safety outcomes indicated that aripiprazole was significantly more likely to cause extrapyramidal symptoms and somnolence than placebo. The manufacturers also presented a network meta-analysis of aripiprazole versus other atypical antipsychotics commonly used to treat manic episodes (olanzapine, quetiapine and risperidone) to show that aripiprazole performed similarly to the comparator drugs in terms of efficacy and safety. Aripiprazole was demonstrated to perform better in safety outcomes of (1) less weight gain than olanzapine and quetiapine; and (2) less prolactin increase than olanzapine, quetiapine and risperidone. Results from the manufacturers' economic evaluation showed that use of aripiprazole second-line dominated all of the other treatment strategies that were considered. However, there was considerable uncertainty in this result, and clinical advisors indicated that the actual treatment strategy employed in practice is likely to be

  8. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents with Irritability Associated with Autistic Disorder

    Science.gov (United States)

    Marcus, Ronald N.; Owen, Randall; Kamen, Lisa; Manos, George; McQuade, Robert D.; Carson, William H.; Aman, Michael G.

    2009-01-01

    Objective: To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Method: Two hundred eighteen children and adolescents (aged 6-17 years) with a diagnosis of autistic disorder, and with behaviors such as tantrums, aggression, self-injurious behavior, or a…

  9. An Open-Label Study of Aripiprazole : Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder

    NARCIS (Netherlands)

    Findling, Robert L.; Kauffman, Ralph; Sallee, Floyd R.; Salazar, Daniel E.; Sahasrabudhe, Vaishali; Kollia, Georgia; Kornhauser, David M.; Vachharajani, Nimish N.; Assuncao-Talbott, Sheila; Mallikaarjun, Suresh; Iwamoto, Taro; McQuade, Robert D.; Boulton, David W.; Blumer, Jeffrey

    2009-01-01

    Objectives: This study evaluated flexible-dose pharmacokinetics, safety, and effectiveness of aripiprazole in children and adolescents with conduct disorder (CD). Methods: This open-label, 15-day, three-center study with an optional 36-month extension enrolled a total of 23 patients: 12 children (6-

  10. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event.

  11. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.

    Science.gov (United States)

    De Berardis, Domenico; Fornaro, Michele; Serroni, Nicola; Marini, Stefano; Piersanti, Monica; Cavuto, Marilde; Valchera, Alessandro; Mazza, Monica; Girinelli, Gabriella; Iasevoli, Felice; Perna, Giampaolo; Martinotti, Giovanni; Di Giannantonio, Massimo

    2014-01-01

    Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side effect, although rare, might occur. Switching drugs should be considered when a patient does not appear to be responding to the previous antipsychotic, thus developing hyperprolactinemia. A cross-taper switch should always be considered, but the risk of a relapse in the disorder may occur more frequently and the patients should be closely monitored. However, limitations must be considered and further studies are needed to definitely elucidate this important issue. Some relevant patents are also described in this review.

  12. An Open-Label Study of Aripiprazole : Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder

    NARCIS (Netherlands)

    Findling, Robert L.; Kauffman, Ralph; Sallee, Floyd R.; Salazar, Daniel E.; Sahasrabudhe, Vaishali; Kollia, Georgia; Kornhauser, David M.; Vachharajani, Nimish N.; Assuncao-Talbott, Sheila; Mallikaarjun, Suresh; Iwamoto, Taro; McQuade, Robert D.; Boulton, David W.; Blumer, Jeffrey

    Objectives: This study evaluated flexible-dose pharmacokinetics, safety, and effectiveness of aripiprazole in children and adolescents with conduct disorder (CD). Methods: This open-label, 15-day, three-center study with an optional 36-month extension enrolled a total of 23 patients: 12 children

  13. Neural correlates of delusional infestation responding to aripiprazole monotherapy: a case report

    Directory of Open Access Journals (Sweden)

    Ponson L

    2015-02-01

    Full Text Available Laura Ponson,1,2 Frédéric Andersson,1 Wissam El-Hage1,2 1Université François-Rabelais de Tours, Inserm, Imagerie et Cerveau UMR U930, Tours, France, 2CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France Background: The pathophysiology and appropriate pharmacological interventions for delusional infestation remain unknown.Case presentation: Here, we report a case of primary delusional infestation successfully treated with aripiprazole. We performed functional magnetic resonance imaging (fMRI to investigate brain structures and functional modifications. Before antipsychotic treatment, pre- versus post-treatment fMRI images revealed a marked increase in brain activation in the supplementary motor area (SMA.Conclusion: Our results highlight the efficacy and safety of aripiprazole in the treatment of delusional infestation and the possible role of SMA dysfunction in delusional infestation. Indeed, our results suggest that psychiatric improvement of delusional infestation is associated with normalization of brain activity, particularly in the SMA. Keywords: supplementary motor area, antipsychotics, fMRI

  14. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.

    Science.gov (United States)

    Preskorn, Sheldon H; Macaluso, Matthew

    2016-03-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder (MDD) and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. This column reviews clinical trial data to assess whether those data support the conclusion that aripiprazole has a low to absent risk of causing TD when used as an augmentation strategy to treat MDD. To date, no randomized, placebo-controlled trials have established a definitive link between exposure to aripiprazole and TD in patients with MDD. One long-term, open-label, safety trial examined aripiprazole as an augmentation strategy in individuals with MDD and found a rare occurrence (4/987, 0.4%, the confidence interval of which overlaps with zero) of an adverse event termed TD. In all 4 cases, the observed movements resolved within weeks of aripiprazole discontinuation, suggesting that they were either amenable to treatment or represented an acute syndrome rather than TD. No cases of TD were reported in the registration trials for the MDD indication for aripiprazole. These data were presented in a pooled analysis of

  15. A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

    Directory of Open Access Journals (Sweden)

    Salvatore Gentile

    2009-02-01

    Full Text Available Salvatore GentileDepartment of Mental Health, ASL Salerno 1, ItalyAbstract: Aripiprazole is a relatively novel second-generation antipsychotic belonging to the chemical class of benzisoxazole derivatives and is characterized by a unique pharmacological profile which suggests that the drug acts as a dopamine-serotonin system stabilizer. Whereas all previously available antipsychotics are antagonists at D2 receptors, aripiprazole is the only available partial agonist at these receptors. Thus, it has been suggested that aripiprazole could be associated with a relatively neutral impact on bodyweight, possibly reducing risks of a detrimental impact on the quality of life that often complicates management for a large number of patients diagnosed with severe and persistent mental disorders (SPMDs treated chronically with antipsychotic medications. However, data from short- and long-term reviewed studies indicate that the prevalence rate of clinically relevant weight gain during therapy with this drug is similar to that occurring during treatments with other antipsychotic agents, either typical or atypical. Moreover, information on the impact of aripiprazole therapy on the quality of life of patients diagnosed with SPMDs is scarce and characterized by conflicting results. Given these results, further, large, well-designed studies are needed before confirming potential advantages of aripiprazole over first-generation antipsychotics and other SGAs.Keywords: aripiprazole, effectiveness, quality of life, safety, weight gain

  16. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.

    Science.gov (United States)

    Park, Chul-Hyun; Park, Tae-Won; Yang, Jong-Chul; Lee, Keon-Hak; Huang, Guang-Biao; Tong, Zhao; Park, Myung-Sook; Chung, Young-Chul

    2012-03-01

    Noncompliance and poor outcome in patients with schizophrenia are closely related to the negative symptoms secondary to antipsychotics. No controlled study has evaluated whether amisulpride and aripiprazole induce negative symptoms. The aim of this study was to assess the effects of single doses of amisulpride, aripiprazole, haloperidol, and risperidone in healthy volunteers. Seventy-eight young volunteers took part in this double-blind, randomized, placebo-controlled, parallel study of four antipsychotics: 400 mg amisulpride, 10 mg aripiprazole, 3 mg haloperidol, and 2 mg risperidone. Assessments of negative symptoms were done 4 h after administration using both subjective rating scales (Neuroleptic Induced Deficit Syndrome Scale and Subjective Deficit Syndrome Scale) and an objective rating scale (Scale for the Assessment of Negative Symptoms). Risperidone only produced significant increases on the avolition score of the Neuroleptic Induced Deficit Syndrome Scale and blunted affect and alogia scores of the Scale for the Assessment of Negative Symptoms compared with placebo. The effect on blunted affect persisted after controlling for mental sedation. Amisulpride, aripiprazole, and haloperidol did not induce negative symptoms. Aripiprazole and risperidone induced mild extrapyramidal symptoms. The most common adverse events were somnolence and cognitive slowing. These data indicate that a single risperidone dose induces negative symptoms in normal volunteers, whereas amisulpride, aripiprazole, and haloperidol do not. These characteristics of antipsychotics should be considered when choosing optimal drugs for patients with psychosis.

  17. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders

    Directory of Open Access Journals (Sweden)

    Cox JH

    2016-06-01

    Full Text Available Joanna H Cox,1 Stefano Seri,2,3 Andrea E Cavanna,2,4,5 1Heart of England NHS Foundation Trust, 2School of Life and Health Sciences, Aston Brain Centre, Aston University, 3Children’s Epilepsy Surgery Programme, The Birmingham Children’s Hospital NHS Foundation Trust, 4Department of Neuropsychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, 5Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and UCL, London, UK Abstract: Tourette syndrome is a childhood-onset chronic tic disorder characterized by multiple motor and vocal tics and often accompanied by specific behavioral symptoms ranging from obsessionality to impulsivity. A considerable proportion of patients report significant impairment in health-related quality of life caused by the severity of their tics and behavioral symptoms and require medical intervention. The most commonly used medications are antidopaminergic agents, which have been consistently shown to be effective for tic control, but are also associated with poor tolerability because of their adverse effects. The newer antipsychotic medication aripiprazole is characterized by a unique mechanism of action (D2 partial agonism, and over the last decade has increasingly been used for the treatment of tics. We conducted a systematic literature review to assess the available evidence on the efficacy and safety of aripiprazole in pediatric patients with Tourette syndrome and other chronic tic disorders (age range: 4–18 years. Our search identified two randomized controlled trials (involving 60 and 61 participants and ten open-label studies (involving between six and 81 participants. The majority of these studies used two validated clinician-rated instruments (Yale Global Tic Severity Scale and Clinical Global Impression scale as primary outcome measures. The combined results from randomized controlled trials and open-label studies showed that aripiprazole is an

  18. Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

    Directory of Open Access Journals (Sweden)

    Hsu YC

    2015-01-01

    Full Text Available Yi-Chien Hsu,1,2 Yu-Ching Chou,3 Hsin-An Chang,1,2,4 Yu-Chen Kao,1,2,5 San-Yuan Huang,1,2 Nian-Sheng Tzeng1,2,4 1Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan; 2School of Medicine, 3School of Public Health, 4Student Counseling Center, National Defense Medical Center, Taipei, Taiwan; 5Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, Taipei, Taiwan Objectives: Refractory major depressive disorder (MDD is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy.Design: Descriptive study.Outcome measures: Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole.Intervention: We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic.Results: Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%. The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%, followed by insurance official policy audit and deletion in the claims review system (30.1%.Conclusion: The prescribing

  19. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.

    Science.gov (United States)

    Frank, Guido K W; Shott, Megan E; Hagman, Jennifer O; Schiel, Marissa A; DeGuzman, Marisa C; Rossi, Brogan

    2017-04-01

    Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target. Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program. The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment. The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated. © 2017 Wiley Periodicals, Inc.

  20. Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

    Directory of Open Access Journals (Sweden)

    Fard Masoumi HR

    2015-10-01

    Full Text Available Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan, Chaw Jiang Lim Nanodelivery Group, Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia Abstract: Aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti­psychotic agent to be approved by the US Food and Drug Administration. Formulation of nanoemulsion-containing aripiprazole was carried out using high shear and high pressure homo­genizers. Mixture experimental design was selected to optimize the composition of nanoemulsion. A very small droplet size of emulsion can provide an effective encapsulation for delivery system in the body. The effects of palm kernel oil ester (3–6 wt%, lecithin (2–3 wt%, Tween 80 (0.5–1 wt%, glycerol (1.5–3 wt%, and water (87–93 wt% on the droplet size of aripiprazole nanoemulsions were investigated. The mathematical model showed that the optimum formulation for preparation of aripiprazole nanoemulsion having the desirable criteria was 3.00% of palm kernel oil ester, 2.00% of lecithin, 1.00% of Tween 80, 2.25% of glycerol, and 91.75% of water. Under optimum formulation, the corresponding predicted response value for droplet size was 64.24 nm, which showed an excellent agreement with the actual value (62.23 nm with residual standard error <3.2%. Keywords: schizoaffective disorder, antipsychotic drug, bipolar I disorder, D-optimal mixture design, optimization formulation

  1. Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

    Directory of Open Access Journals (Sweden)

    Yoram Barak

    2011-01-01

    Full Text Available Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to aripiprazole as it has a pharmacological and clinical profile that may result in an improved weight control. Nine publications from seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaffective patients, 473 (60% men and 311 (40% women, mean age 39.4±7.0 years. The major significant finding was a mean weight reduction by −2.55±1.5 kgs following the switch to aripiprazole (<.001. Switching to an antipsychotic with a lower propensity to induce weight gain needs be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy.

  2. Aripiprazole Injection

    Science.gov (United States)

    ... for them, such as increased sexual urges or behaviors, excessive shopping, and binge eating. Call your doctor if you have intense urges to shop, eat, have sex, or gamble, or if you are unable to control your behavior. Tell your family members about this risk so ...

  3. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA.

    Directory of Open Access Journals (Sweden)

    Hiroshi Ito

    Full Text Available Dopamine D(2 receptor partial agonist antipsychotic drugs can modulate dopaminergic neurotransmission as functional agonists or functional antagonists. The effects of antipsychotics on presynaptic dopaminergic functions, such as dopamine synthesis capacity, might also be related to their therapeutic efficacy. Positron emission tomography (PET was used to examine the effects of the partial agonist antipsychotic drug aripiprazole on presynaptic dopamine synthesis in relation to dopamine D(2 receptor occupancy and the resulting changes in dopamine synthesis capacity in healthy men. On separate days, PET studies with [(11C]raclopride and L-[β-(11C]DOPA were performed under resting condition and with single doses of aripiprazole given orally. Occupancy of dopamine D(2 receptors corresponded to the doses of aripiprazole, but the changes in dopamine synthesis capacity were not significant, nor was the relation between dopamine D(2 receptor occupancy and these changes. A significant negative correlation was observed between baseline dopamine synthesis capacity and changes in dopamine synthesis capacity by aripiprazole, indicating that this antipsychotic appears to stabilize dopamine synthesis capacity. The therapeutic effects of aripiprazole in schizophrenia might be related to such stabilizing effects on dopaminergic neurotransmission responsivity.

  4. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-05-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and reviewed preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. The third column in this series reviewed the registration trial data for aripiprazole across all of its indications and found a raw incidence of TD ranging from 0.004 (4 out of 987) in long-term studies of the drug as an augmentation strategy for major depressive disorder to 0.0016 (19 out of 11,897) based on all short-term (ie, weeks to causal relationship between aripiprazole and TD exists.

  5. SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study.

    Science.gov (United States)

    Patel, Daxesh P; Sharma, Primal; Sanyal, Mallika; Shrivastav, Pranav S

    2013-04-15

    An improved and rugged UPLC-MS/MS method has been developed and validated for sensitive and rapid determination of aripiprazole in human plasma using aripiprazole-d8 as the internal standard (IS). The analyte and IS were extracted from 100 μL of human plasma by solid-phase extraction using Phenomenex Strata-X (30 mg, 1 cc) cartridges. Chromatography was achieved on an Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 μm) analytical column using methanol: 10mM ammonium formate (85:15, v/v) as the mobile phase with isocratic elution. Quantitation was done using multiple reaction monitoring in the positive ionization mode. The linearity of the method was established in the concentration range 0.05-80 ng/mL. The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively. The relative matrix effect in eight different lots of plasma samples, expressed as % CV for the calculated slopes of calibration curves was 1.08%. The stability of aripiprazole was studied under different storage conditions. The validated method was used to support a bioequivalence study of 10mg aripiprazole formulation in 36 healthy Indian subjects.

  6. Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report

    Science.gov (United States)

    Tadokoro, Shigenori; Nonomura, Naho; Kanahara, Nobuhisa; Hashimoto, Kenji; Iyo, Masaomi

    2017-01-01

    Dopamine supersensitivity psychosis (DSP) is a type of acute exacerbation of recurrent psychosis caused by long-term treatment with antipsychotics in schizophrenic patients. Although DSP is exceedingly troublesome for clinicians, effective treatment has not yet been established. Based on clinical research and our animal study, we hypothesize that aripiprazole, an atypical anti-psychotic, may reduce the exacerbation of recurrent psychotic episodes. We report the case of a 46-year-old female who suffered from schizophrenia with DSP. In this case, sustained treatment with a high dose of aripiprazole gradually reduced the severity of her recurrent psychotic episodes. In conclusion, sustained treatment with aripiprazole may reduce the exacerbation of recurrent psychotic episodes in schizophrenic patients with DSP, and may be an effective treatment of DSP. PMID:28138118

  7. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.

    Science.gov (United States)

    Assié, Marie-Bernadette; Carilla-Durand, Elisabeth; Bardin, Laurent; Maraval, Mireille; Aliaga, Monique; Malfètes, Nathalie; Barbara, Michèle; Newman-Tancredi, Adrian

    2008-09-11

    Several novel antipsychotics activate serotonin 5-HT1A receptors as well as antagonising dopamine D2/3 receptors. Such a pharmacological profile is associated with a lowered liability to produce extrapyramidal side effects and enhanced efficacy in treating negative and cognitive symptoms of schizophrenia. However, 5-HT1A receptor agonists increase plasma corticosterone and many antipsychotics disturb the regulation of glucose. Here, we compared the influence on plasma glucose and corticosterone of acute treatments with 'new generation' antipsychotics which target dopamine D2/3 receptors and 5-HT1A receptors, with that of atypical antipsychotics, and with haloperidol. Olanzapine and clozapine, antipsychotics that are known to produce weight gain and diabetes in humans, both at 10 mg/kg p.o., substantially increased plasma glucose (from 0.8 to 1.7 g/l) at 1 h after administration, an effect that returned to control levels after 4 h. In comparison, F15063 (40 mg/kg p.o.) was without effect at any time point. Olanzapine and clozapine dose-dependently increased plasma glucose concentrations as did SLV313 and SSR181507. Haloperidol and risperidone had modest effects whereas aripiprazole, ziprasidone and bifeprunox, antipsychotics that are not associated with metabolic dysfunction in humans, and F15063 had little or no influence on plasma glucose. The same general pattern of response was found for plasma corticosterone levels. The present data provide the first comparative study of conventional, atypical and 'new generation' antipsychotics on glucose and corticosterone levels in rats. A variety of mechanisms likely underlie the hyperglycemia and corticosterone release observed with clozapine and olanzapine, whilst the balance of dopamine D2/3/5-HT1A interaction may contribute to the less favourable impact of SLV313 and SSR181507 compared with that of bifeprunox and F15063.

  8. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

    Directory of Open Access Journals (Sweden)

    Alexander C Tsai

    2011-05-01

    Full Text Available BACKGROUND: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature. METHODS AND FINDINGS: We systematically searched multiple databases to identify double-blind, randomized controlled trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as open-label, acute, and adjunctive studies. We then used a citation search to identify articles that cited these trials and rated the quality of their citations. Our evidence search protocol identified only two publications, both describing the results of a single trial conducted by Keck et al., which met criteria for inclusion in this review. We describe four issues that limit the interpretation of that trial as supporting the use of aripiprazole for bipolar maintenance: (1 insufficient duration to demonstrate maintenance efficacy; (2 limited generalizability due to its enriched sample; (3 possible conflation of iatrogenic adverse effects of abrupt medication discontinuation with beneficial effects of treatment; and (4 a low overall completion rate. Our citation search protocol yielded 80 publications that cited the Keck et al. trial in discussing the use of aripiprazole for bipolar maintenance. Of these, only 24 (30% mentioned adverse events reported and four (5% mentioned study limitations. CONCLUSIONS: A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial's interpretation

  9. Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study.

    Science.gov (United States)

    Liemburg, Edith J; van Es, Frank; Knegtering, Henderikus; Aleman, André

    2017-10-03

    Impaired function of prefrontal brain networks may be the source of both negative symptoms and neurocognitive problems in psychotic disorders. Whereas most antipsychotics may decrease prefrontal activation, the partial dopamine D2-receptor agonist aripiprazole is hypothesized to improve prefrontal function. This study investigated whether patients with a psychotic disorder would show stronger activation of prefrontal areas and associated regions after treatment with aripiprazole compared to risperidone treatment. In this exploratory pharmacological neuroimaging study, 24 patients were randomly assigned to either aripiprazole or risperidone. At baseline and after nine weeks treatment they underwent an interview and MRI session. Here we report on brain activation (measured with arterial spin labeling) during performance of two tasks, the Tower of London and the Wall of Faces. Aripiprazole treatment decreased activation of the middle frontal, superior frontal and occipital gyrus (ToL) and medial temporal and inferior frontal gyrus, putamen and cuneus (WoF), while activation increased after risperidone. Activation increased in the ventral anterior cingulate and posterior insula (ToL), and superior frontal, superior temporal and precentral gyrus (WoF) after aripiprazole treatment and decreased after risperidone. Both treatment groups had increased ventral insula activation (ToL) and middle temporal gyrus (WoF), and decreased occipital cortex, precuneus and caudate head activation (ToL) activation. In conclusion, patients treated with aripiprazole may need less frontal resources for planning performance and may show increased frontotemporal and frontostriatal reactivity to emotional stimuli. More research is needed to corroborate and extend these preliminary findings. Copyright © 2017 Elsevier Inc. All rights reserved.

  10. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics.

    Science.gov (United States)

    Sawant, Krutika; Pandey, Abhijeet; Patel, Sneha

    2016-09-01

    In the present investigation, a Quality by Design strategy was applied for formulation and optimization of aripiprazole (APZ) loaded PCL nanoparticles (APNPs) using nanoprecipitation method keeping entrapment efficiency (%EE) and particle size (PS) as critical quality attributes. Establishment of design space was done followed by analysis of its robustness and sensitivity. Characterization of optimized APNPs was done using DSC, FT-IR, PXRD and TEM studies and was evaluated for drug release, hemocompatibility and nasal toxicity. PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively. In vitro release study showed 90±2.69% drug release after 8h. Nasal toxicity study indicated safety of developed formulation for intranasal administration. APNPs administered via intranasal route facilitated the brain distribution of APZ incorporated with the AUC0→8 in rat brain approximately 2 times higher than that of APNPs administered via intravenous route. Increase in Cmax was observed which might help in dose reduction along with reduction in dose related side effects. The results of the study indicate that intranasally administered APZ loaded PCL NPs can potentially transport APZ via nose to brain and can serve as a non-invasive alternative for the delivery of APZ to brain.

  11. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics

    Energy Technology Data Exchange (ETDEWEB)

    Sawant, Krutika; Pandey, Abhijeet; Patel, Sneha

    2016-09-01

    In the present investigation, a Quality by Design strategy was applied for formulation and optimization of aripiprazole (APZ) loaded PCL nanoparticles (APNPs) using nanoprecipitation method keeping entrapment efficiency (%EE) and particle size (PS) as critical quality attributes. Establishment of design space was done followed by analysis of its robustness and sensitivity. Characterization of optimized APNPs was done using DSC, FT-IR, PXRD and TEM studies and was evaluated for drug release, hemocompatibility and nasal toxicity. PS, zeta potential and %EE of optimized APNPs were found to be 199.2 ± 5.65 nm, − 21.4 ± 4.6 mV and 69.2 ± 2.34% respectively. In vitro release study showed 90 ± 2.69% drug release after 8 h. Nasal toxicity study indicated safety of developed formulation for intranasal administration. APNPs administered via intranasal route facilitated the brain distribution of APZ incorporated with the AUC{sub 0→8} in rat brain approximately 2 times higher than that of APNPs administered via intravenous route. Increase in C{sub max} was observed which might help in dose reduction along with reduction in dose related side effects. The results of the study indicate that intranasally administered APZ loaded PCL NPs can potentially transport APZ via nose to brain and can serve as a non-invasive alternative for the delivery of APZ to brain. - Highlights: • It explores intra-nasal route for treatment of schizophrenia. • Quality by Design strategy has been used for optimization and assessesment of design space robustness. • PCL nanoparticles enhance penetration of drug into brain leading to increased C{sub max} and decrease in T{sub max}. • It can act as potential platform for treatment of schizophrenia with decreased dose related toxicities.

  12. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.

    Science.gov (United States)

    Ryckmans, V; Kahn, J P; Modell, S; Werner, C; McQuade, R D; Kerselaers, W; Lissens, J; Sanchez, R

    2009-05-01

    This study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues. Patients were randomized to an aripiprazole titrated-dose (starting dose 5 mg/day) or fixed-dose (dose 15 mg/day) switching strategy with risperidone down-tapering. Primary endpoint was rate of discontinuation due to adverse events (AEs) during the 12-week study. Secondary endpoints included positive and negative syndrome scale (PANSS), clinical global impressions - improvement of illness scale (CGI-I), preference of medication (POM), subjective well-being under neuroleptics (SWN-K) and GEOPTE (Grupo Español para la Optimización del Tratamiento de la Esquizofrenia) scales. Rates of discontinuations due to AEs were similar between titrated-dose and fixed-dose strategies (3.5% vs. 5.0%; p=0.448). Improvements in mean PANSS total scores were similar between aripiprazole titrated-dose and fixed-dose strategies (-14.8 vs. -17.2; LOCF), as were mean CGI-I scores (2.9 vs. 2.8; p=0.425; LOCF) and SWN-K scores (+8.6 vs.+10.3; OC,+7.8 vs.+9.8; LOCF). Switching can be effectively and safely achieved through a titrated-dose or fixed-dose switching strategy for aripiprazole, with down-titration of risperidone.

  13. Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.

    Science.gov (United States)

    Yalcin, Demet Ozen; Goka, Erol; Aydemir, M Cigdem; Kisa, Cebrail

    2008-05-01

    Leucopenia and neutropenia could be side effects of anti-psychotic drugs, especially clozapine. However, there is evidence that other anti-psychotics can cause leucopenia and neutropenia. We present the clinical follow-up and treatment process of a patient, who had initially developed quetiapine and amisulpride related neutropenia, but not with aripiprazole.

  14. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

    Science.gov (United States)

    Chen, Jing-Xu; Su, Yun-Ai; Bian, Qing-Tao; Wei, Li-He; Zhang, Rong-Zhen; Liu, Yan-Hong; Correll, Christoph; Soares, Jair C; Yang, Fu-De; Wang, Shao-Li; Zhang, Xiang-Yang

    2015-08-01

    Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. Serum prolactin levels were measured at baseline and after 2, 4 and 8 weeks; clinical symptoms and side effects were assessed at baseline and week 8 using the Positive and Negative Syndrome Scale, Clinical Global Impressions Severity scale, Barnes Akathisia Scale, Simpson-Angus Scale and UKU Side Effects Rating Scale. Of 119 randomized patients, 107 (89.9%) completed the 8-week study. At study end, all three aripiprazole doses resulted in significantly lower prolactin levels (beginning at week 2), higher response rates (≥30% prolactin reduction) and higher prolactin normalization rates than placebo. Effects were significantly greater in the 10 and 20mg/day groups than the 5mg/day group. No significant changes were observed in any treatment groups regarding psychopathology and adverse effect ratings. Adjunctive aripiprazole treatment was effective and safe for resolving risperidone-induced hyperprolactinemia, producing significant and almost maximal improvements by week 2 without significant effects on psychopathology and side effects.

  15. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR study (NCT00237913

    Directory of Open Access Journals (Sweden)

    Pans Miranda

    2008-12-01

    Full Text Available Abstract Background The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC, which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]. Method This open-label, 26-week, multi-centre, randomised study compared aripiprazole to SOC (olanzapine, quetiapine or risperidone in patients with schizophrenia (DSM-IV-TR criteria. The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ at Week 26. The outcome research variables included the Arizona Sexual Experience scale (ASEX. This along with the data collected on serum prolactin levels at week 4, 8, 12, 18 and 26 will be the focus of this paper. Results A total of 555 patients were randomised to receive aripiprazole (n = 284 or SOC (n = 271. Both treatment groups experienced improvements in sexual function from baseline ASEX assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater improvement compared with the SOC group (p = 0.007; OC. Although baseline mean serum prolactin levels were similar in the two treatment groups (43.4 mg/dL in the aripiprazole group and 42.3 mg/dL in the SOC group, p = NS at Week 26 OC, mean decreases in serum prolactin were 34.2 mg/dL in the aripiprazole group, compared with 13.3 mg/dL in the SOC group (p Conclusion The study findings suggest that aripiprazole has the potential to reduce sexual dysfunction, which in turn might improve patient compliance.

  16. Beneficial in vivo effect of aripiprazole on neuronal regeneration following neuronal loss in the dentate gyrus: evaluation using a mouse model of trimethyltin-induced neuronal loss/self-repair in the dentate gyrus.

    Science.gov (United States)

    Yoneyama, Masanori; Hasebe, Shigeru; Kawamoto, Noriko; Shiba, Tatsuo; Yamaguchi, Taro; Kikuta, Maho; Shuto, Makoto; Ogita, Kiyokazu

    2014-01-01

    Aripiprazole is used clinically as an atypical antipsychotic. We evaluated the effect of in vivo treatment with aripiprazole on the proliferation and differentiation of neural stem/progenitor cells in a mouse model, trimethyltin-induced neuronal loss/self-repair in the hippocampal dentate gyrus (referred as "impaired animals") [Ogita et al., J Neurosci Res. 82, 609 - 621 (2005)]. In the impaired animals, an increased number of 5-bromo-2'-deoxyuridine (BrdU)-positive cells was seen in the dentate gyrus at the initial time window of the self-repair stage. At the same time window, a single treatment with aripiprazole significantly increased the number of cells positive for both BrdU and nestin in the dentate gyrus of the impaired animals. Chronic treatment with aripiprazole promoted the proliferation/survival and neuronal differentiation of the cells newly-generated following the neuronal loss in the dentate gyrus of the impaired animals. The chronic treatment with aripiprazole improved depression-like behavior seen in the impaired animals. Taken together, our data suggest that aripiprazole had a beneficial effect on neuronal regeneration following neuronal loss in the dentate gyrus through indirectly promoted proliferation/survival and neuronal differentiation of neural stem/progenitor cells in the subgranular zone of the dentate gyrus.

  17. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

    Directory of Open Access Journals (Sweden)

    Oya K

    2015-09-01

    Full Text Available Kazuto Oya, Taro Kishi, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan Objective: We conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (AOM for schizophrenia.Methods: Randomized controlled trials (RCTs on AOM, published until June 25, 2015, were retrieved from PubMed, Cochrane, and PsycINFO databases. Relative risk (RR, standardized mean difference (SMD, 95% confidence intervals (95% CIs, and numbers needed to treat/harm (NNT/NNH were calculated.Results: We identified four relevant RCTs (total n=1,860, two placebo-controlled trials, one noninferiority trial comparing AOM to oral aripiprazole (OA, and one including therapeutic doses of AOM and OA, as well as an AOM dose below therapeutic threshold (control arm. AOM was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS total scores (SMD =-0.65, 95% CI =-0.90 to -0.41, n=1,126. However, PANSS total scores did not differ significantly between pooled AOM and OA groups. The pooled AOM group showed significantly lower incidence of all-cause discontinuation (RR =0.54, 95% CI =0.41–0.71, n=1,139, NNH =4 and inefficacy (RR =0.28, 95% CI =0.21–0.38, n=1,139, NNH =5 than placebo, but was not superior to placebo regarding discontinuation due to adverse events (AEs or death. The AOM group exhibited a lower incidence of all-cause discontinuation than OA (RR =0.78, 95% CI =0.64–0.95, n=986, NNH =14, but there were no intergroup differences in discontinuation due to inefficacy, AEs, or death. There were no significant differences in extrapyramidal symptoms scale scores between AOM and placebo or between AOM and OA. AOM resulted in higher weight gain than placebo (SMD =0.41, 95% CI =0.18–0.64, n=734 but lower than OA (SMD =-0.16, 95% CI =-0.29 to -0.02, n=847.Conclusion: AOM has antipsychotic efficacy and low risk of discontinuation due to AEs. Keywords: schizophrenia

  18. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting

    Directory of Open Access Journals (Sweden)

    Chiu Nan-Ying

    2010-09-01

    Full Text Available Abstract Objective To evaluate the overall long-term effectiveness of aripiprazole in patients with schizophrenia in a general psychiatric practice setting in Taiwan. Methods This was a prospective, open-label, multicenter, post-market surveillance study in Taiwanese patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV diagnosis of schizophrenia or schizoaffective disorder requiring a switch in antipsychotic medication because current medication was not well tolerated and/or clinical symptoms were not well controlled. Eligible patients were titrated to aripiprazole (5-30 mg/day over a 12-week switching phase, during which their previous medication was discontinued. Patients could then enter a 52-week, long-term treatment phase. Aripiprazole was flexibly dosed (5-30 mg/day at the discretion of the treating physicians. Efficacy was assessed using the Clinical Global Impression scale Improvement (CGI-I score, the Clinical Global Impression scale Severity (CGI-S score, The Brief Psychiatry Rating Scale (BPRS, and the Quality of Life (QOL scale, as well as Preference of Medicine (POM ratings by patients and caregivers. Safety and tolerability were also assessed. Results A total of 245 patients were enrolled and switched from their prior antipsychotic medications, and 153 patients entered the 52-week extension phase. In all, 79 patients (32.2% completed the study. At week 64, the mean CGI-I score was 3.10 and 64.6% of patients who showed response. Compared to baseline, scores of CGI-S, QOL, and BPRS after 64 weeks of treatment also showed significant improvements. At week 12, 65.4% of subjects and 58.9% of caregivers rated aripiprazole as better than the prestudy medication on the POM. The most frequently reported adverse events (AEs were headache, auditory hallucinations and insomnia. A total of 13 patients (5.3% discontinued treatment due to AEs. No statistically significant changes were noted with respect to

  19. 阿立哌唑与利培酮治疗精神分裂症疗效比较%Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵辉

    2014-01-01

    目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效。方法将我院2012年10月-2013年6月收治的40例精神分裂症患者按随机数字表法随机分为阿立哌唑组和利培酮组各20例,分别使用阿立哌唑和利培酮对两组患者进行治疗,将两组治疗效果按照CCMD-3精神分裂症的诊断标准进行评价,依据副反应量表( TESS )评定副反应,以阳性与阴性症状量表( PANSS)减分率对疗效进行评定。结果阿立哌唑组痊愈9例,7例显著好转,3例好转,1例无效;利培酮组痊愈10例,5例显著好转,3例好转,2例无效。两组间的疗效比较无显著性差异。阿立哌唑组5例出现不良反应,占25%;利培酮组出现不良反应的有12例,占60%,阿立哌唑组不良反应总发生率显著低于利培酮组(χ2=5.013, P<0.05)。结论阿立哌唑与利培酮治疗精神分裂症的疗效显著,在治疗过程中,两种药物各有千秋,但在不良反应发生率方面,阿立哌唑低于利培酮,阿立哌唑的安全性高于利培酮。%Objective To analyze and compare aripiprazole and risperidone in the treatment of schizophrenia treatment .Methods 40 cases of patients with schizophrenia in hospital from October 2012 to June 2013 were randomly divided into aripiprazole group and the risperidone group,respectively,the two groups of patients were evaluated according to CCMD -3 diagnostic criteria,TESS and PANSS. Results In aripiprazole group ,9 cases recure ,7 cases were significantly improved ,3 cases improved ,and one case was invalid .In risper-idone group,10 cases cured,5 cases were significantly improved,3 cases improved,2 cases were ineffective.There was no significant difference in the efficacy between the two groups (P>0.05).Aripiprazole group had 5 cases of adverse reactions (25%),risperidone group had 12 cases of adverse reactions (60%),incidence of adverse reactions in aripiprazole group was

  20. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-01-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients treated with antipsychotics. The first column in this series began with the case of a 76-year-old man with major depressive disorder who developed orofacial dyskinesias while being treated with aripiprazole as an antidepressant augmentation strategy. It was alleged that a higher than intended dose of aripiprazole (ie, 20 mg/d for 2 wk followed by 10 mg/d for 4 wk instead of the intended dose of 2 mg/d) was the cause of the dyskinetic movements in this man, and the authors were asked to review the case and give their opinion. The principal basis for this theory of causation was the class warning about TD in the package insert for aripiprazole. The rationale for concluding aripiprazole caused TD in the 76-year-old man led to this series of columns about aripiprazole, its potential--if any--to cause TD, and the presence of a class warning about TD in its package insert. The central point is to illustrate why class warnings exist and their implications for practice. The first column in this series focused on the historical background, incidence, prevalence, risk factors, and clinical presentations of tardive and spontaneous dyskinesias and concluded with a discussion of diagnostic considerations explaining why clinicians should avoid making a diagnosis of TD until a thorough differential diagnosis has been considered. This second column in the series reviews the pharmacology of aripiprazole and the preclinical and phase I translational human studies that suggest aripiprazole should have a low to nonexistent risk of causing TD compared with other antipsychotics. The third column in the series

  1. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials.

    Science.gov (United States)

    Srisurapanont, Manit; Suttajit, Sirijit; Maneeton, Narong; Maneeton, Benchalak

    2015-03-01

    Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed, Scopus, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. This review synthesized the data of four short-term (8-24 weeks), placebo-controlled trials (N = 347). The overall relative risk (RR, 95% confidence interval) of discontinuation rates was not significantly different between groups (RR = 1.41, 95% CI = 0.78 to 2.56). The pooled standardized mean differences (SMDs, 95% CIs) (Z-test; number of study; I(2)-index) suggested trends of aripiprazole augmentation benefits on overall psychotic [-0.40 (-0.87 to 0.07) (n = 3; Z = 1.68, p = 0.09; I(2) = 68%)], positive [-1.05 (-2.39 to 0.29) (n = 3; Z = 1.54, p = 0.12; I(2) = 94%)], and negative [-0.36 (-0.77 to 0.05) (n = 3; Z = 1.74, p = 0.08; I(2) = 54%)] symptoms. Despite of no benefit on three cardiometabolic indices (i.e., fasting plasma glucose, triglyceride, and high-density lipoprotein), aripiprazole augmentation was superior for weight change with a mean difference (95% CI) of -1.36 kg (-2.35 to -0.36) (n = 3; Z = 2.67, p = 0.008; I(2) = 39%) and LDL-cholesterol with a mean difference of -11.06 mg/dL (-18.25 to -3.87) (n = 3; Z = 3.02, p = 0.003; I(2) = 31%). Aripiprazole augmentation was not correlated with headache and insomnia but significantly associated with agitation/akathesia (RR = 7.59, 95% CI = 1.43 to 40.18) (n = 3; Z = 2.38, p = 0.02; I(2) = 0%) and anxiety (RR = 2.70, 95% CI = 1.02 to 7.15) (n = 1; Z = 2.00, p = 0.05). The limited short-term data suggested that aripiprazole augmentation of clozapine can minimize the cardiometabolic risk, causes agitation/akathesia, and may be effective in

  2. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

    Science.gov (United States)

    Cosi, Cristina; Carilla-Durand, Elisabeth; Assié, Marie Bernadette; Ormiere, Anne Marie; Maraval, Mireille; Leduc, Nathalie; Newman-Tancredi, Adrian

    2006-03-27

    Dopamine D2 receptor antagonists induce hyperprolactinemia depending on the extent of D2 receptor blockade. We compared the effects of the new antipsychotic agents SSR181507 ((3-exo)-8-benzoyl-N-[[(2 s)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine monohydrochloride), bifeprunox (DU127090: 1-(2-Oxo-benzoxazolin-7-yl)-4-(3-biphenyl)methylpiperazinemesylate) and SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine) with those of aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butyloxy)-3,4-dihydro-2(1 H)-quinolinone), clozapine and haloperidol, on functional measures of dopamine D2 receptor activity in vitro and in vivo: [35S]-GTPgammaS binding to membranes from Sf9 insect cells expressing human dopamine D2 Long (hD2 L) receptors, and serum prolactin levels in the rat. All compounds antagonized apomorphine-induced G protein activation at dopamine hD2 L receptors. Antagonist potencies of aripiprazole, bifeprunox and SLV313 were similar to haloperidol (pK(b) = 9.12), whereas SSR181507 (8.16) and clozapine (7.35) were less potent. Haloperidol, SLV313 and clozapine were silent antagonists but SSR181507, bifeprunox and aripiprazole stimulated [35S]-GTPgammaS binding by 17.5%, 26.3% and 25.6%, respectively, relative to 100 microM apomorphine (Emax = 100%). pEC50s were: SSR181507, 8.08; bifeprunox, 8.97; aripiprazole, 8.56. These effects were antagonized by raclopride. Following oral administration in vivo, the drugs increased prolactin release to different extents. SLV313 and haloperidol potently (ED50 0.12 and 0.22 mg/kg p.o., respectively) stimulated prolactin release up to 86 and 83 ng/ml. Aripiprazole potently (ED50 0.66 mg/kg p.o.) but partially (32 ng/ml) induced prolactin release. SSR181507 (ED50 4.9 mg/kg p.o.) also partially (23 ng/ml) enhanced prolactin release. Bifeprunox only weakly increased prolactin at high doses (13 ng/ml at 40 mg/kg) and clozapine only

  3. Aripiprazol: od wyjątkowego mechanizmu działania do szerokich zastosowań

    Directory of Open Access Journals (Sweden)

    Tomasz Sobów

    2016-09-01

    Full Text Available Efektywne, nastawione na możliwie kompletną poprawę objawową i funkcjonalną leczenie schizofrenii i choroby afektywnej dwubiegunowej pozostaje w dzisiejszym stanie wiedzy zadaniem trudnym. Uważa się, że kluczowe jest kompleksowe podejście do problemów pacjenta, a zastosowanie odpowiedniego leku przeciwpsychotycznego ma ten proces skutecznie wspomagać. Powszechnie obecnie stosowane nowoczesne leki przeciwpsychotyczne są podobnie skuteczne w zwalczaniu pozytywnych objawów psychozy schizofrenicznej oraz manii, natomiast znacznie różnią się w zakresie wpływu na pozostałe objawy, jak również pod względem tolerancji, akceptacji leczenia i szeroko rozumianej współpracy lekarz – pacjent. Aripiprazol wyróżnia się unikalnym mechanizmem działania – inaczej niż pozostałe leki przeciwpsychotyczne, jest częściowym antagonistą D2/D3 (oraz niektórych receptorów serotoninowych. Taki profil farmakologiczny pozwala na uzyskanie nie tylko znacznej, porównywalnej do innych leków przeciwpsychotycznych II generacji, skuteczności w leczeniu ostrej psychozy, ale także korzystnego wpływu na objawy afektywne, poznawcze i negatywne schizofrenii. Dodatkowymi korzyściami wynikającymi z profilu farmakologicznego leku są niskie ryzyko wywoływania parkinsonizmu, korzystny profil w zakresie wpływu na stan metaboliczny (praktycznie brak wpływu na masę ciała oraz niewywoływanie hiperprolaktynemii. Te korzystne cechy farmakologiczne powodują, że aripiprazol może być stosowany nie tylko w preferowanej monoterapii, ale także jako leczenie dodane, w tym w celu poprawy tolerancji innych leków. Nowsze badania wskazują na możliwości poszerzenia panelu wskazań, między innymi o depresję oporną na standardową farmakoterapię oraz zaburzenia zachowania u chorych z otępieniem.

  4. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole

    Directory of Open Access Journals (Sweden)

    Peters-Strickland T

    2016-10-01

    Full Text Available Timothy Peters-Strickland,1 Linda Pestreich,1 Ainslie Hatch,2 Shashank Rohatagi,1 Ross A Baker,1 John P Docherty,2 Lada Markovtsova,1 Praveen Raja,3 Peter J Weiden,4 David P Walling5 1Otsuka Pharmaceutical Development & Commercialization, Inc., 2ODH, Inc., Princeton, NJ, 3Proteus Digital Health, Inc., Redwood City, CA, 4Department of Psychiatry, University of Illinois, Chicago, IL, 5CNS Network, LLC, Long Beach, CA, USA Objective: Digital medicine system (DMS is a novel drug–device combination that objectively measures and reports medication ingestion. The DMS consists of medication embedded with an ingestible sensor (digital medicine, a wearable sensor, and software applications. This study evaluated usability of the DMS in adults with schizophrenia rated by both patients and their health care providers (HCPs during 8-week treatment with prescribed doses of digital aripiprazole.Methods: Six US sites enrolled outpatients into this Phase IIa, open-label study (NCT02219009. The study comprised a screening phase, a training phase (three weekly site visits, and a 5-week independent phase. Patients and HCPs independently rated usability of and satisfaction with the DMS.Results: Sixty-seven patients were enrolled, and 49 (73.1% patients completed the study. The mean age (SD of the patients was 46.6 years (9.7 years; the majority of them were male (74.6%, black (76.1%, and rated mildly ill on the Clinical Global Impression – Severity scale (70.1%. By the end of week 8 or early termination, 82.1% (55/67 of patients had replaced the wearable sensor independently or with minimal assistance, based on HCP rating. The patients used the wearable sensor for a mean (SD of 70.7% (24.7% and a median of 77.8% of their time in the trial. The patients contacted a call center most frequently at week 1. At the last visit, 78% (47/60 of patients were somewhat satisfied/satisfied/extremely satisfied with the DMS.Conclusion: A high proportion of patients with

  5. Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke

    Science.gov (United States)

    Kim, Yu Ri; Kim, Ha Neui; Hong, Ki Whan; Shin, Hwa Kyoung; Choi, Byung Tae

    2017-01-01

    The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS). Compared to treatment with either APZ or CLS alone, the combined treatment resulted in a greater reduction in depressive behaviors, including anhedonia, despair-like behaviors, and memory impairments. This treatment also significantly reduced atrophic changes in the striatum, cortex, and midbrain of CMS-treated ischemic mice, and inhibited neuronal cell apoptosis, particularly in the striatum and the dentate gyrus of the hippocampus. Greater proliferation of neuronal progenitor cells was also observed in the ipsilateral striatum of the mice receiving combined treatment compared to mice receiving either drug alone. Phosphorylation of the cyclic adenosine monophosphate response element binding protein (CREB) was increased in the striatum, hippocampus, and midbrain of mice receiving combined treatment compared to treatment with either drug alone, particularly in the neurons of the striatum and hippocampus, and dopaminergic neurons of the midbrain. Our results suggest that APZ may augment the antidepressant effects of CLS via co-regulation of the CREB signaling pathway, resulting in the synergistic enhancement of their neuroprotective effects. PMID:28208711

  6. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series.

    Science.gov (United States)

    Naono-Nagatomo, Keiko; Naono, Hisao; Abe, Hiroshi; Takeda, Ryuichiro; Funahashi, Hideki; Uchimura, Daisuke; Ishida, Yasushi

    2017-02-01

    Aripiprazole (ARP) is a popular antipsychotic drug that has demonstrated ameliorative effects on hyperprolactinemia. However, no study to date has studied the utility of ARP in patients with a long history of schizophrenia and antipsychotic treatment. We therefore examined the effect of partial antipsychotic regimen replacement with ARP on hyperprolactinemia induced by chronic antipsychotic use in patients with schizophrenia. Sixteen patients with a schizophrenia diagnosis (F2) based on the International Classification of Diseases (version 10) were recruited. At months 0, 1, 3, and 6 of the study, serum prolactin, body weight, and blood glucose were measured, and QOL and psychotic symptoms were assessed using Global Assessment of Functioning scores and Clinical Global Impressions of Improvement (CGI-I) scores. Nine patients with an average age of 46.7±9.6 years and mean disease duration of 15.9±10.4 years were included in the final analysis. Serum prolactin levels significantly decreased and GAF and CGI-I scores improved significantly over the 6-month period after partial replacement with ARP. Additionally, no changes were observed in body weight or blood glucose over the 6-month period. Partial antipsychotic regimen replacement with ARP improves hyperprolactinemia, and may improve the QOL of patients with a long history of schizophrenia. Japan Medical Association, Center for clinical trials D: JMA-IIA00245. Copyright © 2016 Elsevier B.V. All rights reserved.

  7. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  8. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

    Directory of Open Access Journals (Sweden)

    Berger Ariel

    2012-08-01

    Full Text Available Abstract Background Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone. While patients who are hospitalized for schizophrenia and bipolar disorder often receive these agents at discharge, comparatively little information exists on subsequent patterns of pharmacotherapy. Methods Using a database linking hospital admission records to health insurance claims, we identified all patients hospitalized for schizophrenia (ICD-9-CM diagnosis code 295.XX or bipolar disorder (296.0, 296.1, 296.4-296.89 between January 1, 2001 and September 30, 2008 who received aripiprazole, quetiapine, or ziprasidone at discharge. Patients not continuously enrolled for 6 months before and after hospitalization (“pre-admission” and “follow-up”, respectively were excluded. We examined patterns of use of these agents during follow-up, including adherence with treatment (using medication possession ratios [MPRs] and cumulative medication gaps [CMGs] and therapy switching. Analyses were undertaken separately for patients with schizophrenia and bipolar disorder, respectively. Results We identified a total of 43 patients with schizophrenia, and 84 patients with bipolar disorder. During the 6-month period following hospitalization, patients with schizophrenia received an average of 101 therapy-days with the second-generation antipsychotic agent prescribed at discharge; for patients with bipolar disorder, the corresponding value was 68 therapy-days. Mean MPR at 6 months was 55.1% for schizophrenia patients, and 37.3% for those with bipolar disorder; approximately one-quarter of patients switched to another agent over this period. Conclusions Medication compliance is poor in patients with schizophrenia or bipolar disorder who initiate treatment with aripiprazole, quetiapine, or ziprasidone at hospital discharge.

  9. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD. Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group. Assessment was performed by Conners′ rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00, with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894, and mean change in fasting blood sugar (P = 0.671 were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00. Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children.

  10. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.

    Science.gov (United States)

    Preskorn, Sheldon; Flynn, Alexandra; Macaluso, Matthew

    2015-09-01

    This series of columns has 2 main goals: (1) to explain the use of class warnings by the US Food and Drug Administration and (2) to increase clinicians' awareness of movement disorders that may occur in patients being treated with antipsychotic medications and why it is appropriate and good practice to refrain from immediately assuming the diagnosis is tardive dyskinesia/dystonia (TD). This first column in the series will focus on the second goal, which will then serve as a case example for the first goal. Clinicians should refrain from jumping to a diagnosis of TD because a host of other causes need to be ruled out first before inferring iatrogenic causation. The causal relationship between chronic treatment with dopamine antagonists and TD is based on pharmacoepidemiology (ie, the prevalence of such movement disorders is higher in individuals receiving chronic treatment with such agents than in a control group). There is nothing pathognomonic about movement disorders, nor is there any test that can currently prove a drug caused a movement disorder in a specific individual. Another goal of this series is to describe the types of research that would be needed to establish whether a specific agent has a meaningful risk of causing TD. In this first column of the series, we present the case of a patient who developed orofacial dyskinesia while being treated with aripiprazole. In this case, the movement disorder was prematurely called TD, which led to a malpractice lawsuit. This case highlights a number of key questions clinicians are likely to encounter in day-to-day practice. We then review data concerning the historical background, incidence, prevalence, and risk factors for 2 movement disorders, TD and spontaneous dyskinesia. Subsequent columns in this series will review: (1) unique aspects of the psychopharmacology of aripiprazole, (2) the limited and inconsistent data in the literature concerning the causal relationship between aripiprazole and TD, (3) the use of

  11. 利培酮与阿立哌唑治疗精神分裂症的效果比较%Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李正发

    2010-01-01

    Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group ( n = 40) and aripiprazole group( n= 40). According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale ( PANSS ), clinical global impression ( CGI ), treatment emergent symptom scale (TESS) and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline ( P 0. 05 ). Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group (P 0.05).治疗后,利培酮组有效率90%,阿立哌唑组有效率80%,两组差异无统计学意义(P>0.05).阿立哌唑组消化道反应发生率明显高于利培酮组(P<0.05).结论 利培酮治疗精神分裂症的疗效较阿立哌唑略好,安全性高.

  12. Clinical effect observation of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症临床效果观察

    Institute of Scientific and Technical Information of China (English)

    王俊; 孙毅; 卓越; 吕治宇; 严卫国

    2016-01-01

    Objective:To observe the effect of aripiprazole and risperidone in the treatment of schizophrenia.Methods:64 patients with schizophrenia were selected.32 cases treated with aripiprazole were as aripiprazole group.32 cases treated with risperidone were as risperidone group.The treatment effect and adverse reaction between groups were observed.Results:The headache,dry mouth,insomnia incidence in the aripiprazole group were higher than those in risperidone group(P<0.05).In risperidone group, increase the body weight,akathisia,menstrual changes or lactation and tremor of incidence were higher than those in aripiprazole group(P<0.05).Conclusion:The effect of aripiprazole and risperidone in the treatment of schizophrenia are relatively good, but the adverse reaction of aripiprazole is fewer and milder.%目的:观察阿立哌唑与利培酮治疗精神分裂症的效果。方法:收治精神分裂症患者64例,采用阿立哌唑进行治疗的32例患者为阿立哌唑组,应用利培酮进行治疗的32例患者为利培酮组。观察两组的治疗效果和不良反应。结果:阿立哌唑组头痛、口干、失眠的发生率均高于利培酮组(P<0.05),利培酮组体重增加、静坐不能、月经改变或泌乳和震颤的发生率均高于阿立哌唑组(P<0.05)。结论:阿立哌唑与利培酮治疗精神分裂症的效果均比较好,但阿立哌唑产生的不良反应少且轻。

  13. 阿立哌唑与利培酮治疗精神分裂症对比分析%Comparative analysis of aripiprazole and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李红远; 李义会

    2015-01-01

    Objective:To explore the clinical effect and safety of aripiprazole in the treatment of schizophrenia.Methods:120 patients with schizophrenia were randomly divided into two groups.They were treated with aripiprazole and risperidone respectively.The curative effects and adverse reactions of patients in two groups were compared.Results:The treatment total effective rate of the aripiprazole group and the risperidone group were respectively 83.3% and 81.7% .The incidence rate of adverse reaction(33.3%) in the aripiprazole group was significantly lower than 51.7% of the risperidone group(χ 2=4.126,P<0.01).Conclusion:The curative effects of aripiprazole and risperidone in the treatment of schizophrenia are considerable.The adverse reaction of aripiprazole is low than that of risperidone.The safety of aripiprazole is good.%目的:探讨阿立哌唑治疗精神分裂症的临床效果及安全性。方法:将120例精神分裂症患者随机分为两组,分别给予阿立哌唑和利培酮治疗。对两组患者的疗效及不良反应进行比较。结果:阿立哌唑组和利培酮组的总有效率分别为83.3%和81.7%。阿立哌唑组不良反应发生率33.3%明显低于利培酮组的51.7%(χ2=4.126,P<0.01)。结论:阿立哌唑与利培酮治疗精神分裂症的疗效相当,不良反应比利培酮低,安全性好。

  14. 阿立哌唑治疗抗精神病药所致高催乳素血症的疗效观察%A control study of aripiprazole in the treatment for antipsychotics-induced hyperprolactinemia

    Institute of Scientific and Technical Information of China (English)

    刘诏薄; 曹波; 焦峰; 李多聪; 陈海波; 刘伟

    2011-01-01

    OBJECTIVE To explore the effectiveness and safety of aripiprazole in long term treatment for schizophrenia patients with antipsychotics-induced hyperprolactinemia. METHODS 180 schizophrenia patients with antipsychotics-induced hyperprolactinemia were randomly assigned to aripiprazole group(n = 90) and control group(n = 90),which were observed more than 26 weeks. Aripiprazole group patients were additionally treated with aripiprazole(5 mg·d-1). Clinical global impression scale(CGIS) and the extrapyramidal symptoms rating scale(ESES) were administered, also prolactin(PRL), treatment discontinuation ratio and time to discontinuation(TTD) were recorded at the baseline time and the end of 2,4,12,26 weeks. RESULTS PRL of aripiprazole group showed significant decline at the end of 4 weeks,and arrived a stable state at the end of 8 weeks. PRL of control group there was no change. At the end of 26 weeks, the treatment discontinuation ratio of aripiprazole group was 11.1 %, of control group was 31. 1 %. At the end of 52 weeks, the treatment discontinuation ratio of aripiprazole group was 57. 8%,of control group was 76. 7%. There was significant difference of TTD between aripiprazole group and control group [ (297. 3 ± 92. 6) d vs ( 193. 5 ± 103. 1 )d, t = 6. 86, P = 0. 001]. CONCLUSION Combined a low dose aripiprazole to long term treatment for schizophrenia patient antipsychotics-induced hyperprolactinemia is effective and safe.%目的:验证合并使用小剂量阿立哌唑治疗抗精神病药(APS)所致高催乳素(PRL)血症的长期疗效及安全性.方法:对APS所致高PRL患者随机分为2组,一组继续使用APS治疗,一组在APS基础上合并使用5 mg·d-1阿立哌唑治疗.观察时间至少为26周.在基线及第4,8,12,26周末进行临床总体印象量表--严重程度(CGI-S)、锥体外系症状评定量表(ESRS)、血清PRL水平测定,记录停药率及停药前服药时间(TTD).结果:阿立哌唑组PRL在第4周末即明显下降,到第8

  15. Metabolic acidosis

    Science.gov (United States)

    Acidosis - metabolic ... Metabolic acidosis occurs when the body produces too much acid. It can also occur when the kidneys are not ... the body. There are several types of metabolic acidosis. Diabetic acidosis develops when acidic substances, known as ...

  16. Metabolic neuropathies

    Science.gov (United States)

    Neuropathy - metabolic ... can be caused by many different things. Metabolic neuropathy may be caused by: A problem with the ... one of the most common causes of metabolic neuropathies. People who are at the highest risk for ...

  17. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial

    DEFF Research Database (Denmark)

    Pagsberg, Anne Katrine; Jeppesen, Pia; Klauber, Dea Gowers

    2014-01-01

    aripiprazole in children and adolescents with psychosis in order to inform rational, effective and safe treatment selections. METHODS/DESIGN: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised, blinded clinical trial. Based on sample size estimation, 112 patients...... about head-to-head differences in efficacy and tolerability of antipsychotics are scarce in children and adolescents. The TEA trial aims at expanding the evidence base for the use of antipsychotics in early onset psychosis in order to inform more rational treatment decisions in this vulnerable......BACKGROUND: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA) trial is to compare the benefits and harms of quetiapine versus...

  18. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial

    DEFF Research Database (Denmark)

    Pagsberg, Anne Katrine; Jeppesen, Pia; Klauber, Dea Gowers

    2017-01-01

    of quetiapine-extended release (quetiapine-ER) versus aripiprazole in children and adolescents with first-episode psychosis, to determine whether differences between the two treatments were sufficient to guide clinicians in their choice of one drug over the other. Methods In this multicentre, double......-blind, randomised trial in seven Danish university clinics, we recruited children and adolescents aged 12–17 years with a diagnosis of ICD-10 schizophrenia-spectrum disorder, delusional disorder, or affective-spectrum psychotic disorder, and psychotic symptoms scoring at least 4 on at least one of the following......-generated concealed sequence with a block size of 8, and stratified by baseline PANSS positive score (≤20 points or >20 points) and age (12–14 years or 15–17 years). Study drugs were administered in identical capsules, and interventions, assessments, and data analysis were done masked. The primary outcome was PANSS...

  19. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Piantato Ennio

    2009-05-01

    Full Text Available Abstract Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole

  20. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Science.gov (United States)

    Nosè, Michela; Accordini, Simone; Artioli, Paola; Barale, Francesco; Barbui, Corrado; Beneduce, Rossella; Berardi, Domenico; Bertolazzi, Gerardo; Biancosino, Bruno; Bisogno, Alfredo; Bivi, Raffaella; Bogetto, Filippo; Boso, Marianna; Bozzani, Alberto; Bucolo, Piera; Casale, Marcello; Cascone, Liliana; Ciammella, Luisa; Cicolini, Alessia; Cipresso, Gabriele; Cipriani, Andrea; Colombo, Paola; Dal Santo, Barbara; De Francesco, Michele; Di Lorenzo, Giorgio; Di Munzio, Walter; Ducci, Giuseppe; Erlicher, Arcadio; Esposito, Eleonora; Ferrannini, Luigi; Ferrato, Farida; Ferro, Antonio; Fragomeno, Nicoletta; Parise, Vincenzo Fricchione; Frova, Maria; Gardellin, Francesco; Garzotto, Nicola; Giambartolomei, Andrea; Giupponi, Giancarlo; Grassi, Luigi; Grazian, Natalia; Grecu, Lorella; Guerrini, Gualtiero; Laddomada, Francesco; Lazzarin, Ermanna; Lintas, Camilla; Malchiodi, Francesca; Malvini, Lara; Marchiaro, Livio; Marsilio, Alessandra; Mauri, Massimo Carlo; Mautone, Antonio; Menchetti, Marco; Migliorini, Giuseppe; Mollica, Marco; Moretti, Daniele; Mulè, Serena; Nicholau, Stylianos; Nosè, Flavio; Occhionero, Guglielmo; Pacilli, Anna Maria; Pecchioli, Stefania; Percudani, Mauro; Piantato, Ennio; Piazza, Carlo; Pontarollo, Francesco; Pycha, Roger; Quartesan, Roberto; Rillosi, Luciana; Risso, Francesco; Rizzo, Raffella; Rocca, Paola; Roma, Stefania; Rossattini, Matteo; Rossi, Giuseppe; Rossi, Giovanni; Sala, Alessandra; Santilli, Claudio; Saraò, Giuseppe; Sarnicola, Antonio; Sartore, Francesca; Scarone, Silvio; Sciarma, Tiziana; Siracusano, Alberto; Strizzolo, Stefania; Tansella, Michele; Targa, Gino; Tasser, Annamarie; Tomasi, Rodolfo; Travaglini, Rossana; Veronese, Antonio; Ziero, Simona

    2009-01-01

    Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol

  1. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

    Science.gov (United States)

    Tempest, Michael; Sapin, Christophe; Beillat, Maud; Robinson, Paul; Treur, Maarten

    2015-12-01

    Schizophrenia is a severe and debilitating psychiatric disorder. Pharmacological interventions aim to ameliorate symptoms and reduce the risk of relapse and costly hospitalisation. Despite the established efficacy of antipsychotic medication, compliance to treatment is poor, particularly with oral formulation. The emergence of long acting injectable (LAI) antipsychotic formulations in recent years has aimed to counteract the poor compliance rates observed and optimise long term patient outcomes. To estimate the cost-effectiveness of aripiprazole once-monthly 400mg (AOM 400) vs. risperidone long acting injectable (RLAI), paliperidone long acting injectable (PLAI) and olanzapine long acting injectable (OLAI) in the maintenance treatment of chronic, stable schizophrenia patients in the United Kingdom. A Markov model was developed to emulate the treatment pathway of a hypothetical cohort of patients initiating maintenance treatment with LAI antipsychotics. The economic analysis was conducted from a National Health Service (NHS) and Personal Social Services (PSS) perspective over a 10 year time horizon. Efficacy and safety probabilities were derived from mixed treatment comparisons (MTCs) where possible. Analyses were conducted assuming pooled dosing from randomised clinical trials included in the MTCs. The model estimates that AOM 400 improves clinical outcomes by reducing relapses per patient comparative to other LAIs over the model time horizon (2.38, 2.53, 2.70, and 2.67 for AOM 400, RLAI, PLAI and OLAI respectively). In the deterministic analysis, AOM 400 dominated PLAI and OLAI; an incremental cost-effectiveness ratio (ICER) of GBP 3,686 per QALY gained was observed against RLAI. Results from the univariate sensitivity analyses highlighted the probability and cost of relapse as main drivers for cost-effectiveness. In the probabilistic sensitivity analysis, AOM 400 demonstrated a marginally higher probability of being cost-effective (51%) than RLAI, PLAI and OLAI

  2. 阿立哌唑的药理作用及治疗精神分裂症的疗效观察%Observation of the Curative Effect of Pharmacological Effects and Treatment of Mental Aripiprazole Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘丽红

    2015-01-01

    目的:分析阿立哌唑的药理作用,探究其治疗精神分裂症疗效。方法将67例患者分为治疗组34例和对照组33例,分别经阿立哌唑、利培酮治疗。结果两组治疗效果、PANSS评分对比(P>0.05),治疗组不良反应低于对照组(P<0.05)。结论阿立哌唑可有效治疗精神分裂症。%Objective Pharmacological analysis of aripiprazole, explore the treatment effect of schizophrenia. Methods 67 patients were divided into treatment group 34 cases and control group 33 cases, respectively, by aripiprazole risperidone in the treatment of. Results The effect of PANSS treatment, scores of two groups were compared (P>0.05), adverse reaction in the treatment group than in the control group (P<0.05). Conclusion Aripiprazole is more effective in the treatment of schizophrenia.

  3. Interaction of aripiprazole combined with clozapine in treatment of schizophrenia%阿立哌唑与氯氮平联合治疗精神分裂症的交互作用

    Institute of Scientific and Technical Information of China (English)

    陈波; 黄华利; 李玲

    2014-01-01

    Objective To discuss the interaction of aripiprazole combined with clozapine in treatment of schizo-phrenia ,in order to make suitable dose of this combination therapy explicit .Methods A total of 97 cases of schizo-phrenia diagnosed in our hospital between Oct .,2011 and May ,2013 were divided into 4 groups(low dose of aripi-prazole combined with low dose of clozapine ,low dose of aripiprazole combined with high dose of clozapine ,high dose of aripiprazole combined with low dose of clozapine ,high dose of aripiprazole combined with high dose of clozapine ) . The results of efficacy and side effects were all recorded and analyzed .Results In treatment efficacy ,high dose of aripiprazole and clozapine was the best ,when compared with other 3 groups(P<0 .05) ,low dose of aripiprazole and clozapine was the worst (P<0 .05) .On the other hand ,the incidence of side effects was highest in group of high dose of aripiprazole and clozapine ,group of high dose of aripiprazole combined with low dose of clozapine and group of low dose of aripiprazole and clozapine were better than others in safety .Conclusion The efficacy and side effects of aripi-prazole and clozapine are dose dependent ,when using these two medicines to treat schizophrenia ,the doses should be suitable to make good efficacy and avoid side effects .If the side effects are obvious ,the dose of clozapine should be de-creased ,however ,the dose of aripiprazole can be decreased extenuatorily ;If the patients can tolerate the treatment ,the doses of these two medicine can be increased .%目的:探讨阿立哌唑与氯氮平联合治疗精神分裂症的交互作用,以明确两种药物联合治疗精神分裂症时的合适剂量。方法将2011年10月至2013年5月于重庆市黔江中心医院诊治为精神分裂症的97例患者随机分为4组(低剂量阿立哌唑+低剂量氯氮平组、低剂量阿立哌唑+高剂量氯氮平组、高剂量阿立哌唑+低剂量氯氮平组、高剂量阿立

  4. 阿立哌唑与氯丙嗪治疗精神分裂症的安全性系统评价%Systematic review the safety of aripiprazole versus clorpromazine in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杜彪; 李庆平; 母波; 刘福; 周春阳

    2012-01-01

    目的 评价阿立哌唑与氯丙嗪治疗精神分裂症的不良反应的差异.方法 检索国内阿立哌唑与氯丙嗪对照研究治疗精神分裂症的文献,用系统评价方法对10篇文献评估.结果 药物不良反应发生率2组差异有统计学意义(P<0.05).其中,发生头痛、失眠,阿立哌唑组明显比氯丙嗪组多(P<0.05);发生口干、震颤、静坐不能、肌强直、便秘、肝功能异常、心动过速、体重增加、直立性低血压、视物模糊、嗜睡、心电图异常、月经失调、溢乳不良反应,氯丙嗪组明显比阿立哌唑组多(P<0.05).结论 阿立哌唑组发生不良反应的总体风险低于氯丙嗪.%Objective To study the difference in adverse drug reaction ( ADR) between aripiprazole and clorpromazine in the treatment of schizophrenia. Methods A total of 10 paper about control study comparing aripiprazole with clorpromazine in treatment of schizophrenia retrieved were subjected to system evaluation. Results There was significant difference in ADR incidences between the two groups ( P < 0. 05 ). The incidences of ADR ( such as headache insomnia) in aripiprazole group were significantly higher than in clorpromazine group (P < 0. 05 ). The incidences of ADR ( such as dry mouth, tremor, akathisia, rigidity, constipation, abnormal, liver function, tachycardia, weight gain, orthostatic hypotension, blurred vision, drowsiness, menstruation disturbance syndrome) in clorpromazine group were significantly higher than in aripiprazole group ( P < 0. 05 ). Conclusion Aripiprazole has less overall risk of ADR than clorpromazine for the treatment of schizophrenia.

  5. 氨磺必利与阿立哌唑治疗首发精神分裂症对照研究%A Comparative Study of Amisulpride and Aripiprazole in the Treatment of First Episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    仇红杰

    2014-01-01

    目的:探讨氨磺必利与阿立哌唑治疗首发精神分裂症的临床疗效与安全性。方法:将75例首发精神分裂症患者按照随机数字表法分成两组,氨磺必利组37例,阿立哌唑组38例,治疗8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:氨磺必利组的治疗总有效率为89.19%,阿立哌唑组为92.11%,两组比较差异无统计学意义(P>0.05)。治疗第4、6、8周PANSS总分及各因子评分两组比较差异均无统计学意义(P>0.05)。结论:氨磺必利与阿立哌唑治疗首发精神分裂症均有良好效果,不良反应均较少。%Objective:To investigate the efficacy and safety of Amisulpride and Aripiprazole in the treatment of first episode schizophrenia. Method:75 patients of first opisode schizoprenia were randomly divided into two groups(amisulpride 37,aripiprazole 38).Both of the amisulpride and aripiprazole were administered to two groups respectively for 8 weeks. Their symptoms were assessed with PANSS and their side effects were assessed with TESS before and after the treatment. Result:The total cure rates were 89.19%in amisulpride group and 92.11%in aripiprazole group,with no significant difference between the two groups(P>0.05). PANSS score and each factor score in treatment of 4,6,8 weeks between the two groups had no statistical significance(P>0.05). Conclusion:Both of the amisulpride and aripiprazole have notable curative effect with less side-effect in the treatment of first episode schizophrenia.

  6. Metabolic Panel

    Science.gov (United States)

    ... basic metabolic panel (BMP) and comprehensive metabolic panel (CMP). The BMP checks your blood sugar, calcium, and ... as creatinine to check your kidney function. The CMP includes all of those tests, as well as ...

  7. Metabolic Disorders

    Science.gov (United States)

    ... as your liver, muscles, and body fat. A metabolic disorder occurs when abnormal chemical reactions in your body ... that produce the energy. You can develop a metabolic disorder when some organs, such as your liver or ...

  8. Metabolic Syndrome

    Science.gov (United States)

    Metabolic syndrome is a group of conditions that put you at risk for heart disease and diabetes. These ... doctors agree on the definition or cause of metabolic syndrome. The cause might be insulin resistance. Insulin is ...

  9. [Metabolic syndrome].

    Science.gov (United States)

    Mitsuishi, Masanori; Miyashita, Kazutoshi; Itoh, Hiroshi

    2009-02-01

    Metabolic syndrome, which is consisted of hypertension, dyslipidemia and impaired glucose tolerance, is one of the most significant lifestyle-related disorders that lead to cardiovascular diseases. Among many upstream factors that are related to metabolic syndrome, obesity, especially visceral obesity, plays an essential role in its pathogenesis. In recent studies, possible mechanisms which connect obesity to metabolic syndrome have been elucidated, such as inflammation, abnormal secretion of adipokines and mitochondrial dysfunction. In this review, we focus on the relationship between obesity and metabolic syndrome; and illustrate how visceral obesity contributes to, and how the treatments for obesity act on metabolic syndrome.

  10. Nucleotide Metabolism

    DEFF Research Database (Denmark)

    Martinussen, Jan; Willemoës, M.; Kilstrup, Mogens

    2011-01-01

    Metabolic pathways are connected through their utilization of nucleotides as supplier of energy, allosteric effectors, and their role in activation of intermediates. Therefore, any attempt to exploit a given living organism in a biotechnological process will have an impact on nucleotide metabolism....... The aim of this article is to provide knowledge of nucleotide metabolism and its regulation to facilitate interpretation of data arising from genetics, proteomics, and transcriptomics in connection with biotechnological processes and beyond....

  11. Nucleotide Metabolism

    DEFF Research Database (Denmark)

    Martinussen, Jan; Willemoës, M.; Kilstrup, Mogens

    2011-01-01

    Metabolic pathways are connected through their utilization of nucleotides as supplier of energy, allosteric effectors, and their role in activation of intermediates. Therefore, any attempt to exploit a given living organism in a biotechnological process will have an impact on nucleotide metabolism....... The aim of this article is to provide knowledge of nucleotide metabolism and its regulation to facilitate interpretation of data arising from genetics, proteomics, and transcriptomics in connection with biotechnological processes and beyond....

  12. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

    Science.gov (United States)

    Mizuno, Yuya; Suzuki, Takefumi; Nakagawa, Atsuo; Yoshida, Kazunari; Mimura, Masaru; Fleischhacker, Walter Wolfgang; Uchida, Hiroyuki

    2014-11-01

    Antipsychotic-induced metabolic adversities are often difficult to manage. Using concomitant medications to counteract these adversities may be a rational option. To systematically determine the effectiveness of medications to counteract antipsychotic-induced metabolic adversities in patients with schizophrenia. Published articles until November 2013 were searched using 5 electronic databases. Clinical trial registries were searched for unpublished trials. Double-blind randomized placebo-controlled trials focusing on patients with schizophrenia were included if they evaluated the effects of concomitant medications on antipsychotic-induced metabolic adversities as a primary outcome. Variables relating to participants, interventions, comparisons, outcomes, and study design were extracted. The primary outcome was change in body weight. Secondary outcomes included clinically relevant weight change, fasting glucose, hemoglobin A1c, fasting insulin, insulin resistance, cholesterol, and triglycerides. Forty trials representing 19 unique interventions were included in this meta-analysis. Metformin was the most extensively studied drug in regard to body weight, the mean difference amounting to -3.17 kg (95% CI: -4.44 to -1.90 kg) compared to placebo. Pooled effects for topiramate, sibutramine, aripiprazole, and reboxetine were also different from placebo. Furthermore, metformin and rosiglitazone improved insulin resistance, while aripiprazole, metformin, and sibutramine decreased blood lipids. When nonpharmacological strategies alone are insufficient, and switching antipsychotics to relatively weight-neutral agents is not feasible, the literature supports the use of concomitant metformin as first choice among pharmacological interventions to counteract antipsychotic-induced weight gain and other metabolic adversities in schizophrenia. © The Author 2014. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For

  13. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome.

    Science.gov (United States)

    Zimbron, Jorge; Khandaker, Golam M; Toschi, Chiara; Jones, Peter B; Fernandez-Egea, Emilio

    2016-09-01

    Metabolic complications are commonly found in people treated with clozapine. Reviews on the management of this problem have generally drawn conclusions by grouping different types of studies involving patients treated with various different antipsychotics. We carried out a systematic review and meta-analysis of pharmacological and non-pharmacological treatments for clozapine-induced obesity or metabolic syndrome. Two researchers independently searched PubMed and Embase for randomised controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome. All other types of studies were excluded. We only included RCTs where more than 50% of participants were taking clozapine. We identified 15 RCTs. Effective pharmacological treatments for clozapine-induced obesity and metabolic syndrome include metformin, aripiprazole, and Orlistat (in men only). Meta-analysis of three studies showed a robust effect of metformin in reducing body mass index and waist circumference but no effects on blood glucose, triglyceride levels, or HDL levels. In addition, there is limited evidence for combined calorie restriction and exercise as a non-pharmacological alternative for the treatment of clozapine-induced obesity, but only in an in-patient setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, modafinil, and atomoxetine have not shown to be beneficial, despite reports of efficacy in other populations treated with different antipsychotics. We conclude that randomised-controlled trial data support the use of metformin, aripiprazole, and Orlistat (in men only) for treating clozapine-induced obesity. Calorie restriction in combination with an exercise programme may be effective as a non-pharmacological alternative. Findings from trials in different populations should not be extrapolated to people being treated with clozapine.

  14. 阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性%Efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王占敏; 宓为峰; 王晓志; 卢天兰; 付艺; 王雪芹; 郝晓楠; 李玲芝; 张鸿燕

    2012-01-01

    Objective To investigate the clinical efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Methods A randomized, controlled clinical trial was designed. One hundred and sixty - nine patients with schizophrenia were randomized into aripiprazole group (n = 79, 8 weeks, 10 -30 mg ? D-1) and quetiapine group (n = 90, 8 weeks, 400 - 750 mg ? D -1 ). The positive and negative syndrome scale (PANSS) and response rate were mainly used to evaluate efficacy. The safety was assessed by using the laboratory examination, vital signs and electrocardiogram ( ECG) at the baseline, week 4, 8. Results Compared with the baseline, total scores of PANSS in both groups decreased significantly at week 4 and week 8 ( P < 0. 01 ). At week 8 of treatment the mean reduction scores of PANSS and the clinical response rates were approximate, there were no significant differences between both groups. The incidence of adverse drug reactions related to the drugs 25. 3% (20/79) in aripiprazole and 17. 7% ( 16/90) in quetiapine treatment was approximate in both groups, with lower liability for heart rate in aripiprazole than in quetiapine treatment. The triglyceride(TG) and QRS interval in aripiprazole group showed more significant differences at week 8 than the baseline ( P < 0. 05 ). But the heart rate, body mass, body mass index ( BMI) , hemoglobin ( HGB ) , total cholesterol ( TC ) and low density lipoprotein ( LDL) in quetiapine group different significantly when compared with those at baseline (P < 0. 01). Conclusion Aripiprazole and quetiapine both have good efficacy in the treatment of schizophrenia. They have similar incidence of adverse drug reaction related to the drugs.%目的 评价阿立哌唑与喹硫平治疗精神分裂症的疗效及安全性.方法 169例符合DSM-Ⅳ(第4版)精神分裂症患者,阿立哌唑组79例,剂量10~30mg·d-1;喹硫平组90例,剂量400~ 750 mg·d-1,疗程均8周.治疗前,治疗第4,8周用阳性和阴性症状

  15. 阿立哌唑治疗利培酮所致精神分裂症女性患者高催乳素血症的研究%Aripiprazole in treatment of female schizophrenics with risperidone induced hyperprolactinemia

    Institute of Scientific and Technical Information of China (English)

    纪菊英; 宋梓祥; 徐乐平; 孙剑; 施建安; 赵汉清; 王焕林

    2008-01-01

    Objective To explore the efficacy and safety of aripiprasole in treatment of female schizophrenics with risperidone induced hyperprolactinemia. Methods All 117 female schizophrenics with hyperprolactinemia after fixed dose risperidone treatment were randomly assigned to aripiprazole group (n=60) and control group (n=57), and received additional aripiprazole 5 nag daily or placebo for 6 weeks respectively. The plasma prolactin (PBL) level was measured at weeks 0 and 6, and the Brief Psychiatric Bating Scale (BPBS) and Treatment Emergent Symptom Scale (TESS) were assessed. Results (1)Plasma prolactin levels were significantly reduced after the study compared with the baseline [(26±6) μg/L vs. (112±40)μg/L] in aripiprazole group (P= 0.000), however there were no significant difference between pre- and post treatment in control group (P =0.180). (2) At weeks 6, the decline rate and the normal ratio of plasma prolactin levels were significantly higher in aripiprazole group [(75±8) % vs. 82%]than in control group [(5±30) % vs. 4%] respectively (beth P = 0.000 ). (3) Compared with the baseline, the BPRS score showed significant reduction in both groups at the end of the study (both P=0.045). The incidence of side effects showed no significant difference between aripiprazole and control group(P =0.553). Conclusion The results indicate that aripiprazole may be effective and safe for the treatment of female schizophrenics with risperidone induced hyperprolactinemis.%目的 探讨阿立哌唑治疗利培酮所致女性患者高催乳素血症的疗效及安全性.方法 117例利培酮所致高催乳素血症的女性患者,随机分为治疗组(60例)和对照组(57例).维持原有利培酮治疗不变,治疗组加用阿立哌唑5 mg,对照组加用安慰剂治疗,疗程均为6周.于治疗第0,6周末检测催乳素,评定简明精神病量表(BPRS)、治疗中需处理的不良反应症状量表(TESS).结果 (1)治疗第6周末,治疗组催乳素[(26±6)

  16. A clinical comparative study in first-onset schizophrenia patients treated with Aripiprazole and Quetiapine%阿立哌唑与喹硫平治疗首发精神分裂症的临床对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2012-01-01

    Objective To study the clinical effects of Aripiprazole and Quetiapine in the treatment of first -onset schizophrenia. Methods 63 adult patients who were diagnosed as schizophreniain accordance with the CCMD-3 diagnosis standard were recruited in this study. All the cases were randomized into two groups and were treated with Aripiprazole and Quetiapine for 8 weeks. The positive and negative syndrome scale (PANSS) and treatment emergent side effect scale (TESS) were used to evaluate efficacy and adverse effects respectively. Results The significant efficacy rates of Aripiprazole was 93.55%, Quetiapine was 90.63%, there was no significant difference (P > 0.05). Before and after treatment between Aripiprazole group and Quetiapine group, the PANSS score had no significant difference (P > 0.05). The level of LEP and TG was elevated which were treated by Aripiprazole, the difference was statistically significant (P < 0.05). The level of LEP, PRL, BG and TG was elevated which were treated by Quetiapine, the difference was statistically significant (P < 0.05). Conclusion The curative effect of first-onset schizophrenia between Aripiprazole and Quetiapine is quite, but the adverse reactions are different, the former is better than the latter.%目的 探讨阿立哌唑与喹硫平治疗首发精神分裂症的临床疗效.方法 63例首发精神分裂症患者,符合CCMD-3精神分裂症诊断标准,随机分成两组,分别使用阿立哌唑和喹硫平治疗,疗程共8周.采用阳性和阴性症状量表(PANSS)和不良反应症状量表(TESS)进行副反应评定.结果 阿立哌唑组总有效率为93.55%,喹硫平组总有效率为90.63%,差异无统计学意义(P>0.05).阿立哌唑组和喹硫平组两组患者治疗前后PANSS量表评分,差异无统计学意义(P>0.05);阿立哌唑组治疗前后相比,瘦素和三酰甘油水平升高,差异有统计学意义(P<0.05),喹硫平组治疗前后瘦素、催乳素、血糖和三酰甘油水平升

  17. 氟西汀合并阿立哌唑对强迫症疗效的对照研究%Fluoxetine combined with Aripiprazole in the treatment of obsessive compulsive disorder

    Institute of Scientific and Technical Information of China (English)

    王道杰

    2013-01-01

    Objective To investigate the efficacy of fluoxetine combined with Aripiprazole in the treatment of obsessive-compulsive disorder(OCD).Method :64 patients with OCD were randomly treated with fluoxetine only and fluoxetine combining with Aripiprazole .The efficacy wad measured with Yale-Brown obsessive compulsive scale(Y-BOCS),Hamilton anxiety scale(HAMA) and Hamilton depression scale(HAMD).Results :There were significant differences between two groups in overall response showed by the reducation rate of Y-BOCS,HAMA and HAMD total scores.Conclusion: It is suggested that fluoxetine combining with Aripiprazole wave a superior effectiveness in the treatment of OCD.%目的探讨氟西汀合并阿立哌唑治疗强迫症的疗效。方法64例强迫症患者随机分为氟西汀组和氟西汀合并阿立哌唑组,疗程8周,采用强迫症量表(Y-BOCS),汉密尔顿焦虑量表(HAMA),汉密尔顿抑郁量表(HAMD),评定疗效。结果治疗结束时两组Y-BOCS,HAMA,HAMD的评分均显著下降,而合并阿立哌唑组更明显。结论氟西汀合并阿立哌唑治疗强迫症可以提高疗效。

  18. Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis

    Science.gov (United States)

    Bechdolf, Andreas; Müller, Hendrik; Stützer, Hartmut; Wagner, Michael; Maier, Wolfgang; Lautenschlager, Marion; Heinz, Andreas; de Millas, Walter; Janssen, Birgit; Gaebel, Wolfgang; Michel, Tanja Maria; Schneider, Frank; Lambert, Martin; Naber, Dieter; Brüne, Martin; Krüger-Özgürdal, Seza; Wobrock, Thomas; Riedel, Michael; Klosterkötter, Joachim

    2011-01-01

    Antipsychotics, cognitive behavioral therapy (CBT), and omega-3-fatty acids have been found superior to control conditions as regards prevention of psychosis in people at-risk of first-episode psychosis. However, no large-scale trial evaluating the differential efficacy of CBT and antipsychotics has been performed yet. In PREVENT, we evaluate CBT, aripiprazole, and clinical management (CM) as well as placebo and CM for the prevention of psychosis in a randomized, double-blind, placebo-controlled trial with regard to the antipsychotic intervention and a randomized controlled trial with regard to the CBT intervention with blinded ratings. The hypotheses are first that CBT and aripiprazole and CM are superior to placebo and CM and second that CBT is not inferior to aripiprazole and CM combined. The primary outcome is transition to psychosis. By November 2010, 156 patients were recruited into the trial. The subjects were substantially functionally compromised (Social and Occupational Functioning Assessment Scale mean score 52.5) and 78.3% presented with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I comorbid diagnosis. Prior to randomization, 51.5% of the participants preferred to be randomized into the CBT arm, whereas only 12.9% preferred pharmacological treatment. First, assessments of audiotaped treatment sessions confirmed the application of CBT-specific skills in the CBT condition and the absence of those in CM. The overall quality rating of the CBT techniques applied in the CBT condition was good. When the final results of the trial are available, PREVENT will substantially expand the current limited evidence base for best clinical practice in people at-risk (prodromal) of first-episode psychosis. PMID:21860040

  19. Different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics%阿立哌唑和利培酮对精神分裂症患者自发脑活动的不同影响

    Institute of Scientific and Technical Information of China (English)

    常鑫; 罗程; 侯昌月; 陈琳; 陈曦; 贺辉; 段明君; 蒋宇超; 尧德中

    2015-01-01

    Objective To explore the difference in effects of taking two different kinds of drugs aripiprazole and risperidone on spontaneous brain activity among schizophrenics. Methods Nineteen patients(9 patients taking aripiprazole and 10 patients taking risperidone),who were recruited in the Fourth Peopleˊs Hospital of Chengdu were underwent a resting - state scanning at the Center for Information in Medicine of University of Electronic Science and Technology of China. Two groupsˊfractional amplitude of low - frequency (fALFF)value were calculated and compared using two sample t - test. Results Compared with the aripiprazole group,risperidone group showed significantly decreasing areas of fALFF,including bilateral putamen,olfactory,caudate,orbitofrontal and right palli-dum;left middle temporal gyrus and left supramarginal gyrus where also shown to have increasing areas. Conclusion Indeed,there are different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics,which is consistent with the pharmacological mechanism of two drugs.%目的:探究临床常用抗精神病药物阿立哌唑和利培酮对精神分裂症患者自发性脑活动的不同影响。方法纳入就诊于成都市第四人民医院的长期服用阿立哌唑进行单药治疗的精神分裂症患者9例,服用利培酮单药治疗的精神分裂症患者10例,进行静息态功能磁共振(fMRI)扫描。分析两组患者 fMRI 信号的分数低频振幅(fALFF)的组间差异。结果与阿立哌唑组比较,利培酮组 fALFF 显著降低的脑区有双侧壳核、嗅皮质、尾状核、眶部额下回和右侧苍白球;fALFF 显著增高脑区有左侧颞中回和左侧缘上回(P <0.05)。结论阿立哌唑和利培酮会对大脑产生不同影响,差异脑区符合两种药物的不同药理机制。

  20. Clinical efficacy comparison of escitalopram treatment combined with aripiprazole on obsessive compulsive disorder%艾司西酞普兰联合阿立哌唑治疗强迫症患者的疗效观察

    Institute of Scientific and Technical Information of China (English)

    姜涛

    2011-01-01

    Objective; To investigate the effectiveness and safety of escitalopram with or without aripi-prazole in the treatment of obsessive-compulsive disorder. Method;60 patients with obsessive compulsive disorder were randomly assigned to receive escitalopram with or without aripiprazole. Effectiveness and adverse effect were assessed by Yale-Brown obsessive compulsive scale (Y-BOCS) and treatment emergent symptom scale ( TESS) , respectively. Results; Patients both received escitalopram and escitalopram with aripiprazole showed significant improvement by Y-BOCS scores after treatment,while the combination group showed a better outcome. There was no significant difference in TESS evaluation between the two groups. Conclusion; Escitalopram could effectively treat obsessive-compulsive disorder, while escitalopram combined with aripiprazole is more effective.%目的:探讨艾司西酞普兰与阿立哌唑联合治疗强迫症的疗效及不良反应.方法:对60例强迫症患者随机分为单用艾司西酞普兰组(单用组)及艾司西酞普兰与阿立哌唑联合用药组(合用组)治疗强迫症患者各30例进行开放、随机、对照研究,通过耶鲁布朗强迫量表(Y-BOCS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应. 结果:艾司西酞普兰治疗后显著改善强迫症状,艾司西酞普兰联合阿立哌唑也能显著改善强迫症状,后者改善效果更好;两组不良反应轻微.结论:艾司西酞普兰联合阿立哌唑较单用艾司西酞普兰的抗强迫效果更好.

  1. Optimization and pharmacokinetics of the sustained release microspheres of aripiprazole%阿立哌唑缓释微球的工艺优化及体内药动学研究

    Institute of Scientific and Technical Information of China (English)

    杨蕾; 彭博; 王明新; 刘津爱; 王毅飞; 王东凯

    2012-01-01

    目的:制备阿立哌唑缓释微球,使用星点设计-效应面法优化工艺,并对其体内血药浓度进行分析.方法:采用乳化溶剂挥发法制备阿立哌唑微球;以油相二氯甲烷体积、水相聚乙烯醇质量分数及乳化转速为自变量,以微球的平均粒径、跨距、载药量、包封率、产率及突释量为因变量,对制备工艺进行优化,并对优化后的工艺进行验证.采用HPLC法测定家兔血浆中药物浓度.结果:最佳工艺为二氯甲烷体积1.62mL,聚乙烯醇质量分数1.91%,乳化转速2161 r·min-1;按优化工艺制备的微球外观圆整、流动性好;平均粒径为41.54μm,跨距为1.01,载药量为18.82%,包封率为75.39%,产率为85.17%,突释为1.68%.自制徽球制剂在家兔体内d1有少量的突释,d5 ~d20维持较稳定的血药浓度,缓慢释放,之后浓度开始下降.结论:所优化的制备工艺重现性好,简单易行;星点设计-效应面法优化微球制备工艺预测性良好,所制备的微球具有较好的体外缓释特性;阿立哌唑缓释微球在家兔体内缓慢释放,该释药行为达到了预期的目的.%Objective: To prepare the sustained release microspheres of aripiprazole, to optimize the formulation by central composite design-response surface methodology, and to evaluate the pharmacokinetics of aripiprazole in rabbits. Methods: Emulsification-solvent evaporation method was used to prepare aripiprazole micro-spheres. The volume of CH2CI2 .polyvinyl alcohol (PVA) concentration and speed of mechanical stirring were listed as three independent variables; the dependent variables were mean diameter, span, durg content, encapsulation efficiency, yield and initial release. The central composite design-response surface methodology was constructed to optimize the formulations, and the optimized formulation was validated. HPLC method was used for the determination of aripiprazole in rabbit plasma. Results: The optimized preparation

  2. Efficacy and adverse reactions of Aripiprazole and Risperidone in treatment of patients with schizophrenia%阿立哌唑与利培酮治疗精神分裂症患者的疗效及不良反应

    Institute of Scientific and Technical Information of China (English)

    臧双九

    2015-01-01

    目的::观察阿立哌唑、利培酮治疗精神分裂症患者的疗效、不良反应及安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予患者阿立哌唑、利培酮治疗8周,于治疗前以及治疗2、4和8周采用阳性与阴性症状量表( PANSS)评定患者的疗效,不良反应量表( TESS)评定患者的不良反应。结果:两组患者治疗的疗效相当。利培酮组患者的锥体外系反应、内分泌以及体重增加多于阿立哌唑组。结论:阿立哌唑治疗精神分裂症患者的疗效与利培酮相似,但不良反应更少。%Objective: To observe efficacy, adverse reactions and safety of Aripiprazole and Risperidone in treatment of pa-tients with schizophrenia. Methods: 60 cases meeting CCMD3 diagnostic criteria for schizophrenia were randomly divided into 2 groups. They were treated with Aripiprazole and Risperidone for 8 weeks, respectively. Before and 2, 4 and 8 weeks after the treat-ment, PANSS (positive and negative symptom scale) and TESS (treatment emergent symptom scale) were used to evaluate the efficacy and adverse reactions. Results:The two groups had a similar efficacy;however, the extrapyramidal system reactions, endocrine, and weight gain in Risperidone group were more than those of Aripiprazole group. Conclusions:Aripiprazole in the treatment of the patients with schizophrenia has a similar efficacy with Risperidone, but has fewer adverse reactions.

  3. Observation of the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症的临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘卫平

    2015-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的疗效。方法:收治精神分裂症患者60例,随机分为对照组和观察组,对照组采用利培酮治疗,观察组采用阿立哌唑治疗,比较两组治疗效果。结果:对照组总有效率86.7%,观察组总有效率90.0%,P>0.05;对照组出现不良反应18例(60.0%),观察组出现不良反应6例(20.0%),P<0.05。结论:在精神分裂症的治疗中利培酮与阿立哌唑均具有显著的疗效,然而相对于利培酮而言,阿立哌唑具有较低的不良反应发生率,因此其具有较高的安全性。%Objective:To explore the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia.Methods:60 patients with schizophrenia were selected.They were randomly divided into the control group and the observation group.The control group was treated with risperidone,and the observation group was treated with aripiprazole.We compared the treatment effect of the two groups.Results:In the control group,the total efficiency was 86.7%;in the observation group,the total efficiency was 90%,P>0.05.In the control group,18 cases(60%) had adverse reactions;in the observation group,6 cases(20%) had adverse reactions,P<0.05.Conclusion:In the treatment of schizophrenia,risperidone and aripiprazole all had significant curative effect,but compared with risperidone,aripiprazole had low adverse reaction rate,so it had a high safety.

  4. Use of Antipsychotics in Children Is Criticized%阻止精神病药"标签外"用途

    Institute of Scientific and Technical Information of China (English)

    Gardiner Harris; 雪梅

    2008-01-01

    @@ Risperdal (risperidone) 和 Zyprexa (olanzapine)是两种近年来十分常用的精神障碍治疗药.随着近年美国被诊断出患有双相情感障碍的儿童数量突然增加,包括上述两种抗精神病药物在内的一系列药物如Seroquel (quetiapine)、Abilify (aripiprazole)和Geodon(ziprasidone)用于儿童的处方量也迅速上升.

  5. Metabolic acidosis.

    Science.gov (United States)

    Lim, Salim

    2007-01-01

    Acute metabolic acidosis is frequently encountered in critically ill patients. Metabolic acidosis can occur as a result of either the accumulation of endogenous acids that consumes bicarbonate (high anion gap metabolic acidosis) or loss of bicarbonate from the gastrointestinal tract or the kidney (hyperchloremic or normal anion gap metabolic acidosis). The cause of high anion gap metabolic acidosis includes lactic acidosis, ketoacidosis, renal failure and intoxication with ethylene glycol, methanol, salicylate and less commonly with pyroglutamic acid (5-oxoproline), propylene glycole or djenkol bean (gjenkolism). The most common causes of hyperchloremic metabolic acidosis are gastrointestinal bicarbonate loss, renal tubular acidosis, drugs-induced hyperkalemia, early renal failure and administration of acids. The appropriate treatment of acute metabolic acidosis, in particular organic form of acidosis such as lactic acidosis, has been very controversial. The only effective treatment for organic acidosis is cessation of acid production via improvement of tissue oxygenation. Treatment of acute organic acidosis with sodium bicarbonate failed to reduce the morbidity and mortality despite improvement in acid-base parameters. Further studies are required to determine the optimal treatment strategies for acute metabolic acidosis.

  6. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

    Directory of Open Access Journals (Sweden)

    Tamara Melnik

    Full Text Available CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline (1966-2009, Controlled Trials of the Cochrane Collaboration (2009, Issue 2, Embase (Excerpta Medica (1980-2009, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs (1982-2009. There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

  7. A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder.

    Science.gov (United States)

    Findling, Robert L; Youngstrom, Eric A; Rowles, Brieana M; Deyling, Elizabeth; Lingler, Jacqui; Stansbrey, Robert J; McVoy, Molly; Lytle, Sarah; Calabrese, Joseph R; McNamara, Nora K

    2017-07-31

    To determine if acute treatment with aripiprazole (APZ) would be superior to treatment with placebo in reducing dysfunctional symptoms of elevated mood and/or irritability in symptomatic children and adolescents at familial high risk for bipolar disorder (BPD) whose mood episodes occur spontaneously. These are patients we have previously referred to as suffering from "cyclotaxia." This was single-site, randomized, double-blind, placebo-controlled outpatient clinical trial in which youths aged 5-17 years who met diagnostic criteria for either cyclothymic disorder (CYC) or BPD not otherwise specified (BP-NOS) were randomly assigned to receive either APZ or placebo. Eligible participants had at least one parent with BPD, another first- or second-degree relative afflicted with a mood disorder, and also had not responded to psychotherapy. Treatment with APZ was initiated at a dose of approximately 0.1 mg/kg/day and could be increased by approximately 0.05 mg/kg/day at each study visit. Patients were seen weekly for 4 weeks and then every other week thereafter for 12 weeks. The primary outcome measure was mean change from baseline on Young Mania Rating Scale (YMRS) total score. A total of 59 patients (30 APZ, 29 placebo) aged 11.8 (SD = 2.7) years were randomized and returned for at least one postbaseline assessment. The mean total daily doses of active APZ and placebo were 7.1 mg (SD = 3.7) and 7.4 mg (SD = 4.2), respectively. At the 12-week time point, APZ was superior to placebo on the primary outcome measure (p children and adolescents with cyclotaxia.

  8. Metabolic encephalopathies.

    Science.gov (United States)

    Angel, Michael J; Young, G Bryan

    2011-11-01

    Kinnier Wilson coined the term metabolic encephalopathy to describe a clinical state of global cerebral dysfunction induced by systemic stress that can vary in clinical presentation from mild executive dysfunction to deep coma with decerebrate posturing; the causes are numerous. Some mechanisms by which cerebral dysfunction occurs in metabolic encephalopathies include focal or global cerebral edema, alterations in transmitter function, the accumulation of uncleared toxic metabolites, postcapillary venule vasogenic edema, and energy failure. This article focuses on common causes of metabolic encephalopathy, and reviews common causes, clinical presentations and, where relevant, management.

  9. The comparison of blood prolactin in the female patients with psychosis treated by aripiprazole and Sulpiride%阿立哌唑与舒必利对女性患者血清催乳素影响的对照研究

    Institute of Scientific and Technical Information of China (English)

    祖鑫

    2013-01-01

    目的:探讨阿立哌唑与舒必利对女性患者血清催乳素的影响。方法:将64例精神分裂症女性患者随机分为阿立哌唑组和舒必利组,比较两组治疗前后的血清催乳素变化。结果:阿立哌唑与舒必利对女性患者血清催乳素的影响有显著差异。结论:阿立哌唑对女性患者血清催乳素的影响较舒必利不明显。%Objective:To investigate the change of blood prolactin in female patients with p sychosis treated by aripiprazole and Sulpiride .Methods:64 female patients with schizophrenia or schizophrenia form psychosis were randomized to aripiprazole and Sulpiride .The blood prolactin at the baseline and after treatment were compared.Results:There were significant differences in the blood prolactin after treatment between aripiprazole and Sulpiride groups . Conclusions:The change of blood prolactin in the female patients with psychosis caused by aripiprazole was little then Sulpiride .

  10. Metabolic Syndrome

    Science.gov (United States)

    ... hypertension, hypertriglyceridemia, insulin resistance syndrome, low HDL cholesterol, Metabolic Syndrome, overweight, syndrome x, type 2 diabetes Family Health, Kids and Teens, Men, Women January 2005 Copyright © American Academy of Family PhysiciansThis ...

  11. Metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Gogia Atul

    2006-02-01

    Full Text Available The Metabolic syndrome is a widely prevalent and multi-factorial disorder. The syndrome has been given several names, including- the metabolic syndrome, the insulin resistance syndrome, the plurimetabolic syndrome, and the deadly quartet. With the formulation of NCEP/ATP III guidelines, some uniformity and standardization has occurred in the definition of metabolic syndrome and has been very useful for epidemiological purposes. The mechanisms underlying the metabolic syndrome are not fully known; however resistance to insulin stimulated glucose uptake seems to modify biochemical responses in a way that predisposes to metabolic risk factors. The clinical relevance of the metabolic syndrome is related to its role in the development of cardiovascular disease. Management of the metabolic syndrome involves patient-education and intervention at various levels. Weight reduction is one of the main stays of treatment. In this article we comprehensively discuss this syndrome- the epidemiology, pathogenesis, clinical relevance and management. The need to do a comprehensive review of this particular syndrome has arisen in view of the ever increasing incidence of this entitiy. Soon, metabolic syndrome will overtake cigarette smoking as the number one risk factor for heart disease among the US population. Hardly any issue of any primary care medical journal can be opened without encountering an article on type 2 diabetes, dyslipidemia or hypertension. It is rare to see type 2 diabetes, dyslipidemia, obesity or hypertension in isolation. Insulin resistance and resulting hyperinsulinemia have been implicated in the development of glucose intolerance (and progression to type 2 diabetes, hypertriglyceridemia, hypertension, polycystic ovary yndrome, hypercoagulability and vascular inflammation, as well as the eventual development of atherosclerotic cardiovascular disease manifested as myocardial infarction, stroke and myriad end organ diseases. Conversely

  12. Lipid Metabolism

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    2008393 Effects of angiotensin Ⅱ type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats. RAN Jianmin(冉建民), et al. Dept Endocrinol, Guangzhou Red Cross Hosp, 4th Hosp Med Coll, Jinan Univ, Guangzhou 510220. Natl Med J China 2008;88(22):1557-1561. Objective To investigate the effects of angiotensin receptor blocker (ARB) on triglyceride (TG) metabolism and mechanism thereof.

  13. 阿立哌唑与奥氮平治疗酒精所致精神障碍对照研究%A control study of aripiprazole vs .olanzapine in the treatment of mental disorders due to alcohol

    Institute of Scientific and Technical Information of China (English)

    刘娟; 高营

    2014-01-01

    目的:探讨阿立哌唑与奥氮平治疗酒精所致精神障碍的临床疗效和安全性。方法将66例酒精所致精神障碍患者随机分为两组,分别口服阿立哌唑与奥氮平治疗,观察8周。治疗前后采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末阿立哌唑组显效率87.5%,总有效率96.9%,奥氮平组分别为88.2%、97.0%,两组显效率、总有效率比较差异无显著性(χ2=0.19、0.00,P>0.05)。两组不良反应较轻微,阿立哌唑组主要表现为头痛、失眠等;奥氮平组主要表现为嗜睡、体质量增加等。结论阿立哌唑与奥氮平均能快速改善酒精所致精神障碍的精神症状,总体疗效相当,安全性高,但不良反应表现形式有所不同,临床上可根据不同患者选用不同的药物治疗。%Objective To explore the efficacy and safety of aripiprazole vs .olanzapine in the treatment of mental disorders due to alcohol (MDA) .Methods Sixty-six MDA patients were randomly divided into two groups taking orally aripiprazole or olanzapine respectively for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Syndrome Scale (TESS) .Results At the end of the 8th week ,obvious and total ef-fective rate were respectively 87 .5% and 96 .9% in aripiprazole and 88 .2% and 97 .0% in olanzapine group ,which showed no significant differences (χ2 =0 .19 ,0 .00 ;P>0 .05) .Adverse reactions of both groups were mild ,mainly headache ,insomnia etc .in aripiprazole and hypersomnia and weight gain etc .in olanzapine group .Conclusion Both aripiprazole and olanzapine could improve mental symptoms of MDA quickly ,their total efficacy are equivalent ,both have higher safety ,but manifestations of adverse reactions are somew hat different ,so different pharmacotherapies

  14. 阿立哌唑与喹硫平治疗精神分裂症的疗效与安全性%Efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘永桥; 杜波; 宓为峰; 王晓志; 施莹; 李玲芝; 马文斌; 金超; 杨勇峰; 张鸿燕

    2014-01-01

    Objective To evaluate the efficacy and safety of quetiapine and aripiprazole on patients with schizophrenia.Methods The random-ized, open, multi-center trial recruited 168 patients with schizophrenia , who received a 8-week treatment of aripiprazole (n=79, 10-30 mg· d -1 ) or quetiapine ( n=89 , 400-800 mg · d -1 ).The psychotic syn-dromes were rated with the positive and negative syndrome scale ( PAN-SS)at the baseline, the end of the fourth week and the eighth week.The disease severity was evaluated by the Clinical global impression -severity scale ( CGI-S ) and the Clinical global impression -improvement scale ( CGI-I).The safety was evaluated based on the incidences of adverse events and the comparison of laboratory or electrocardiography examina-tions prior and post the treatment.Results The response rates of aripi-prazole and quetiapine were 71.4%and 72.9%.There was no statistical difference ( P>0.05 ).The incidence rates of adverse events related to aripiprazole and quetiapine were 54.05% and 41.77%.The incidence rate of extrapyramidal symptoms ( EPS ) of the two groups were 36.7%and 4.6%( P<0.001 ).Conclusion Aripiprazole and quetiapine both show similar efficacy in the treatment of schizophrenia.The incidence rates of adverse events are similar but with different profiles.%目的:评价阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性。方法用随机、开放、多中心的研究方法。入选精神分裂症患者168例,随机分入阿立哌唑组79例,剂量10~30 mg· d-1;喹硫平组89例,剂量400~800 mg· d-1,疗程均8周。在基线,4,8周末,用阳性症状与阴性症状量表(PANSS)评价精神病性症状,以临床总体印象量表-严重程度(CGI-S)、疗效总评(CGI-I)评价疾病严重程度;以不良事件、实验室检查、心电图检查等评价安全性。结果阿立哌唑组与喹硫平组有效率分别为71.4%和72.9%,2组差异无统计学意义( P>0.05)。

  15. Metabolic Syndrome (For Parents)

    Science.gov (United States)

    ... Old Feeding Your 1- to 2-Year-Old Metabolic Syndrome KidsHealth > For Parents > Metabolic Syndrome A A A ... this is a condition called metabolic syndrome . About Metabolic Syndrome Not to be confused with metabolic disease (which ...

  16. Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.

    Science.gov (United States)

    Teff, Karen L; Rickels, Karl; Alshehabi, Erica; Rickels, Michael R

    2015-10-01

    The second-generation antipsychotics (SGAs) are associated with weight gain and an increased incidence of metabolic diseases. The metabolic impairments are assumed a consequence of increased body adiposity secondary to central nervous system-associated increases in food intake. We have previously reported that, independent of weight gain, 9 days of olanzapine administration to control subjects is associated with insulin resistance and increases in postprandial levels of insulin and glucagon-like peptide 1 to a mixed meal challenge. This current report describes previously unpublished data on the effects of the SGAs olanzapine and aripiprazole compared with placebo on detailed hunger and satiety responses over the 12-day inpatient evaluation as well as postprandial ghrelin and leptin responses prior to and following administration of the 2 SGAs. We found no changes in hunger, fullness, or in the orexigenic hormone ghrelin or satiety hormone leptin, consistent with our previous report indicating no change in weight during this study. The results indicate that the SGAs are associated with metabolic changes prior to changes in hunger, satiety, and food intake, and this temporal separation suggests that there are differential mechanisms mediating SGA-associated changes in metabolism and food intake.

  17. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.

    Science.gov (United States)

    Citrome, Leslie; Kamat, Siddhesh A; Sapin, Christophe; Baker, Ross A; Eramo, Anna; Ortendahl, Jesse; Gutierrez, Benjamin; Hansen, Karina; Bentley, Tanya G K

    2014-08-01

    To develop a decision-analytic model to estimate the cost-effectiveness of initiating maintenance treatment with aripiprazole once-monthly (AOM) vs paliperidone long-acting injectable (PLAI) once-monthly among patients with schizophrenia in the US. A decision-analytic model was developed to evaluate a hypothetical cohort of patients initiating maintenance treatment with AOM or PLAI. Rates of relapse, adverse events (AEs), and direct medical costs were estimated for 1 year. Patients either remained on initial treatment or discontinued treatment due to lack of efficacy, AEs, or other reasons, including non-adherence. Data from placebo-controlled pivotal trials and product prescribing information (PI) were used to estimate treatment efficacy and AEs. Analyses were performed assuming dosing of clinical trials, real-world practice, PIs, and highest therapeutic dose available, because of variation in practice settings. The main outcome of interest was incremental cost per schizophrenia hospitalization averted with AOM vs PLAI. Based on placebo-controlled pivotal trials' dosing, AOM improved clinical outcomes by reducing schizophrenia relapses vs PLAI (0.181 vs 0.277 per person per year [pppy]) at an additional cost of US$1276 pppy, resulting in an incremental cost-effectiveness ratio (ICER) of US$13,280/relapse averted. When PI dosing was assumed, this ICER increased to US$19,968/relapse averted. When real-world dosing and highest available dosing were assumed, AOM was associated with fewer relapses and lower overall treatment costs vs PLAI. AOM consistently provided favorable clinical benefits. Under various dosing scenarios, AOM results indicated fewer relapses at lower overall costs or a reasonable cost-effectiveness threshold (i.e., less than the cost of a hospitalization relapse) vs PLAI. Given the heterogeneous nature of schizophrenia and variability in treatment response, health plans may consider open access for treatments like AOM. Since model inputs were based

  18. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

    Directory of Open Access Journals (Sweden)

    Michele Wilson

    2016-03-01

    Full Text Available Background: Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC therapy to AOM in a multicenter, open-label, mirror-image study of patients with schizophrenia. Because of the increasing need to improve patient outcomes while containing costs, it is important to understand the impact of AOM treatment initiation on medical costs associated with psychiatric hospitalizations and antipsychotic pharmacy costs. Methods: In the current study, an economic model was developed using data from the AOM mirror-image study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before (retrospective period and after (prospective period the AOM treatment initiation. The economic model evaluated cost-saving potential of AOM among all patients (n=433 as well as a subset of patients with ≥1 prior hospitalization (n=165 who switched from oral SOC to AOM. Unit cost data were obtained from publicly available sources. Results: Both hospitalizations and hospital days were reduced following a switch from oral SOC to AOM. As a result, psychiatric hospitalization-related costs were lower during the prospective period when compared with the retrospective period. Furthermore, the increase in antipsychotic pharmacy costs due to switching from oral SOC to AOM was offset by a reduction in psychiatric hospitalization-related medical costs. Per-patient costs were reduced by $1,046 (USD in the overall population and by $20,353 in a subset of patients who had at least 1 psychiatric hospitalization during the retrospective period. Results were most sensitive to changes in hospitalization costs. Conclusions: AOM is associated with reducing the risk of relapse among patients with

  19. Metabolic syndrome

    Institute of Scientific and Technical Information of China (English)

    Charles Shaeffer

    2004-01-01

    @@ The emergence of cardiac disease as the number one world-wide cause of death justifies efforts to identify individuals at higher risk for preventive therapy. The metabolic syndrome, originally described by Reaven, 1 has been associated with higher cardiovascular disease risk. 2 Type Ⅱ diabetes is also a frequent sequela. 3

  20. Clinical studies of aripiprazole in child and adolescent tic dis-order%阿立哌唑治疗儿童青少年抽动障碍临床研究

    Institute of Scientific and Technical Information of China (English)

    高蓉; 周渊东; 黄自勇; 金婷婷

    2014-01-01

    目的:探讨阿立哌唑治疗儿童青少年抽动障碍患者的临床疗效和安全性。方法对25例应用其他药物治疗效果不佳或耐受性较差的儿童青少年抽动障碍患者换用阿立哌唑治疗,观察10周。于治疗前后采用耶鲁抽动量表评定临床疗效,副反应量表评定不良反应。结果本组患者治疗10周末耶鲁抽动量表总分及运动抽动、发声抽动、功能损害评分均较基线显著下降(P<0.01);不良反应较轻微,主要表现为失眠、激越、头痛等。结论阿立哌唑治疗儿童青少年抽动障碍疗效显著,安全性高,依从性好。%Objective To explore the efficacy and safety of aripiprazole in child and adolescent tic disorder . Methods Twenty-five tic disorder children and adolescents who had poor treatment effectiveness or toler-ance with other drugs were treated with aripiprazole for 10 weeks .Efficacies with assessed with the Yale Global Tic Severity Scale (YGTSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 10th week total ,motor tic ,vocal tic and functional lesion score of the YGTSS lowered more significantly compared with pretreatment (P<0 .01);adverse reactions were mild and mainly insomnia ,agitation ,headache and so on .Conclusion Aripiprazole has an evident effect ,higher safety and better compliance in child and adolescent tic disorder .

  1. A control study of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression%度洛西汀联合阿立哌唑治疗难治性抑郁症对照研究

    Institute of Scientific and Technical Information of China (English)

    邓良华; 莫翠英; 吴廷娟; 杨子民

    2014-01-01

    Objective To explore the efficacy and safety of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression (TRD) .Meth-ods Ninety-three TRD patients were randomly divided into two groups ,research group (n=47) was trea-ted with oral duloxetine plus aripiprazol and control group (n=46) with single duloxetine for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week ,obvious effective and effective rate were respectively 59 .1% and 77 .3% in research and 31 .1% and 42 .2% in control group , the former was significantly than the latter (χ2 = 7 .04 ,11 .35 ;P0 .05) .Conclusion Duloxetine plus aripiprazol takes effect more rapidly and has an evident effect and higher safety compared with single duloxetine in the treatment of T RD .%目的:探讨度洛西汀联合阿立哌唑治疗难治性抑郁症的临床疗效和安全性。方法将93例难治性抑郁症患者随机分为两组,研究组口服度洛西汀联合阿立哌唑治疗,对照组单用度洛西汀治疗,观察8周。采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组显效率59.1%、有效率77.3%,对照组分别为31.1%、42.2%,研究组显效率、有效率均显著高于对照组(χ2=7.04、11.35,P<0.01)。两组不良反应较轻微,发生率比较差异无显著性(P>0.05)。结论度洛西汀联合阿立哌唑治疗难治性抑郁症起效快,疗效显著,安全性高,显著优于单用度洛西汀治疗。

  2. 地西泮联合小剂量阿立哌唑治疗酒依赖患者的疗效观察%The clinical effect observation of diazepam combined with aripiprazole in patients with alcohol dependence

    Institute of Scientific and Technical Information of China (English)

    高晓奇; 冯芳; 刘艳江; 石秀华; 李克松; 张国辉

    2014-01-01

    目的:观察地西泮联合小剂量阿立哌唑治疗酒依赖患者的临床效果。方法将144例酒依赖患者随机分为治疗组和对照组各72例。2组均接受常规治疗,治疗组在常规治疗基础上加服阿立哌唑治疗,对比2组治疗前后戒断症状评分。结果2组治疗前戒断症状评分差异无统计学意义(P>0.05)。治疗后2组戒断症状评分均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论地西泮联合小剂量阿立哌唑治疗酒依赖患者疗效较好,且起效时间短,不良反应轻微,值得推广应用。%Objective To observe the clinical efficacy of diazepam combined with aripiprazole in patients with alcohol dependence .Methods 144 cases patients with alcohol dependence were divided into treatment group and control group ,each of 72 cases.The 2 groups were treated by conventional treatment .Treatment group,on the basis of conventional treatment ,was treated by diazepam combined with aripiprazole .After treatment,compared the withdrawal symptoms score of 2 groups.Results Before treatment,the withdrawal symptoms score of 2 groups was no statistically significant (P>0.05).After treatment,the with-drawal symptoms score of 2 groups were less than that of control group ,and the withdrawal symptoms score of treatment group was less than that of control group ,the difference was statistically significant ( P<0.05) .Conclusion Diazepam combined with arip-iprazole in patients with alcohol dependence has an good efficacy ,less adverse reactions ,and worthy of application .

  3. Control study of Wujibaifeng pills and aripiprazole in the treatment of female schizophrenia patients with hyperprolactinemia split caused by risperidone%乌鸡白凤丸与阿立哌唑治疗利培酮所致女性精神分裂症患者高催乳素血症的对照研究

    Institute of Scientific and Technical Information of China (English)

    于丽燕; 丁良; 李玉欣

    2015-01-01

    目的:探讨乌鸡白凤丸与阿立哌唑对女性精神分裂症患者服用利培酮所致高催乳素血症的影响及其安全性。方法将应用利培酮治疗导致高催乳素血症的67例女性精神分裂症患者随机分为乌鸡白凤丸组和阿立哌唑组,疗程4周。结果乌鸡白凤丸组完成28例,阿立哌唑组完成30例,乌鸡白凤丸组血清催乳素明显低于入组前(t=7.624,P=0.000),阿立哌唑组血清催乳素明显低于入组前(t=8.278,P=0.000),两组血清催乳素水平无明显差异(t=1.965,P=0.054)。结论乌鸡白凤丸与阿立哌唑均能降低利培酮所致高催乳素水平,安全性好。%Objective To explore the efifcacy and safety of Wujibaifeng pills and aripiprazole in the treatment of female hyperprolactinemia caused by risperidone.Methods 67 female schizophrenia patients with hyperprolactinemia caused by risperidone and aripiprazole were randomly assigned into Wujibaifeng pills group and aripiprazole group treated for 4 weeks. Results In Wujibaifeng pills group 28 cases were completed the treatment,in aripiprazole group 30 cases completed. In Wujibaifeng pills group, the serum prolactin was significantly lower than before treatment (t=7.624,P=0.000), serum prolactin in aripiprazole group was signiifcantly lower than that before treatment (t=8.278,P=0.000). The serum prolactin levels in the two groups had no significant difference (t=1.965,P=0.054) .Conclusion Wujibaifeng pills and aripiprazole can reduce risperidone induced hyperprolactinemia level with good safety.

  4. Metabolic Syndrome

    Directory of Open Access Journals (Sweden)

    Sevil Ikinci

    2010-10-01

    Full Text Available Metabolic Syndrome is a combination of risk factors including common etiopathogenesis. These risk factors play different roles in occurence of atherosclerotic diseases, type 2 diabetes, and cancers. Although a compromise can not be achieved on differential diagnosis for MS, the existence of any three criterias enable to diagnose MS. These are abdominal obesity, dislipidemia (hypertrigliceridemia, hypercholesterolemia, and reduced high density lipoprotein hypertension, and elevated fasting blood glucose. According to the results of Metabolic Syndrome Research (METSAR, the overall prevalence of MS in Turkey is 34%; in females 40%, and in males it is 28%. As a result of “Western” diet, and increased frequency of obesity, MS is observed in children and in adolescents both in the world and in Turkey. Resulting in chronic diseases, it is thought that the syndrome can be prevented by healthy lifestyle behaviours. [TAF Prev Med Bull 2010; 9(5.000: 535-540

  5. Efficacy and safety of aripiprazole in treating negative symptoms of schizophrenia%阿立哌唑与利培酮治疗精神分裂症阴性症状的疗效和安全性观察

    Institute of Scientific and Technical Information of China (English)

    贾天成

    2014-01-01

    目的:探讨阿立哌唑治疗精神分裂症阴性症状的疗效和安全性。方法80名精神分裂症患者随机分为研究组(阿立哌唑治疗)和对照组(利培酮治疗),每组40例,在治疗前及治疗的2、4、8周末分别采用潘氏阳性与阴性症状量表(PANSS)、阴性症状评定量表(SANS)评分,并记录治疗期间发生的不良反应。结果两组患者治疗后的 PANSS 量表总分及 SANS 总分均明显降低(P <0.05),但同一时期,两组患者间的 PANSS 量表总分及 SANS 量表评分差异无统计学意义(P >0.05)。在治疗后第4、8周,研究组患者“思维贫乏”及“意志缺乏”的因子分较对照组明显下降(P <0.05),而对照组患者“兴趣/社交缺乏”的评分则明显低于同期的研究组患者(P <0.05)。阿立哌唑不良反应发生率小于利培酮(P <0.05)。结论阿立哌唑与利培酮均能改善精神分裂症患者的阴性症状,且总体疗效相似,但阿立哌唑更善于改善患者的情感与认知症状,而利培酮则对患者的情感与行为症状更有效。阿立哌唑的用药安全性总体上优于利培酮。%Objective To explore the efficacy and safety of aripiprazole in treating negtive symptoms of schizophrenia.Methods Eighty patients with schizophrenia were randomly assigned to the experimental group(treated with aripiprazole)and the control group(treated with risperidone),with 40 cases in each group.Positive and Negative Syndrome Scale(PANSS)and Scale for Assessment of Negative Symptoms(SANS)were used before treatment,and at the weekend of 2nd,4th,8th after treatment respectively.Results The scores of PANSS and SANS in both groups were decreased in comparison with those pretreatment(P 0.05).At the 4th,8th weekends of post-treatment,the scores of“poverty of thought”and“abulia”in experimental group were decreased in comparison with those in the control group(P 0.05).The

  6. What is Metabolic Syndrome?

    Science.gov (United States)

    ... from the NHLBI on Twitter. What Is Metabolic Syndrome? Metabolic syndrome is the name for a group of ... that may play a role in causing metabolic syndrome. Outlook Metabolic syndrome is becoming more common due to a ...

  7. Study on the Efficacy of Aripiprazole in the Treatment of Type II Schizophrenia Spirit%阿立哌唑治疗Ⅱ型精神分裂症疗效研究

    Institute of Scientific and Technical Information of China (English)

    刘林虎; 侯连凤

    2014-01-01

    Objective To investigate the clinical ef ects of aripiprazole in type II schizophrenia therapy. Methods Our hospital in January 2013 ~ January 2014 treated 60 patients with type IIschizophrenic patients as research subjects, using a random list of numbers divided into study group and control group, 30 cases in each. In the control group were treated with risperidone treatment, the study group were treated with aripiprazole treatment, 6 weeks of treatment, both groups of patients with clinical ef icacy and adverse reactions. Results The comparison of the clinical ef icacy of the study group and the control group, the dif erence was not statistical y significant ( >0.05);adverse reactions in the study group extrapyramidal reactions and weight gain was significantly lower than the control group, the dif erence was statistical y significant ( 0.05);研究组不良反应中锥体外系反应和体重增加反应明显低于对照组,差异有统计学意义(P<0.05)。结论通过采用阿立哌唑对Ⅱ型精神分裂症患者进行治疗,可以取得良好的临床疗效,并且锥体外系反应少,患者体重变化少,安全性也比较高,非常值得在临床上进行推广。

  8. To observe the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia%阿立哌唑与利培酮治疗女性精神分裂症的临床效果探讨

    Institute of Scientific and Technical Information of China (English)

    龚日东; 黄书梅

    2014-01-01

    Objective To investigate the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia. Methods 100 cases of female spirit admitted in our hospital in 2012 January to 2014 January between the schizophrenia patients for clinical research,The patients were randomly divided into aripiprazole group and risperidone group, compared two groups of patients with clinical curative effect. Results In the two groups before treatment PANSS clinical psychopathology, negative symptoms, positive symptoms and score of contrast was no significant statistical difference (P>0.05), the clinical treatment for 2 weeks, 4 weeks of treatment and 8 weeks after the treatment, PANSS psychopathology, negative symptoms, positive symptoms and total score compared with the statistically significant difference (P0.05),临床治疗2周、治疗4周和治疗8周后PANSS精神病理、阴性症状、阳性症状和总分对比差异具有统计学意义(P<0.05)。两组女性精神分裂症患者临床治疗的总有效率和不良反应发生率对比差异具有统计学意义(P<0.05)。结论该次医学研究结果证实,阿立哌唑用于女性精神分裂症的临床治疗,具有更高的有效率和安全性,因而临床推广和应用价值更高。

  9. Efficacy observation of Aripiprazole and Risperidone in treatment of schizophrenia%阿立哌唑和利培酮治疗精神分裂症的疗效观察

    Institute of Scientific and Technical Information of China (English)

    曲秀颖

    2015-01-01

    目的::探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:选取76例符合CCMD-3精神分裂症诊断标准的患者随机分为阿立哌唑组和利培酮组,每组38例。两组患者分别给予阿立哌唑和利培酮治疗,6周后进行临床疗效评价及不良反应评定。结果:阿立哌唑组患者总有效率为89.47%,利培酮组患者总有效率为86.84%,两组患者总体疗效相当(P>0.05)。两组患者治疗前后PANSS评分比较,差异有统计学意义(P0.05)。治疗6周,阿立哌唑组患者不良反应发生率低于利培酮组(P0. 05). There was a statistical difference in the PANSS score between the two group before and after the treatment (P0. 05). Six weeks after the treatment, the inci-dence rates of adverse reactions of Aripiprazole group were lower than those of Risperidone group (P<0. 05). Conclusions: In the treatment of schizophrenia, Aripiprazole has a similar efficacy with Risperidone, but is superior in influences on extrapyramidal reac-tions, endocrine and weight than Risperidone.

  10. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  11. 阿立哌唑与利培酮治疗精神分裂症的疗效与安全性对比分析%Analysis of Efficacy and Safety of Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程道猛; 刘靖雯; 黄鹏; 徐世超; 王春江

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的收益和风险,优化临床治疗效果与安全性,指导临床合理治疗。方法:将60例符合入组标准的精神分裂症按随机数字表分为阿立哌唑组与利培酮组,各30例,分别给予阿立哌唑与利培酮,8周为1个疗程,治疗前、后观察患者症状,进行阳性症状量表和阴性症状量表(PANSS)评分及不良反应量表(T ESS )评分,评价两组患者的临床疗效与安全性。结果:阿立哌唑组和利培酮组的总有效率均为93.33%,P>0.05;阿立哌唑组和利培酮组的阳性症状量表(PANSS)评分、阴性症状量表(PANSS)评分及量表总评分差异均无统计学意义,均 P>0.05;阿立哌唑组和利培酮组头痛、口干、血压降低、失眠差异无统计学意义,均 P>0.05,但阿立哌唑组锥体外系反应、体质量增加、闭经溢乳的发生率明显低于利培酮,差异具有统计学意义,均 P<0.05。结论:阿立哌唑起效速度、安全性、依从性明显优于利培酮,尤其能明显降低现锥体外系反应、体质量增加、闭经溢乳的副反应,是治疗精神分裂症的首选药物。%Objective :To investigate benefits and risks of aripiprazole and risperidone in the treatment of schizophreni-a ,to optimize clinical efficacy and safety ,guide clinical treatment .Methods :60 schizophrenia patients met the inclusion criteria were randomly divided into aripiprazole group and risperidone group ,30 cases of each group ,each group were given aripiprazole and risperidone ,8 weeks for an effect ,observed symptoms ,made a positive and negative symptom scale symptom scale (PANSS) scores and adverse reactions scale (TESS) scores ,to evaluate the clinical efficacy and safety .Results:The total effective rate of aripiprazole group and risperidone group was 93 .33% ,P>0 .05 ;the positive symptom scale (PANSS) score ,negative

  12. Endocrine and Metabolic Adverse Effects of Psychotropic Drugs in Children and Adolescents

    Directory of Open Access Journals (Sweden)

    Evrim Aktepe

    2011-12-01

    Full Text Available ABSTRACT Much as an increase in the use of psychotropic drugs is observed in children and adolescents over the last decade, the endocrine and metabolic side effects of these drugs can limit their use. Atypical antipsychotics can cause many side effects, which are not suitable for the developmental periods of children and adolescents, such as those related with thyroid, blood sugar, level of sex hormones, growth rate and bone metabolism. Children are under a more serious risk regarding the weight increasing effects of atypical antipsychotics and weight gain that is not proportionate with age is especially important due to the association between glucose or lipid abnormalities and cardiovascular mortality. Aripiprazole and ziprasidone are the least risky antipsychotic drugs when it comes to metabolic side affects. The antipsychotic drug that is associated with weight increase and diabetes in children and adolescents most is olanzapine. Even though there are no comparative long-term data concerning children, it is suggested by the currently available information that metabolic side effects including dyslipidemia and impaired glucose tolerance are at an alarming level when it comes to long-term treatment with antipsychotics. The most risky agents in terms of hyperglycemia and glucosuria development are olanzapine and clozapine. Use of risperidone and haloperidol should be undertaken with caution since it may bring about the risk of hyperprolactinemia. Among the antidepressants associated with weight loss and suppression of appetite are selective serotonin reuptake inhibitors, bupropion and venlafaxine. Thyroid functions can be affected by lithium, carbamazepine and valproate treatments. It is reported that the side effect most frequently associated with valproate is weight increase. The relationship between valproate treatment and the development of hyperandrogenism and polycystic ovary syndrome in young women should also be kept in mind. [TAF Prev

  13. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics.

    Directory of Open Access Journals (Sweden)

    Joseph McEvoy

    Full Text Available There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-naïve patients with a first episode of schizophrenia (FE group, 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group, and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs, including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.

  14. Carbohydrate Metabolism Disorders

    Science.gov (United States)

    ... you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) ... metabolic disorder, something goes wrong with this process. Carbohydrate metabolism disorders are a group of metabolic disorders. ...

  15. 博思清与氯氮平治疗单纯型精神分裂症疗效与安全性评价%Efficacy and safety evaluation of aripiprazole and clozapine in the treatment of simple type schizophrenia

    Institute of Scientific and Technical Information of China (English)

    毕见好; 高丽静

    2015-01-01

    AIM:To evaluate the efficacy and safety of aripi-prazole and clozapine in the treatment of simple type schizophreni-a.METHODS:100 cases of simple type schizophrenia meeting ICD-10 criteria were analyzed in our hospital from November 2008 to December 2014,and they were divided randomly into two groups.Aripiprazole group was treated with aripiprazol,while clozapine group was treated with clozapine.PANSS reducing rates were used to evaluate the curative effect after 3 months and half a year,and the difference treatment effect and adverse reaction of two groups were analyzed.RESULTS:The total effective rate of two groups was comparative after 3 months (P >0.05);and the total effective rate of aripiprazole group was better than clozapine group after half a year (P <0.05).The incidence of adverse reac-tion of two groups had significant difference,and the incidence of adverse reaction of aripiprazole is lower than clozapine group's (P <0.05).CONCLUSION:The effect is relatively in recent of aripiprazole and clozapine in the treatment of simple type schiz-ophrenia,but aripiprazole has obvious advantages for the long-term efficacy and safety.Its security is greater,and is worthy of promotion.%目的:对博思清与氯氮平治疗单纯型精神分裂症疗效与安全性进行评价.方法:研究对象选取本院2008-11/2014-12收治的100例符合 ICD-10单纯型精神分裂症诊断标准的患者,按随机方法分为两组.博思清组患者采用博思清治疗,氯氮平组患者给予氯氮平治疗.治疗3个月和6个月分别采用 PANSS 量表减分率评价疗效,对比分析两组患者治疗效果和不良反应的差异性.结果:经过3个月治疗后氯氮平组患者总有效率与博思清组相当(P >0.05);而治疗6个月后博思清组治疗总有效率明显优于氯氮平组(P <0.05);两组患者治疗期间不良反应发生率有显著差异,博思清组发生率明显低于氯氮平组(P <0.05)

  16. Cost-effectiveness analysis of Risperidone and Aripiprazole in the treat-ment of outpatients with schizophrenia%利培酮、阿立哌唑治疗门诊精神分裂症患者成本-效果分析

    Institute of Scientific and Technical Information of China (English)

    吴宇杰; 李君; 杜鹏; 饶顺曾; 吴彦

    2015-01-01

    Objective To compare therapeutic cost-effects and safety between Risperidone and Aripiprazole in treatment of outpatients with schizophrenia. Methods The schizophrenia patients, who were going on treating with Risperidone or Aripiprazole at discharge, were followed-up 1 year in outpatient. While economic cost-effectiveness and adverse reaction were observed and analyzed. Results Comparing the efficacy between the two groups, it was better in Risperidone group than Aripiprazole group, but there was no statistically significant difference (字2= 0.804, P= 0.84). Drug costs in the Risperidone group was slightly lower than the Aripiprazole group, but there was no statistically significant difference (t = 0.39, P=0.69). The cost-effectiveness of Risperidone was better than Aripiprazole (62.41 v s 64.40). The incidence of high prolactin was up to 26.19% (11/42) in Risperidone group, while in Aripiprazole group had no high prolactin occurring. Conclusion The expenses and efficacy are considerably between Risperidone and Aripiprazole, but the adverse reaction of high prolactin often appears in Risperidone treatment, must be cause caution, for young female patients chosen Risperidone is better.%目的:比较单用利培酮或阿立哌唑治疗门诊精神分裂症患者的经济效果及安全性。方法对出院时使用利培酮治疗方案或阿立哌唑治疗方案的精神分裂症患者门诊随访1年,运用经济学成本-效果分析比较两组优劣,观察治疗不良反应。结果两组在疗效方面比较,利培酮组较阿立哌唑组差,但差异无统计学意义(字2=0.804,P=0.84);利培酮组药物费用略低于阿立哌唑组,但差异无统计学意义(t=0.39,P=0.69);成本-效果方面利培酮组优于阿立哌唑组(62.41比64.40);利培酮组高泌乳素发生率高达26.19%(11/42),而阿立哌唑无高泌乳素发生。结论使用利培酮及阿立哌唑费用及疗效相当,而利培酮引起的高泌乳素副作用发生率较高,

  17. 阿立哌唑辅治酒精所致精神障碍临床观察%Clinical Observation on Aripiprazole to Treat Mental Disorders Due to Alcohol

    Institute of Scientific and Technical Information of China (English)

    马文斌

    2015-01-01

    目的:探讨阿立哌唑辅治酒精所致精神障碍的临床疗效。方法选取2012年5月~2013年6月我院收治的因酒精中毒所致的精神功能障碍患者46例,将其随机平均分为对照组和实验组,两组均采用常规综合治疗方式,实验组采用阿立哌唑辅助治疗,对照组采用传统抗精神病药物氟哌啶醇治疗,观察两组患者的治疗前后的临床疗效、阳性与阴性症状量表评分以及副反应发生情况。结果实验组的治疗总有效率为95.7%(22/23),对照组的治疗总有效率为78.3%(18/23),实验组的治疗总有效率明显高于对照组治疗总有效率,差异有统计学意义(P<0.05);治疗后实验组的阳性与阴性症状量表评分明显低于对照组,差异有统计学意义(P<0.05)。结论阿立哌唑辅治酒精所致精神障碍临床疗效显著,用药安全,副作用少,能够有效促进患者精神功能恢复。%ObjectiveTo explore the effect of Aripiprazole to treat mental disorders due t Alcohol.Methods Selected 46 cases of mental disorders due to alcohol poisoning from May 2012 to June 2013 in our hospital patients, they were randomly divided into control group and experimental group, two groups both used the conventional comprehensive treatment, the experimental group was using the Aripiprazole therapy, the control group was treated with traditional antipsychotic drugs haloperidol treatment, observed the clinical effects of two groups of patients before and after treatment, the positive and negative symptoms rating scale and side effects. Results Treatment group total effective rate was 95.7% (22/23), the treatment of control group total effective rate was 78.3% (18/23), treatment group total effective rate was significantly higher than the control group total effective rate, the difference was statistically signiifcant (P<0.05). The experimental group after treatment of positive and negative symptoms scale score

  18. Escitalopram combined with aripiprazole in the treatment of 46 patients with obsessive compulsive disorder%艾司西酞普兰联合阿立哌唑治疗强迫症46例

    Institute of Scientific and Technical Information of China (English)

    陈红生

    2012-01-01

    目的 探讨艾司西酞普兰与阿立哌唑联合治疗强迫症临床效果及安全性.方法 强迫症患者97例,随机分为两组,其中对照组51例,采用艾司西酞普兰口服治疗,观察组46例,在上述基础上加用阿立哌唑口服治疗;治疗结束后评价临床疗效及不良反应发生情况.结果 观察组患者治疗总有效率为89.1%明显优于对照组68.6%(x2=12.32,P<0.05);观察组患者治疗后Y-BOCS评分(21.82 ±2.88)分亦明显优于对照组患者的(23.68±2.74)分(t=2.64,P<0.05);而两组患者治疗结束后TESS评分及不良反应发生率均差异无统计学意义(t=0.61;x2 =0.03,均P>0.05).结论 艾司西酞普兰联合阿立哌唑治疗强迫症临床效果显著,且不良反应少,具有临床推广使用价值.%Objective To observe and explore the clinical efficacy and safety of escitalopram combined with aripiprazole in the treatment of obsessive-compulsive disorder.Methods 97 patients with obsessive-compulsive disorder were randomly divided into two groups,control group of 51 patients were given oral administration of escitalopram treatment,46 patients in the experimental group received escitalopram and oral aripiprazole treatment.At the end of treatment,the clinical efficacy and adverse events were evaluated.Results In control group and experimental group patients overall effective rate was 68.6%,89.1% ;The experimental group the total effective rate was higher than the control group,the difference between two groups was statistically significant( x2 =12.32,P <0.05 ),The control group and experimental group after treatment Y-BOCS scores were (23.68 ± 2.74 ) points,( 21.82 ± 2.88 ) points ; The experimental group after treatment Y-BOCS score was significantly better than the control group,between the two groups the difference was statistically significant ( t =2.64,P < 0.05 ) ; While after treatment the TESS score and incidence of adverse reactions between the two groups were

  19. Effect of treatment with Aripiprazole on mismatch negativity potentials in schizophrenia%阿立哌唑对精神分裂症患者失匹配性负波电位的影响

    Institute of Scientific and Technical Information of China (English)

    姚建军; 张紫娟; 周振和

    2012-01-01

    Objective To study the effects of Aripiprazole on mismatch negativity potentials in schizophrenia. Methods 30 patients (age of 18 - 65 years old) met DSM-IV schizophrenia criteria were enrolled as research group and 30 healthy persons were selected as normal control group that performed the frequency and duration deviant MMN task. MMN latency and amplitude at Fz electrodes were obtained. The research group was treated with Quetipine for 8 weeks and assessed with PANSS. MMN amplitudes and latencies of two groups were compared between the groups. Results Aripiprazole decreased all PANSS scales (P < 0. 05). Patients showed smaller mean amplitudes of frequency and duration MMN than that of normal controls (P < 0. 05). A repeated measure ANOVA in MMN type (frequency vs. Duration) and session as between-subject factors revealed no significant MMN type or MMN type X session interaction for MMN amplitudes but significant effects of session. A multiple comparisons by LSD tests demonstrated significant differences in MMN amplitudes at after 8 - week treatment from that at baseline (P < 0. 05) and after 4 - week treatment (P < 0. 05). There was no significant differences in MMN amplitudes between 4- week treatment and baseline (P>0. 05). MMN amplitudes at 8- week treatment were higher than that at 4 -week treatment and at baseline (P < 0. 05). Conclusions It presents cognitive dysfunction in schizophrenia. In neuroelectrophysical aspect,MMN offers objective evidence for Aripiprazole to improves cognitive function in schizophrenia.%目的 探讨阿立哌唑对精神分裂症患者失匹配性负波电位(MMN)的影响.方法 随机选自18~65岁符合DSM-精神分裂症标准患者30例作为研究组,30例健康人作为对照组.研究组于阿立哌唑治疗前、4,8周后予MMN检测,同时予PANSS评定病情严重程度.对照组入组时预MMN检测.观察MMN波幅、潜伏期的变化.结果 研究组在治疗4,8周后PANSS量

  20. A control study of aripiprazole vs .risperidone in type II schiz-ophrenia%阿立哌唑与利培酮治疗Ⅱ型精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    徐烨; 何益群

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗Ⅱ型精神分裂症患者的临床疗效和安全性。方法将120例Ⅱ型精神分裂症患者随机分为两组,观察组口服阿立哌唑治疗,对照组口服利培酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,采用韦氏成人智力量表、韦氏记忆量表及韦斯康星卡片分类测验评定认知功能,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降,言语量表、操作量表、全量表和记忆量表评分均较治疗前显著升高( P<0.01);治疗12周末,观察组有效率为85.0%,对照组为88.3%,两组比较差异无显著性( P>0.05)。两组不良反应均轻微,但观察组锥体外系反应、泌乳/闭经、体质量增加、血糖升高发生率显著低于对照组( P<0.05或0.01)。结论阿立哌唑治疗Ⅱ型精神分裂症疗效显著,总体疗效与利培酮相当,但阿立哌唑治疗安全性更高,依从性更好。%Objective To explore the efficacy and safety of aripiprazole vs .risperidone in type II schizo-phrenia .Methods A total of 120 patients with type Ⅱ schizophrenia were randomly divided into two groups ,observation group took orally aripiprazole and control group did risperidone for 12 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) ,cog-nitive fundions with the WAIS-R ,WMS and WCST and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor scores of both groups lowered more significantly compared with pre-treatment ,verbal ,performance ,full and memory scale score height-ened (P 0 .05) .Adverse reactions of both groups were mild ,but the incidence of extrapyramidal reaction ,lactation/amenorrhea ,weight gain ,blood glu-cose elevation were

  1. Clinical Observation on Fluvoxamine and Aripiprazole as Adjunctive Therapy in the Treatment of Obsessive-compulsive Disorders%阿立哌唑辅助氟伏沙明治疗强迫障碍的临床观察

    Institute of Scientific and Technical Information of China (English)

    魏宏强; 康瑞; 李爱玲; 赵秀娟

    2013-01-01

    Objective:To explore the efficacy and safety of fluvoxamine and aripiprazole as adjunctive therapy in the treatment of obsessive-compulsive disorders patients.Method:Total 54 obsessive-compulsive disorders patients were randomly divided into two groups:Fluvoxamine(250-300 mg/d)auxiliaried by aripiprazole(2.5-10 mg/d)group(study group)and fluvoxamine(250-300 mg/d)group(contral group),27 for each. Each group had a 8-week treatment.The efficacy were assessed and analyzed by Yale-Brown Obsessive Compulsive Scale(Y-BOCS) at baseline and at week 2,4,6 and 8. The side effects were assessed by Treatment Emergent Syptom Scale(TESS)during the treatment. Result:Study group and contral group had 1,2 case being off respectively. The obsession and compulsion scores of study group had all statistical difference at baseline and week 2,4 ,6,8 each other(P0.05). At week 4,in both groups,the compulsion scores had statistical difference(P0.05). Conclusion:Fluvoxamine and aripiprazole as adjunctive therapy can effectively continue to improve the compulsive symptoms in the treatment of obsessive-compulsive disorders patients,the rate of side effects is similar to that of simple fluvoxamine therapy.%  目的:探讨阿立哌唑辅助氟伏沙明治疗强迫障碍的临床疗效及安全性.方法:将54例强迫障碍患者随机分为两组(各27例):阿立哌唑(2.5~10 mg/d)辅助氟伏沙明(250~300 mg/d)组(研究组)、氟伏沙明(250~300 mg/d)组(对照组),治疗观察期均为8周.两组患者于基线及治疗2、4、6、8周末分别评定Yale-Brown强迫量表(Y-BOCS),并采用副反应量表(TESS)评定治疗期间的不良反应.结果:研究组、对照组分别脱落1例、2例.研究组的强迫思维和强迫行为评分在基线及2、4、6、8周末时点间比较差异均有统计学意义(P0.05);4周末时,两组间的强迫行为评分比较差异有统计学意义(P0.05).结论:阿立哌唑辅助氟伏沙明可有效、持续地改善强迫障

  2. Effect of aripiprazole combined with clozapine on quality of life in patients with schizophrenia%阿立哌唑合并氯氮平对精神分裂症患者生活质量的影响

    Institute of Scientific and Technical Information of China (English)

    王小红; 周云云; 兰润林; 侯凌峰; 董继雪; 武建斌

    2013-01-01

    Objective:To investigate the effect of aripiprazole combined with clozapine on quality of life in patients with schizophrenia.Method:According to the therapeutic schedule,78 recurrent patients with schizophrenics who were clinical recovery or remarkable progress by the acute treatment were divided into the study group (38 cases) and control group (40 cases).The maintenance treatment was aripiprazole combined with lower dose clozapine in study group and single clozapine in control group.The quality of life was evaluated by scale of general quality of life (GQOL1-74) in the two groups before and after 6,12 months of maintenance treatment,respectively.The results were compared.Results:After 6 and 12 months of maintenance treatment,the scores of GQOL1-74 in in the two groups were significantly increased than before maintenance treatment,and the improvement of score in the study group was more obvious (P <0.01 or P <0.001).The scores of physical function dimension,social function dimension,self-esteem score in psychological functions dimensions in the study group were significantly higher than those in the control group (P < 0.05 or P < 0.01).Conclusion:The quality of life is better in patients with schizophrenia who had the maintenance treatment with aripiprazole combined lower dose clozapine than those with purely clozapine.%目的:探讨阿立哌唑合并氯氮平对精神分裂症患者生活质量的影响. 方法:将78例经急性期治疗达临床痊愈及显著进步的复发性精神分裂症患者按治疗方案分为研究组(38例)和对照组(40例),分别给予阿立哌唑合并低剂量氯氮平及氯氮平单药维持治疗.分别在维持治疗前、6及12个月时采用生活质量综合评定问卷(GQOLl-74)对两组患者生活质量进行评定和比较. 结果:维持治疗6及12个月时,两组GQOLl-74总分较维持治疗前显著提高,且研究组更显著(P<0.01或P<0.001);研究组的躯体功能、社会功能维度评分以及

  3. Aripiprazole combined with clozapine in the treatment of refractory schizophrenia%阿立哌唑合并氯氮平治疗难治性精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    尹永珍

    2015-01-01

    目的:探讨阿立哌唑合并氯氮平治疗难治性精神分裂症的临床疗效及安全性。方法:将68例难治性精神分裂症患者随机分为两组,组34例,研究组口服阿立哌唑联合氯氮平治疗,对照组单用氯氮平治疗,观察8周,于治疗前及治疗第2周,第4周,第8周末采用阳性与阴性症状量表及副反应量表评定临床疗效和不良反应。结果:两组治疗2周末起阳性与阴性症状量表评分均较治疗前有显著下(P<0.05),研究同期两组间比较均无显著性差异(P>0.05),治疗8周末研究组有效率为63.48%,对照组为51.73%,两组无显著性差异(P>0.05),研究组不良反应发生率为31.23%,对照组为57.27%,研究组显著低于对照组(P<0.05),研究组主要表现为静坐不能、震颤、体重增加。对照组主要为流涎、心电图异常、肝功能异常、白细胞减少、嗜睡、头昏、体重增加等。结论:阿立哌唑联合氯氮平治疗难治性精神分裂症疗效显著,安全性高,依从性好。%ObjectiveThe clinical efficacy and safety of aripiprazole combined with clozapine in the treatment of refractory schizophrenia.Methods68 patients with refractory schizophrenia were randomly divided into two groups, each group have 34 cases,the study group use aripiprazole combined with clozapine to treatment, the control group used clozapine treatment, observe 8 weeks, before treatment and second weeks, fourth weeks and eighth weeks using the positive and negative symptoms scale and side effects scale to evaluated the clinical efficacy and adverse reactions.Results The positive and negative symptom scale scores of the two groups after 2 weeks treatment were significantly lower (P 0.05), after 8 weeks the studygroup effective rate was 63.48%, the control group is 51.73%, the two groups was not statistically significant difference (P> 0.05), the incidence of adverse reactions was 31.23% in

  4. Shorterm and mid - term curative effect of Aripiprazole in hyperprolactinemia induced by Risperdai.%阿立哌唑对利培酮所致高催乳素血症的中短期影响

    Institute of Scientific and Technical Information of China (English)

    葛旭峰; 陆燕华; 王佩青; 范慧斌; 刘燕

    2011-01-01

    Objective To study the safety and effectiveness of Aripiprazole in the treatment of hyperprolactinemia induced by Risperdal. Methods Totally 38 female patients with hyperprolactinemia induced by Risperdal received 5mg/d Aripiprazole combination treatment for 24 weeks. The serum prolactin (PRL)level, Risperdal blood concentration and PANSS were measured at baseline and at the end of 4th, 8th, 12th ,24th week respectively. Results After 4 weeks combination treatment, PRL level decreased significantly from 67.58 ± 49. 12ng/ml to 36. 18 ± 35.32ng/ml ( P =0.000). Compared with the baseline, PRL level also decreased significantly at the end of 8th and 12th month(P <0.05 ). The PRL level was stable after 12 weeks treatment. The effective rate was 86.8% and 81.6% respectively at the end of 12th and 24th month. The PRL level of five patients rebounded at the end of 24th month compared with that at the end of 12th month, and two of those five patients' PRL level was higher than normal range. There were no significant differences in PANSS score at each viewpoint compared with the baseline (P > 0. 05 ). Conclusion Aripiprazole is effective and safety in the short - and mid - term treatment of hyperprolactinemia induced by Risperdal, but the long -term effectiveness are not warranted.%目的 探讨利培酮所致高催乳素血症的女性精神分裂症合并应用小剂量阿立哌唑的有效性和安全性.方法 对38例利培酮所致高催乳素血症的女性精神分裂症患者,合并应用阿立哌唑5mg/d,分别于治疗前、治疗第4、8、12、24周末检测血清催乳素水平(PRL)、利培酮血浓度,并评定阳性与阴性症状量表(PANSS).结果 合并治疗4周后PRL显著下降[(67.58+49.12)ng/ml vs(36.18±35.32)ng/ml,P=0.000],在合并治疗的第8周末、第12周末PRL的下降仍存在统计学差异(P0.05).8周末有效率达86.8%,24周末有效率81.6%.全部患者中,有5例在第24周末的PRL浓度较第12

  5. Cancer stem cell metabolism

    National Research Council Canada - National Science Library

    Peiris-Pagès, Maria; Martinez-Outschoorn, Ubaldo E; Pestell, Richard G; Sotgia, Federica; Lisanti, Michael P

    2016-01-01

    .... Cancer stem cells also seem to adapt their metabolism to microenvironmental changes by conveniently shifting energy production from one pathway to another, or by acquiring intermediate metabolic phenotypes...

  6. A Comparative Study on Aripiprazole and Sulpiride in Treating Schizophrenia Negative Symptoms%阿立哌唑与舒必利治疗精神分裂症阴性症状对照研究

    Institute of Scientific and Technical Information of China (English)

    陈妙扬; 肖垚南; 陈丁玲; 黎艳芳

    2014-01-01

    Objective To evaluate the efficacy and safety of aripiprazole and sulpiride in treatment of schizophrenia negative symptoms. Methods 120 cases of schizophrenia whose predominant clin-ical features were negative symptoms were randomly assigned to treat with either aripiprezole or sulpiride for 3 months each. They were all assessed by SANS and TESS. Results There was a significant difference in efficacy between the groups assessed by SANS. Side effects of aripiprezole were significantly fewer than sulpiride assessed by TESS. Conclusions Aripiprazole has better ef-fect on schizophrenia whose negative symptoms as target symptom and less side effects.%目的:比较阿立哌唑与舒必利治疗精神分裂症阴性症状的疗效和安全性。方法选取120例符合中国精神疾病诊断标准(CCMD3)诊断为精神分裂症且以阴性症状为主的患者,根据随机对照的方法分为研究组(60例)和对照组(60例),研究组应用阿立哌唑治疗,对照组舒必利治疗,疗程均为3个月;用阴性症状评定量表(SANS)、用药物副反应量表(TESS)进行评定。结果两组治疗前后1个月比较有显著性差异(P<0.05),治疗后2、3个月与治疗前比较亦有显著性差异(P<0.05);两组药物副反应比较,阿立哌唑组明显舒必利组少,有显著性差异(P<0.05)。结论阿立哌唑对分裂症阴性症状有较好的治疗效果,药物副反应少,使用安全较高。

  7. Profiling metabolic networks to study cancer metabolism.

    Science.gov (United States)

    Hiller, Karsten; Metallo, Christian M

    2013-02-01

    Cancer is a disease of unregulated cell growth and survival, and tumors reprogram biochemical pathways to aid these processes. New capabilities in the computational and bioanalytical characterization of metabolism have now emerged, facilitating the identification of unique metabolic dependencies that arise in specific cancers. By understanding the metabolic phenotype of cancers as a function of their oncogenic profiles, metabolic engineering may be applied to design synthetically lethal therapies for some tumors. This process begins with accurate measurement of metabolic fluxes. Here we review advanced methods of quantifying pathway activity and highlight specific examples where these approaches have uncovered potential opportunities for therapeutic intervention.

  8. Metabolism disrupting chemicals and metabolic disorders.

    Science.gov (United States)

    Heindel, Jerrold J; Blumberg, Bruce; Cave, Mathew; Machtinger, Ronit; Mantovani, Alberto; Mendez, Michelle A; Nadal, Angel; Palanza, Paola; Panzica, Giancarlo; Sargis, Robert; Vandenberg, Laura N; Vom Saal, Frederick

    2017-03-01

    The recent epidemics of metabolic diseases, obesity, type 2 diabetes(T2D), liver lipid disorders and metabolic syndrome have largely been attributed to genetic background and changes in diet, exercise and aging. However, there is now considerable evidence that other environmental factors may contribute to the rapid increase in the incidence of these metabolic diseases. This review will examine changes to the incidence of obesity, T2D and non-alcoholic fatty liver disease (NAFLD), the contribution of genetics to these disorders and describe the role of the endocrine system in these metabolic disorders. It will then specifically focus on the role of endocrine disrupting chemicals (EDCs) in the etiology of obesity, T2D and NAFLD while finally integrating the information on EDCs on multiple metabolic disorders that could lead to metabolic syndrome. We will specifically examine evidence linking EDC exposures during critical periods of development with metabolic diseases that manifest later in life and across generations.

  9. A Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials.

    Science.gov (United States)

    Fornaro, Michele; Ciampa, Giovanni; Mosti, Nicola; Del Carlo, Alessandra; Ceraudo, Giuseppe; Colicchio, Salvatore

    2010-01-01

    Mental Retardation (MR) is a developmental disability characterized by impairments in adaptive daily life skills and difficulties in social and interpersonal functioning. Since multiple causes may contribute to MR, associated clinical pictures may vary accordingly. Nevertheless, when psychiatric disorders as Treatment Resistant Depression (TRD) and/or alcohol abuse co-exist, their proper detection and management is often troublesome, essentially due to a limited vocabulary MR people could use to describe their symptoms, feelings and concerns, and the lack of reliable screening tools. Furthermore, MR people are among the most medicated subjects, with (over) prescription of antidepressants and/or typical antipsychotics being the rule rather than exception. Thus, treatment resistance or even worsening of depression, constitute frequent occurrences. This report describes the case of a person with MR who failed to respond to repetitive trials of antidepressant monotherapies, finally recovering using aripiprazole to fluvoxamine augmentation upon consideration of a putative bipolar diathesis for "agitated" TRD. Although further controlled investigations are needed to assess a putative bipolar diathesis in some cases of MR associated to TRD, prudence is advised in the long-term prescription of antidepressant monotherapies in such conditions.

  10. Relationship between serum concentration and clinical efficacy of aripiprazole in the treatment of patients with schizophrenia%阿立派唑治疗精神分裂症的血药浓度与临床效应关系研究

    Institute of Scientific and Technical Information of China (English)

    李建华; 钟华; 沈卫民; 孙菊水; 陈海支; 范振国; 卢桂华

    2011-01-01

    目的:研究阿立哌唑治疗精神分裂症的血药浓度与临床效应之间关系,探索阿立哌唑血药浓度的治疗窗.方法:采用前瞻性研究方法,应用非固定剂量药物治疗8周.以高效液相色谱仪测定阿立哌唑的谷浓度,阳性和阴性症状量表(PANSS),临床总体印象-病情严重程度量表(CGI-SI)评定疗效,治疗时出现的症状量表(TESS)评定不良反应.采用受试者运筹特征曲线(ROC曲线)获得血药浓度的最佳截断值,结合四分位间距法推测阿立哌唑血药浓度的治疗窗.并分析血药浓度与药物剂量、临床疗效、不良反应等之间的相关性.结果:入组80例患者,治疗有效47例、无效29例,另外4例脱落.总的不良反应发生率为32.5%.阿立哌唑血药浓度与药物剂量、PANSS减分率及TESS分值间呈正相关,与CGI-SI分值呈负相关.药物剂量与疗效无相关性.最低有效血药浓度为363 μg/L,发生不良反应的血药浓度阈值为540 μg/L.有效组血药浓度的四分位间距为348~623 μg/L.血药浓度在350~540 μg/L的范围内疗效较好,副反应较轻.结论:阿立哌唑治疗精神分裂症的血药浓度与临床效应之间存在相关性,较适宜的治疗窗是350~540 μg/L.%AIM: To explore the relationship between serum concentration and clinical efficacy of aripiprazole in the treatment of patients with schizophrenia, and the suitable therapeutic window of aripiprazole. METHODS: Prospective study method was adopted. The dosages of aripiprazole were unfixed for eight weeks. The trough serum concentrations were determined by high performance liquid chromatography (HPLC). The clinical efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity of Illnes (CGI-SI), side effects were done with the Treatment Emergent Symptom Scale (TESS). The optimized cutoff value of serum concentration was procured by the receiver operator curve (ROC), and the

  11. Effects of long-term use of aripiprazole and clozapine on myo-cardial enzymes of patients with schizophrenia%长期服用阿立哌唑与氯氮平对精神分裂症患者血清心肌酶的影响

    Institute of Scientific and Technical Information of China (English)

    王冬梅; 李素芝; 王新红

    2016-01-01

    Objective To explore the effects of long‐term use of aripiprazole and clozapine on myocardial enzymes of patients with schizophrenia .Methods Serum myocardial enzymes lev‐els were detected and analyzed in 84 schizophrenics on aripiprazole and 85 ones on clozapine > 3 years ,in‐dexes consisted of creatine kinase (CK) ,creatine kinase isoenzyme MB (CK‐MB) ,lactate dehydrogenase ( LDH) and aspertate aminotransferase (AST ) .Results The CK ,CK‐MB and LDH levels of both groups were all higher than normal value ,but those significantly higher in clizapine than in aripiprazole group (P<0 .05 or 0 .01);AST levels of both groups had no significant difference from normal value . Conclusion Long‐term use of aripiprazole or clozapine could induce the increases of serum myocardial en‐zymes levels in schizophrenics in different degrees ,especially clozapine ,as should be paid attention to .%目的:探讨长期服用阿立哌唑与氯氮平对精神分裂症患者血清心肌酶水平的影响。方法对84例服用阿立哌唑及85例服用氯氮平治疗时间>3 a的精神分裂症患者进行血清心肌酶水平检测分析,指标包括肌酸激酶、肌酸激酶同工酶MB亚型、乳酸脱氢酶和天门冬氨酸氨基转移酶。结果两组肌酸激酶、肌酸激酶同工酶MB亚型、乳酸脱氢酶水平均高于正常值,但氯氮平组显著高于阿立哌唑组( P<0.05或0.01);两组天门冬氨酸氨基转移酶水平与正常值比较均无明显变化。结论精神分裂症患者长期服用阿立哌唑与氯氮平治疗均可导致血清心肌酶水平不同程度的升高,氯氮平升高更为显著,应引起临床医师的关注。

  12. Mangiferin modulation of metabolism and metabolic syndrome.

    Science.gov (United States)

    Fomenko, Ekaterina Vladimirovna; Chi, Yuling

    2016-09-10

    The recent emergence of a worldwide epidemic of metabolic disorders, such as obesity and diabetes, demands effective strategy to develop nutraceuticals or pharmaceuticals to halt this trend. Natural products have long been and continue to be an attractive source of nutritional and pharmacological therapeutics. One such natural product is mangiferin (MGF), the predominant constituent of extracts of the mango plant Mangifera indica L. Reports on biological and pharmacological effects of MGF increased exponentially in recent years. MGF has documented antioxidant and anti-inflammatory effects. Recent studies indicate that it modulates multiple biological processes involved in metabolism of carbohydrates and lipids. MGF has been shown to improve metabolic abnormalities and disorders in animal models and humans. This review focuses on the recently reported biological and pharmacological effects of MGF on metabolism and metabolic disorders. © 2016 BioFactors, 42(5):492-503, 2016.

  13. Cold-induced metabolism

    NARCIS (Netherlands)

    Lichtenbelt, W. van Marken; Daanen, H.A.M.

    2003-01-01

    Purpose of review Cold response can be insulative (drop in peripheral temperature) or metabolic (increase in energy expenditure). Nonshivering thermogenesis by sympathetic, norepinephrine-induced mitochondrial heat production in brown adipose tissue is a well known component of this metabolic

  14. Cold-induced metabolism

    NARCIS (Netherlands)

    van Marken Lichtenbelt, W.D.; Daanen, A.M.

    2003-01-01

    Cold-induced metabolism. van Marken Lichtenbelt WD, Daanen HA. Department of Human Biology, Maastricht University, Maastricht, The Netherlands. PURPOSE OF REVIEW: Cold response can be insulative (drop in peripheral temperature) or metabolic (increase in energy expenditure). Nonshivering thermogenesi

  15. Lipid Metabolism Disorders

    Science.gov (United States)

    ... metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They ...

  16. Mineral metabolism in cats

    OpenAIRE

    Pineda Martos, Carmen María

    2014-01-01

    The present Doctoral Thesis wa metabolism in the feline species. Through a series of studies, the relationship between calcium metabolism and the main hormones involved in it has been determined metabolism during the juvenile stage of growing cats effects linked to feeding calculolytic diets on feline mineral metabolism. The first part of the work was aimed the quantification of intact (I-PTH) and whole PTH) and to characterize the dynamics of PTH secretion, including ...

  17. Engineering Cellular Metabolism

    DEFF Research Database (Denmark)

    Nielsen, Jens; Keasling, Jay

    2016-01-01

    of metabolic engineering and will discuss how new technologies can enable metabolic engineering to be scaled up to the industrial level, either by cutting off the lines of control for endogenous metabolism or by infiltrating the system with disruptive, heterologous pathways that overcome cellular regulation....

  18. Metabolic Engineering X Conference

    Energy Technology Data Exchange (ETDEWEB)

    Flach, Evan [American Institute of Chemical Engineers

    2015-05-07

    The International Metabolic Engineering Society (IMES) and the Society for Biological Engineering (SBE), both technological communities of the American Institute of Chemical Engineers (AIChE), hosted the Metabolic Engineering X Conference (ME-X) on June 15-19, 2014 at the Westin Bayshore in Vancouver, British Columbia. It attracted 395 metabolic engineers from academia, industry and government from around the globe.

  19. 阿立哌唑联合利培酮治疗慢性精神分裂症对照研究%A controlled study on aripiprazole combined with risperidone in the treatment of chronic schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨永秀; 陈斌华; 徐小杰; 陶云海; 施剑飞

    2013-01-01

    目的 评价阿立哌唑联合利培酮治疗慢性精神分裂症的疗效和安全性.方法 212例慢性精神分裂症患者随机分为阿立哌唑联合利培酮组(治疗组,105例)和利培酮组(对照组,107例).分别于治疗前及治疗后第2,4,8周末用阳性症状和阴性症状量表(PANSS)评价疗效,副反应量表(TESS)评价药物不良反应.结果 治疗组完成105例,对照组完成104例.治疗组有效率为92.38%,显著率为77.14%;对照组有效率为85.58%,显著率为66.35%,2组疗效差异无统计学意义(P>0.05).PANSS总分减分及PANSS阴性因子减分在第2,4,8周末治疗组均优于对照组(P <0.05或P<0.01).2组药物不良反应均较轻微,经对症处理大多能缓解,其中在震颤、静坐不能、体重增加及泌乳、月经紊乱等发生率,治疗组明显低于对照组(P<0.05).结论 利培酮联合阿立哌唑治疗慢性精神分裂症疗效良好,不良反应小,患者治疗依从性好.%Objective To evaluate the effectiveness and safety of aripiprazole combined risperidone in the treatment of chronic schizophrenia.Methods A total of 212 patients diagnosed as chronic schizophrenia were randomly divided into aripiprazole combined risperidone group (treatment group,n =105) and risperidone group (control group,n =107).Clinical effectiveness was assessed with the positive and negative syndrome scale(PANSS)and adverse reactions with the treatment emergent symptom scale (TESS) before treatment and at the end of the 2,4,8 week.Results One hundred and five patients of the treatment group and 104 patients of the control group had completed the course.The effective rate and the apparent effect rate in treatment group was 92.38% and 77.14%,whereas that was 85.58% and 66.35% in control group.There was no significant difference between two groups (P > 0.05).Effectiveness of treatment group was superior to control group at the end of the 2,4,8 week by PANSS total scores'subtraction and

  20. 氨磺必利与阿立哌唑治疗首发精神分裂症对照研究%A controlled study of amisulpride vs aripiprazole in the first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陆强

    2015-01-01

    Objective To explore the efficacy and safety of amisulpride and aripi‐prazole in the treatment of first‐episode schizophrenia .Methods Using randomized ,double‐blind ,double‐dummy parallel controlled method 124 first‐episode schizophrenics were assigned to two groups taking o‐rally amisulpride and aripiprazole respectively for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the PANSS and CGI scores of both groups lowered more significantly compared with pretreatment (P 0 .05) .Ad‐verse reactions were mild ,there were no group significant difference in incidence of adverse reaction (P>0 .05) .Conclusion Both amisulpride and aripiprazole have an equivalent evident effect in first‐episode schizophrenia ,take effect rapidly ,and have higher safety and better compliance .%目的:探讨氨磺必利与阿立哌唑治疗首发精神分裂症的疗效及安全性。方法将124例首发精神分裂症患者按随机数字表分为两组,采用双盲、双模拟平行对照的方法分别口服氨磺必利和阿立哌唑治疗,观察8周。采用阳性与阴性症状量表、临床疗效总评量表评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表和临床疗效总评量表评分均较治疗前显著性下降( P<0.05或0.01);治疗8周末氨磺必利组显效率63.3%、总有效率88.3%,阿立哌唑组分别为64.4%、91.5%,两组比较差异无显著性(χ2=0.01、0.33,P>0.05)。不良反应均较轻微,发生率比较差异无显著性(P>0.05)。结论氨磺必利与阿立哌唑治疗首发精神分裂症疗效显著,总体疗效相当,起效快,安全性高,依从性好。

  1. Systems Biology of Metabolism.

    Science.gov (United States)

    Nielsen, Jens

    2017-06-20

    Metabolism is highly complex and involves thousands of different connected reactions; it is therefore necessary to use mathematical models for holistic studies. The use of mathematical models in biology is referred to as systems biology. In this review, the principles of systems biology are described, and two different types of mathematical models used for studying metabolism are discussed: kinetic models and genome-scale metabolic models. The use of different omics technologies, including transcriptomics, proteomics, metabolomics, and fluxomics, for studying metabolism is presented. Finally, the application of systems biology for analyzing global regulatory structures, engineering the metabolism of cell factories, and analyzing human diseases is discussed.

  2. 阿立哌唑与舒必利治疗以阴性症状为主精神分裂症临床对照观察%Aripiprazole vs Sulpiride in Treatment of Schizophrenia with Negative Symptoms

    Institute of Scientific and Technical Information of China (English)

    董雪刚; 郭丽春; 刘祖松; 曾德志

    2015-01-01

    Objective:To explore the efficacy and safety of aripiprazole in treatment of schizophrenia with negative symptoms .Methods:All 80 patients with negative schizophrenia were randomly assigned to study group and control group ,each 40 cases.The patients were treated with aripiprazole or sulpiride re-spectively for 12 weeks.The Positive and Negative Syndrome Scale ( PANSS) and Treatment Emergent Side effect Scale ( TESS ) were used to evaluate the efficacy and adverse effect respectively .Results:①The scores of PANSS were significantly lower after treatment than those before treatment in the both group .②Contrast comparing:in the 4th,8th,12th weekend after treatment ,the scores of PANSS with negative and general mental pathological symptoms factors in the study group were significantly lower than those in the control group(t=-2.014,-4.359,-6.162,-2.180,-3.042,-6.810;P<0.05).So as the total score of PANSS in the 8th,12th weekend after treatment(t=-3.235,-6.080;P<0.01).But the scores of PANSS with positive factor in the study group were significantly higher than those in the control group in the 8th, 12th weekend after treatment(t=4.630,6.142;P<0.01).③The clinical efficacy in the study group in the 12 th weekend after treatment was significantly better than that in the control group .④The incidence of adverse effect in the study group was significantly lower than that in the control group .Conclusion:Aripiprazole is rather effective and safe in treatment of schizophrenia with negative symptoms .It is much better than sulpiride .%目的:探讨阿立哌唑治疗以阴性症状为主精神分裂症的疗效与安全性。方法:将80例以阴性症状为主精神分裂症患者随机分入研究组和对照组,每组40例,分别使用阿立哌唑和舒必利治疗12周,用阳性与阴性综合征量表( PANSS)和副反应量表( TESS)评定临床疗效和安全性。结果:①两组治疗后PANSS评分均较治疗前下降(P<0.01或0.05

  3. 阿立哌唑与利培酮治疗女性精神分裂症的临床疗效分析%Effective analysis of aripiprazole and risperidone for patients with first-episode female Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张加明

    2014-01-01

    目的:对阿立哌唑与利培酮对女性首发精神分裂症的临床疗效以及对患者认知功能的影响进行观察和分析。方法:将我院2010年4月~2013年11月收治的128例女性首发精神分裂患者随机分为阿立哌唑组和利培酮组,每组各64例。2组患者分别于治疗前后采用阳性与阴性症状量表(PANSS)、临床总体印象量表(CGI)以及副反应量表(TESS)对患者的临床疗效和副反应进行评定和比较。结果:2组患者治疗后其阳性症状、阴性症状、一般病理、PANSS总分以及CGI总分均较治疗前显著降低(P<0.01),但组间比较并无明显差异(P>0.05)。治疗后阿立哌唑组和利培酮组的临床显效率和有效率分别为73.44%、96.88%和70.31%、90.62%,差异均不具有统计学意义( P>0.05),而TESS评定结果显示,阿立哌唑组患者评分8.31±4.20分明显低于利培酮组患者评分9.29±4.16分。结论:阿立哌唑和利培酮治疗女性首发精神分裂症上均可有效改善患者的阳性症状、阴性症状、一般病理而起到良好的临床疗效,但相比而言阿立哌唑在治疗过程中副反应更小,因而更加安全有效。%Objective:To explore the efficacy of aripiprazole and risperidone in the treatment of first -episode female schizophrenia . Methods:To select 128 cases of patients with first-episode female schizophrenia who were treated in our hospital from April 2010 to No-vember 2013,and were randomly divided into the saripiprazole group and the risperidone group ,each group was 64 cases.Two groups of patients were take the positive and negative symptoms scale ( PANSS) , the clinical general impression scale (CGI) and the treatment e-mergent symptom scale ( TESS) respectively before and after treatment to evaluated the clinical efficacy and the adverse event .Results:The positive symptoms , negative symptoms , general pathology , PANSS

  4. Sustained metabolic scope.

    Science.gov (United States)

    Peterson, C C; Nagy, K A; Diamond, J

    1990-03-01

    Sustained metabolic rates (SusMR) are time-averaged metabolic rates that are measured in free-ranging animals maintaining constant body mass over periods long enough that metabolism is fueled by food intake rather than by transient depletion of energy reserves. Many authors have suggested that SusMR of various wild animal species are only a few times resting (basal or standard) metabolic rates (RMR). We test this conclusion by analyzing all 37 species (humans, 31 other endothermic vertebrates, and 5 ectothermic vertebrates) for which SusMR and RMR had both been measured. For all species, the ratio of SusMR to RMR, which we term sustained metabolic scope, is less than 7; most values fall between 1.5 and 5. Some of these values, such as those for Tour de France cyclists and breeding birds, are surely close to sustainable metabolic ceilings for the species studied. That is, metabolic rates higher than 7 times RMR apparently cannot be sustained indefinitely. These observations pose several questions: whether the proximate physiological causes of metabolic ceilings reside in the digestive tract's ability to process food or in each tissue's metabolic capacity; whether ceiling values are independent of the mode of energy expenditure; whether ceilings are set by single limiting physiological capacities or by coadjusted clusters of capacities (symmorphosis); what the ultimate evolutionary causes of metabolic ceilings are; and how metabolic ceilings may limit animals' reproductive effort, foraging behavior, and geographic distribution.

  5. A control study of influence of amisulpride,clozapine and aripiprazole on electrocardiogram and serum levels of myocardial enzymogram in patients with schizophrenia%氨磺必利与氯氮平、阿立哌唑对精神分裂症患者心肌酶和心电图影响的对比研究

    Institute of Scientific and Technical Information of China (English)

    常学润; 张敬悬; 何云鹏

    2015-01-01

    Objective To study the influence of amisulpride,clozapine and aripiprazole on electrocardiogram and serum levels of myocardial enzymogram in patients with schizophrenia.Methods 180 schizophrenic patients were randomly divided into amisulpride group (n =60),clozapine group (n =60)and aripiprazole group (n =60)treated with amisulpride,clozapine and aripiprazole respectively.The electrocardiogram and serum levels of myocardial enzymogram including AST,CK,CK-MB, LDH,α-HBDH were measured at baseline and at the end of the 2nd ,4th ,8th and 12th week of the treatment.Results (1)At the end of the 8th week,serum level of AST in aripiprazole group,as well as serum levels of CK-MB and LDH in amisulpride group were significantly higher than those at baseline (P <0.05 ).Serum levels of CK and α-HBDH in 3 groups were significantly higher at the 4th,8th and 12th week of the treatment than those at baseline (P <0.05).(2)There was significant difference in incidence of abnormal T wave among 3 groups at the 12th week (P <0.05).The incidence of abnormal T wave in clozapine group was significantly higher than that in amisulpride group and aripiprazole group (P <0.05).(3)The incidence rate of abnormal electrocardiogram showed significant difference among 3 groups at the 12th week (P <0.01 ),and was significantly higher in clozapine group than that in amisulpride group and aripiprazole group (P <0.05).Inner-group comparison showed that incidence rates of abnormal electrocardiogram in amisulpride group and aripiprazole group were significantly lower at the end of the 12th week than that at the end of the 2nd week respectively (P <0.05).Conclusion Amisulpride,clozapine and aripiprazole can cause a certain adverse effects on electrocardiogram and myocardial enzymogram in patients with schizophrenia. The influence on electrocardiogram is relatively more obvious in clozapine treated patients and is likely to be more serious with the progress of treatment.%目的:比较氨磺必利与氯

  6. 首发精神分裂症患者使用阿立哌唑后血清IL-2、IL-4水平变化的探讨%Explore the level changes of IL-2,IL-4 in the first-episode schizophrenia after the treatment of arip-iprazole

    Institute of Scientific and Technical Information of China (English)

    刘倩倩; 李亚飞; 朱祥路; 蒋天玉

    2014-01-01

    Objective To explore the differences of serum IL-2 ,IL-4 in the first-episode schizo-phrenia and healthy controls were explored ,and to compare the changes of symptoms before and after aripiprazole treatment and the changes of serum IL-2 ,IL-4 .Methods Serum of IL-2 ,IL-4 was exam-ined with Flow Cytometry in 35 healthy volunteers and 35 first episode patients .The symptoms of pa-tients were evaluated with Positive and Negative Syndrome Scale .Results There were no statistical sig-nificantly differents in the serum of IL-2 ,IL-4 in the first-episode schizophrenia than normal .controls (P>0 .05) .The serum levels of IL-4 was lower in patients with first-episode schizophrenia after aripi-prazole treatment (P<0 .01) .IL-2 and IL-4 levels were increased in positive symptoms of schizophre-nia patients before aripiprazole treatment (positive symptoms) than normal controls (P<0 .05) .IL-2 and IL-4 levels were different in positive symptoms of schizophrenia patients before and after aripi-prazole treatment (P<0 .05) .Conclusion The patients with schizophrenia have immune dysfunction ;Aripiprazole of antipsychotics have lowered the level of IL-2 ,IL-4 and positive symptoms also im-proved .Conclusion.%目的:探讨首发精神分裂症患者血清细胞因子IL-2、IL-4与正常人的差异,比较分析首发精神分裂症患者经过阿立哌唑治疗前后症状改变及细胞因子IL-2、IL-4的变化。方法选择35例首发精神分裂症患者作为研究组,35例健康志愿者作为对照组,通过流式细胞学技术测定血清标本中IL-2、IL-4的水平,用PANSS量表评定精神症状。结果(1)首发精神分裂症患者IL-2、IL-4水平与正常对照组相比,差异无统计学意义(P>0.05)。(2)首发精神分裂症患者阿立哌唑治疗后较治疗前IL-4水平降低,差异有统计学意义(P<0.01)。(3)首发精神分裂症阳性症状患者血清IL-2、IL-4水平在治疗前均高于对照组(P<0.05

  7. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of Efifcacy and Safety of Aripiprazole and Risperidone Treating Behavioral and Psychological Symptoms of Dementia

    Institute of Scientific and Technical Information of China (English)

    李洪涛

    2015-01-01

    目的:通过临床试验对阿立哌唑和利培酮对于痴呆精神行为的疗效和安全性进行观察和探讨。方法将本科室近来收治的有痴呆精神行为症状的患者72人进行随机分组,每组36人,并分别用阿立哌唑(A组)和利培酮来(B组)对患者进行为期8 w的治疗,在治疗之前以及治疗的第2、4以及第8周的最后一天对72名患者采用BEHAV-AD对患者的病理行为进行评定,以此来对两种药物的有效性进行对比;同时采用TESS(不良反应检测表)来对药物的安全性进行分析和比较。结果通过阿立哌唑和利培酮进行治疗的两组患者在治疗后BEHAV-AD评分较治疗之前有了明显的降低,A、B两组患者的治疗之前与治疗之后的BEHAV-AD评分相比较具有较为明显的统计学差异(P<0.05)。另外服用阿立哌唑的A组患者的不良反应发生率明显比服用利培酮的B组患者的不良反应发生率低,通过对差异进行分析发现,此差异同样具有统计学意义(P<0.01)。结论阿立哌唑和利培酮对于痴呆精神行为都具有较为明显的疗效,但是利培酮的安全性相比阿立哌唑较差。%Objective Observe and investigate the efficacy and safety of aripiprazole and risperidone for spirit behavior of dementia. Methods 72 patients with behavioral and psychological symptoms of dementia were randomly assigned into two groups, 36 people in each group , they were treated with aripiprazole (A group) and risperidone to (group B) respectively for a period of 8 w, assessed the behavior of the patients by BEHAV-AD at the points of prior to treatment, treatment of 2, 4 and 8 weeks , and the last day, compared the effectiveness of the two drugs, at the same time using the TESS (adverse reaction detection table) to assess the safety of the drugs. Results After the treatment of aripiprazole and risperidone, BEHAV-AD score signiifcantly reduced in two groups, there were

  8. 氨磺必利与阿立哌唑口崩片治疗以阴性症状为主的精神分裂症的临床对照研究%A controlled clinical study of amisulpride and aripiprazole orally disintegrating tablets in treatment of negative schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘晓

    2014-01-01

    目的:比较氨磺必利和阿立哌唑口崩片治疗以阴性症状为主的精神分裂症的临床疗效和安全性。方法采用随机对照研究,将64例符合《中国精神障碍分类与诊断标准(第3版)》(CCMD-3)诊断标准的以阴性症状为主的精神分裂症患者按照入组先后顺序分为氨磺必利组(研究组)和阿立哌唑口崩片组(对照组)各32例,疗程8周,采用阳性和阴性症状量表( PANSS)评定疗效,采用副反应量表( TESS)评定不良反应。结果治疗8周后,两组PANSS评分均下降(P>0.05),氨磺必利组和阿立哌唑口崩片组有效率分别为90.63%,87.5%,差异无统计学意义(P>0.05)。两组TESS评分分别为(3.98±1.03)分、(4.07±1.89)分,差异无统计学意义(P>0.05)。结论氨磺必利与阿立哌唑口崩片治疗以阴性症状为主的精神分裂症疗效相当,不良反应轻。%Objective To compare the efficacy and safety between amisulpride and aripiprazole in treatment of negative schizo-phrenia. Methods Using randomized controlled trials in this study, 64 patients diagnosed with negative schizophrenia were randomly divided into amisulpride group (study group) and aripiprazole orally disintegrating tablets group (control group). The positive and negative scale ( PANSS) was used to evaluate the efficacy, and treatment emergent side effect scale ( TESS) was used to evaluate the advese reactions. The course of treatment was eight weeks. Results PANSS(P>0. 05) scores of the two groups were both significant-ly decreased after 8 weeks, the efficacy rates of amisulpride group and aripiprazole orally disintegrating tablets group were 90. 63% and 87. 5%, which two groups showed no significant difference fromχ2 test (P>0. 05). The TESS scores of amisulpride group and aripi-prazole group were(3. 98 ± 1. 03)and(4. 07 ± 1. 89), The TESS scores of two groups also showed no significant difference by t-test (P>0. 05). Conclusion Amisulpride are as effective as Aripiprazole orally

  9. Metabolic enzymes link morphine withdrawal with metabolic disorder

    Institute of Scientific and Technical Information of China (English)

    Xi Jiang; Jing Li; Lan Ma

    2007-01-01

    @@ Energy metabolism is a fundamental biological process that is vital for the survival of all species. Disorders in the metabolic system result in deficiency or redundancy of certain nutrients, including carbohydrates, lipids, amino acids, etc. Abnormality of the energy metabolism system leads to a number of metabolic diseases, such as the metabolic syndrome. Broadly speaking, the term "metabolic diseases" now tends to be widened to the category that refers to all diseases with metabolism disorder.

  10. Engineering Cellular Metabolism.

    Science.gov (United States)

    Nielsen, Jens; Keasling, Jay D

    2016-03-10

    Metabolic engineering is the science of rewiring the metabolism of cells to enhance production of native metabolites or to endow cells with the ability to produce new products. The potential applications of such efforts are wide ranging, including the generation of fuels, chemicals, foods, feeds, and pharmaceuticals. However, making cells into efficient factories is challenging because cells have evolved robust metabolic networks with hard-wired, tightly regulated lines of communication between molecular pathways that resist efforts to divert resources. Here, we will review the current status and challenges of metabolic engineering and will discuss how new technologies can enable metabolic engineering to be scaled up to the industrial level, either by cutting off the lines of control for endogenous metabolism or by infiltrating the system with disruptive, heterologous pathways that overcome cellular regulation.

  11. Metabolic syndrome and migraine

    Directory of Open Access Journals (Sweden)

    Amit eSachdev

    2012-11-01

    Full Text Available Migraine and metabolic syndrome are highly prevaleirnt and costly conditions.The two conditions coexist, but it is unclear what relationship may exist between the two processes. Metabolic syndrome involves a number of findings, including insulin resistance, systemic hypertension, obesity, a proinflammatory state, and a prothrombotic state. Only one study addresses migraine in metabolic syndrome, finding significant differences in the presentation of metabolic syndrome in migraineurs. However, controversy exists regarding the contribution of each individual risk factor to migraine pathogensis and prevalence. It is unclear what treatment implications, if any, exist as a result of the concomitant diagnosis of migraine and metabolic syndrome. The cornerstone of migraine and metabolic syndrome treatments is prevention, relying heavily on diet modification, sleep hygiene, medication use, and exercise.

  12. Metabolic disorders in menopause

    OpenAIRE

    Grzegorz Stachowiak; Tomasz Pertyński; Magdalena Pertyńska-Marczewska

    2015-01-01

    Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopaus...

  13. METABOLISM OF IRON STORES

    OpenAIRE

    Saito, Hiroshi

    2014-01-01

    ABSTRACT Remarkable progress was recently achieved in the studies on molecular regulators of iron metabolism. Among the main regulators, storage iron, iron absorption, erythropoiesis and hepcidin interact in keeping iron homeostasis. Diseases with gene-mutations resulting in iron overload, iron deficiency, and local iron deposition have been introduced in relation to the regulators of storage iron metabolism. On the other hand, the research on storage iron metabolism has not advanced since th...

  14. Genetic and metabolic engineering

    OpenAIRE

    Yang,Yea-Tyng; Bennett, George N.; San, Ka-yiu

    1998-01-01

    Recent advances in molecular biology techniques, analytical methods and mathematical tools have led to a growing interest in using metabolic engineering to redirect metabolic fluxes for industrial and medical purposes. Metabolic engineering is referred to as the directed improvement of cellular properties through the modification of specific biochemical reactions or the introduction of new ones, with the use of recombinant DNA technology (Stephanopoulos, 1999). This multidisciplinary field dr...

  15. Inflammation and metabolic cardiomyopathy.

    Science.gov (United States)

    Nishida, Kazuhiko; Otsu, Kinya

    2017-03-15

    Excessive feeding is associated with an increase in the incidence of chronic metabolic diseases, such as obesity, insulin resistance, and type 2 diabetes. Metabolic disturbance induces chronic low-grade inflammation in metabolically-important organs, such as the liver and adipose tissue. Many of the inflammatory signalling pathways are directly triggered by nutrients. The pro-inflammatory mediators in adipocytes and macrophages infiltrating adipose tissue promote both local and systemic pro-inflammatory status. Metabolic cardiomyopathy is a chronic metabolic disease characterized by structural and functional alterations and interstitial fibrosis without coronary artery disease or hypertension. In the early stage of metabolic cardiomyopathy, metabolic disturbance is not accompanied by substantial changes in myocardial structure and cardiac function. However, metabolic disturbance induces subcellular low-grade inflammation in the heart, and in turn, subcellular component abnormalities, such as oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, and impaired calcium handling, leading to impaired myocardial relaxation. In the advanced stage, the vicious cycle of subcellular component abnormalities, inflammatory cell infiltration, and neurohumoral activation induces cardiomyocyte injury and death, and cardiac fibrosis, resulting in impairment of both diastolic and systolic functions. This review discusses some recent advances in understanding involvement of inflammation in metabolic cardiomyopathy. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.

  16. What is Nutrition & Metabolism?

    Science.gov (United States)

    Feinman, Richard D; Hussain, M Mahmood

    2004-08-17

    A new Open Access journal, Nutrition & Metabolism (N&M) will publish articles that integrate nutrition with biochemistry and molecular biology. The open access process is chosen to provide rapid and accessible dissemination of new results and perspectives in a field that is of great current interest. Manuscripts in all areas of nutritional biochemistry will be considered but three areas of particular interest are lipoprotein metabolism, amino acids as metabolic signals, and the effect of macronutrient composition of diet on health. The need for the journal is identified in the epidemic of obesity, diabetes, dyslipidemias and related diseases, and a sudden increase in popular diets, as well as renewed interest in intermediary metabolism.

  17. Mathematical modelling of metabolism

    DEFF Research Database (Denmark)

    Gombert, Andreas Karoly; Nielsen, Jens

    2000-01-01

    Mathematical models of the cellular metabolism have a special interest within biotechnology. Many different kinds of commercially important products are derived from the cell factory, and metabolic engineering can be applied to improve existing production processes, as well as to make new processes...... available. Both stoichiometric and kinetic models have been used to investigate the metabolism, which has resulted in defining the optimal fermentation conditions, as well as in directing the genetic changes to be introduced in order to obtain a good producer strain or cell line. With the increasing...... availability of genomic information and powerful analytical techniques, mathematical models also serve as a tool for understanding the cellular metabolism and physiology....

  18. Fluoroacetylcarnitine: metabolism and metabolic effects in mitochondria

    Energy Technology Data Exchange (ETDEWEB)

    Bremer, J.; Davis, E.J.

    1973-01-01

    The metabolism and metabolic effects of fluoroacetylcarnitine have been investigated. Carnitineacetyltransferase transfers the fluoro-acetyl group of fluoroacetylcarnitine nearly as rapidly to CoA as the acetyl group of acetylcarnitine. Fluorocitrate is then formed by citrate synthase, but this second reaction is relatively slow. The fluorocitrate formed intramitochondrially inhibits the metabolism of citrate. In heart and skeletal muscle mitochondria the accumulated citrate inhibits citrate synthesis and the ..beta..-oxidation of fatty acids. Free acetate is formed, presumably because accumulated acetyl-CoA is hydrolyzed. In liver mitochondria the accumulation of citrate leads to a relatively increased rate of ketogenesis. Increased ketogenesis is obtained also upon the addition of citrate to the reaction mixture.

  19. Attractor metabolic networks.

    Directory of Open Access Journals (Sweden)

    Ildefonso M De la Fuente

    Full Text Available BACKGROUND: The experimental observations and numerical studies with dissipative metabolic networks have shown that cellular enzymatic activity self-organizes spontaneously leading to the emergence of a Systemic Metabolic Structure in the cell, characterized by a set of different enzymatic reactions always locked into active states (metabolic core while the rest of the catalytic processes are only intermittently active. This global metabolic structure was verified for Escherichia coli, Helicobacter pylori and Saccharomyces cerevisiae, and it seems to be a common key feature to all cellular organisms. In concordance with these observations, the cell can be considered a complex metabolic network which mainly integrates a large ensemble of self-organized multienzymatic complexes interconnected by substrate fluxes and regulatory signals, where multiple autonomous oscillatory and quasi-stationary catalytic patterns simultaneously emerge. The network adjusts the internal metabolic activities to the external change by means of flux plasticity and structural plasticity. METHODOLOGY/PRINCIPAL FINDINGS: In order to research the systemic mechanisms involved in the regulation of the cellular enzymatic activity we have studied different catalytic activities of a dissipative metabolic network under different external stimuli. The emergent biochemical data have been analysed using statistical mechanic tools, studying some macroscopic properties such as the global information and the energy of the system. We have also obtained an equivalent Hopfield network using a Boltzmann machine. Our main result shows that the dissipative metabolic network can behave as an attractor metabolic network. CONCLUSIONS/SIGNIFICANCE: We have found that the systemic enzymatic activities are governed by attractors with capacity to store functional metabolic patterns which can be correctly recovered from specific input stimuli. The network attractors regulate the catalytic patterns

  20. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of efficacy and safety of aripiprazole and risperidone treating behavioral and psychological symptoms of dementia

    Institute of Scientific and Technical Information of China (English)

    罗克勇; 刘克祥; 王瑞超; 付华斌

    2013-01-01

    目的 观察阿立哌唑和利培酮治疗老年痴呆精神行为症状的疗效及安全性.方法 采用随机对照研究,将具有精神行为症状的痴呆患者68例完全随机分为阿立哌唑组及利培酮组,各34例.阿立哌唑组患者服用阿立哌唑,起始剂量2.5 mg/d,最大剂量不超过15 mg/d;利培酮组患者口服利培酮,起始剂量0.5 mg/d,最大剂量不超过3 mg/d.疗程均为8周.治疗前和治疗第2、4、8周末采用痴呆病理分析评定量表(BEHAVE-AD)评定疗效,用副反应量表(TESS)评定不良反应,并于入组时和治疗第8周末分别检测2组患者空腹血糖、餐后2h血糖、TC、TG、LDL-C、HDL-C及体重.结果 阿立哌唑组和利培酮组患者治疗2、4、8周后BEHAVE-AD评分均明显低于治疗前[阿立哌唑组:(14.8±4.2)、(10.2±3.6)、(6.8±2.8)分比(16.4±4.6)分;利培酮组:(15.2±3.9)、(11.8±3.8)、(7.2±3.0)分比(17.2±5.0)分,P <0.05或P<0.01].2组患者间治疗前及治疗后BEHAVE-AD评分比较,差异均无统计学意义(P>0.05).2组不良反应发生率均为8.8% (3/34),差异无统计学意义(P>0.05).利培酮组治疗8周末体重较治疗前增加明显[(71±6)kg比(66±6) kg,P<0.05],TG及LDL-C升高[分别为(1.62±0.46) mmol/L比(0.96±0.29) mmol/L,(3.82±0.86) mmol/L比(3.08±0.74) mmol/L],而阿立哌唑组则改变不明显(均P>0.05).结论 阿立哌唑治疗老年痴呆精神行为症状总体疗效、安全性与利培酮相当,但阿立哌唑对患者血糖、血脂及体重影响小于利培酮.%Objective To assess the effect and safety of aripiprazole and risperidone in the treatment of behavioral and psychological symptoms of dementia (BPSD).Methods All 68 dementia were randomly divided into aripiprazole group (n =34) and risperidone group (n =34) with a course of 8 weeks.Aripiprazole was administered by patients in aripiprazole group with a starting dose of 2.5 mg/d and less than the maximum dose 15 mg/d,risperidone was administered

  1. Cold-induced metabolism

    NARCIS (Netherlands)

    Lichtenbelt, W. van Marken; Daanen, H.A.M.

    2003-01-01

    Purpose of review Cold response can be insulative (drop in peripheral temperature) or metabolic (increase in energy expenditure). Nonshivering thermogenesis by sympathetic, norepinephrine-induced mitochondrial heat production in brown adipose tissue is a well known component of this metabolic respon

  2. Circadian Systems and Metabolism

    NARCIS (Netherlands)

    Roenneberg, Till; Merrow, Martha

    1999-01-01

    Circadian systems direct many metabolic parameters and, at the same time, they appear to be exquisitely shielded from metabolic variations. Although the recent decade of circadian research has brought insights into how circadian periodicity may be generated at the molecular level, little is known ab

  3. Metabolic Engineering VII Conference

    Energy Technology Data Exchange (ETDEWEB)

    Kevin Korpics

    2012-12-04

    The aims of this Metabolic Engineering conference are to provide a forum for academic and industrial researchers in the field; to bring together the different scientific disciplines that contribute to the design, analysis and optimization of metabolic pathways; and to explore the role of Metabolic Engineering in the areas of health and sustainability. Presentations, both written and oral, panel discussions, and workshops will focus on both applications and techniques used for pathway engineering. Various applications including bioenergy, industrial chemicals and materials, drug targets, health, agriculture, and nutrition will be discussed. Workshops focused on technology development for mathematical and experimental techniques important for metabolic engineering applications will be held for more in depth discussion. This 2008 meeting will celebrate our conference tradition of high quality and relevance to both industrial and academic participants, with topics ranging from the frontiers of fundamental science to the practical aspects of metabolic engineering.

  4. Disorders of fructose metabolism.

    Science.gov (United States)

    Froesch, E R

    1976-11-01

    There are fundamental differences between the metabolic fate of fructose and of glucose. Whereas the metabolism of glucose is controlled by hormones such as insulin, fructose uptake and phosphorylation in the liver occurs independently of hormones and its ultimate metabolic fate is unpredictable. Essential fructosuria, a harmless inherited anomaly of fructose metabolism, is the least harmful of the disorders of fructose metabolism. Hereditary fructose intolerance and fructose-1,6-diphosphatase deficiency are discussed in greater detail with regard to biochemical abnormalities and clinical aspects. HFI is most serious in bottle-fed infants who cannot reject their sucrose-containing diet. Patients with HFI will have no clinical symptoms if kept on a fructose-free diet. In contrast, patients with fructose-1,6-diphosphatase deficiency can tolerate frucose. However, severe infections precipitate attacks of hypoglycaemia and lactic acidosis.

  5. Primary Metabolic Pathways and Metabolic Flux Analysis

    DEFF Research Database (Denmark)

    2015-01-01

    his chapter introduces the metabolic flux analysis (MFA) or stoichiometry-based MFA, and describes the quantitative basis for MFA. It discusses the catabolic pathways in which free energy is produced to drive the cell-building anabolic pathways. An overview of these primary pathways provides...

  6. 研究阿立哌唑与奋乃静联合治疗酒精中毒性精神障碍的临床效果%Clinical Study on the Effect of Aripiprazole and Perphenazine Combined Treatment of Alcoholism Mental Disorder

    Institute of Scientific and Technical Information of China (English)

    肖开提; 苏理旦

    2015-01-01

    目的:研究探讨阿立哌唑与奋乃静联合应用治疗酒精中毒性精神障碍的临床效果。方法选取我院2010年9月~2013年5月间就诊的酒精中毒性精神障碍患者60例,随机分为观察组和对照组。对照组单用奋乃静片进行治疗,观察组在对照组的基础上联用阿立哌唑片进行治疗。结果观察组总有效率为93.3%,对照组总有效率为73.3%,两组相比,差异显著;治疗一段时间后,观察组患者不良反应的发生率为20.0%,对照组患者不良反应的发生率为46.7%,两组相比差异显著。结论采用阿立哌唑与奋乃静联合使用对酒精中毒性精神障碍进行治疗,不良反应少,临床疗效较好。%Objective To explore clinical curative effect of aripiprazole and perphenazine combination in the treatment of alcoholism mental disorder. Methods 60 cases of patients with mental disorders were selected in our hospital in 2010 September~2013 May between the treatment of alcoholism, were randomly divided into observation group and control group. The control treatment group with single Perphenazine Tablets, on the basis of the observation group in the control group were treated with AripiprazoleTablets. Results the total effective rate of observation group was 93.3%, the control group the total effective rate was 73.3%, compared to the two groups, significant difference;after a period of treatment, patients in the observation group the incidence rate of adverse reactions of 20%patients in the control group, the incidence rate of adverse reactions was 46.7%, difference between the two groups was significant. Conclusion the use of aripiprazole and perphenazine combined use of treatment for alcoholic psychosis, less adverse reaction, good clinical curative effect.

  7. 阿立哌唑合并氯氮平对难治性精神分裂症疗效和认知功能影响的研究%A self-controlled study of aripiprazole combined with clozapine on efficacy and cognitive function in patients with treatment-resistant schizophrenia

    Institute of Scientific and Technical Information of China (English)

    司桂梅; 王爱波; 秦爱玲

    2012-01-01

    Objective To explore the effects of aripiprazole combined with clozapine on efficacy and cognitive function for patients with treatment-resistant schizophrenia. Methods A total of 45 treatment-resistant schizophrenic patients treated with clozapine were combined with aripiprazole (10-30mg/d) for 12 weeks,at the same time clozapine was lowered to maintenance does within 2 weeks. The efficacy and side effects were assessed with Positive and Negative Symptom Scale (PANSS) and Treatment Emergent Symptoms Scale (TESS) ,the cognitive function were measured with Wisconsion Card Sorting Test (WCST) and Continuous Performance Test (CPT) at baseline and at the 12th weekend of the treatment. Results At the end of the treatment, scores of PANSS and TESS decreased significantly, and each parameters of cognitive function was significantly improved when compared with those at baseline. Conclusion Aripiprazole combined with clozapine can effectively improve the negative symptoms and cognitive functions in patients with treatment-resistant schizophrenia with few side effects.%目的 探讨阿立哌唑合并氯氮平对难治性精神分裂症疗效及认知功能的影响.方法 对45例原服用氯氮平治疗的难治性精神分裂症患者合并阿立哌唑( 10~30) mg/d治疗12周,同时2周内将氯氮平减量至维持剂量后不再变化,并于合并治疗前及治疗后12周末用阳性与阴性症状量表( PA NSS)、副反应量表(TESS)评定疗效和副反应,以威斯康星卡片(WCST)和连续作业测验(CPT)评定患者的认知功能.结果 合并阿立哌唑治疗后12周末PANSS总分和TESS评分较合并前有明显差异(P<0.01,P<0.05),各项认知功能指标均有不同程度改善.结论 阿立哌唑合并氯氮平对难治性精神分裂症阴性症状及认知功能的改善明显,副反应减少.

  8. 阿立哌唑合并康复训练改善精神分裂症患者生活质量的临床研究%Clinical Study of Aripiprazole Combined with Rehabilitation Training to Improve the Quality of Life in Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程闯; 张新风

    2013-01-01

    Objective:To explore the effect of aripiprazole combined with rehabilitation training in patients with schizophrenia quality of life of the spirit.Method:Met the Chinese classification and diagnostic criteria of mental disorders Third Edition(CCMD-3)criteria for the diagnosis of 90 patients with schizophrenia were randomly divided into two groups,aripiprazole and clozapine in the treatment of,a total of 8 weeks,two groups were psychiatric rehabilitation training. The positive and negative symptoms scale before and after treatment(PANSS)was introduced in June to assess the efficacy,the side effects scale(TESS)assessment of adverse reactions,the WHO quality of life scale(WHOQOL-100)assessment of quality of life.Result:Aripiprazole group and clozapine group markedly effective rate were 73.3%and 75.6%,with no significant difference between two groups(P>0.05);4,8 weeks after treatment,two groups of PANSS scale scores were decreased than that before treatment(P0.05);治疗后4、8周,两组PANSS量表各项因子分均较治疗前下降(P<0.05),但治疗后8周阿立哌唑组阴性症状及一般精神病理分较氯氮平组差异有统计学意义(P<0.05);阿立哌唑组不良反应发生率显著低于氯氮平组(P<0.05);治疗6个月后两组在(WHOQOL-100)量表各领域均较治疗前有统计学意义(P<0.05),但阿立哌唑组在生理领域、心理领域、社会关系领域、精神支柱、生活质量方面较氯氮平组差异有统计学意义(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,合并精神康复治疗可显著改善精神分裂症患者的生活质量。

  9. Metabolic disorders in menopause

    Directory of Open Access Journals (Sweden)

    Grzegorz Stachowiak

    2015-04-01

    Full Text Available Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women’s life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases in menopause, including the role of a tailored menopausal hormone therapy (HT. According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy. Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.

  10. Metabolic disorders in menopause.

    Science.gov (United States)

    Stachowiak, Grzegorz; Pertyński, Tomasz; Pertyńska-Marczewska, Magdalena

    2015-03-01

    Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance - IGT, type 2 diabetes mellitus - T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women's life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases) in menopause, including the role of a tailored menopausal hormone therapy (HT). According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy). Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.

  11. Regulation of lipid metabolism

    Institute of Scientific and Technical Information of China (English)

    Peng LI

    2011-01-01

    @@ Lipids including cholesterol, phospholipids, fatty acids and triacylglycerols are important cellular constituents involved in membrane structure, energy homeostasis and many biological processes such as signal transduction, organelle development and cell differentiation.Recently, the area of lipid metabolism has drawn a great deal of attention due to its emerging role in the development of metabolic disorders such as obesity, diabetes, atherosclerosis and liver steatosis.We decided to organize a special issue of Frontiers in Biology focusing on our current understanding of lipid metabolism.

  12. A Metabolic Switch

    DEFF Research Database (Denmark)

    Hjorth, Poul G.

    Our muscles are metabolically flexible, i.e., they are capable of `switching' between two types of oxidation: (1) when fasting, a predominantly lipid oxidation with high rates of fatty acid uptake, and (2) when fed, suppression of lipid oxidation in favour of increased glucose uptake, oxidation...... and storage, in response to insulin. One of the many manifestations of obesity and Type 2 diabetes is an insulin resistance of the skeletal muscles, which suppresses this metabolic switch. This talk describes recent development of a low-dimensional system of ODEs that model the metabolic switch, displaying...

  13. Sirtuins, Metabolism and Cancer

    Directory of Open Access Journals (Sweden)

    Barbara eMartinez-Pastor

    2012-02-01

    Full Text Available More than a decade ago, sirtuins were discovered as a highly conserved family of NAD+-dependent enzymes that extend lifespan in lower organisms. In mammals, sirtuins are key regulators of stress responses and metabolism, influencing a range of diseases, including diabetes, neurodegeneration and cancer. In recent years, new functions of sirtuins have been characterized, uncovering the underlying mechanisms of their multifaceted role in metabolism. Here, we specifically review recent progress on the role of sirtuins in DNA repair and energy metabolism, further discussing the implication of sirtuins in the biology of cancer.

  14. Clinical observation of aripiprazole orally disintegrating tablets in the improvement of women's weight,prolactin increase caused by risperidone,sulpiride,olanzapine%阿立哌唑口腔崩解片改善利培酮、舒必利、奥氮平致女性体重、泌乳素增加的临床观察

    Institute of Scientific and Technical Information of China (English)

    卓子禄; 王群英; 熊英; 胡俊英

    2015-01-01

    目的:探讨阿立哌唑口腔崩解片改善利培酮、舒必利、奥氮平等精神类药物所致体重、泌乳素增加的临床效果。方法:收治因服用利培酮、舒必利、奥氮平等精神类药物后引起体重增加及高催乳素血症患者60例,所有患者均维持原抗精神类药物的治疗方案,根据随机数字表将患者分为阿立哌唑口腔崩解片组(观察组)30例和安慰剂组(对照组)30例,两组患者干预12周后测量患者体质指数(BMI)变化及催乳素(PRI)的水平,同时采用不良反应量表(TESS)评定阿立哌唑口腔崩解片治疗的不良反应。结果:与对照组相比,观察组治疗后 BMI 及PRL 显著下降,差异有统计学意义(P<0.01)。观察组总有效率93.33%,对照组总有效率76.67%,两组比较有统计学意义(P<0.05)。TESS 评分观察组(5.12±1.12)分,对照组(4.98±1.08)分,两组比较差异无统计学意义(P>0.05)。结论:阿立哌唑口腔崩解片能有效改善利培酮、舒必利、奥氮平等抗精神病药所致体重、泌乳素增加症状,且安全、可靠,值得临床应用和推广。%Objective:To explore the clinical effect of aripiprazole orally disintegrating tablets in the improvement of women's weight,prolactin increase caused by sulpiride,risperidone,olanzapine.Methods:60 cases of weight gain and hyperprolactinemic patients caused by sulpiride,risperidone,olanzapine were selected.All patients maintained antipsychotic drug treatment scheme of the original.According to the random number table,they were divided into the aripiprazole orally disintegrating tablets group(observation group) with 30 cases and the placebo group(control group) with 30 cases.After 12 weeks of treatment,we measured body mass index patients(BMI) changes and prolactin(PRI) level.At the same time,we evaluated the adverse reactions of aripiprazole orally disintegrating tablets treatment using side effects scale

  15. 舒肝解郁胶囊联合阿立哌唑治疗老年精神分裂症阴性症状的临床研究%Clinical research of Shugan Jieyu capsule and aripiprazole in the treatment of senile schizophrenia negative symptoms

    Institute of Scientific and Technical Information of China (English)

    李刚

    2014-01-01

    目的:探讨舒肝解郁胶囊联合阿立哌唑治疗老年精神分裂症阴性症状的临床效果。方法选取本院2011年1月~2013年1月老年精神分裂症阴性症状患者84例,随机分为两组,42例患者采用阿立哌唑治疗为对照组,42例患者采用舒肝解郁胶囊联合阿立哌唑治疗为观察组,治疗前后行阳性与阴性症状量表评定,比较两组患者治疗效果和不良反应情况。结果治疗后,两组患者阳性症状评分、阴性症状评分、一般精神病理症状评分、总分均显著降低。观察组阳性症状评分、阴性症状评分、一般精神病理症状评分、总分均明显低于对照组,观察组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率高于对照组,差异无统计学意义(P>0.05)。结论舒肝解郁胶囊联合阿立哌唑可明显改善老年精神分裂症阴性症状,提高治愈率,且安全性较高。%Objective To investigate clinical effect of Shugan Jieyu capsule and aripiprazole in the treatment of senile schizophrenia negative symptoms. Methods 84 elderly patients with schizophrenia negative symptoms were selected in hospital from January 2010 to January 2013, who were randomly divided into two groups.42 patients treated with aripiprazole as control group.42 patients treated with Shugan Jieyu capsule and aripiprazole as observation group. Therapeutic effect and adverse reaction were compared by positive and negative symptom scale before and after treatment between the two groups. Results Positive symptoms score, negative symptoms score, general psychopathology symptoms score, total score in two groups decreased significantly after treatment. Positive symptoms score, negative symptoms score, general psychopathology symptoms score, total score in observation group were significantly lower than control group. Total effective rate in observation group was significantly

  16. 阿立哌唑与奥氮平治疗老年期痴呆精神行为症状的效果观察%Effect observation on senile dementia with behavioral and psychological symptoms in the treatment with Aripiprazole and olanzapine

    Institute of Scientific and Technical Information of China (English)

    秦素萍

    2012-01-01

    Objective To Investigate the clinical efficacy on senile dementia with behavioral and psychological symptoms in the treatment with Aripiprazole and Olanzapine. Methods 84 patients with senile dementia associated with behavioral and psychiatric symptoms were selected in the hospital from March 2009 to December 2011, who were divided into two groups randomly. 42 patients who used Olanzapine treatment were as the control group. 42 patients who used Aripiprazole in the treatment were as the observation group. The course of treatment was 8 weeks. After treatment of 1 weeks, 2 weeks, 4 weeks, 8 weeks, AD behavioral pathology In scale (BEHAVE-AD), treatment emergent symptom scale (TESS) of patients were performed. Before the treatment and after treatment of 8 weeks, minimum mental state examination was performed. Results After treatment, AD behavioral pathology in scale total score and each factor scores in the control group and observation group decreased significantly. The incidence rate of adverse drug reactions (19.0%) in the observation group was significantly lower than that In the control group (45.2%), the differences were statistically significant (P < 0.05). Minimum mental state examination scores in the control group and observation group evaluated. Total efficiency of AD behavioral pathology In scale score and minimum mental state examination score In the observation group was slightly higher than those In the control group, while there were no significant differences between them (P > 0.05}. Conclusion Aripiprazole and Olanzapine in the treatment of senile dementia with behavioral and psychological symptoms have equivalent clinical efficacy. But Aripiprazole has better security, which is more suitable for clinical use.%目的 探讨阿立哌唑与奥氮平治疗老年期痴呆的精神行为症状的临床疗效.方法 选取我院2009年3月~2011年12月收治的老年期痴呆伴精神行为症状患者84例,随机分为两

  17. Vitamin D metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Deluca, H.F.

    1977-01-01

    During the past decade, an explosion of information has become available on the metabolism and function of vitamin D which is of great importance to clinicians in the treatment of metabolic bone disease. We have learned that vitamin D is the precursor of at least one hormone and that this hormone carries out functions in calcium and phosphorus metabolism bringing about mineralization of bone on one hand, and the prevention of hypocalcaemic tetany on the other. It may also function in the prevention of such degenerative bone diseases as osteoporosis. An important analogue of this hormone, 1..cap alpha..-hydroxyvitamin D/sub 3/ has been prepared and is used successfully in the treatment of a variety of clinical conditions. This presentation will summarize these findings and their possible implications in these metabolic bone diseases.

  18. What is Nutrition & Metabolism?

    Directory of Open Access Journals (Sweden)

    Feinman Richard D

    2004-08-01

    Full Text Available Abstract A new Open Access journal, Nutrition & Metabolism (N&M will publish articles that integrate nutrition with biochemistry and molecular biology. The open access process is chosen to provide rapid and accessible dissemination of new results and perspectives in a field that is of great current interest. Manuscripts in all areas of nutritional biochemistry will be considered but three areas of particular interest are lipoprotein metabolism, amino acids as metabolic signals, and the effect of macronutrient composition of diet on health. The need for the journal is identified in the epidemic of obesity, diabetes, dyslipidemias and related diseases, and a sudden increase in popular diets, as well as renewed interest in intermediary metabolism.

  19. Metabolism. Part III: Lipids.

    Science.gov (United States)

    Bodner, George M.

    1986-01-01

    Describes the metabolic processes of complex lipids, including saponification, activation and transport, and the beta-oxidation spiral. Discusses fatty acid degradation in regard to biochemical energy and ketone bodies. (TW)

  20. Amino Acid Metabolism Disorders

    Science.gov (United States)

    ... this process. One group of these disorders is amino acid metabolism disorders. They include phenylketonuria (PKU) and maple syrup urine disease. Amino acids are "building blocks" that join together to form ...

  1. Sleep & the metabolic syndrome

    National Research Council Canada - National Science Library

    Lam, Jamie C M; Ip, Mary S M

    2010-01-01

    Sleep is an essential part of our daily living, and sleep disturbances may intervene with the biological and physiological processes in human body leading to the development of metabolic dysfunction...

  2. Epigenetics and Cellular Metabolism

    Science.gov (United States)

    Xu, Wenyi; Wang, Fengzhong; Yu, Zhongsheng; Xin, Fengjiao

    2016-01-01

    Living eukaryotic systems evolve delicate cellular mechanisms for responding to various environmental signals. Among them, epigenetic machinery (DNA methylation, histone modifications, microRNAs, etc.) is the hub in transducing external stimuli into transcriptional response. Emerging evidence reveals the concept that epigenetic signatures are essential for the proper maintenance of cellular metabolism. On the other hand, the metabolite, a main environmental input, can also influence the processing of epigenetic memory. Here, we summarize the recent research progress in the epigenetic regulation of cellular metabolism and discuss how the dysfunction of epigenetic machineries influences the development of metabolic disorders such as diabetes and obesity; then, we focus on discussing the notion that manipulating metabolites, the fuel of cell metabolism, can function as a strategy for interfering epigenetic machinery and its related disease progression as well. PMID:27695375

  3. [Metabolic syndrome and melatonin].

    Science.gov (United States)

    Rapoport, S I; Molchanov, A Iu; Golichenkov, V A; Burlakova, O V; Suprunenko, E S; Savchenko, E S

    2013-01-01

    Metabolic syndrome (MS) is characterized by the following symptoms: obesity, AH, dyslipidemia, insulin resistance. Pathophysiologically, MS is underlain by disorders of many biochemical and physiological processes, such as elevated levels of low density lipoproteins, hyperstimulation of pancreatic b-cells, increased insulin secretion, substitution of lipid metabolism for carbohydrate one, overgrowth of adipose tissue, excess production of adiponectin, leptin and other signal molecules and a rise in their local intravascular concentration, weight gain. Endogenous and exogenous melatonin inhibits these pathophysiological mechanisms, normalizes metabolism, equilibrates insulin secretion, prevents pancreatic hyperfunction, phosphorylates insulin receptors, inactivates active oxygen and nitrogen species including those produced in LDLP metabolism. Melatonin has specific MT1 and MT2 receptors localized in all body cells. Due to this, it exerts combined preventive action in patients with MS. Recently, melatonin has been reported to have therapeutic effect in MS; it may be recommended to treat this condition.

  4. Endocrine and Metabolic Disorders

    Science.gov (United States)

    ... for disorders of endocrine glands other than the thyroid, compared to 3.1 percent of visits made by women. The rate of visits due to metabolic and immunity disorders was also higher among men than women (2. ...

  5. Hypothalamic Hormones and Metabolism

    OpenAIRE

    Thio, Liu Lin

    2012-01-01

    The ketogenic diet is an effective treatment for medically intractable epilepsy and may have antiepileptogenic, neuroprotective, and antitumor properties. While on a ketogenic diet, the body obtains most of its calories from fat rather than carbohydrates. This dramatic change in caloric composition results in a unique metabolic state. In turn, these changes in caloric composition and metabolism alter some of the neurohormones that participate in the complex neuronal network regulating energy ...

  6. 帕罗西汀联合不同剂量阿立哌唑治疗强迫症临床疗效观察%Observation on effect and safety of paroxetine combined with different doses of aripiprazole in treating obsessive-compulsive disorder

    Institute of Scientific and Technical Information of China (English)

    李真; 李雪铮

    2016-01-01

    Objective To investigate the effect and safety of paroxetine combined with different doses of aripiprazole in treating obsessive-compulsive disorder. Methods One hundred and ten patients with obsessive-compulsive disorder admitted in our hospital from May 2013 to May 2015 were randomly divided into 5 groups with 22 cases in each group and respectively given single paroxetine(40 mg/d) and paroxetine(40 mg/d) combined 2.5,5.0,7.5,10.0 mg/d of aripiprazole. The effects and adverse effect oc-currence situation were assessed after 8 weeks. Results After treatment,the total score of the Yale-Brown Obsessive Compulsive Scale (YBOCS) in 5 groups were significantly decreased,the score-reducing rate of Y-BOCS in the 2.5,5.0 mg/d groups was sig nificantly higher than that in the single drug group,the difference was statistically significant(P0.05) and the occurrence rate of adverse reactions in the 7.5 ,10.0mg/d groups was significantly higher than that in the single drug group ,the difference was statistically significant(P0.05),7.5、10.0 mg/d组不良反应发生率明显高于单药组,差异均有统计学意义(P<0.05)。结论帕罗西汀联合阿立哌唑用药剂量为2.5、5.0 mg/d时治疗强迫症的临床疗效优于单用帕罗西汀的临床疗效,而安全性无明显差异。

  7. Tumor cell metabolism

    Science.gov (United States)

    Romero-Garcia, Susana; Lopez-Gonzalez, Jose Sullivan; B´ez-Viveros, José Luis; Aguilar-Cazares, Dolores

    2011-01-01

    Cancer is a genetic disease that is caused by mutations in oncogenes, tumor suppressor genes and stability genes. The fact that the metabolism of tumor cells is altered has been known for many years. However, the mechanisms and consequences of metabolic reprogramming have just begun to be understood. In this review, an integral view of tumor cell metabolism is presented, showing how metabolic pathways are reprogrammed to satisfy tumor cell proliferation and survival requirements. In tumor cells, glycolysis is strongly enhanced to fulfill the high ATP demands of these cells; glucose carbons are the main building blocks in fatty acid and nucleotide biosynthesis. Glutaminolysis is also increased to satisfy NADPH regeneration, whereas glutamine carbons replenish the Krebs cycle, which produces metabolites that are constantly used for macromolecular biosynthesis. A characteristic feature of the tumor microenvironment is acidosis, which results from the local increase in lactic acid production by tumor cells. This phenomenon is attributed to the carbons from glutamine and glucose, which are also used for lactic acid production. Lactic acidosis also directs the metabolic reprogramming of tumor cells and serves as an additional selective pressure. Finally, we also discuss the role of mitochondria in supporting tumor cell metabolism. PMID:22057267

  8. Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor Metabolic side effects of antipsychotics and mood stabilizers

    Directory of Open Access Journals (Sweden)

    Paulo José Ribeiro Teixeira

    2006-08-01

    use of lithium and valproic acid once again directed the attention to their metabolic effects. This study aims to review the medical literature with regard to metabolic side effects associated with the use of antipsychotics and mood stabilizers. METHOD: Research was carried out at MEDLINE and LILACS through October 2005. CONCLUSION: Metabolic side effects remain a major concern for psychopharmacology. Clinically relevant weight gain occurs frequently in patients taking antipsychotics and mood stabilizers, particularly clozapine, olanzapine, lithium, and valproic acid. Clozapine and olanzapine are also associated with higher incidence of diabetes mellitus and dyslipidemias, either due to weight gain or because of a direct deleterious action on glucose metabolism. Incidence of obesity and other metabolic disorders is lower with risperidone when compared to olanzapine or clozapine. Carbamazepine is associated with lower weight gain when compared to lithium or valproic acid. Drugs such as haloperidol, ziprasidone, aripiprazole and lamotrigine are not associated with significant weight gain or with higher incidence of diabetes mellitus. They are alternatives for patients more likely to develop these adverse effects.

  9. Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level%阿立哌唑与奥氮平对首发精神分裂症 急性期疗效及对催乳素的影响

    Institute of Scientific and Technical Information of China (English)

    吴小立; 王继辉; 钟智勇; 韩自力

    2011-01-01

    AIM:To study the efficacy on first-episode acute schizophrenia treated with aripiprazole and olanzapine and the effect on plasma prolactin level. METHODS: 65 inpatients with first-episode acute schizophrenia were divided into either olanzapine group [n = 42, M21, F21; age(23. 9±6. 6)year] or aripiprazole group[(n=23, M1l, F12; age (23. 7 ± 7. 2) year] for 4 week treatment. The plasma prolactin level, the Positive and Negative Syndrome Scale (PANSS) and clinical global impressionglobal improvement (CGI-I) were measured before and after 4 week treatment. RESULTS: The score of PANSS (59 ± 13) after therapy in olanzapine group was significantly lower than that before therapy (103+15) (P 0.05) in the CGI-I score between the two groups. The difference of negative symptoms and general psychopathological sub-scale scoreschanging from base to end between the two groups was statistically significant (P<0. 01). Compared with the prolactin baseline level (547 ±382) uIu/mL,the plasma prolactin level (418 ±362) ulu/mL in olanzapine group was significantly decreased after treatment, and there was no difference. Compared with the prolactin baseline level (351 ±299) ulu/mL, the plasma prolactin level (123 ±114) ulu/mL in aripiprazole group was significantly decreased after treatment, and there was significant difference ( P < 0.01). CONCLUSION: The therapeutic effects were similar in the aripiprazole and olanzapine group for first-episode acute schizophrenia. Olanzapine is better for the general psychopathological symptoms, and aripiprazole is better for the negative symptoms. Aripiprazole maybe decrease the plasma prolactin level of first-episode acute schizophrenia.%目的:研究奥氮平和阿立哌唑对首发精神分裂症患者急性期疗效及对血中催乳素(PRI)水平的影响.方法:65例首发精神分裂症患者分为奥氮平组42例[男21例,女21例;年龄(23.9±6.6)岁]和阿立哌唑组23例[男11例,女12例;年龄(23.7±7.2)岁].分别给予奥

  10. Evolutionary dynamics of metabolic adaptation

    NARCIS (Netherlands)

    van Hoek, M.J.A.

    2008-01-01

    In this thesis we study how organisms adapt their metabolism to a changing environment. Metabolic adaptation occurs at different timescales. Organisms adapt their metabolism via metabolic regulation, which happens in the order of minutes to hours and via evolution, which takes many generations. Here

  11. Evolutionary dynamics of metabolic adaptation

    NARCIS (Netherlands)

    van Hoek, M.J.A.

    2008-01-01

    In this thesis we study how organisms adapt their metabolism to a changing environment. Metabolic adaptation occurs at different timescales. Organisms adapt their metabolism via metabolic regulation, which happens in the order of minutes to hours and via evolution, which takes many generations. Here

  12. Metabolism, temperature, and ventilation.

    Science.gov (United States)

    Mortola, Jacopo P; Maskrey, Michael

    2011-10-01

    In mammals and birds, all oxygen used (VO2) must pass through the lungs; hence, some degree of coupling between VO2 and pulmonary ventilation (VE) is highly predictable. Nevertheless, VE is also involved with CO2 elimination, a task that is often in conflict with the convection of O2. In hot or cold conditions, the relationship between VE and VO2 includes the participation of the respiratory apparatus to the control of body temperature and water balance. Some compromise among these tasks is achieved through changes in breathing pattern, uncoupling changes in alveolar ventilation from VE. This article examines primarily the relationship between VE and VO2 under thermal stimuli. In the process, it considers how the relationship is influenced by hypoxia, hypercapnia or changes in metabolic level. The shuffling of tasks in emergency situations illustrates that the constraints on VE-VO2 for the protection of blood gases have ample room for flexibility. However, when other priorities do not interfere with the primary goal of gas exchange, VE follows metabolic rate quite closely. The fact that arterial CO2 remains stable when metabolism is changed by the most diverse circumstances (moderate exercise, cold, cold and exercise combined, variations in body size, caloric intake, age, time of the day, hormones, drugs, etc.) makes it unlikely that VE and metabolism are controlled in parallel by the condition responsible for the metabolic change. Rather, some observations support the view that the gaseous component of metabolic rate, probably CO2, may provide the link between the metabolic level and VE.

  13. Metabolic surgery: quo vadis?

    Science.gov (United States)

    Ramos-Leví, Ana M; Rubio Herrera, Miguel A

    2014-01-01

    The impact of bariatric surgery beyond its effect on weight loss has entailed a change in the way of regarding it. The term metabolic surgery has become more popular to designate those interventions that aim at resolving diseases that have been traditionally considered as of exclusive medical management, such as type 2 diabetes mellitus (T2D). Recommendations for metabolic surgery have been largely addressed and discussed in worldwide meetings, but no definitive consensus has been reached yet. Rates of diabetes remission after metabolic surgery have been one of the most debated hot topics, with heterogeneity being a current concern. This review aims to identify and clarify controversies regarding metabolic surgery, by focusing on a critical analysis of T2D remission rates achieved with different bariatric procedures, and using different criteria for its definition. Indications for metabolic surgery for patients with T2D who are not morbidly obese are also discussed. Copyright © 2013 SEEN. Published by Elsevier Espana. All rights reserved.

  14. Nutrition and metabolic syndrome.

    Directory of Open Access Journals (Sweden)

    Albornoz López, Raúl

    2012-12-01

    Full Text Available The metabolic syndrome comprises a cluster of metabolic abnormalities that increase the risk for cardiovascular disease and type 2 diabetes mellitus. The exact etiology is unclear, although it is known thatthere is a complex interaction between genetic, metabolic and environmental factors. Among the environmental factors, dietary habits play an important role in the treatment and prevention of this condition. General classic recommendations include control of obesity, increased physical activity, decreased intake of saturated fat and cholesterol, reduced intake of simple sugars and increased intake of fruits and vegetables. It has been studied the influence of diets low in carbohydrates, diets rich in polyunsaturated and monounsaturated fatty acids, fiber intake, the Mediterranean diet and the glycemic index in relation to metabolic syndrome.Other nutrients recently studied are the micronutrients (magnesium and calcium, soy and other phytochemicals. Evidence suggests that a healthy diet like the Mediterranean protects against metabolic syndrome,caracterized for a low content in saturated and trans fat, high in monounsaturated and polyunsaturated fatty acids, balanced intake of carbohydrates and high in fiber, fruits and vegetables. There is more controversy about the type of diet of choice for the control ofmetabolic syndrome (low-carbohydrate diets or lowfat, needing more studies on the role of soy and other phytochemicals.

  15. Apelin and energy metabolism

    Directory of Open Access Journals (Sweden)

    Chantal eBertrand

    2015-04-01

    Full Text Available A wide range of adipokines identified over the past years has allowed considering white adipose tissue as a secretory organ closely integrated into overall physiological and metabolic control. Apelin, an ubiquitous peptide was known to exert different physiological effects mainly on the cardiovascular system and the regulation of fluid homeostasis until its identification as an adipokine. This has increased its broad range of action and apelin now appears clearly as a new player in energy metabolism alongside leptin and adiponectin. Apelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion. Moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes. This mini-review will focus on the various systemic apelin effects on energy metabolism by addressing its mechanisms of action. The advances concerning the role of apelin in metabolic diseases in relation with the recent reports on apelin concentrations in obese and/or diabetic subjects will also be discussed.

  16. Metabolism of phencyclidine

    Energy Technology Data Exchange (ETDEWEB)

    Hoag, M.K.P.

    1987-01-01

    Phencyclidine (PCP) is a drug of abuse which may produce, in some users, a persistent schizophreniform psychosis. The possibility that long term effects of PCP are mediated by metabolic activation of the parent compound to reactive species is consistent with the demonstration of metabolism-dependent covalent binding of radiolabeled PCP in vivo and in vitro to macromolecules in rodent lung, liver, and kidney. Formation of the electrophilic iminium ion metabolite of PCP is believed to be critical for covalent binding since binding was inhibited by cyanide ion at concentrations which did not inhibit metabolism of PCP but did trap the iminium ion to form the corresponding alpha-aminonitrile. The present studies were designed to characterize further the biological fate of PCP by identifying possible macromolecular targets of the reactive metabolite(s).

  17. Analytics for Metabolic Engineering.

    Science.gov (United States)

    Petzold, Christopher J; Chan, Leanne Jade G; Nhan, Melissa; Adams, Paul D

    2015-01-01

    Realizing the promise of metabolic engineering has been slowed by challenges related to moving beyond proof-of-concept examples to robust and economically viable systems. Key to advancing metabolic engineering beyond trial-and-error research is access to parts with well-defined performance metrics that can be readily applied in vastly different contexts with predictable effects. As the field now stands, research depends greatly on analytical tools that assay target molecules, transcripts, proteins, and metabolites across different hosts and pathways. Screening technologies yield specific information for many thousands of strain variants, while deep omics analysis provides a systems-level view of the cell factory. Efforts focused on a combination of these analyses yield quantitative information of dynamic processes between parts and the host chassis that drive the next engineering steps. Overall, the data generated from these types of assays aid better decision-making at the design and strain construction stages to speed progress in metabolic engineering research.

  18. Metabolism and neurogenesis.

    Science.gov (United States)

    Knobloch, Marlen; Jessberger, Sebastian

    2017-02-01

    The generation of neurons in the developing and adult mammalian brain by neural stem/progenitor cells (NSPCs) depends on a tight control of NSPC activity and neuronal differentiation that is regulated by a plethora of intrinsic and extrinsic molecular cues. Besides well-studied morphogenic signaling pathways and transcriptional codes that govern the distinct developmental steps from the dividing NSPC to a functional neuron, a critical role of cellular metabolism to determine the functional properties of NSPCs and newborn neurons has been recently identified. Here, we review advances in our understanding of how metabolism affects NSPC behavior and subsequent neuronal differentiation and suggest how metabolism may serve as a common signal integrator to ensure life-long addition of new neurons in the mammalian brain.

  19. Circadian physiology of metabolism.

    Science.gov (United States)

    Panda, Satchidananda

    2016-11-25

    A majority of mammalian genes exhibit daily fluctuations in expression levels, making circadian expression rhythms the largest known regulatory network in normal physiology. Cell-autonomous circadian clocks interact with daily light-dark and feeding-fasting cycles to generate approximately 24-hour oscillations in the function of thousands of genes. Circadian expression of secreted molecules and signaling components transmits timing information between cells and tissues. Such intra- and intercellular daily rhythms optimize physiology both by managing energy use and by temporally segregating incompatible processes. Experimental animal models and epidemiological data indicate that chronic circadian rhythm disruption increases the risk of metabolic diseases. Conversely, time-restricted feeding, which imposes daily cycles of feeding and fasting without caloric reduction, sustains robust diurnal rhythms and can alleviate metabolic diseases. These findings highlight an integrative role of circadian rhythms in physiology and offer a new perspective for treating chronic diseases in which metabolic disruption is a hallmark.

  20. Endocannabinoids and Metabolic Disorders.

    Science.gov (United States)

    Gatta-Cherifi, Blandine; Cota, Daniela

    2015-01-01

    The endocannabinoid system (ECS) is known to exert regulatory control on essentially every aspect related to the search for, and the intake, metabolism and storage of calories, and consequently it represents a potential pharmacotherapeutic target for obesity, diabetes and eating disorders. While the clinical use of the first generation of cannabinoid type 1 (CB(1)) receptor blockers has been halted due to the psychiatric side effects that their use occasioned, recent research in animals and humans has provided new knowledge on the mechanisms of actions of the ECS in the regulation of eating behavior, energy balance, and metabolism. In this review, we discuss these recent advances and how they may allow targeting the ECS in a more specific and selective manner for the future development of therapies against obesity, metabolic syndrome, and eating disorders.

  1. Nitrile Metabolizing Yeasts

    Science.gov (United States)

    Bhalla, Tek Chand; Sharma, Monica; Sharma, Nitya Nand

    Nitriles and amides are widely distributed in the biotic and abiotic components of our ecosystem. Nitrile form an important group of organic compounds which find their applications in the synthesis of a large number of compounds used as/in pharmaceutical, cosmetics, plastics, dyes, etc>. Nitriles are mainly hydro-lyzed to corresponding amide/acid in organic chemistry. Industrial and agricultural activities have also lead to release of nitriles and amides into the environment and some of them pose threat to human health. Biocatalysis and biotransformations are increasingly replacing chemical routes of synthesis in organic chemistry as a part of ‘green chemistry’. Nitrile metabolizing organisms or enzymes thus has assumed greater significance in all these years to convert nitriles to amides/ acids. The nitrile metabolizing enzymes are widely present in bacteria, fungi and yeasts. Yeasts metabolize nitriles through nitrilase and/or nitrile hydratase and amidase enzymes. Only few yeasts have been reported to possess aldoxime dehydratase. More than sixty nitrile metabolizing yeast strains have been hither to isolated from cyanide treatment bioreactor, fermented foods and soil. Most of the yeasts contain nitrile hydratase-amidase system for metabolizing nitriles. Transformations of nitriles to amides/acids have been carried out with free and immobilized yeast cells. The nitrilases of Torulopsis candida>and Exophiala oligosperma>R1 are enantioselec-tive and regiospecific respectively. Geotrichum>sp. JR1 grows in the presence of 2M acetonitrile and may have potential for application in bioremediation of nitrile contaminated soil/water. The nitrilase of E. oligosperma>R1 being active at low pH (3-6) has shown promise for the hydroxy acids. Immobilized yeast cells hydrolyze some additional nitriles in comparison to free cells. It is expected that more focus in future will be on purification, characterization, cloning, expression and immobilization of nitrile metabolizing

  2. Metabolic changes in malnutrition.

    Science.gov (United States)

    Emery, P W

    2005-10-01

    This paper is concerned with malnutrition caused by inadequate intake of all the major nutrients rather than deficiency diseases relating to a single micronutrient. Three common situations are recognised: young children in third world countries with protein-energy malnutrition; adults in the same countries who are chronically adapted to subsisting on marginally inadequate diets; and patients who become malnourished as a result of chronic diseases. In all these situations infectious diseases are often also present, and this complicates the interpretation of biochemical and physiological observations. The metabolic response to starvation is primarily concerned with maintaining a supply of water-soluble substrates to supply energy to the brain. Thus there is an initial rise in metabolic rate, reflecting gluconeogenic activity. As fasting progresses, gluconeogenesis is suppressed to minimise muscle protein breakdown and ketones become the main fuel for the brain. With chronic underfeeding the basal metabolic rate per cell appears to fall, but the mechanistic basis for this is not clear. The main adaptation to chronic energy deficiency is slow growth and low adult body size, although the reduction in energy requirement achieved by this is partially offset by the preservation of the more metabolically active organs at the expense of muscle, which has a lower metabolic rate. The interaction between malnutrition and the metabolic response to trauma has been studied using an animal model. The rise in energy expenditure and urinary nitrogen excretion following surgery were significantly attenuated in malnourished rats, suggesting that malnutrition impairs the ability of the body to mobilise substrates to support inflammatory and reparative processes. However, the healing process in wounded muscle remained unimpaired in malnutrition, suggesting that this process has a high biological priority.

  3. Hypothyroidism in metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Sunil Kumar Kota

    2012-01-01

    Full Text Available Aim: Metabolic syndrome (MetS and hypothyroidism are well established forerunners of atherogenic cardiovascular disease. Considerable overlap occurs in the pathogenic mechanisms of atherosclerotic cardiovascular disease by metabolic syndrome and hypothyroidism. Insulin resistance has been studied as the basic pathogenic mechanism in metabolic syndrome. [1] This cross sectional study intended to assess thyroid function in patients with metabolic syndrome and to investigate the association between hypothyroidism and metabolic syndrome. Materials and Methods: One hundred patients with metabolic syndrome who fulfilled the National Cholesterol Education Program- Adult Treatment Panel (NCEP-ATP III criteria [ 3 out of 5 criteria positive namely blood pressure ≥ 130/85 mm hg or on antihypertensive medications, fasting plasma glucose > 100 mg/dl or on anti-diabetic medications, fasting triglycerides > 150 mg/dl, high density lipoprotein cholesterol (HDL-C 102 cms in men and 88 cms in women] were included in the study group. [2] Fifty patients who had no features of metabolic syndrome (0 out of 5 criteria for metabolic syndrome were included in the control group. Patients with liver disorders, renal disorders, congestive cardiac failure, pregnant women, patients on oral contraceptive pills, statins and other medications that alter thyroid functions and lipid levels and those who are under treatment for any thyroid related disorder were excluded from the study. Acutely ill patients were excluded taking into account sick euthyroid syndrome. Patients were subjected to anthropometry, evaluation of vital parameters, lipid and thyroid profile along with other routine laboratory parameters. Students t-test, Chi square test and linear regression, multiple logistic regression models were used for statistical analysis. P value < 0.05 was considered significant. Results: Of the 100 patients in study group, 55 were females (55% and 45 were males (45%. Of the 50

  4. Toxic and Metabolic Myelopathies.

    Science.gov (United States)

    Ramalho, Joana; Nunes, Renato Hoffmann; da Rocha, Antonio José; Castillo, Mauricio

    2016-10-01

    Myelopathy describes any neurologic deficit related to the spinal cord. It is most commonly caused by its compression by neoplasms, degenerative disc disease, trauma, or infection. Less common causes of myelopathy include spinal cord tumors, infection, inflammatory, neurodegenerative, vascular, toxic, and metabolic disorders. Conditions affecting the spinal cord must be recognized as early as possible to prevent progression that may lead to permanent disability. Biopsy is rarely performed, thus the diagnosis and management rely on patient׳s history, physical examination, laboratory results, and imaging findings. Here we review the clinical presentations, pathophysiological mechanisms, and magnetic resonance imaging findings of myelopathies related to metabolic or toxic etiologies.

  5. Metabolic Factors in Fatigue

    Institute of Scientific and Technical Information of China (English)

    Mark Hargreaves

    2006-01-01

    Increased non-oxidative and oxidative ATP production via metabolic pathways in skeletal muscle is essential for the maintenance of force and power production during exercise. However, substrate depletion and accumulation of metabolic byproducts are potential causes of fatigue. Reduced PCr availability can limit power production during sprint exercise, whereas carbohydrate depletion is a major limitation to endurance performance. During sprint exercise increased Pi and H+ may contribute to fatigue, and during prolonged strenuous exercise, the accumulation of NH3, reactive oxygen species, and heat can limit performance. Appropriate training programs and nutritional interventions are potential strategies to enhance fatigue resistance and exercise performance.

  6. Sleep and Metabolism: An Overview

    Directory of Open Access Journals (Sweden)

    Sunil Sharma

    2010-01-01

    Full Text Available Sleep and its disorders are increasingly becoming important in our sleep deprived society. Sleep is intricately connected to various hormonal and metabolic processes in the body and is important in maintaining metabolic homeostasis. Research shows that sleep deprivation and sleep disorders may have profound metabolic and cardiovascular implications. Sleep deprivation, sleep disordered breathing, and circadian misalignment are believed to cause metabolic dysregulation through myriad pathways involving sympathetic overstimulation, hormonal imbalance, and subclinical inflammation. This paper reviews sleep and metabolism, and how sleep deprivation and sleep disorders may be altering human metabolism.

  7. Metabolism at Evolutionary Optimal States

    Directory of Open Access Journals (Sweden)

    Iraes Rabbers

    2015-06-01

    Full Text Available Metabolism is generally required for cellular maintenance and for the generation of offspring under conditions that support growth. The rates, yields (efficiencies, adaptation time and robustness of metabolism are therefore key determinants of cellular fitness. For biotechnological applications and our understanding of the evolution of metabolism, it is necessary to figure out how the functional system properties of metabolism can be optimized, via adjustments of the kinetics and expression of enzymes, and by rewiring metabolism. The trade-offs that can occur during such optimizations then indicate fundamental limits to evolutionary innovations and bioengineering. In this paper, we review several theoretical and experimental findings about mechanisms for metabolic optimization.

  8. Macrophage Polarization in Metabolism and Metabolic Disease

    Directory of Open Access Journals (Sweden)

    Anna Meiliana

    2013-08-01

    Full Text Available BACKGROUND: Obesity is now recognized as the main cause of the worldwide epidemic of type 2 diabetes. Obesity-associated chronic inflammation is a contributing key factor for type 2 diabetes and cardiovascular disease. Numbers of studies have clearly demonstrated that the immune system and metabolism are highly integrated. CONTENT: Macrophages are an essential component of innate immunity and play a central role in inflammation and host defense. Moreover, these cells have homeostatic functions beyond defense, including tissue remodeling in ontogenesis and orchestration of metabolic functions. Diversity and plasticity are hallmarks of cells of the monocyte-macrophage lineage. In response to interferons (IFNs, toll-like receptor (TLR, or interleukin (IL-4/IL-13 signals, macrophages undergo M1 (classical or M2 (alternative activation. Progress has now been made in defining the signaling pathways, transcriptional networks, and epigenetic mechanisms underlying M1, M2 or M2-like polarized activation. SUMMARY: In response to various signals, macrophages may undergo classical M1 activation (stimulated by TLR ligands and IFN-γ or alternative M2 activation (stimulated by IL-4/IL-13; these states mirror the T helper (Th1–Th2 polarization of T cells. Pathology is frequently associated with dynamic changes in macrophage activation, with classically activated M1 cells implicate in initiating and sustaining inflammation, meanwhile M2 or M2-like activated cells associated with resolution or smoldering chronic inflammation. Identification of the mechanisms and molecules that are associated with macrophage plasticity and polarized activation provides a basis for macrophage centered diagnostic and therapeutic strategies. KEYWORDS: obesity, adipose tissue, inflammation, macrophage polarization.

  9. Aripiprazole in the treatment of Alzheimer's disease

    NARCIS (Netherlands)

    De Deyn, P.P.; Drenth, Annemieke F. J.; Kremer, B.P.; Oude Voshaar, R.C.; Van Dam, D.

    2013-01-01

    Introduction: Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and care-giver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because of increased

  10. Aripiprazole in the treatment of Alzheimer's disease

    NARCIS (Netherlands)

    Deyn, P.P. de; Drenth, A.F.; Kremer, B.; Oude Voshaar, R.C.; Dam, D. Van

    2013-01-01

    INTRODUCTION: Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and caregiver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because of increased m

  11. ENDOCRINOLOGY AND METABOLISM

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    2006162 Change of vascular endothelial function in patients with disorders of glucose metabolism. ZHANG Songjing,(张松菁),et al. Dept Endocrinol ,1st Hosp, Fujian Med Univ ,Fuzhou 350005. Chin J Endocrinol Metab 2006;22(1): 11 - 14. Objective: To observe the changes of the endothelium - dependent vasodilation ( EDF) and serum superoxide

  12. Sterol metabolism of insects

    NARCIS (Netherlands)

    Ritter, F.J.; Wientjens, W.H.J.M.

    1967-01-01

    This article surveys the present knowledge of the sterol metabolism of insects. It is emphasized that a high degree of purity of the dietary sterols and the climination of the influence of symbionts are essential to present ambiguity in interpreting results. It is pointed out that a sharp distinctio

  13. Lipoprotein(a) metabolism

    Science.gov (United States)

    Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein. The metabolism of this lipoprotein is still not well understood. It has long been known that the plasma concentration of Lp(a) is highly heritable, with its genetic determinants located in the apo(a) locus and regulating the rate of hepatic apo(a...

  14. Ghrelin and Metabolic Surgery

    Directory of Open Access Journals (Sweden)

    Dimitrios J. Pournaras

    2010-01-01

    Full Text Available Metabolic surgery is the most effective treatment for morbid obesity. Ghrelin has been implicated to play a role in the success of these procedures. Furthermore, these operations have been used to study the gut-brain axis. This article explores this interaction, reviewing the available data on changes in ghrelin levels after different surgical procedures.

  15. Methanogenesis: Syntrophic metabolism

    NARCIS (Netherlands)

    Sieber, J.R.; McInerney, M.J.; Plugge, C.M.; Schink, B.; Gunsales, R.P.

    2009-01-01

    "Water is life!" All active cellular systems require water as the medium and solvent of their metabolic activities. Hydrophobic compounds and structures, which tend to exclude water, though providing inter alia excellent sources of energy and a means of biological compartmentalization, present

  16. Glial metabolism of valine.

    Science.gov (United States)

    Murín, Radovan; Mohammadi, Ghasem; Leibfritz, Dieter; Hamprecht, Bernd

    2009-07-01

    The three essential amino acids, valine, leucine and isoleucine, constitute the group of branched-chain amino acids (BCAAs). BCAAs are rapidly taken up into the brain parenchyma, where they serve several distinct functions including that as fuel material in brain energy metabolism. As one function of astrocytes is considered the production of fuel molecules that support the energy metabolism of adjacent neural cells in brain. Astroglia-rich primary cultures (APC) were shown to rapidly dispose of the BCAAs, including valine, contained in the culture medium. While the metabolisms of leucine and isoleucine by APC have already been studied in detail, some aspects of valine metabolism remained to be determined. Therefore, in the present study an NMR analysis was performed to identify the (13)C-labelled metabolites that are generated by APC during catabolism of [U-(13)C]valine and that are subsequently released into the incubation medium. The results presented show that APC (1) are potently disposing of the valine contained in the incubation medium; (2) are capable of degrading valine to the tricarboxylic acid (TCA) cycle member succinyl-CoA; and (3) release into the extracellular milieu valine catabolites and compounds generated from them such as [U-(13)C]2-oxoisovalerate, [U-(13)C]3-hydroxyisobutyrate, [U-(13)C]2-methylmalonate, [U-(13)C]isobutyrate, and [U-(13)C]propionate as well as several TCA cycle-dependent metabolites including lactate.

  17. Prebiotic metabolic networks?

    OpenAIRE

    Luisi, Pier Luigi

    2014-01-01

    A prebiotic origin of metabolism has been proposed as one of several scenarios for the origin of life. In their recent work, Ralser and colleagues (Keller et al, 2014) observe an enzyme‐free, metabolism‐like reaction network under conditions reproducing a possible prebiotic environment.

  18. Sucrose Metabolism in Plastids

    NARCIS (Netherlands)

    Gerrits, N.; Turk, S.C.H.J.; Dun, van K.P.M.; Hulleman, H.D.; Visser, R.G.F.; Weisbeek, P.J.; Smeekens, S.C.M.

    2001-01-01

    The question whether sucrose (Suc) is present inside plastids has been long debated. Low Suc levels were reported to be present inside isolated chloroplasts, but these were argued to be artifacts of the isolation procedures used. We have introduced Suc-metabolizing enzymes in plastids and our experi

  19. Prebiotic metabolic networks?

    OpenAIRE

    2014-01-01

    A prebiotic origin of metabolism has been proposed as one of several scenarios for the origin of life. In their recent work, Ralser and colleagues (Keller et al, 2014) observe an enzyme‐free, metabolism‐like reaction network under conditions reproducing a possible prebiotic environment.

  20. Methanogenesis: Syntrophic metabolism

    NARCIS (Netherlands)

    Sieber, J.R.; McInerney, M.J.; Plugge, C.M.; Schink, B.; Gunsales, R.P.

    2009-01-01

    "Water is life!" All active cellular systems require water as the medium and solvent of their metabolic activities. Hydrophobic compounds and structures, which tend to exclude water, though providing inter alia excellent sources of energy and a means of biological compartmentalization, present probl

  1. Rethinking Guard Cell Metabolism.

    Science.gov (United States)

    Santelia, Diana; Lawson, Tracy

    2016-11-01

    Stomata control gaseous fluxes between the internal leaf air spaces and the external atmosphere and, therefore, play a pivotal role in regulating CO2 uptake for photosynthesis as well as water loss through transpiration. Guard cells, which flank the stomata, undergo adjustments in volume, resulting in changes in pore aperture. Stomatal opening is mediated by the complex regulation of ion transport and solute biosynthesis. Ion transport is exceptionally well understood, whereas our knowledge of guard cell metabolism remains limited, despite several decades of research. In this review, we evaluate the current literature on metabolism in guard cells, particularly the roles of starch, sucrose, and malate. We explore the possible origins of sucrose, including guard cell photosynthesis, and discuss new evidence that points to multiple processes and plasticity in guard cell metabolism that enable these cells to function effectively to maintain optimal stomatal aperture. We also discuss the new tools, techniques, and approaches available for further exploring and potentially manipulating guard cell metabolism to improve plant water use and productivity. © 2016 American Society of Plant Biologists. All Rights Reserved.

  2. Metabolic Syndrome (For Parents)

    Science.gov (United States)

    ... the road to heart disease and type 2 diabetes . Kids with metabolic syndrome have at least three of ... previous 1 • 2 • 3 • 4 For Teens For Kids For Parents MORE ON THIS TOPIC Diabetes Center Acanthosis Nigricans Overweight and Obesity Can Diabetes ...

  3. Diversified glucosinolate metabolism

    DEFF Research Database (Denmark)

    Frisch, Tina; Motawie, Mohammed Saddik; Olsen, Carl Erik;

    2015-01-01

    were biosynthesized from methionine. The biosynthesis of alliarinoside was shown not to bifurcate from sinigrin biosynthesis at the oxime level in contrast to the general scheme for hydroxynitrile glucoside biosynthesis. Instead, the aglucon of alliarinoside was formed from metabolism of sinigrin...

  4. Dysregulated metabolism contributes to oncogenesis

    Science.gov (United States)

    Hirschey, Matthew D.; DeBerardinis, Ralph J.; Diehl, Anna Mae E.; Drew, Janice E.; Frezza, Christian; Green, Michelle F.; Jones, Lee W.; Ko, Young H.; Le, Anne; Lea, Michael A.; Locasale, Jason W.; Longo, Valter D.; Lyssiotis, Costas A.; McDonnell, Eoin; Mehrmohamadi, Mahya; Michelotti, Gregory; Muralidhar, Vinayak; Murphy, Michael P.; Pedersen, Peter L.; Poore, Brad; Raffaghello, Lizzia; Rathmell, Jeffrey C.; Sivanand, Sharanya; Vander Heiden, Matthew G.; Wellen, Kathryn E.

    2015-01-01

    Cancer is a disease characterized by unrestrained cellular proliferation. In order to sustain growth, cancer cells undergo a complex metabolic rearrangement characterized by changes in metabolic pathways involved in energy production and biosynthetic processes. The relevance of the metabolic transformation of cancer cells has been recently included in the updated version of the review “Hallmarks of Cancer”, where the dysregulation of cellular metabolism was included as an emerging hallmark. While several lines of evidence suggest that metabolic rewiring is orchestrated by the concerted action of oncogenes and tumor suppressor genes, in some circumstances altered metabolism can play a primary role in oncogenesis. Recently, mutations of cytosolic and mitochondrial enzymes involved in key metabolic pathways have been associated with hereditary and sporadic forms of cancer. Together, these results suggest that aberrant metabolism, once seen just as an epiphenomenon of oncogenic reprogramming, plays a key role in oncogenesis with the power to control both genetic and epigenetic events in cells. In this review, we discuss the relationship between metabolism and cancer, as part of a larger effort to identify a broad-spectrum of therapeutic approaches. We focus on major alterations in nutrient metabolism and the emerging link between metabolism and epigenetics. Finally, we discuss potential strategies to manipulate metabolism in cancer and tradeoffs that should be considered. More research on the suite of metabolic alterations in cancer holds the potential to discover novel approaches to treat it. PMID:26454069

  5. Hypoxamirs and Mitochondrial Metabolism

    Science.gov (United States)

    Cottrill, Katherine A.; Chan, Stephen Y.

    2014-01-01

    Abstract Significance: Chronic hypoxia can drive maladaptive responses in numerous organ systems, leading to a multitude of chronic mammalian diseases. Oxygen homeostasis is intimately linked with mitochondrial metabolism, and dysfunction in these systems can combine to form the backbone of hypoxic-ischemic injury in multiple tissue beds. Increased appreciation of the crucial roles of hypoxia-associated miRNA (hypoxamirs) in metabolism adds a new dimension to our understanding of the regulation of hypoxia-induced disease. Recent Advances: Myriad factors related to glycolysis (e.g., aldolase A and hexokinase II), tricarboxylic acid cycle function (e.g., glutaminase and iron-sulfur cluster assembly protein 1/2), and apoptosis (e.g., p53) have been recently implicated as targets of hypoxamirs. In addition, several hypoxamirs have been implicated in the regulation of the master transcription factor of hypoxia, hypoxia-inducible factor-1α, clarifying how the cellular program of hypoxia is sustained and resolved. Critical Issues: Central to the discussion of metabolic change in hypoxia is the Warburg effect, a shift toward anaerobic metabolism that persists after normal oxygen levels have been restored. Many newly discovered targets of hypoxia-driven microRNA converge on pathways known to be involved in this pathological phenomenon and the apoptosis-resistant phenotype associated with it. Future Directions: The often synergistic functions of miRNA may make them ideal therapeutic targets. The use of antisense inhibitors is currently being considered in diseases in which hypoxia and metabolic dysregulation predominate. In addition, exploration of pleiotripic miRNA functions will likely continue to offer unique insights into the mechanistic relationships of their downstream target pathways and associated hypoxic phenotypes. Antioxid. Redox Signal. 21, 1189–1201. PMID:24111795

  6. SIRT1 and energy metabolism

    Institute of Scientific and Technical Information of China (English)

    Xiaoling Li

    2013-01-01

    Sirtuin 1 (SIRT1) is the most conserved mammalian NAD+-dependent protein deacetylase that has emerged as a key metabolic sensor in various metabolic tissues.In response to different environmental stimuli,SIRT1 directly links the cellular metabolic status to the chromatin structure and the regulation of gene expression,thereby modulating a variety of cellular processes such as energy metabolism and stress response.Recent studies have shown that SIRT1 controls both glucose and lipid metabolism in the liver,promotes fat mobilization and stimulates brown remodeling of the white fat in white adipose tissue,controls insulin secretion in the pancreas,senses nutrient availability in the hypothalamus,influences obesityinduced inflammation in macrophages,and modulates the activity of circadian clock in metabolic tissues.This review focuses on the role of SIRT1 in regulating energy metabolism at different metabolic tissues.

  7. How Is Metabolic Syndrome Treated?

    Science.gov (United States)

    ... page from the NHLBI on Twitter. How Is Metabolic Syndrome Treated? Heart-healthy lifestyle changes are the first line of treatment for metabolic syndrome. If heart-healthy lifestyle changes aren’t enough, ...

  8. Autophagy research: Lessons from metabolism

    NARCIS (Netherlands)

    A.J. Meijer

    2009-01-01

    Autophagy research continues to expand exponentially. Clearly autophagy and metabolism are intimately connected; however, the rapid expansion of research into this topic inevitably brings the risk that important basic knowledge of metabolism will be overlooked when considering experimental data. Unf

  9. Metabolic Syndrome, Androgens, and Hypertension

    OpenAIRE

    Moulana, Mohadetheh; Lima, Roberta; Reckelhoff, Jane F.

    2011-01-01

    Obesity is one of the constellation of factors that make up the definition of the metabolic syndrome. Metabolic syndrome is also associated with insulin resistance, dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus. The presence of obesity and metabolic syndrome in men and women is also associated with increased risk of cardiovascular disease and hypertension. In men, obesity and metabolic syndrome are associated with reductions in testosterone levels. In women, obesity and met...

  10. Metabolic syndrome and professional aptitude

    OpenAIRE

    Dorota Rębak; Edyta Suliga; Stanisław Głuszek

    2016-01-01

    The development of civilisation has resulted in a growing problem of metabolic diseases, including metabolic syndrome. Scientific studies show that this disease is an epidemic of the 21st century. Metabolic syndrome is a collection of mutually related metabolic factors, such as obesity, impaired glucose tolerance, lipid disorders, arterial hypertension, and pro-inflammatory and prothrombotic state, increasing the risk of the development of atherosclerosis and type 2 diabetes, and their cardio...

  11. Metabolism of hyperthermophiles.

    Science.gov (United States)

    Schönheit, P; Schäfer, T

    1995-01-01

    Hyperthermophiles are characterized by a temperature optimum for growth between 80 and 110°C. They are considered to represent the most ancient phenotype of living organisms and thus their metabolic design might reflect the situation at an early stage of evolution. Their modes of metabolism are diverse and include chemolithoautotrophic and chemoorganoheterotrophic. No extant phototrophic hyperthermophiles are known. Lithotrophic energy metabolism is mostly anaerobic or microaerophilic and based on the oxidation of H2 or S coupled to the reduction of S, SO inf4 (sup2-) , CO2 and NO inf3 (sup-) but rarely to O2. the substrates are derived from volcanic activities in hyperthermophilic habitats. The lithotrophic energy metabolism of hyperthermophiles appears to be similar to that of mesophiles. Autotrophic CO2 fixation proceeds via the reductive citric acid cycle, considered to be one of the first metabolic cycles, and via the reductive acetyl-CoA/carbon monoxide dehydrogenase pathway. The Calvin cycle has not been found in hyperthermophiles (or any Archaea). Organotrophic metabolism mainly involves peptides and sugars as substrates, which are either oxidized to CO2 by external electron acceptors or fermented to acetate and other products. Sugar catabolism in hyperthermophiles involves non-phosphorylated versions of the Entner-Doudoroff pathway and modified versions of the Embden-Meyerhof pathway. The 'classical' Embden-Meyerhof pathway is present in hyperthermophilic Bacteria (Thermotoga) but not in Archaea. All hyperthermophiles (and Archaea) tested so far utilize pyruvate:ferredoxin oxidoreductase for acetyl-CoA formation from pyruvate. Acetyl-CoA oxidation in anaerobic sulphur-reducing and aerobic hyperthermophiles proceeds via the citric acid cycle; in the hyperthermophilic sulphate-reducer Archaeoglobus an oxidative acetyl-CoA/carbon monoxide dehydrogenase pathway is operative. Acetate formation from acetyl-CoA in Archaea, including hyperthermophiles, is

  12. COMT基因多态性与精神分裂症发病风险及阿立哌唑治疗效应的相关性研究%Association of COMT Gene Polymorphism with Risk of Schizophrenia and Efficacy of Aripiprazole

    Institute of Scientific and Technical Information of China (English)

    李广学; 高树贵; 成佳; 姚文鸣; 郑孝荣; 徐永明

    2014-01-01

    Objective To investigate the association between catechol-O-methyltransferase ( COMT) gene polymorphism and onset risk of schizophrenia , efficacy of aripiprazole.Methods A total of 78 Chinese Han schizophrenic patients and 65 healthy subjects were recruited in this stud-y.All the patients were diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders ( DSM-Ⅳ) .The Positive and Negative Syndrome Scale ( PANSS ) and Clinical Global Impression (CGI) were used to evaluate the clinical efficacy of aripiprazole.Polymerase chain reaction (PCR) and restriction fragment length polymorphism ( RFLP ) were employed to detect COMT geno-types.Results The COMT Val158 Met genotype and allele distributions in schizophrenia patients were significantly different from those in health subjects ( P0.05 ) .Conclusions The polymorphism of COMT gene Val 158/Met is correlated with the onset of schizophrenia , but has no effect on the clinical efficacy of aripiprazole.%目的:探讨儿茶酚氧位甲基转移酶(the catechol-O-methyltransferase, COMT)基因多态性与精神分裂症发病风险及阿立哌唑治疗效应之间的相关性。方法采用病例-对照研究设计,在中国汉族人群中收集78例符合美国精神障碍诊断与统计手册第4版( DSM-Ⅳ)精神分裂症诊断标准的首发精神分裂症患者,并与65例健康志愿者进行对照。用阳性与阴性症状评定量表( PANSS )、临床大体评定量表( CGI )评定阿立哌唑治疗的疗效。运用聚合酶链式反应-限制性片段长度多态分析( PCR-RFLP)方法进行基因分型。结果患者组与正常对照组基因型和等位基因频率分布存在显著性差异( P均<0.05); COMT基因多态性也与精神分裂症患者年龄、病程相关联。经阿立哌唑治疗后,患者精神症状及临床疗效总评分均有明显改善,但其改善程度在3种基因型间比较无明显差异。结论 COMT基因Val158/108 Met

  13. 阿立哌唑治疗抗精神病药所致闭经的精神分裂症对照研究%A comparison study of aripiprazole in the treatment of schizophrenic patients with amenorrhea induced by antipsychotics

    Institute of Scientific and Technical Information of China (English)

    黄平; 廖彦浔; 叶慧; 虞晓兰

    2011-01-01

    目的:探讨阿立哌唑对抗精神病药所致闭经的精神分裂症患者的影响.方法:69例抗精神病药引起闭经的女性精神分裂症患者,随机分为A组(单用阿立哌唑治疗)34例和B组(用其他抗精神病药联合中药血府逐瘀汤治疗)35例,观察疗程3个月.于治疗前、治疗后1、2、3个月测定血清催乳素浓度,并评定闭经的疗效.结果:治疗后两组血清催乳素浓度均较治疗前降低;以A组血清催乳素浓度(15.21±6.17)μg/L显著低于B组(85.91±24.86)μg/L(t=-15.870,P=0.000);A组闭经治疗总有效率100%显著高于B组84.85%(χ2=67.00,P=0.000).结论:阿立哌唑治疗因抗精神病药所致闭经的精神分裂症患者安全、有效.%Objective:To study the clinical effect of aripiprazole in the treatment of schizophrenic patients with amenorrhea induced by antipsychotics.Method:69 female schizophrenic patients with amenorrhea induced by antipsychotics were randomly divided into two groups, group A (n =34, treated by aripiprazole) and group B (n = 35, treated by other antipsychotics combined with traditional Chinese medicine Xuefuzhuyu soup) ,for 3 months treatment.The serum level of prolactin was measured before and after 1,2 and 3 months treatment.The efficacy on amenorrhea was evaluated.Results:The serum level of prolactin decreased in both group after treatment, with significant decrease in group A compared with that in group B[(15.21 ± 6.17 ) μg/L vs.( 85.91 ± 24.86) μg/L( t = - 15.870, P = 0.000).The total treatment response rate for amenorrhea was 100% in patients of group A, significanfiy higher than that 84.85% in group B (x2 = 67.00, P=0.000).Conclusion:Aripiprazole can treat amenorrhea induced by antipsychotics in patients with schizophrenia efficaciously and safely.

  14. The Effect of Aripiprazole on Replacement of Risperidone in the Treatment of Serum Prolactin Levels in Female Schizophrenia Patients%研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    赵晓玲

    2016-01-01

    目的:观察阿立哌唑替换利培酮对精神分裂症患者治疗期血清催乳素水平的影响。方法选取我院2016年1~7月收治的精神分裂症患者100例作为研究对象,按就诊时间先后分为两组,每组各50例患者。观察组使用阿立哌唑治疗,对照组使用利培酮治疗。比较两组患者在治疗期间的血清催乳素变化。结果经5周治疗后,观察组血清催乳素含量为(6.41±1.04)ng/ml,与治疗前比较,下降量为(24.18±2.64)ng/ml;对照组为(38.17±1.67)ng/ml,与治疗前比较,上升量为(6.73±2.46)ng/ml,治疗后两组患者血清催乳素水平对比,差异具有统计学意义(P<0.05)。观察组BMI值为(28.14±1.34) kg/m2,对照组为(27.54±1.84)kg/m2,两组数据对比,差异具有统计学意义(P<0.05)。结论使用阿立哌唑对精神分裂症患者进行治疗,可有效降低体内血清催乳素含量,提升疗效。%Objective To observe the effect of aripiprazole replacement risperidone on serum prolactin levels in patients with schizophrenia treatment.Methods 100 cases of schizophrenia in our hospital from January to July 2016 in our hospital were selected as study subjects. According to the treatment time has been divided into two groups, 50 cases of patients in each group. The observation group was treated with aripiprazole, the control group was treated with risperidone. The change of serum prolactin in two groups were compared.ResultsAfter 5 weeks of treatment, the observation group serum prolactin content (6.41 ± 1.04) ng/ml, compared with before treatment decreased weight (24.18 ± 2.64) ng/ml control group, the average content is (38.17 ± 1.67) ng/ml, compared with before treatment increased weight (6.73 ± 2.46) ng/ml, there were significant differences two groups of patients with serum prolactin levels after treatment with statistical signiifcance,P <0.05. Observation group BMI (28.14 ± 1.34) kg/m2

  15. 阿立哌唑治疗利培酮所致高催乳素血症75例疗效观察%Observation on Effect of Aripiprazole in Treatment of Hyperprolactinemia Caused by Risperidone in Schizophrenic Patients in 75 Cases

    Institute of Scientific and Technical Information of China (English)

    唐萍; 冯婧; 夏南

    2015-01-01

    Objective To study the effectiveness and safety of the combined use of small dose of aripiprazole in the treatment of hyper-prolactinemia caused by risperidone. Methods 150 schizophrenic patients with risperidone caused hyperprolactinemia were randomly as-signed to the research group ( n=75 ) and the control group ( n=75 ) . The two groups maintained the original risperidone treatment. The research group was combined with the use of aripiprazole 5-10 mg/d. Serum prolactin levels at the base line, and the ends of 4, 8 and 12 weeks were measured and the scores of PANSS, CGI-S and UKU at the base line and the end of 12 weeks were as-sessed. Results Serum prolactin level at the end of 12 weeks in the research group was ( 17. 01 0 4. 27 )μg/L, which was significantly reduced compared with ( 95. 73 0 48. 77 )μg/L at the baseline ( P ﹤ 0. 05 ) , the effective rate was 84. 00%. However serum prolactin lev-el in the control group had no statistically significant difference between before and after treatment ( P ﹥ 0. 05 ) . The scores of PANSS and CGI-S and the incidence rate of adverse reactions in the two groups had no statistical differences between before and after treat-ment ( P ﹥ 0. 05 ) . Conclusion Aripiprazole can effectively decrease risperidone caused hyperprolactinemia with few adverse reactions. But the long-term effect needs to be further observed.%目的:探讨利培酮所致高催乳素血症的精神分裂症合并应用小剂量阿立哌唑的有效性和安全性。方法将150例患者随机分为研究组和对照组,各75例。对照组维持原有利培酮治疗不变,研究组在对照组基础上合并用阿立哌唑5~10 mg/d;两组于基线及治疗4,8,12周末检测血清催乳素水平,于基线及治疗12周末评定阳性和阴性综合征量表( PANSS )、临床总体印象量表( CGI-S )、UKU副作用评定量表。结果研究组在第12周末催乳素水平为(17.0104.27)μg/L,较基线(95.73048.77)

  16. Effect of Aripiprazole on Hyperprolactinemia in Patients with Senile Schizophrenia Induced by Antipsychotic Drugs%阿立哌唑对抗精神病药物所致的老年精神分裂症患者高催乳素血症的影响分析

    Institute of Scientific and Technical Information of China (English)

    孙伟; 马世发; 高天飞

    2015-01-01

    目的:探讨阿立哌唑对抗精神病药物所致的老年精神分裂症患者高催乳素血症的影响。方法根据治疗方法对该院于2012年5月-2014年10月收治的患者进行分组,两组患者均继续沿用原有抗精神病药物,在此基础上给予观察组患者阿立哌唑。分别测定两组治疗前、治疗4、8周末血清催乳素水平,同时采用精神病评定量表(BPRS)对精神病症状进行评定,比较两组药物不良反应。结果观察组患者治疗4周、8周末血清催乳素水平显著降低,与对照组比较,差异有统计学意义(P0.05);两组患者药物不良反应发生率差异无统计学意义(P>0.05)。结论阿立哌唑能够有效降低抗精神病药物所致的老年精神分裂症患者高催乳素血症状,且未出现严重药物不良反应,具有有效性和安全性,可作为治疗用药。%Objective To investigate the effect of aripiprazole on hyperprolactinemia in patients with senile schizophrenia induced by antipsychotic drugs. Methods The patients from 2012 May to 2014 October in our hospital were divided according to the meth-ods of treatment. All the patients continued to use original antipsychotic drugs, based on which patients in the observation group were given aripiprazole. Serum prolactin level before the operation, four weeks after operation, 8 weeks after operation of the two groups was detected respectively;and psychiatric symptoms were assessed by Brief Psychiatric Rating Scale (BPRS), and adverse drug reaction of the two groups was compared. Results In the observation group, serum prolactin level after 4 weeks treatment and that after 8 weeks treatment both decreased significantly, and compared with those of the control group, there were significant dif-ferences (P0.05; No obvious sig-nificant difference was found in the rate of adverse drug reactions of the two groups,P>0.05. Conclusion Without serious adverse drug reactions, and with efficacy and

  17. Study on the escitalopram combined with low dose of aripiprazole in the treatment of depression with somatic symptoms%艾司西酞普兰联合小剂量阿立哌唑治疗伴躯体症状抑郁症的研究

    Institute of Scientific and Technical Information of China (English)

    夏金校; 姚华华; 王一冰; 曹世林; 甘建光; 段迪; 吕柏军

    2011-01-01

    AIM: To explore the clinical efficacy of escitalopram combined with low dose of aripiprazole in the treatment of depression with somatic symptoms. METHODS: Eighty patients suffering from depression with somatic symptoms were randomly divided into study group (n = 41) and control group (n = 39), who received either escitalopram combined with low dose of aripiprazole or escitalopram only, respectively. The clinical efficacy and safety were evaluated with Hamilton Depression Rating Scale (HAMD), Self-rating Depression Scale (SDS), Clinical Global Impression (CGD , Treatment E-mergent Symptom Scale (TESS) and Dysfunctional Attitudes Scales (DAS) at the point of baseline and the 1st, 2nd, 4th and 8th weekend. Meanwhile, the medication compliance andsymptom recrudescence rate of two groups were also assessed in 3 months. RESULTS: Scores of HAMD, SDS and CGI decreased in both groups, but more significantly and quickly in study group. There was no difference between two groups in TESS. Patients in study group had better compliance, fewer symptom recrudescence rate and lower scores in DAS in 3 months, compared with control group. CONCLUSION: Escitalopram combined with low dose of aripiprazole works better in the treatment of depression with somatic symptoms than using escitalopram only.%目的:观察艾司西酞普兰联合小剂量阿立哌唑治疗伴躯体症状抑郁症的临床疗效.方法:将80例伴躯体症状抑郁症患者随机分为服用艾司西酞普兰联合小剂量阿立哌唑(简称观察组)41例和单用艾司西酞普兰(简称对照组)39例.从药物起效、症状改善时间,治疗1、2、4及8周末汉密尔顿抑郁量表(HAMD)、抑郁自评量表(SDS)、临床疗效总评量表(CGI)有不良反应量表(TESS)评定,3个月内服药依从性、症状复燃率及DAS评定.结果:治疗后两组HAMD、SDS、CGI分值较治疗前均有显著下降,观察组下降更明显,起效与症状改善上观察组均较对照组快,两组的TESS评分差

  18. 喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效与安全性研究%Efficacy and safety of quetiapine,aripiprazole and amisulpride in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张智勇; 谢玲银; 黄伟波

    2015-01-01

    Objective To study the antipsychotic efficacy and safety of three kinds of drugs on patients with schizophrenia. Methods Patients with schizophrenia in our hospital from January to October in 2014 were selected and randomly divided into three groups,quetiapine group (n=98)accepted quetiapine 400 ~800 (512 ± 128)mg/d,aripi-prazole group (n=100) accepted aripiprazole 10~30 (20 ±6) mg/d,amisulpride group (n=102) accepted amisul-pride 400~800(635 ± 147) mg/d respectively for eight weeks. The efficacy and adverse reactions were evaluated by PANSS and TESS,and the social function was evaluated by PSP before and after 4 and 8 weeks of treatment. Results The total effective rate of quetiapine group,aripiprazole group and amisulpride group was 68. 4%,70.0% and 69. 6%respectively,there was no significant difference among the three groups(P>0.05). The score of CGI and PSP of each group increased significantly. Conclusion Quetiapine,aripiprazole and amisulpride have similar efficiency in the treat-ment of schizophrenic patients,but the adverse reactions features are different.%目的 研究喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效与安全性. 方法 选择2014年1-10月在我院精神科住院的300例精神分裂症患者,随机分为喹硫平组、阿立哌唑组、氨磺必利组,分别给予喹硫平[400~800 mg/d,平均(512 ±128)mg/d]、阿立哌唑[10~30 mg/d,平均(20 ±6)mg/d]、氨磺必利[400~800 mg/d,平均(635 ± 147)mg/d]治疗8周. 于分组前及治疗后4、8周用评估阳性和阴性症状量表(PANSS)、不良反应量表( TESS)评定疗效和不良反应,用社会功能量表( PSP)评定患者的社会功能. 结果 喹硫平组总有效率为68. 4%,阿立哌唑组总有效率为70.0%,氨磺必利组总有效率为69. 6%,三组总有效率比较,差异无统计学意义(P>0.05);三组患者CGI评分及PSP评分均显著增加. 结论 喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效相当,但不良反应特点不同.

  19. Macrophages and Iron Metabolism.

    Science.gov (United States)

    Soares, Miguel P; Hamza, Iqbal

    2016-03-15

    Iron is a transition metal that due to its inherent ability to exchange electrons with a variety of molecules is essential to support life. In mammals, iron exists mostly in the form of heme, enclosed within an organic protoporphyrin ring and functioning primarily as a prosthetic group in proteins. Paradoxically, free iron also has the potential to become cytotoxic when electron exchange with oxygen is unrestricted and catalyzes the production of reactive oxygen species. These biological properties demand that iron metabolism is tightly regulated such that iron is available for core biological functions while preventing its cytotoxic effects. Macrophages play a central role in establishing this delicate balance. Here, we review the impact of macrophages on heme-iron metabolism and, reciprocally, how heme-iron modulates macrophage function.

  20. Neuroendocrine control of metabolism.

    Science.gov (United States)

    Kuliczkowska-Plaksej, J; Milewicz, A; Jakubowska, J

    2012-03-01

    Metabolism is controlled through homeostatic system consisting of central centers, gut hormones, hormones from adipose tissue and the other hormonal axes. This cooperation is based on cross-talk between central and peripheral signals. Among them the hypothalamus plays a crucial role, with interconnected nuclei forming neuronal circuits. Other regions in the brain, such as the brain stem, the endocannabinoid system, the vagal afferents, are also involved in energy balance. The second component is peripheral source of signals--the gastrointestinal tract hormones. Additionally, adipokines from adipose tissue, thyrotropic, gonadotropic and somatotropic axes play a role in energy homeostasis. Knowledge about all components of this neuroendocrine circuit will be helpful in developing novel therapeutic approaches against the metabolic syndrome and its components.

  1. Autophagy, Metabolism, and Cancer.

    Science.gov (United States)

    White, Eileen; Mehnert, Janice M; Chan, Chang S

    2015-11-15

    Macroautophagy (autophagy hereafter) captures intracellular proteins and organelles and degrades them in lysosomes. The degradation breakdown products are released from lysosomes and recycled into metabolic and biosynthetic pathways. Basal autophagy provides protein and organelle quality control by eliminating damaged cellular components. Starvation-induced autophagy recycles intracellular components into metabolic pathways to sustain mitochondrial metabolic function and energy homeostasis. Recycling by autophagy is essential for yeast and mammals to survive starvation through intracellular nutrient scavenging. Autophagy suppresses degenerative diseases and has a context-dependent role in cancer. In some models, cancer initiation is suppressed by autophagy. By preventing the toxic accumulation of damaged protein and organelles, particularly mitochondria, autophagy limits oxidative stress, chronic tissue damage, and oncogenic signaling, which suppresses cancer initiation. This suggests a role for autophagy stimulation in cancer prevention, although the role of autophagy in the suppression of human cancer is unclear. In contrast, some cancers induce autophagy and are dependent on autophagy for survival. Much in the way that autophagy promotes survival in starvation, cancers can use autophagy-mediated recycling to maintain mitochondrial function and energy homeostasis to meet the elevated metabolic demand of growth and proliferation. Thus, autophagy inhibition may be beneficial for cancer therapy. Moreover, tumors are more autophagy-dependent than normal tissues, suggesting that there is a therapeutic window. Despite these insights, many important unanswered questions remain about the exact mechanisms of autophagy-mediated cancer suppression and promotion, how relevant these observations are to humans, and whether the autophagy pathway can be modulated therapeutically in cancer. See all articles in this CCR Focus section, "Cell Death and Cancer Therapy."

  2. Epigenetics and Cellular Metabolism

    OpenAIRE

    Wenyi Xu; Fengzhong Wang; Zhongsheng Yu; Fengjiao Xin

    2016-01-01

    Living eukaryotic systems evolve delicate cellular mechanisms for responding to various environmental signals. Among them, epigenetic machinery (DNA methylation, histone modifications, microRNAs, etc.) is the hub in transducing external stimuli into transcriptional response. Emerging evidence reveals the concept that epigenetic signatures are essential for the proper maintenance of cellular metabolism. On the other hand, the metabolite, a main environmental input, can also influence the proce...

  3. Metabolism and Brain Cancer

    OpenAIRE

    Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo

    2011-01-01

    Cellular energy metabolism is one of the main processes affected during the transition from normal to cancer cells, and it is a crucial determinant of cell proliferation or cell death. As a support for rapid proliferation, cancer cells choose to use glycolysis even in the presence of oxygen (Warburg effect) to fuel macromolecules for the synthesis of nucleotides, fatty acids, and amino acids for the accelerated mitosis, rather than fuel the tricarboxylic acid cycle and oxidative phosphorylati...

  4. Analytics for metabolic engineering

    Directory of Open Access Journals (Sweden)

    Christopher J Petzold

    2015-09-01

    Full Text Available Realizing the promise of metabolic engineering has been slowed by challenges related to moving beyond proof-of-concept examples to robust and economically viable systems. Key to advancing metabolic engineering beyond trial-and-error research is access to parts with well-defined performance metrics that can be readily applied in vastly different contexts with predictable effects. As the field now stands, research depends greatly on analytical tools that assay target molecules, transcripts, proteins, and metabolites across different hosts and pathways. Screening technologies yield specific information for many thousands of strain variants while deep omics analysis provide a systems-level view of the cell factory. Efforts focused on a combination of these analyses yield quantitative information of dynamic processes between parts and the host chassis that drive the next engineering steps. Overall, the data generated from these types of assays aid better decision-making at the design and strain construction stages to speed progress in metabolic engineering research.

  5. Genetics of metabolic syndrome.

    Science.gov (United States)

    Stančáková, Alena; Laakso, Markku

    2014-12-01

    Metabolic syndrome (MetS) is a cluster of metabolic traits associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. Central obesity and insulin resistance are thought to play key roles in the pathogenesis of the MetS. The MetS has a significant genetic component, and therefore linkage analysis, candidate gene approach, and genome-wide association (GWA) studies have been applied in the search of gene variants for the MetS. A few variants have been identified, located mostly in or near genes regulating lipid metabolism. GWA studies for the individual components of the MetS have reported several loci having pleiotropic effects on multiple MetS-related traits. Genetic studies have provided so far only limited evidence for a common genetic background of the MetS. Epigenetic factors (DNA methylation and histone modification) are likely to play important roles in the pathogenesis of the MetS, and they might mediate the effects of environmental exposures on the risk of the MetS. Further research is needed to clarify the role of genetic variation and epigenetic mechanisms in the development of the MetS.

  6. Analytics for Metabolic Engineering

    Science.gov (United States)

    Petzold, Christopher J.; Chan, Leanne Jade G.; Nhan, Melissa; Adams, Paul D.

    2015-01-01

    Realizing the promise of metabolic engineering has been slowed by challenges related to moving beyond proof-of-concept examples to robust and economically viable systems. Key to advancing metabolic engineering beyond trial-and-error research is access to parts with well-defined performance metrics that can be readily applied in vastly different contexts with predictable effects. As the field now stands, research depends greatly on analytical tools that assay target molecules, transcripts, proteins, and metabolites across different hosts and pathways. Screening technologies yield specific information for many thousands of strain variants, while deep omics analysis provides a systems-level view of the cell factory. Efforts focused on a combination of these analyses yield quantitative information of dynamic processes between parts and the host chassis that drive the next engineering steps. Overall, the data generated from these types of assays aid better decision-making at the design and strain construction stages to speed progress in metabolic engineering research. PMID:26442249

  7. Dysregulated lipid metabolism in cancer

    Institute of Scientific and Technical Information of China (English)

    2012-01-01

    Alteration of lipid metabolism has been increasingly recognized as a hallmark of cancer cells. The changes of expression and activity of lipid metabolizing enzymes are directly regulated by the activity of oncogenic signals. The dependence of tumor cells on the dysregulated lipid metabolism suggests that proteins involved in this process are excellent chemotherapeutic targets for cancer treatment. There are currently several drugs under development or in clinical trials that are based on specifically targeting the altered lipid metabolic pathways in cancer cells. Further understanding of dysregulated lipid metabolism and its associated signaling pathways will help us to better design efficient cancer therapeutic strategy.

  8. Metabolic pathways of trichothecenes.

    Science.gov (United States)

    Wu, Qinghua; Dohnal, Vlastimil; Huang, Lingli; Kuca, Kamil; Yuan, Zonghui

    2010-05-01

    Trichothecenes are a group of mycotoxins mainly produced by the fungi of Fusarium genus. Consumers are particularly concerned over the toxicity and food safety of trichothecenes and their metabolites from food-producing animals. The metabolism of T-2 toxin, deoxynivalenol (DON), nivalenol (NIV), fusarenon-X (FX), diacetoxyscirpenol (DAS), 3-acetyldeoxy-nivalenol (3-aDON), and 15-acetyldeoxynivalenol (15-aDON) in rodents, swine, ruminants, poultry, and humans are reviewed in this article. Metabolic pathways of these mycotoxins are very different. The major metabolic pathways of T-2 toxin in animals are hydrolysis, hydroxylation, de-epoxidation, and conjugation. After being transformed to HT-2 toxin, it undergoes further hydroxylation at C-3' to yield 3'-hydroxy-HT-2 toxin, which is considered as an activation pathway, whereas transformation from T-2 to T-2 tetraol is an inactivation pathway in animals. The typical metabolites of T-2 toxin in animals are HT-2 toxin, T-2 triol, T-2 tetraol, neosolaniol (NEO), 3'-hydroxy-HT-2, and 3'-hydroxy-T-2, whereas HT-2 toxin is the main metabolite in humans. De-epoxidation is an important pathway for detoxification in animals. De-epoxy products, DOM-1, and de-epoxy-NIV are the main metabolites of DON and NIV in most animals, respectively. However, the two metabolites are not found in humans. Deacetyl can occur rapidly on the acetyl derivatives, 3-aDON, 15-aDON, and FX. DAS is metabolized in animals to 15-monoacetoxyscirpenol (15-MAS) via C-4 deacetylation and then transformed to scirpentriol (SCP) via C-15 deacetylation. Finally, the epoxy is lost, yielding de-epoxy-SCP. De-epoxy-15-MAS is also the main metabolite of DAS. 15-MAS is the main metabolite in human skin. The review on the metabolism of trichothecenes will help one to well understand the fate of these toxins' future in animals and humans, as well as provide basic information for the risk assessment of them for food safety.

  9. 阿立哌唑治疗抗精神病药物所致高催乳素血症疗效及安全性的M eta分析%The efficacy of aripiprazole in the treatment of antipsychotic-induced hyperprolactinemia and safety meta-analysis

    Institute of Scientific and Technical Information of China (English)

    温美玲; 张瑞岭; 崔桂梅

    2016-01-01

    Objective To explore the efficacy and safety of aripiprazole in the treatment of antipsychotic‐induced hyperprolactinemia .Methods Relevant randomized controlled studies prior to June 2015 ,method‐ology quality assessments of included studies performed ,and data extracted for meta‐analysis .Results A total of 16 literatures were recruited ,1 ,304 patients included ,685 ones were in intervention and 619 ones in control group .Meta‐analysis showed that cure rate was significantly higher and serum prolactin levels lowered more significantly in intervention than in control group at the end of the study ,differences were significant (P0 .05) .Conclusion Short‐term aripiprazole adjunctive treatment for other antipsychotic‐induced hyperprolactinemia is safe and effective .%目的:探讨阿立哌唑治疗抗精神病药物所致高催乳素血症的临床疗效及安全性。方法检索2015年6月之前相关的随机对照研究,对纳入研究进行方法学质量评估并提取数据进行M eta分析。结果共纳入16篇文献,总计1304例患者,干预组685例,对照组619例。M eta分析结果显示,在研究终点时,干预组治愈率显著高于对照组且血清催乳素水平显著降低,差异均有显著性(P<0.01);总体不良反应发生率及简明精神病评定量表总分改变两组间比较差异均无显著性(P>0.05)。结论短期内辅加阿立哌唑治疗其他抗精神病药物所致高催乳素血症安全有效。

  10. Tumor Metabolism of Malignant Gliomas

    Energy Technology Data Exchange (ETDEWEB)

    Ru, Peng; Williams, Terence M.; Chakravarti, Arnab; Guo, Deliang, E-mail: deliang.guo@osumc.edu [Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center & Arthur G James Cancer Hospital, Columbus, OH 43012 (United States)

    2013-11-08

    Constitutively activated oncogenic signaling via genetic mutations such as in the EGFR/PI3K/Akt and Ras/RAF/MEK pathways has been recognized as a major driver for tumorigenesis in most cancers. Recent insights into tumor metabolism have further revealed that oncogenic signaling pathways directly promote metabolic reprogramming to upregulate biosynthesis of lipids, carbohydrates, protein, DNA and RNA, leading to enhanced growth of human tumors. Therefore, targeting cell metabolism has become a novel direction for drug development in oncology. In malignant gliomas, metabolism pathways of glucose, glutamine and lipid are significantly reprogrammed. Moreover, molecular mechanisms causing these metabolic changes are just starting to be unraveled. In this review, we will summarize recent studies revealing critical gene alterations that lead to metabolic changes in malignant gliomas, and also discuss promising therapeutic strategies via targeting the key players in metabolic regulation.

  11. Tumor Metabolism of Malignant Gliomas

    Directory of Open Access Journals (Sweden)

    Deliang Guo

    2013-11-01

    Full Text Available Constitutively activated oncogenic signaling via genetic mutations such as in the EGFR/PI3K/Akt and Ras/RAF/MEK pathways has been recognized as a major driver for tumorigenesis in most cancers. Recent insights into tumor metabolism have further revealed that oncogenic signaling pathways directly promote metabolic reprogramming to upregulate biosynthesis of lipids, carbohydrates, protein, DNA and RNA, leading to enhanced growth of human tumors. Therefore, targeting cell metabolism has become a novel direction for drug development in oncology. In malignant gliomas, metabolism pathways of glucose, glutamine and lipid are significantly reprogrammed. Moreover, molecular mechanisms causing these metabolic changes are just starting to be unraveled. In this review, we will summarize recent studies revealing critical gene alterations that lead to metabolic changes in malignant gliomas, and also discuss promising therapeutic strategies via targeting the key players in metabolic regulation.

  12. Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats.

    Science.gov (United States)

    Zbukvic, Isabel C; Ganella, Despina E; Perry, Christina J; Madsen, Heather B; Bye, Christopher R; Lawrence, Andrew J; Kim, Jee Hyun

    2016-06-01

    Adolescent drug users display resistance to treatment such as cue exposure therapy (CET), as well as increased liability to relapse. The basis of CET is extinction learning, which involves dopamine signaling in the medial prefrontal cortex (mPFC). This system undergoes dramatic alterations during adolescence. Therefore, we investigated extinction of a cocaine-associated cue in adolescent and adult rats. While cocaine self-administration and lever-alone extinction were not different between the two ages, we observed that cue extinction reduced cue-induced reinstatement in adult but not adolescent rats. Infusion of the selective dopamine 2 receptor (D2R)-like agonist quinpirole into the infralimbic cortex (IL) of the mPFC prior to cue extinction significantly reduced cue-induced reinstatement in adolescents. This effect was replicated by acute systemic treatment with the atypical antipsychotic aripiprazole (Abilify), a partial D2R-like agonist. These data suggest that adolescents may be more susceptible to relapse due to a deficit in cue extinction learning, and highlight the significance of D2R signaling in the IL for cue extinction during adolescence. These findings inspire new tactics for improving adolescent CET, with aripiprazole representing an exciting potential pharmacological adjunct for behavioral therapy.

  13. Uncovering transcriptional regulation of metabolism by using metabolic network topology

    DEFF Research Database (Denmark)

    Patil, Kiran Raosaheb; Nielsen, Jens

    2005-01-01

    therefore developed an algorithm that is based on hypothesis-driven data analysis to uncover the transcriptional regulatory architecture of metabolic networks. By using information on the metabolic network topology from genome-scale metabolic reconstruction, we show that it is possible to reveal patterns...... in the metabolic network that follow a common transcriptional response. Thus, the algorithm enables identification of so-called reporter metabolites (metabolites around which the most significant transcriptional changes occur) and a set of connected genes with significant and coordinated response to genetic...... changes induced by complex regulatory mechanisms coordinating the activity of different metabolic pathways. It is difficult to map such global transcriptional responses by using traditional methods, because many genes in the metabolic network have relatively small changes at their transcription level. We...

  14. Gut microbiome and metabolic syndrome.

    Science.gov (United States)

    Mazidi, Mohsen; Rezaie, Peyman; Kengne, Andre Pascal; Mobarhan, Majid Ghayour; Ferns, Gordon A

    2016-01-01

    The gut microbiome contributes approximately 2kg of the whole body weight, and recent studies suggest that gut microbiota has a profound effect on human metabolism, potentially contributing to several features of the metabolic syndrome. Metabolic syndrome is defined by a clustering of metabolic disorders that include central adiposity with visceral fat accumulation, dyslipidemia, insulin resistance, dysglycemia and non-optimal blood pressure levels. Metabolic syndrome is associated with an increased risk of cardiovascular diseases and type 2 diabetes. It is estimated that around 20-25 percent of the world's adult population has metabolic syndrome. In this manuscript, we have reviewed the existing data linking gut microbiome with metabolic syndrome. Existing evidence from studies both in animals and humans support a link between gut microbiome and various components of metabolic syndrome. Possible pathways include involvement with energy homeostasis and metabolic processes, modulation of inflammatory signaling pathways, interferences with the immune system, and interference with the renin-angiotensin system. Modification of gut microbiota via prebiotics, probiotics or other dietary interventions has provided evidence to support a possible beneficial effect of interventions targeting gut microbiota modulation to treat components or complications of metabolic syndrome.

  15. Metabolic syndrome and pregnancy

    Directory of Open Access Journals (Sweden)

    A V Khromilev

    2014-06-01

    Full Text Available Metabolic syndrome (MS is a major problem of public health and health care system, with rising prevalence in the world. There is evidence that obesity, as the main component of MS, is strongly associated with the presence of gestational complications: fetal growth retardation, fetal macrosomia, gestational diabetes, preeclampsia, preterm delivery, stillbirth and perinatal death. The underlying mechanisms of this association are actively investigated nowadays. The importance of MS in pregnancy is also determined by the increase of the risk of venous trombosis.

  16. Metabolism and Endocrinology

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    2009039 A survey of glucose and lipid metabolism and concomitant diseases among inpatients in Guangdong province. TANG Kuanxiao(唐宽晓), et al. Dept Endocrinol, 3rd Affili Hosp, Sun Yat-sen Univ, Guangzhou 510630. Chin J Intern Med 2009;48(3):196-200. Objectives To investigate the epidemiological and clinical characteristics of dyslipidemia as well as its treatment and influence on accompanying diseases in impaired glucose status among inpatients. Methods A cross-sectional survey was conducted among the inpatients registered in ten university hospitals of Guangdong, China during the week before the Diabetes Day in 2004.

  17. Metabolic impact of shift work.

    Science.gov (United States)

    Zimberg, Ioná Zalcman; Fernandes Junior, Silvio A; Crispim, Cibele Aparecida; Tufik, Sergio; de Mello, Marco Tulio

    2012-01-01

    In developing countries, shift work represents a considerable contingent workforce. Recently, studies have shown that overweight and obesity are more prevalent in shift workers than day workers. In addition, shift work has been associated with a higher propensity for the development of many metabolic disorders, such as insulin resistance, diabetes, dislipidemias and metabolic syndrome. Recent data have pointed that decrease of the sleep time, desynchronization of circadian rhythm and alteration of environmental aspects are the main factors related to such problems. Shortened or disturbed sleep is among the most common health-related effects of shift work. The plausible physiological and biological mechanisms are related to the activation of the autonomic nervous system, inflammation, changes in lipid and glucose metabolism, and related changes in the risk for atherosclerosis, metabolic syndrome, and type II diabetes. The present review will discuss the impact of shift work on obesity and metabolic disorders and how disruption of sleep and circadian misalignment may contribute to these metabolic dysfunctions.

  18. Metabolic syndrome, androgens, and hypertension.

    Science.gov (United States)

    Moulana, Mohadetheh; Lima, Roberta; Reckelhoff, Jane F

    2011-04-01

    Obesity is one of the constellation of factors that make up the definition of the metabolic syndrome. Metabolic syndrome is also associated with insulin resistance, dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus. The presence of obesity and metabolic syndrome in men and women is also associated with increased risk of cardiovascular disease and hypertension. In men, obesity and metabolic syndrome are associated with reductions in testosterone levels. In women, obesity and metabolic syndrome are associated with increases in androgen levels. In men, reductions in androgen levels are associated with inflammation, and androgen supplements reduce inflammation. In women, increases in androgens are associated with increases in inflammatory cytokines, and reducing androgens reduces inflammation. This review discusses the possibility that the effects of androgens on metabolic syndrome and its sequelae may differ between males and females.

  19. Metabolic syndrome, diet and exercise.

    Science.gov (United States)

    De Sousa, Sunita M C; Norman, Robert J

    2016-11-01

    Polycystic ovary syndrome (PCOS) is associated with a range of metabolic complications including insulin resistance (IR), obesity, dyslipidaemia, hypertension, obstructive sleep apnoea (OSA) and non-alcoholic fatty liver disease. These compound risks result in a high prevalence of metabolic syndrome and possibly increased cardiovascular (CV) disease. As the cardiometabolic risk of PCOS is shared amongst the different diagnostic systems, all women with PCOS should undergo metabolic surveillance though the precise approach differs between guidelines. Lifestyle interventions consisting of increased physical activity and caloric restriction have been shown to improve both metabolic and reproductive outcomes. Pharmacotherapy and bariatric surgery may be considered in resistant metabolic disease. Issues requiring further research include the natural history of PCOS-associated metabolic disease, absolute CV risk and comparative efficacy of lifestyle interventions.

  20. Metabolic topography of Parkinsonism

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Jae Seung [Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)

    2007-04-15

    Parkinson's disease is one of the most frequent neurodegenerative diseases, which mainly affects the elderly. Parkinson's disease is often difficult to differentiate from atypical parkinson disorder such as progressive supranuclear palsy, multiple system atrophy, dementia with Lewy body, and corticobasal ganglionic degeneration, based on the clinical findings because of the similarity of phenotypes and lack of diagnostic markers. The accurate diagnosis of Parkinson's disease and atypical Parkinson disorders is not only important for deciding on treatment regimens and providing prognosis, but also it is critical for studies designed to investigate etiology and pathogenesis of parkinsonism and to develop new therapeutic strategies. Although degeneration of the nigrostriatal dopamine system results in marked loss of striatal dopamine content in most of the diseases causing parkinsonism, pathologic studies revealed different topographies of the neuronal cell loss in Parkinsonism. Since the regional cerebral glucose metabolism is a marker of integrated local synaptic activity and as such is sensitive to both direct neuronal/synaptic damage and secondary functional disruption at synapses distant from the primary site of pathology, and assessment of the regional cerebral glucose metabolism with F-18 FDG PET is useful in the differential diagnosis of parkinsonism and evaluating the pathophysiology of Parkinsonism.

  1. Purine and pyrimidine metabolism.

    Science.gov (United States)

    Zöllner, N

    1982-09-01

    The pathways of purine biosynthesis and degradation have been elucidated during the last 30 years; the regulation of the mechanisms involved is not yet fully understood, particularly with respect to quantitative aspects. Research into inborn errors of purine metabolism has provided valuable insights into purine synthesis and salvage pathways. Nutrition experiments using purine-free formula diets and supplements with defined purine sources permit precise descriptions of the influence of various dietary purines on uric acid formation. Supplements of dietary purines produce dose-proportional increases in plasma uric acid concentrations, uric acid pool size and renal uric acid excretion. The magnitude of these increases depends on the type of purine compound administered, which may limit the value of food tables for human dietetics. Purine content of food must be related not only to weight but also to energy and to protein, particularly if new foodstuffs or a vegetarian diet are ingested. Dietary purines appear to influence the biosynthesis of pyrimidines. In contrast to dietary purines, pyrimidines in the diet, if administered as nucleosides or nucleotides, are utilized in animals for the synthesis of nucleic acids. Much further work is necessary for a better understanding of the inter-relationships of purine and pyrimidine metabolism.

  2. Biochemical Hypermedia: Galactose Metabolism.

    Directory of Open Access Journals (Sweden)

    J.K. Sugai

    2013-05-01

    Full Text Available Introduction: Animations of biochemical processes and virtual laboratory environments lead to true molecular simulations. The use of interactive software’s in education can improve cognitive capacity, better learning and, mainly, it makes information acquisition easier. Material and Methods: This work presents the development of a biochemical hypermedia to understanding of the galactose metabolism. It was developed with the help of concept maps, ISIS Draw, ADOBE Photoshop and FLASH MX Program. Results and Discussion: A step by step animation process shows the enzymatic reactions of galactose conversion to glucose-1-phosphate (to glycogen synthesis, glucose-6-phosphate (glycolysis intermediary, UDP-galactose (substrate to mucopolysaccharides synthesis and collagen’s glycosylation. There are navigation guide that allow scrolling the mouse over the names of the components of enzymatic reactions of via the metabolism of galactose. Thus, explanatory text box, chemical structures and animation of the actions of enzymes appear to navigator. Upon completion of the module, the user’s response to the proposed exercise can be checked immediately through text box with interactive content of the answer. Conclusion: This hypermedia was presented for undergraduate students (UFSC who revealed that it was extremely effective in promoting the understanding of the theme.

  3. Posttransplant Metabolic Syndrome

    Directory of Open Access Journals (Sweden)

    M. Shadab Siddiqui

    2012-01-01

    Full Text Available Metabolic syndrome (MS is a cluster of metabolic derangements associated with insulin resistance and an increased risk of cardiovascular mortality. MS has become a major health concern worldwide and is considered to be the etiology of the current epidemic of diabetes and cardiovascular disease. In addition to cardiovascular disease, the presence of MS is also closely associated with other comorbidities including nonalcoholic fatty liver disease (NAFLD. The prevalence of MS in patients with cirrhosis and end-stage liver disease is not well established and difficult to ascertain. Following liver transplant, the prevalence of MS is estimated to be 44–58%. The main factors associated with posttransplant MS are posttransplant diabetes, obesity, dyslipidemia, and hypertension. In addition to developing NAFLD, posttransplant MS is associated with increased cardiovascular mortality that is 2.5 times that of the age- and sex-matched individuals. Additionally, the presence of posttransplant MS has been associated with rapid progression to fibrosis in individuals transplanted for HCV cirrhosis. There is an urgent need for well-designed prospective studies to fully delineate the natural history and risk factors associated with posttransplant MS. Until then, early recognition, prevention, and treatment of its components are vital in improving outcomes in liver transplant recipients.

  4. Arginine metabolism in wounds

    Energy Technology Data Exchange (ETDEWEB)

    Albina, J.E.; Mills, C.D.; Barbul, A.; Thirkill, C.E.; Henry, W.L. Jr.; Mastrofrancesco, B.; Caldwell, M.D.

    1988-04-01

    Arginine metabolism in wounds was investigated in the rat in 1) lambda-carrageenan-wounded skeletal muscle, 2) Schilling chambers, and 3) subcutaneous polyvinyl alcohol sponges. All showed decreased arginine and elevated ornithine contents and high arginase activity. Arginase could be brought to the wound by macrophages, which were found to contain arginase activity. However, arginase was expressed by macrophages only after cell lysis and no arginase was released by viable macrophages in vitro. Thus the extracellular arginase of wounds may derive from dead macrophages within the injured tissue. Wound and peritoneal macrophages exhibited arginase deiminase activity as demonstrated by the conversion of (guanido-/sup 14/C)arginine to radiolabeled citrulline during culture, the inhibition of this reaction by formamidinium acetate, and the lack of prokaryotic contamination of the cultures. These findings and the known metabolic fates of the products of arginase and arginine deiminase in the cellular populations of the wound suggest the possibility of cooperativity among cells for the production of substrates for collagen synthesis.

  5. Pharmacogenetics of olanzapine metabolism.

    Science.gov (United States)

    Söderberg, Mao Mao; Dahl, Marja-Liisa

    2013-08-01

    The pharmacokinetics of the atypical antipsychotic, olanzapine, display large interindividual variation leading to multiple-fold differences in drug exposure between patients at a given dose. This variation in turn gives rise to the need for individualized dosing in order to avoid concentration-dependent adverse effects or therapeutic failure. Genetically determined differences in olanzapine metabolism represent a less studied source of variability in comparison to environmental and physiological factors. In this review, we summarize available in vitro and in vivo data addressing the influence of polymorphisms in drug-metabolizing enzymes on olanzapine serum exposure. The polymorphic CYP2D6 enzyme appears to have no significant influence on olanzapine steady-state serum concentrations. The formation of the various olanzapine metabolites is influenced by polymorphisms in the genes coding for CYP1A2, CYP1A expression regulator AHR, UGT1A4 and UGT2B10, as well as FMO3. An impact on steady-state olanzapine serum concentrations has been suggested for variants of CYP1A2 and UGT1A4, with somewhat conflicting findings. The potential involvement of FMO1 and CYP3A43 in olanzapine disposition has also been suggested but needs future validation.

  6. 中药血府逐瘀汤辅助阿立哌唑治疗闭经的精神分裂症对照观察%Controlled observation of traditional Chinese medicine Xuefuzhuyu decoction combined with aripiprazole in treatment of schizophrenic patients with antipsychotic-induced amenorrhea

    Institute of Scientific and Technical Information of China (English)

    黄平; 杨泽云

    2011-01-01

    Objective To study the clinical effects of Xuefuzhuyu decoction (a traditional Chinese medicine) combined with aripiprazole in the treatment of schizophrenic patients with antipsychotic-induced amenorrhea. Methods Sixty-seven schizophrenic patients with antipsychotic-induced amenorrhea were randomly divided into group A (33 patients) treated with Xuefuzhuyu decoction combined with aripiprazole, and group B (34 patients) treated with aripiprazole alone. The treatment course was 3 months. The concentrations of prolactin (PRL) in serum were measured at the beginning of the study and at the end of each month, and the clinical effects on antipsychotic-induced amenorrhea were compared. The clinical effects on schizophrenosis were assessed using Positive and Negative Syndrome Scale (PANSS) at the beginning and the end of the study.Results The differences between PRL concentrations (base line and at the end of the 1st, 2nd, and 3rd months) of group A (113.88 ±40.84 μg/L, 43.59 ±17.35 μg/L, 16.88 ±8.42 μg/L and 15.53 ±6.28 μg/L)and group B (111.94±39.27 μg/L, 42.15 ±17.27 μg/L, 17.59 ±7.22 μg/L and 16.26 ±5.46 μg/L)had no statistical significance (t =0. 196 -0.600, P =0. 845 -0.550). The curative rate of antipsychotic-induced amenorrhea of group A ( 100.00% ) was not significantly different from that of group B (97.06%) (Chi square =0.956, P =0. 328). The total PANSS score of group A (45.69 ± 13.28) was significantly lower than that of group B (54.0318.52) at the end of the 3-month study (t= -2.091, P=0.040). Conclusion In the treatment of schizophrenic patients with antipsychotic-induced amenorrhea, Xuefuzhuyu decoction combined with aripiprazole can help to restore menstruation and improve the curative effect on schizophrenia.%目的 探讨中药血府逐瘀汤辅助阿立哌唑治疗闭经的精神分裂症患者临床疗效.方法 将67例抗精神病药引起闭经的精神分裂症患者按分层随机分为A组(n=33)、B组(n=34),A组中药血

  7. 帕罗西汀合并不同剂量阿立哌唑治疗强迫症的临床观察%Observing the effect of Paroxetine combined with different doses of ariPiPrazole on obsessive-comPulsive disorder

    Institute of Scientific and Technical Information of China (English)

    朱立毛; 舒菊红; 戴升太

    2014-01-01

    Objective:To investigate the effectiveness and safety of paroxetine combined with different doses of aripiprazole on obsessive-compulsive disorder. Method:One hundred and sixty-four patients with obsessive-compulsive disorder were randomly divided into 2 groups:the paroxetine only group( n = 33),the 2. 2 mg/ d group(n = 32),the 2 mg/ d group(n = 34),the 7. 2mg group(n = 32),the 10 mg/ d group(n = 33). Each group was treated with paroxetine 40 mg/ d combined with corresponding doses of aripiprazole for 8 weeks. Effectiveness and adverse effect were assessed respectively by Yale-Brown obsessive compulsive scale( Y-BOCS)and treatment emergent symptom scale(TESS). Results:After 8 weeks treatment,in the five groups, the scores of Y-BOCS significantly decreased(P ﹤ 0. 02 or P ﹤ 0. 01),the 2. 2 mg/ d group and the 2 mg group were more obvious(all P ﹤ 0. 01). The decreased score rate of Y-BOCS were significantly different between the paroxetine only group and the 2. 2 mg/ d group or the 2 mg group(all P ﹤ 0. 02). After 8 weeks treatment,no significant difference was found in the rates of adverse effect in 2. 2 mg/ d group and 2 mg/ d group compared with paroxetine only group;but in 7. 2 mg/ d group and 10 mg/ d group were sifnificantly higher than paroxetine only group(P ﹤ 0. 02 or P ﹤ 0. 01). Conclusion:The paroxetine combined the 2. 2-2 mg/ d aripiprazole trea-ting patients with obsessive compulsive disorder is more effective than the paroxetine combined the 7. 2-10 mg/d aripiprazole and paroxetine only.%目的:探讨盐酸帕罗西汀联合不同剂量阿立哌唑治疗强迫症的疗效及安全性。方法:164例强迫症患者随机分为帕罗西汀治疗(单药)组及帕罗西汀+阿立哌唑2.2 mg/ d 组、2 mg/ d 组、7.2 mg/d 组及10 mg/ d 组,每组给予帕罗西汀40 mg/ d 及相应剂量的阿立哌唑治疗8周。治疗前后进行耶鲁布朗强迫量表(Y-BOCS)及治疗过程中出现的症状量表

  8. Comparison of efficacy after adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia between different gender%阿立哌唑治疗利培酮所致高催乳素血症效果的性别差异

    Institute of Scientific and Technical Information of China (English)

    陈景旭; 梁雪梅; 卞清涛; 刘可智; 张立刚; 张荣珍; 李伟; 刘艳红

    2015-01-01

    Objective To compare the efficacy and safety of adjunctive treatment with aripiprazole on hyperprolactinemia induced ky risperidone ketween different gender. Methods By using a stratified randomization protocol,116 schizophrenic patients with risperi=done- induced hyperprolactinemia were assigned to research group(28 male and 31 female)and control group(26 male and 31 female), and received 20mg·d-1 aripiprazole or placeko for adjunctive treatment respectively. Serum prolactin levels was measured at kaseline, the end of the 2nd,4th and 8th weed and UKU Side Effects Rating Scale(UKU)were assessed at kaseline and the end of 8th weed. Re-sults Compared with the kaseline,koth male and female in research group showed statistical difference in serum prolactin at the end of the 2nd,4th and 8th weed(P﹤0.001),kut here were no significant difference ketween the 2nd,4th and 8th weed in research group ketween and after treatment in control group(P﹥0. 05). At the end of the 8th weed,there was no statistical deference ketween male and female in research group in the decline rate of serum prolactin levels[(79. 61 ± 17. 81)%(,75. 54 ± 12. 96)%],and the normal ratio of male pa=tients were significantly higher(92. 9%)than that of female patients in research group(58. 1%)(χ2 =9. 39,P﹤0. 001). Conclusion Adjunctive aripiprazole treatment may ke effective for treating risperidone -induced hyperprolactinemia and achieved almost all of its effects after the 2nd weed. The effects on male patients was ketter than female patients with the same e dosage of aripiprazole.%目的探讨阿立哌唑治疗利培酮所致高催乳素血症的效果是否存在性别差异。方法采用分层随机方法将116例利培酮所致高催乳素血症的精神分裂症患者分为研究组(男性28例,女性31例)和对照组(男性26例,女性31例)。维持原有利培酮治疗方案不变,研究组合并用阿立哌唑20mg·d-1,对照组合并安慰剂治

  9. Analysis of the contrast effect of aripiprazole, risperidone and clozapine in patients with schizophrenia%阿立哌唑、利培酮和氯氮平治疗精神分裂症的临床效果分析

    Institute of Scientific and Technical Information of China (English)

    曾荟宇

    2015-01-01

    ObjectiveTo analyze the clinical effect and the damage of cognitive function of aripiprazole, risperidone and clozapine in treatment of patients with schizophrenia.Methods 234 patients with schizophrenia diagnosed and treated in our hospital from September 2011 to October 2013 were randomly divided into three groups A, B and C, 78 cases in each group. Group A received therapy of aripiprazole oral, group B received treatment of risperidone oral, Group C received oral clozapine treatment, after treatment, the clinical efficacy among the three groups were compared, the changes of positive and negative syndrome scale (PANSS) score, the Wechsler adult Intelligence Scale (WAIS-RC) of the total IQ score points and Clinical memory Scale (CMS) score were compared between before and after treatment.ResultsBefore treatment, PANSS, WAIS-RC, CMS scores of A, B, C three groups, the difference was not statistically significant (P>0.05), indicating a good comparability between the three groups. After treatment, A, B, C three groups PANSS, WAIS-RC scores were compared, without statistically significant differences (P>0.05). CMS score of group A after treatment was significantly higher than that of B, C groups, the difference was statistically significant (P0.05). A, B, C three groups after treatment PANSS scores were significantly higher than the scores before treatment (P0.05). Conclusion Aripiprazole compared with risperidone and clozapine, aripiprazole has better clinical efficacy.%目的:分析阿立哌唑、利培酮和氯氮平在精神分裂症患者临床治疗效果及对认知功能的损害情况。方法将我院2011年9月~2013年10月确诊并收治的234例精神分裂症患者随机分为甲、乙、丙三组,每组78例。甲组应用阿立哌唑实施口服治疗,乙组应用利培酮实施口服治疗,丙组应用氯氮平实施口服治疗,治疗结束后比照三组临床疗效,治疗前后的阳性和阴性症状量表(PANSS)评分、韦氏

  10. Oxidative stress in metabolic syndrome

    OpenAIRE

    Sharma, Praveen; Mishra, Sandhya; Ajmera, Peeyush; Mathur, Sandeep

    2005-01-01

    As antioxidants play a protective role in the pathophysiology of diabetes and cardiovascular diseases, understanding the physiological status of antioxidant concentration among people at high risk for developing these conditions, such as Metabolic Syndrome, is of interest. In present study out of 187 first degree non-diabetic relatives and 192 non-diabetic spouses, 33.1% and 19.7% were found to have metabolic syndrome respectively. Subjects with metabolic syndrome (≥3 risk factors) had poor a...

  11. Brain glutamate metabolism during metabolic alkalosis and acidosis.

    Science.gov (United States)

    Ang, R C; Hoop, B; Kazemi, H

    1992-12-01

    Glutamate modifies ventilation by altering neural excitability centrally. Metabolic acid-base perturbations may also alter cerebral glutamate metabolism locally and thus affect ventilation. Therefore, the effect of metabolic acid-base perturbations on central nervous system glutamate metabolism was studied in pentobarbital-anesthetized dogs under normal acid-base conditions and during isocapnic metabolic alkalosis and acidosis. Cerebrospinal fluid transfer rates of radiotracer [13N]ammonia and of [13N]glutamine synthesized de novo via the reaction glutamate+NH3-->glutamine in brain glia were measured during normal acid-base conditions and after 90 min of acute isocapnic metabolic alkalosis and acidosis. Cerebrospinal fluid [13N]ammonia and [13N]glutamine transfer rates decreased in metabolic acidosis. Maximal glial glutamine efflux rate jm equals 85.6 +/- 9.5 (SE) mumol.l-1 x min-1 in all animals. No difference in jm was observed in metabolic alkalosis or acidosis. Mean cerebral cortical glutamate concentration was significantly lower in acidosis [7.01 +/- 0.45 (SE) mumol/g brain tissue] and tended to be larger in alkalosis, compared with 7.97 +/- 0.89 mumol/g in normal acid-base conditions. There was a similar change in cerebral cortical gamma-aminobutyric acid concentration. Within the limits of the present method and measurements, the results suggest that acute metabolic acidosis but not alkalosis reduces glial glutamine efflux, corresponding to changes in cerebral cortical glutamate metabolism. These results suggest that glutamatergic mechanisms may contribute to central respiratory control in metabolic acidosis.

  12. Drug-Induced Metabolic Acidosis.

    Science.gov (United States)

    Pham, Amy Quynh Trang; Xu, Li Hao Richie; Moe, Orson W

    2015-01-01

    Metabolic acidosis could emerge from diseases disrupting acid-base equilibrium or from drugs that induce similar derangements. Occurrences are usually accompanied by comorbid conditions of drug-induced metabolic acidosis, and clinical outcomes may range from mild to fatal. It is imperative that clinicians not only are fully aware of the list of drugs that may lead to metabolic acidosis but also understand the underlying pathogenic mechanisms. In this review, we categorized drug-induced metabolic acidosis in terms of pathophysiological mechanisms, as well as individual drugs' characteristics.

  13. Gut Microbiota and Metabolic Disorders

    Directory of Open Access Journals (Sweden)

    Kyu Yeon Hur

    2015-06-01

    Full Text Available Gut microbiota plays critical physiological roles in the energy extraction and in the control of local or systemic immunity. Gut microbiota and its disturbance also appear to be involved in the pathogenesis of diverse diseases including metabolic disorders, gastrointestinal diseases, cancer, etc. In the metabolic point of view, gut microbiota can modulate lipid accumulation, lipopolysaccharide content and the production of short-chain fatty acids that affect food intake, inflammatory tone, or insulin signaling. Several strategies have been developed to change gut microbiota such as prebiotics, probiotics, certain antidiabetic drugs or fecal microbiota transplantation, which have diverse effects on body metabolism and on the development of metabolic disorders.

  14. Drug-Induced Metabolic Acidosis

    Science.gov (United States)

    Pham, Amy Quynh Trang; Xu, Li Hao Richie; Moe, Orson W.

    2015-01-01

    Metabolic acidosis could emerge from diseases disrupting acid-base equilibrium or from drugs that induce similar derangements. Occurrences are usually accompanied by comorbid conditions of drug-induced metabolic acidosis, and clinical outcomes may range from mild to fatal. It is imperative that clinicians not only are fully aware of the list of drugs that may lead to metabolic acidosis but also understand the underlying pathogenic mechanisms. In this review, we categorized drug-induced metabolic acidosis in terms of pathophysiological mechanisms, as well as individual drugs’ characteristics. PMID:26918138

  15. Metabolic Adaptation to Muscle Ischemia

    Science.gov (United States)

    Cabrera, Marco E.; Coon, Jennifer E.; Kalhan, Satish C.; Radhakrishnan, Krishnan; Saidel, Gerald M.; Stanley, William C.

    2000-01-01

    Although all tissues in the body can adapt to varying physiological/pathological conditions, muscle is the most adaptable. To understand the significance of cellular events and their role in controlling metabolic adaptations in complex physiological systems, it is necessary to link cellular and system levels by means of mechanistic computational models. The main objective of this work is to improve understanding of the regulation of energy metabolism during skeletal/cardiac muscle ischemia by combining in vivo experiments and quantitative models of metabolism. Our main focus is to investigate factors affecting lactate metabolism (e.g., NADH/NAD) and the inter-regulation between carbohydrate and fatty acid metabolism during a reduction in regional blood flow. A mechanistic mathematical model of energy metabolism has been developed to link cellular metabolic processes and their control mechanisms to tissue (skeletal muscle) and organ (heart) physiological responses. We applied this model to simulate the relationship between tissue oxygenation, redox state, and lactate metabolism in skeletal muscle. The model was validated using human data from published occlusion studies. Currently, we are investigating the difference in the responses to sudden vs. gradual onset ischemia in swine by combining in vivo experimental studies with computational models of myocardial energy metabolism during normal and ischemic conditions.

  16. Cerebral metabolic adaptation and ketone metabolism after brain injury

    Science.gov (United States)

    Prins, Mayumi L

    2010-01-01

    The developing central nervous system has the capacity to metabolize ketone bodies. It was once accepted that on weaning, the ‘post-weaned/adult’ brain was limited solely to glucose metabolism. However, increasing evidence from conditions of inadequate glucose availability or increased energy demands has shown that the adult brain is not static in its fuel options. The objective of this review is to summarize the body of literature specifically regarding cerebral ketone metabolism at different ages, under conditions of starvation and after various pathologic conditions. The evidence presented supports the following findings: (1) there is an inverse relationship between age and the brain’s capacity for ketone metabolism that continues well after weaning; (2) neuroprotective potentials of ketone administration have been shown for neurodegenerative conditions, epilepsy, hypoxia/ischemia, and traumatic brain injury; and (3) there is an age-related therapeutic potential for ketone as an alternative substrate. The concept of cerebral metabolic adaptation under various physiologic and pathologic conditions is not new, but it has taken the contribution of numerous studies over many years to break the previously accepted dogma of cerebral metabolism. Our emerging understanding of cerebral metabolism is far more complex than could have been imagined. It is clear that in addition to glucose, other substrates must be considered along with fuel interactions, metabolic challenges, and cerebral maturation. PMID:17684514

  17. Metabolic interrelationships software application: Interactive learning tool for intermediary metabolism

    NARCIS (Netherlands)

    A.J.M. Verhoeven (Adrie); M. Doets (Mathijs); J.M.J. Lamers (Jos); J.F. Koster (Johan)

    2005-01-01

    textabstractWe developed and implemented the software application titled Metabolic Interrelationships as a self-learning and -teaching tool for intermediary metabolism. It is used by undergraduate medical students in an integrated organ systems-based and disease-oriented core curriculum, which start

  18. Metabolic interrelationships software application: Interactive learning tool for intermediary metabolism

    NARCIS (Netherlands)

    A.J.M. Verhoeven (Adrie); M. Doets (Mathijs); J.M.J. Lamers (Jos); J.F. Koster (Johan)

    2005-01-01

    textabstractWe developed and implemented the software application titled Metabolic Interrelationships as a self-learning and -teaching tool for intermediary metabolism. It is used by undergraduate medical students in an integrated organ systems-based and disease-oriented core curriculum, which

  19. Structural control of metabolic flux.

    Directory of Open Access Journals (Sweden)

    Max Sajitz-Hermstein

    Full Text Available Organisms have to continuously adapt to changing environmental conditions or undergo developmental transitions. To meet the accompanying change in metabolic demands, the molecular mechanisms of adaptation involve concerted interactions which ultimately induce a modification of the metabolic state, which is characterized by reaction fluxes and metabolite concentrations. These state transitions are the effect of simultaneously manipulating fluxes through several reactions. While metabolic control analysis has provided a powerful framework for elucidating the principles governing this orchestrated action to understand metabolic control, its applications are restricted by the limited availability of kinetic information. Here, we introduce structural metabolic control as a framework to examine individual reactions' potential to control metabolic functions, such as biomass production, based on structural modeling. The capability to carry out a metabolic function is determined using flux balance analysis (FBA. We examine structural metabolic control on the example of the central carbon metabolism of Escherichia coli by the recently introduced framework of functional centrality (FC. This framework is based on the Shapley value from cooperative game theory and FBA, and we demonstrate its superior ability to assign "share of control" to individual reactions with respect to metabolic functions and environmental conditions. A comparative analysis of various scenarios illustrates the usefulness of FC and its relations to other structural approaches pertaining to metabolic control. We propose a Monte Carlo algorithm to estimate FCs for large networks, based on the enumeration of elementary flux modes. We further give detailed biological interpretation of FCs for production of lactate and ATP under various respiratory conditions.

  20. Metabolism during hypodynamia

    Science.gov (United States)

    Federov, I. V.

    1980-01-01

    Physical immobilization, inaction due to space travel, a sedentary occupation, or bed confinement due to a chronic illness elicit similar alternations in the metabolism of man and animals (rat, rabbit, dog, mouse). After a preliminary period of weight loss, there is eventually weight gain due to increased lipid storage. Protein catabolism is enhanced and anabolism depressed, with elevated urinary excretion of amino acids, creatine, and ammonia. Glycogen stores are depleted and glyconeogenesis is accelerated. Polyuria develops with subsequent redistribution of body fluids in which the blood volume of the systemic circulation is decreased and that of pulmonary circulation increased. This results in depressed production of vasopressin by the posterior pituitary which further enhances urinary water and salt loss.

  1. The metabolic syndrome.

    Science.gov (United States)

    Harris, Mark F

    2013-08-01

    The metabolic syndrome (MetSy) is increasingly common in Australia. It is associated with the rise in obesity and lifestyle risk behaviours. It is also controversial - its value in predicting cardiovascular disease and diabetes risk and in guiding therapy has been challenged. This article aims to provide advice on the diagnosis of the MetSy and the principles for its prevention and management in the context of primary care, taking into consideration aetiological factors and the complexity of managing its constituent risk factors. Diagnosis of the MetSy is useful in focusing attention on central adiposity and insulin resistance as risk factors both for the syndrome, and cardiovascular and diabetes morbidity and mortality. Its assessment requires measurement of waist circumference - a simple but seldom performed procedure in general practice. The most essential components for the prevention and management of the MetSy are measures to change diet and physical activity in order to achieve and sustain weight loss.

  2. Regulation of Terpene Metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Rodney Croteau

    2004-03-14

    OAK-B135 Research over the last four years has progressed fairly closely along the lines initially proposed, with progress-driven expansion of Objectives 1, 2 and 3. Recent advances have developed from three research thrusts: 1. Random sequencing of an enriched peppermint oil gland cDNA library has given access to a large number of potential pathway and regulatory genes for test of function; 2. The availability of new DNA probes and antibodies has permitted investigation of developmental regulation and organization of terpenoid metabolism; and 3. The development of a transformation system for peppermint by colleagues at Purdue University has allowed direct transgenic testing of gene function and added a biotechnological component to the project. The current status of each of the original research objectives is outlined below.

  3. [Regulation of terpene metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Croteau, R.

    1989-11-09

    Terpenoid oils, resins, and waxes from plants are important renewable resources. The objective of this project is to understand the regulation of terpenoid metabolism using the monoterpenes (C[sub 10]) as a model. The pathways of monoterpene biosynthesis and catabolism have been established, and the relevant enzymes characterized. Developmental studies relating enzyme levels to terpene accumulation within the oil gland sites of synthesis, and work with bioregulators, indicate that monoterpene production is controlled by terpene cyclases, the enzymes catalyzing the first step of the monoterpene pathway. As the leaf oil glands mature, cyclase levels decline and monoterpene biosynthesis ceases. Yield then decreases as the monoterpenes undergo catabolism by a process involving conversion to a glycoside and transport from the leaf glands to the root. At this site, the terpenoid is oxidatively degraded to acetate that is recycled into other lipid metabolites. During the transition from terpene biosynthesis to catabolism, the oil glands undergo dramatic ultrastructural modification. Degradation of the producing cells results in mixing of previously compartmentized monoterpenes with the catabolic enzymes, ultimately leading to yield decline. This regulatory model is being applied to the formation of other terpenoid classes (C[sub 15] C[sub 20], C[sub 30], C[sub 40]) within the oil glands. Preliminary investigations on the formation of sesquiterpenes (C[sub 15]) suggest that the corresponding cyclases may play a lesser role in determining yield of these products, but that compartmentation effects are important. From these studies, a comprehensive scheme for the regulation of terpene metabolism is being constructed. Results from this project wail have important consequences for the yield and composition of terpenoid natural products that can be made available for industrial exploitation.

  4. Renal metabolism of calcitonin

    Energy Technology Data Exchange (ETDEWEB)

    Simmons, R.E.; Hjelle, J.T.; Mahoney, C.; Deftos, L.J.; Lisker, W.; Kato, P.; Rabkin, R.

    1988-04-01

    The kidneys account for approximately two-thirds of the metabolism of calcitonin, but relatively little is known regarding the details thereof. To further characterize this process, we examined the renal handling and metabolism of human calcitonin (hCT) by the isolated perfused rat kidney. We also studied the degradation of radiolabeled salmon calcitonin (sCT) by subcellular fractions prepared from isolated rabbit proximal tubules. The total renal (organ) clearance of immunoreactive hCT by the isolated kidney was 1.96 +/- 0.18 ml/min. This was independent of the perfusate total calcium concentration from 5.5 to 10.2 mg/dl. Total renal clearance exceeded the glomerular filtration rate (GFR, 0.68 +/- 0.05 ml/min), indicating filtration-independent removal. Urinary calcitonin clearance as a fraction of GFR averaged 2.6%. Gel filtration chromatography of medium from isolated kidneys perfused with /sup 125/I-labeled sCT showed the principal degradation products to be low molecular weight forms eluting with monoiodotyrosine. Intermediate size products were not detected. In the subcellular fractionation experiments, when carried out at pH 5.0, calcitonin hydrolysis exclusively followed the activities of the lysosomal enzyme N-acetyl-beta-glucosaminidase. Typically, at pH 7.5, 42% of total degradation occurred in the region of the brush-border enzyme alanyl aminopeptidase and 29% occurred in the region of the cytosolic enzyme phosphoglucomutase. Although 9% of the calcitonin-degrading activity was associated with basolateral membrane fractions, most of this activity could be accounted for by the presence of brush-border membranes.

  5. Cancer Metabolism and Drug Resistance

    Directory of Open Access Journals (Sweden)

    Mahbuba Rahman

    2015-09-01

    Full Text Available Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs.

  6. Selected Metabolic Responses to Skateboarding

    Science.gov (United States)

    Hetzler, Ronald K.; Hunt, Ian; Stickley, Christopher D.; Kimura, Iris F.

    2011-01-01

    Despite the popularity of skateboarding worldwide, the authors believe that no previous studies have investigated the metabolic demands associated with recreational participation in the sport. Although metabolic equivalents (METs) for skateboarding were published in textbooks, the source of these values is unclear. Therefore, the rise in…

  7. Multidimensional optimality of microbial metabolism

    NARCIS (Netherlands)

    Schuetz, Robert; Zamboni, Nicola; Zampieri, Mattia; Heinemann, Matthias; Sauer, Uwe

    2012-01-01

    Although the network topology of metabolism is well known, understanding the principles that govern the distribution of fluxes through metabolism lags behind. Experimentally, these fluxes can be measured by (13)C-flux analysis, and there has been a long-standing interest in understanding this functi

  8. Metabolic alterations in dialysis patients

    NARCIS (Netherlands)

    Drechsler, Christiane

    2010-01-01

    Assessing metabolic risk in dialysis patients, three main aspects are important: a) the pathophysiologic effects of metabolic disturbances as known from the general population are unlikely to completely reverse once patients reach dialysis. b) Specific additional problems related to chronic kidney d

  9. Sex steroids and lipoprotein metabolism

    NARCIS (Netherlands)

    Gevers Leuven, J.A.

    1994-01-01

    Lipoprotein metabolism is involved in atherogenesis. Female sex-hormones have substantial effects on both lipoprotein metabolism and the vessel wall. Cholesterol, one of the major lipids in lipoproteins, is both the substrate for, and the target of, the steroidal sex hormones.

  10. Estrogen Signaling in Metabolic Inflammation

    Directory of Open Access Journals (Sweden)

    Rosário Monteiro

    2014-01-01

    Full Text Available There is extensive evidence supporting the interference of inflammatory activation with metabolism. Obesity, mainly visceral obesity, is associated with a low-grade inflammatory state, triggered by metabolic surplus where specialized metabolic cells such as adipocytes activate cellular stress initiating and sustaining the inflammatory program. The increasing prevalence of obesity, resulting in increased cardiometabolic risk and precipitating illness such as cardiovascular disease, type 2 diabetes, fatty liver, cirrhosis, and certain types of cancer, constitutes a good example of this association. The metabolic actions of estrogens have been studied extensively and there is also accumulating evidence that estrogens influence immune processes. However, the connection between these two fields of estrogen actions has been underacknowledged since little attention has been drawn towards the possible action of estrogens on the modulation of metabolism through their anti-inflammatory properties. In the present paper, we summarize knowledge on the modification inflammatory processes by estrogens with impact on metabolism and highlight major research questions on the field. Understanding the regulation of metabolic inflammation by estrogens may provide the basis for the development of therapeutic strategies to the management of metabolic dysfunctions.

  11. Metabolic syndrome and oxidative stress.

    Science.gov (United States)

    Ando, Katsuyuki; Fujita, Toshiro

    2009-08-01

    Metabolic syndrome is an obesity-associated collection of disorders, each of which contributes to cardiovascular risk. Metabolic syndrome is also associated with overproduction of reactive oxygen species (ROS). ROS contribute to the interrelationship between metabolic syndrome and salt-sensitive hypertension, which are both caused by obesity and excess salt consumption and are major threats to health in developed countries. ROS can induce insulin resistance, which is indispensable for the progression of metabolic syndrome, and salt-sensitive hypertension stimulates ROS production, thereby promoting the development of metabolic syndrome. Moreover, ROS activate mineralocorticoid receptors (MRs) and the sympathetic nervous system, which can contribute to the development of metabolic syndrome and salt-sensitive hypertension. Salt-induced progression of cardiovascular disease (CVD) is also accelerated in animal models with metabolic syndrome, probably owing to further stimulation of ROS overproduction and subsequent ROS-induced MR activation and sympathetic excitation. Therefore, ROS contribute to the progression of the metabolic syndrome itself and to the CVD accompanying it, particularly in conjunction with excessive salt consumption.

  12. Metabolic alterations in dialysis patients

    NARCIS (Netherlands)

    Drechsler, Christiane

    2010-01-01

    Assessing metabolic risk in dialysis patients, three main aspects are important: a) the pathophysiologic effects of metabolic disturbances as known from the general population are unlikely to completely reverse once patients reach dialysis. b) Specific additional problems related to chronic kidney

  13. Lysophosphatidylinositol Signalling and Metabolic Diseases

    Directory of Open Access Journals (Sweden)

    Syamsul A. Arifin

    2016-01-01

    Full Text Available Metabolism is a chemical process used by cells to transform food-derived nutrients, such as proteins, carbohydrates and fats, into chemical and thermal energy. Whenever an alteration of this process occurs, the chemical balance within the cells is impaired and this can affect their growth and response to the environment, leading to the development of a metabolic disease. Metabolic syndrome, a cluster of several metabolic risk factors such as abdominal obesity, insulin resistance, high cholesterol and high blood pressure, and atherogenic dyslipidaemia, is increasingly common in modern society. Metabolic syndrome, as well as other diseases, such as diabetes, obesity, hyperlipidaemia and hypertension, are associated with abnormal lipid metabolism. Cellular lipids are the major component of cell membranes; they represent also a valuable source of energy and therefore play a crucial role for both cellular and physiological energy homeostasis. In this review, we will focus on the physiological and pathophysiological roles of the lysophospholipid mediator lysophosphatidylinositol (LPI and its receptor G-protein coupled receptor 55 (GPR55 in metabolic diseases. LPI is a bioactive lipid generated by phospholipase A (PLA family of lipases which is believed to play an important role in several diseases. Indeed LPI can affect various functions such as cell growth, differentiation and motility in a number of cell-types. Recently published data suggest that LPI plays an important role in different physiological and pathological contexts, including a role in metabolism and glucose homeostasis.

  14. Cancer Metabolism and Drug Resistance

    Science.gov (United States)

    Rahman, Mahbuba; Hasan, Mohammad Rubayet

    2015-01-01

    Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs. PMID:26437434

  15. Gait Dynamics and Locomotor Metabolism

    Science.gov (United States)

    2014-12-01

    26 47. Taylor CR, Heglund NC, Maloiy GMO . Energetics and mechanics of terrestrial locomotion. I. Metabolic energy consumption as a function of...San Diego, CA: Academic Press, 1994. 110 47. Taylor CR, Heglund NC, Maloiy GMO . Energetics and mechanics of terrestrial locomotion. I. Metabolic

  16. [Hypovitaminosis D and metabolic syndrome].

    Science.gov (United States)

    Miñambres, Inka; de Leiva, Alberto; Pérez, Antonio

    2014-12-23

    Metabolic syndrome and hypovitaminosis D are 2 diseases with high prevalence that share several risk factors, while epidemiological evidence shows they are associated. Although the mechanisms involved in this association are not well established, hypovitaminosis D is associated with insulin resistance, decreased insulin secretion and activation of the renin-angiotensin system, mechanisms involved in the pathophysiology of metabolic syndrome. However, the apparent ineffectiveness of vitamin D supplementation on metabolic syndrome components, as well as the limited information about the effect of improving metabolic syndrome components on vitamin D concentrations, does not clarify the direction and the mechanisms involved in the causal relationship between these 2 pathologies. Overall, because of the high prevalence and the epidemiological association between both diseases, hypovitaminosis D could be considered a component of the metabolic syndrome.

  17. Retinoid Metabolism and Diabetes Mellitus

    Directory of Open Access Journals (Sweden)

    Eun-Jung Rhee

    2012-06-01

    Full Text Available Retinoid acid is a metabolite of vitamin A and functions as an important factor in cell survival, differentiation and death. Most previous studies on retinoid metabolism have focused on its association with cancer, hematologic and dermatologic disorders. Given the special concern over the recent increase in the prevalence of diabetes worldwide, the role of retinoid metabolism on glucose metabolism and insulin resistance in the human body is of marked importance. Therefore, in this issue, we review the literature on the association of retinoid metabolism with glucose tolerance, with regard to insulin secretion, pancreatic autoimmunity, insulin sensitivity and lipid metabolism. Further, we tried to assess the possibility of using retinoids as a novel therapeutic strategy for diabetes.

  18. Metabolic regulation of circadian clocks.

    Science.gov (United States)

    Haydon, Michael J; Hearn, Timothy J; Bell, Laura J; Hannah, Matthew A; Webb, Alex A R

    2013-05-01

    Circadian clocks are 24-h timekeeping mechanisms, which have evolved in plants, animals, fungi and bacteria to anticipate changes in light and temperature associated with the rotation of the Earth. The current paradigm to explain how biological clocks provide timing information is based on multiple interlocking transcription-translation negative feedback loops (TTFL), which drive rhythmic gene expression and circadian behaviour of growth and physiology. Metabolism is an important circadian output, which in plants includes photosynthesis, starch metabolism, nutrient assimilation and redox homeostasis. There is increasing evidence in a range of organisms that these metabolic outputs can also contribute to circadian timing and might also comprise independent circadian oscillators. In this review, we summarise the mechanisms of circadian regulation of metabolism by TTFL and consider increasing evidence that rhythmic metabolism contributes to the circadian network. We highlight how this might be relevant to plant circadian clock function.

  19. [Hypertension and the metabolic syndrome.

    DEFF Research Database (Denmark)

    Olsen, Michael; Jeppesen, Jørgen; Larsen, Mogens

    2009-01-01

    risk associated with increased blood pressure. As the definition of the metabolic syndrome is based on dichotomization of cardiovascular risk factors with a continuously increasing risk, it cannot match risk stratification tools like the HeartScore for calculation of prognosis. However, the metabolic......The metabolic syndrome is a relatively prevalent condition characterized by co-existence of several metabolic and cardiovascular risk factors including hypertension. Patients with hypertension have an increased risk of developing the metabolic syndrome which, in turn, increases the cardiovascular...... syndrome is of clinical importance as it makes the treating physician test for other elements of the syndrome in patients with one of the elements, e.g. hypertension. Udgivelsesdato: 2009-Jun-15...

  20. CIDE proteins and lipid metabolism.

    Science.gov (United States)

    Xu, Li; Zhou, Linkang; Li, Peng

    2012-05-01

    Lipid homeostasis is maintained through the coordination of lipid metabolism in various tissues, including adipose tissue and the liver. The disruption of lipid homeostasis often results in the development of metabolic disorders such as obesity, diabetes mellitus, liver steatosis, and cardiovascular diseases. Cell death-inducing DNA fragmentation factor 45-like effector family proteins, including Cidea, Cideb, and Fsp27 (Cidec), are emerging as important regulators of various lipid metabolic pathways and play pivotal roles in the development of metabolic disorders. This review summarizes the latest cell death-inducing DNA fragmentation factor 45-like effector protein discoveries related to the control of lipid metabolism, with emphasis on the role of these proteins in lipid droplet growth in adipocytes and in the regulation of very low-density lipoprotein lipidation and maturation in hepatocytes.

  1. Vasomotor symptoms and metabolic syndrome.

    Science.gov (United States)

    Tuomikoski, Pauliina; Savolainen-Peltonen, Hanna

    2017-03-01

    A vast majority of menopausal women suffer from vasomotor symptoms, such as hot flushes and night sweats, the mean duration of which may be up to 7-10 years. In addition to a decreased quality of life, vasomotor symptoms may have an impact on overall health. Vasomotor symptoms are associated with overactivity of the sympathetic nervous system, and sympathetic overdrive in turn is associated with metabolic syndrome, which is a known risk factor for cardiovascular disease. Menopausal hot flushes have a complex relationship to different features of the metabolic syndrome and not all data point towards an association between vasomotor symptoms and metabolic syndrome. Thus, it is still unclear whether vasomotor symptoms are an independent risk factor for metabolic syndrome. Research in this area is constantly evolving and we present here the most recent data on the possible association between menopausal vasomotor symptoms and the metabolic syndrome.

  2. 六种非经典抗精神病药对首发精神分裂症患者代谢的影响%Influences of six atypical antipsychotics on metabolism in the treatment for patients with first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    亓高超

    2012-01-01

    Objective To explore the influences of 6 atypical antipsychotics on blood triglyceride (TG), high density lipoproteins (HDL), glucose, glycohemoglobin (HbAlC) and body weight in the treatment for patients with frist-episode schizophrenia. Methods A total of 210 patients with frist-episode schizophrenia were divided into clozapine group ( 38 cases) , olanzapine group (34 cases) , quetiapine group ( 32 cases ) , risperidone group ( 37 cases ) , amisulpride group (33 cases) and aripiprazole group (36 cases) for 8 weeks treatment. The blood TG, HDL, glucose, HbA1C and body weight were measured at baseline and at the end of the treatment. Results Compared with the baseline, there were no significant differences in blood level of TG, HDL, glucose, HbAlC and body weight of patients in aripiprazole group after the 8-week treatment. All the indexes mentioned above in clozapine group and olanzapine group increased significantly after the treatment (P <0. 05 or P <0. 01). Body weight increased significantly after the treatment in patients in quetiapine group, risperidone group and amisulpride group (P<0.01), however, no significant differences were found on TG, HDL, glucose and HbA1C in the 3 groups after the treatment compared with the baseline. Conclusion Aripiprazole has no effect on metabolic markers in patients with schizophrenia, but clozapine and olanzapine can heighten the blood TG, HDL, glucose, HbAlC and body weight. Quetiapine, risperidone, amisulpride only result in body weight gain in schizophrenic patients.%目的 探讨非经典抗精神病药对精神分裂症患者血甘油三酯(TG)、高密度脂蛋白(HDL)、血糖、糖化血红蛋白(HbA1C)和体质量的影响.方法 将210例精神分裂症患者分为氯氮平组38例、奥氮平组34例、喹硫平组32例、利培酮组37例、氨磺必利组33例、阿立哌唑组36例,治疗8周.于治疗前和治疗8周测量空腹血TG、HDL、血糖、HbA1C和体质量.结果 治疗前后

  3. [EEG manifestations in metabolic encephalopathy].

    Science.gov (United States)

    Lin, Chou-Ching K

    2005-09-01

    Normal brain function depends on normal neuronal metabolism, which is closely related to systemic homeostasis of metabolites, such as glucose, electrolytes, amino acids and ammonia. "Metabolic encephalopathy" indicates diffuse brain dysfunction caused by various systemic derangements. Electroencephalogram (EEG) is widely used to evaluate metabolic encephalopathy since 1937, when Berger first observed slow brain activity induced by hypoglycemia. EEG is most useful in differentiating organic from psychiatric conditions, identifying epileptogenicity, and providing information about the degree of cortical or subcortical dysfunction. In metabolic encephalopathy, EEG evolution generally correlates well with the severity of encephalopathy. However, EEG has little specificity in differentiating etiologies in metabolic encephalopathy. For example, though triphasic waves are most frequently mentioned in hepatic encephalopathy, they can also be seen in uremic encephalopathy, or even in aged psychiatric patients treated with lithium. Spike-and-waves may appear in hyper- or hypo-glycemia, uremic encephalopathy, or vitamin deficiencies, etc. Common principles of EEG changes in metabolic encephalopathy are (1) varied degrees of slowing, (2) assorted mixtures of epileptic discharge, (3) high incidence of triphasic waves, and (4), as a rule, reversibility after treatment of underlying causes. There are some exceptions to the above descriptions in specific metabolic disorders and EEG manifestations are highly individualized.

  4. Martial Arts and Metabolic Diseases

    Directory of Open Access Journals (Sweden)

    Hidetaka Hamasaki

    2016-05-01

    Full Text Available Different forms of martial arts are practiced worldwide, each with various intensities of physical activity. These disciplines are potentially an effective exercise therapy for metabolic diseases. Tai chi is the most well-studied style of martial arts and has shown evidence of its effect on metabolic diseases; however, little evidence is available regarding the association between other styles of martial arts and metabolic health. To summarize and evaluate the effects of martial arts on metabolic diseases, eligible articles were searched by using Pubmed. To date, systematic reviews provide no definite conclusion on the effectiveness of tai chi for treating metabolic diseases because of a small numbers of subjects, short durations of clinical trials, and some biases involved in testing. However, there are several clinical studies on subjects with metabolic diseases, which show that tai chi improves obesity, glycemic control, blood pressure control, and lipid profiles. Currently, some limited evidence suggests that other martial arts, such as kung fu and karate, may be beneficial for body composition, glycemic control, and arterial stiffness. To clarify the effectiveness of martial arts for treating metabolic diseases, well-designed prospective studies, preferably with a larger number of subjects and of longer duration, are warranted.

  5. Metabolic syndrome and eye diseases.

    Science.gov (United States)

    Poh, Stanley; Mohamed Abdul, Riswana Banu Binte; Lamoureux, Ecosse L; Wong, Tien Y; Sabanayagam, Charumathi

    2016-03-01

    Metabolic syndrome is becoming a worldwide medical and public health challenge as it has been seen increasing in prevalence over the years. Age-related eye diseases, the leading cause of blindness globally and visual impairment in developed countries, are also on the rise due to aging of the population. Many of the individual components of the metabolic syndrome have been shown to be associated with these eye diseases. However, the association of metabolic syndrome with eye diseases is not clear. In this review, we reviewed the evidence for associations between metabolic syndrome and certain ocular diseases in populations. We also reviewed the association of individual metabolic syndrome components with ocular diseases due to a paucity of research in this area. Besides, we also summarised the current understanding of etiological mechanisms of how metabolic syndrome or the individual components lead to these ocular diseases. With increasing evidence of such associations, it may be important to identify patients who are at risk of developing metabolic syndrome as prompt treatment and intervention may potentially decrease the risk of developing certain ocular diseases.

  6. Lactate metabolism in acute uremia.

    Science.gov (United States)

    Leverve, Xavier; Mustafa, Iqbal; Novak, Ivan; Krouzecky, Ales; Rokyta, Richard; Matejovic, Martin; Ichai, Carole

    2005-01-01

    Lactate is a key metabolite that is produced by every cell and oxidized by most of them, provided that they do contain mitochondria. Its metabolism is connected to energetic homeostasis and the cellular redox state. It is well recognized as an indicator of severe outcome in severely ill patients, however, it is not a detrimental factor per se. Conversely, some recent data tend even to indicate a beneficial effect in several metabolic disorders. Although the liver has long been recognized as a key organ in lactate homeostasis, the kidney also plays a major role as a gluconeogenic organ significantly involved in the glucose-lactate cycle. In acute renal failure, sodium lactate is widely used as a buffer in replacement fluids because the anion (lactate - ) is metabolized and the cation (Na + ) remains, leading to decreased water dissociation and proton concentration. The metabolic disorders related to acute renal failure or associated with it, such as liver failure, may affect lactate metabolism, and therefore they are often regarded as limiting factors for the use of lactate-containing fluids in such patients. By investigating endogenous lactate production in severe septic patients with acute renal failure, we found that an acute exogenous load of lactate did not affect the basal endogenous lactate production and metabolism. This indicates that exogenous lactate is well metabolized even in patients suffering from acute renal failure and severe sepsis with a compromised hemodynamic status.

  7. Xenobiotic Metabolism and Gut Microbiomes

    Science.gov (United States)

    Das, Anubhav; Srinivasan, Meenakshi; Ghosh, Tarini Shankar; Mande, Sharmila S.

    2016-01-01

    Humans are exposed to numerous xenobiotics, a majority of which are in the form of pharmaceuticals. Apart from human enzymes, recent studies have indicated the role of the gut bacterial community (microbiome) in metabolizing xenobiotics. However, little is known about the contribution of the plethora of gut microbiome in xenobiotic metabolism. The present study reports the results of analyses on xenobiotic metabolizing enzymes in various human gut microbiomes. A total of 397 available gut metagenomes from individuals of varying age groups from 8 nationalities were analyzed. Based on the diversities and abundances of the xenobiotic metabolizing enzymes, various bacterial taxa were classified into three groups, namely, least versatile, intermediately versatile and highly versatile xenobiotic metabolizers. Most interestingly, specific relationships were observed between the overall drug consumption profile and the abundance and diversity of the xenobiotic metabolizing repertoire in various geographies. The obtained differential abundance patterns of xenobiotic metabolizing enzymes and bacterial genera harboring them, suggest their links to pharmacokinetic variations among individuals. Additional analyses of a few well studied classes of drug modifying enzymes (DMEs) also indicate geographic as well as age specific trends. PMID:27695034

  8. MicroRNAs in Metabolism

    DEFF Research Database (Denmark)

    Vienberg, Sara; Geiger, Julian; Madsen, Søren

    2017-01-01

    MicroRNAs (miRNAs) have within the past decade emerged as key regulators of metabolic homeostasis. Major tissues in intermediary metabolism important during development of the metabolic syndrome, such as β-cells, liver, skeletal and heart muscle as well as adipose tissue have all been shown to be...... diabetes and atherosclerosis stresses their potential as therapeutic targets. This review emphasizes current ideas and controversies within miRNA research in metabolism. This article is protected by copyright. All rights reserved.......MicroRNAs (miRNAs) have within the past decade emerged as key regulators of metabolic homeostasis. Major tissues in intermediary metabolism important during development of the metabolic syndrome, such as β-cells, liver, skeletal and heart muscle as well as adipose tissue have all been shown...... to be affected by miRNAs. In the pancreatic β-cell a number of miRNAs are important in maintaining the balance between differentiation and proliferation (miR-200 and miR-29 families) and insulin exocytosis in the differentiated state is controlled by miR-7, miR-375 and miR-335. MiR-33a and -33b play crucial...

  9. [Regulation of terpene metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Croteau, R.

    1991-01-01

    During the last grant period, we have completed studies on the key pathways of monoterpene biosynthesis and catabolism in sage and peppermint, and have, by several lines of evidence, deciphered the rate-limiting step of each pathway. We have at least partially purified and characterized the relevant enzymes of each pathway. We have made a strong case, based on analytical, in vivo, and in vitro studies, that terpene accumulation depends upon the balance between biosynthesis and catabolism, and provided supporting evidence that these processes are developmentally-regulated and very closely associated with senescence of the oil glands. Oil gland ontogeny has been characterized at the ultrastructural level. We have exploited foliar-applied bioregulators to delay gland senescence, and have developed tissue explant and cell culture systems to study several elusive aspects of catabolism. We have isolated pure gland cell clusters and localized monoterpene biosynthesis and catabolism within these structures, and have used these preparations as starting materials for the purification to homogeneity of target regulatory'' enzymes. We have thus developed the necessary background knowledge, based on a firm understanding of enzymology, as well as the necessary experimental tools for studying the regulation of monoterpene metabolism at the molecular level. Furthermore, we are now in a position to extend our systematic approach to other terpenoid classes (C[sub 15]-C[sub 30]) produced by oil glands.

  10. Physics of metabolic organization.

    Science.gov (United States)

    Jusup, Marko; Sousa, Tânia; Domingos, Tiago; Labinac, Velimir; Marn, Nina; Wang, Zhen; Klanjšček, Tin

    2016-09-09

    We review the most comprehensive metabolic theory of life existing to date. A special focus is given to the thermodynamic roots of this theory and to implications that the laws of physics-such as the conservation of mass and energy-have on all life. Both the theoretical foundations and biological applications are covered. Hitherto, the foundations were more accessible to physicists or mathematicians, and the applications to biologists, causing a dichotomy in what always should have been a single body of work. To bridge the gap between the two aspects of the same theory, we (i) adhere to the theoretical formalism, (ii) try to minimize the amount of information that a reader needs to process, but also (iii) invoke examples from biology to motivate the introduction of new concepts and to justify the assumptions made, and (iv) show how the careful formalism of the general theory enables modular, self-consistent extensions that capture important features of the species and the problem in question. Perhaps the most difficult among the introduced concepts, the utilization (or mobilization) energy flow, is given particular attention in the form of an original and considerably simplified derivation. Specific examples illustrate a range of possible applications-from energy budgets of individual organisms, to population dynamics, to ecotoxicology.

  11. Physics of metabolic organization

    Science.gov (United States)

    Jusup, Marko; Sousa, Tânia; Domingos, Tiago; Labinac, Velimir; Marn, Nina; Wang, Zhen; Klanjšček, Tin

    2017-03-01

    We review the most comprehensive metabolic theory of life existing to date. A special focus is given to the thermodynamic roots of this theory and to implications that the laws of physics-such as the conservation of mass and energy-have on all life. Both the theoretical foundations and biological applications are covered. Hitherto, the foundations were more accessible to physicists or mathematicians, and the applications to biologists, causing a dichotomy in what always should have been a single body of work. To bridge the gap between the two aspects of the same theory, we (i) adhere to the theoretical formalism, (ii) try to minimize the amount of information that a reader needs to process, but also (iii) invoke examples from biology to motivate the introduction of new concepts and to justify the assumptions made, and (iv) show how the careful formalism of the general theory enables modular, self-consistent extensions that capture important features of the species and the problem in question. Perhaps the most difficult among the introduced concepts, the utilization (or mobilization) energy flow, is given particular attention in the form of an original and considerably simplified derivation. Specific examples illustrate a range of possible applications-from energy budgets of individual organisms, to population dynamics, to ecotoxicology.

  12. Regulation of sphingomyelin metabolism.

    Science.gov (United States)

    Bienias, Kamil; Fiedorowicz, Anna; Sadowska, Anna; Prokopiuk, Sławomir; Car, Halina

    2016-06-01

    Sphingolipids (SFs) represent a large class of lipids playing diverse functions in a vast number of physiological and pathological processes. Sphingomyelin (SM) is the most abundant SF in the cell, with ubiquitous distribution within mammalian tissues, and particularly high levels in the Central Nervous System (CNS). SM is an essential element of plasma membrane (PM) and its levels are crucial for the cell function. SM content in a cell is strictly regulated by the enzymes of SM metabolic pathways, which activities create a balance between SM synthesis and degradation. The de novo synthesis via SM synthases (SMSs) in the last step of the multi-stage process is the most important pathway of SM formation in a cell. The SM hydrolysis by sphingomyelinases (SMases) increases the concentration of ceramide (Cer), a bioactive molecule, which is involved in cellular proliferation, growth and apoptosis. By controlling the levels of SM and Cer, SMSs and SMases maintain cellular homeostasis. Enzymes of SM cycle exhibit unique properties and diverse tissue distribution. Disturbances in their activities were observed in many CNS pathologies. This review characterizes the physiological roles of SM and enzymes controlling SM levels as well as their involvement in selected pathologies of the Central Nervous System, such as ischemia/hypoxia, Alzheimer disease (AD), Parkinson disease (PD), depression, schizophrenia and Niemann Pick disease (NPD). Copyright © 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

  13. MicroRNAs in Metabolism and Metabolic Disorders

    Science.gov (United States)

    Rottiers, Veerle; Näär, Anders M.

    2014-01-01

    MicroRNAs (miRNAs) have recently emerged as key regulators of metabolism. For example, miR-33a and b play a crucial role in controlling cholesterol and lipid metabolism in concert with their host genes, the SREBP transcription factors. Metabolic miRNAs such as miR-103 and miR-107 regulate insulin and glucose homeostasis, while others, such as miR-34a, may be key regulators of hepatic lipid homeostasis. The discovery of circulating miRNAs has highlighted their potential as both endocrine signalling molecules and disease markers. Dysregulation of miRNAs may contribute to metabolic abnormalities, suggesting that miRNAs may potentially serve as therapeutic targets to ameliorate cardiometabolic disorders. PMID:22436747

  14. Brain Regulation of Energy Metabolism.

    Science.gov (United States)

    Roh, Eun; Kim, Min Seon

    2016-12-01

    In healthy individuals, energy intake is in balance with energy expenditure, which helps to maintain a normal body weight. The brain's inability to control energy homeostasis underlies the pathology of hyperphagia and obesity. The brain detects body energy excess and deficit by sensing the levels of circulating metabolic hormones and nutrients and by receiving metabolic information from the periphery via the autonomic nervous system. A specialized neuronal network coordinates energy intake behavior and the metabolic processes affecting energy expenditure. Here, we briefly review neuronal mechanisms by which our body maintains energy balance.

  15. Citrate Metabolism by Pediococcus halophilus

    OpenAIRE

    Kanbe, Chiyuki; Uchida, Kinji

    1987-01-01

    Several strains of non-citrate-metabolizing Pediococcus halophilus have previously been isolated from soy sauce mash or moromi. The factors controlling the metabolism of citrate in soy pediococci were studied. All the soy pediococcal strains tested which failed to decompose citrate did not possess citrate lyase [citrate (pro-3S)-lyase; EC 4.1.3.6] activity. In P. halophilus, citrate lyase was an inducible enzyme, and the optimum pH for activity was 7.0. The metabolism of citrate in P. halophi...

  16. Retinoic acid and iron metabolism

    DEFF Research Database (Denmark)

    Chakraborty, Surajit; Bhattacharyya, Rajasri; Sayal, Kirtimaan

    2014-01-01

    tuberculosis controlling molecules in the days to come. Iron has proven to be essential for pathogenesis of tuberculosis and retinoic acid is known to influence the iron metabolism pathway. Retenoic acid is also known to exhibit antitubercular effect in in vivo system. Therefore there is every possibility...... that retinoic acid by affecting the iron metabolism pathway exhibits its antimycobacterial effect. These aspects are reviewed in the present manuscript for understanding the antimycobacterial role of retinoic acid in the context of iron metabolism and other immunological aspects....

  17. Human metabolic atlas: an online resource for human metabolism.

    Science.gov (United States)

    Pornputtapong, Natapol; Nookaew, Intawat; Nielsen, Jens

    2015-01-01

    Human tissue-specific genome-scale metabolic models (GEMs) provide comprehensive understanding of human metabolism, which is of great value to the biomedical research community. To make this kind of data easily accessible to the public, we have designed and deployed the human metabolic atlas (HMA) website (http://www.metabolicatlas.org). This online resource provides comprehensive information about human metabolism, including the results of metabolic network analyses. We hope that it can also serve as an information exchange interface for human metabolism knowledge within the research community. The HMA consists of three major components: Repository, Hreed (Human REaction Entities Database) and Atlas. Repository is a collection of GEMs for specific human cell types and human-related microorganisms in SBML (System Biology Markup Language) format. The current release consists of several types of GEMs: a generic human GEM, 82 GEMs for normal cell types, 16 GEMs for different cancer cell types, 2 curated GEMs and 5 GEMs for human gut bacteria. Hreed contains detailed information about biochemical reactions. A web interface for Hreed facilitates an access to the Hreed reaction data, which can be easily retrieved by using specific keywords or names of related genes, proteins, compounds and cross-references. Atlas web interface can be used for visualization of the GEMs collection overlaid on KEGG metabolic pathway maps with a zoom/pan user interface. The HMA is a unique tool for studying human metabolism, ranging in scope from an individual cell, to a specific organ, to the overall human body. This resource is freely available under a Creative Commons Attribution-NonCommercial 4.0 International License.

  18. Plant Metabolic Modeling: Achieving New Insight into Metabolism and Metabolic Engineering

    Science.gov (United States)

    Baghalian, Kambiz; Hajirezaei, Mohammad-Reza; Schreiber, Falk

    2014-01-01

    Models are used to represent aspects of the real world for specific purposes, and mathematical models have opened up new approaches in studying the behavior and complexity of biological systems. However, modeling is often time-consuming and requires significant computational resources for data development, data analysis, and simulation. Computational modeling has been successfully applied as an aid for metabolic engineering in microorganisms. But such model-based approaches have only recently been extended to plant metabolic engineering, mainly due to greater pathway complexity in plants and their highly compartmentalized cellular structure. Recent progress in plant systems biology and bioinformatics has begun to disentangle this complexity and facilitate the creation of efficient plant metabolic models. This review highlights several aspects of plant metabolic modeling in the context of understanding, predicting and modifying complex plant metabolism. We discuss opportunities for engineering photosynthetic carbon metabolism, sucrose synthesis, and the tricarboxylic acid cycle in leaves and oil synthesis in seeds and the application of metabolic modeling to the study of plant acclimation to the environment. The aim of the review is to offer a current perspective for plant biologists without requiring specialized knowledge of bioinformatics or systems biology. PMID:25344492

  19. Redesigned Human Metabolic Simulator

    Science.gov (United States)

    Duffield, Bruce; Jeng, Frank; Lange, Kevin

    2008-01-01

    A design has been formulated for a proposed improved version of an apparatus that simulates atmospheric effects of human respiration by introducing controlled amounts of carbon dioxide, water vapor, and heat into the air. Denoted a human metabolic simulator (HMS), the apparatus is used for testing life-support equipment when human test subjects are not available. The prior version of the HMS, to be replaced, was designed to simulate the respiratory effects of as many as four persons. It exploits the catalytic combustion of methyl acetate, for which the respiratory quotient (the molar ratio of carbon dioxide produced to oxygen consumed) is very close to the human respiratory quotient of about 0.86. The design of the improved HMS provides for simulation of the respiratory effects of as many as eight persons at various levels of activity. The design would also increase safety by eliminating the use of combustion. The improved HMS (see figure) would include a computer that would exert overall control. The computer would calculate the required amounts of oxygen removal, carbon dioxide addition, water addition, and heat addition by use of empirical equations for metabolic profiles of respiration and heat. A blower would circulate air between the HMS and a chamber containing a life-support system to be tested. With the help of feedback from a mass flowmeter, the blower speed would be adjusted to regulate the rate of flow according to the number of persons to be simulated and to a temperature-regulation requirement (the air temperature would indirectly depend on the rate of flow, among other parameters). Oxygen would be removed from the circulating air by means of a commercially available molecular sieve configured as an oxygen concentrator. Oxygen, argon, and trace amounts of nitrogen would pass through a bed in the molecular sieve while carbon dioxide, the majority of nitrogen, and other trace gases would be trapped by the bed and subsequently returned to the chamber. If

  20. Testosterone and metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Glenn R Cunningham

    2015-04-01

    Full Text Available Controversies surround the usefulness of identifying patients with the metabolic syndrome (MetS. Many of the components are accepted risk factors for cardiovascular disease (CVD. Although the MetS as defined includes many men with insulin resistance, insulin resistance is not universal. The low total testosterone (TT and sex hormone binding globulin (SHBG levels in these men are best explained by the hyperinsulinism and increased inflammatory cytokines that accompany obesity and increased waist circumference. It is informative that low SHBG levels predict future development of the MetS. Evidence is strong relating low TT levels to CVD in men with and without the MetS; however, the relationship may not be causal. The recommendations of the International Diabetes Federation for managing the MetS include cardiovascular risk assessment, lifestyle changes in diet, exercise, weight reduction and treatment of individual components of the MetS. Unfortunately, it is uncommon to see patients with the MetS lose and maintain a 10% weight loss. Recent reports showing testosterone treatment induced dramatic changes in weight, waist circumference, insulin sensitivity, hemoglobin A1c levels and improvements in each of the components of the MetS are intriguing. While some observational studies have reported that testosterone replacement therapy increases cardiovascular events, the Food and Drug Administration in the United States has reviewed these reports and found them to be seriously flawed. Large, randomized, placebo-controlled trials are needed to provide more definitive data regarding the efficacy and safety of this treatment in middle and older men with the MetS and low TT levels.

  1. Metabolic Syndrome in Nurses

    Directory of Open Access Journals (Sweden)

    María Escasany

    2014-01-01

    Full Text Available Objectives: To estimate the prevalence of metabolic syndrome (MS in female nurses in the Hospital Juan A. Fernandez (HJAF, Buenos Aires, Argentina, and to determine whether work, rest, diet, and health, are predictive of it.Materials and methods: For the first objective, a descriptive, observational and cross-sectional study was conducted, and for the second, a multivariate cross-sectional observational multivariate analysis was made comparing independent samples. A total of 192 nurses were studied between October 2008 and March 2009. They completed a questionnaire that include indicators that could be predictors of MS. Anthropometric measurements, including blood pressure were taken, was well as a blood sample to analyze fasting glucose, HDL-C and plasma triglycerides.Results: It was found that 35% and 41% of nurses were overweight and obese, respectively. A total of 92% had centro-abdominal obesity. The prevalence of MS found was 33.3% (95%CI, 26.7 to 40.5. Those who had this disease were between 53±9 years. Statistically significant differences were found in the bivariate analysis between MS and the variables, age, length of service, time worked during night shift, and academic studies.Conclusions: The prevalence of MS was 64/192 in HJAF nurses (33.3% I 95%CI, 26.7-40.5. There were no statistically significant differences with the indicators of, age, “time worked during night shift”, and “studies”. These results suggest that age is the most important variable in predicting the onset of MS in the population of nurses.

  2. Testosterone and metabolic syndrome.

    Science.gov (United States)

    Cunningham, Glenn R

    2015-01-01

    Controversies surround the usefulness of identifying patients with the metabolic syndrome (MetS). Many of the components are accepted risk factors for cardiovascular disease (CVD). Although the MetS as defined includes many men with insulin resistance, insulin resistance is not universal. The low total testosterone (TT) and sex hormone binding globulin (SHBG) levels in these men are best explained by the hyperinsulinism and increased inflammatory cytokines that accompany obesity and increased waist circumference. It is informative that low SHBG levels predict future development of the MetS. Evidence is strong relating low TT levels to CVD in men with and without the MetS; however, the relationship may not be causal. The recommendations of the International Diabetes Federation for managing the MetS include cardiovascular risk assessment, lifestyle changes in diet, exercise, weight reduction and treatment of individual components of the MetS. Unfortunately, it is uncommon to see patients with the MetS lose and maintain a 10% weight loss. Recent reports showing testosterone treatment induced dramatic changes in weight, waist circumference, insulin sensitivity, hemoglobin A1c levels and improvements in each of the components of the MetS are intriguing. While some observational studies have reported that testosterone replacement therapy increases cardiovascular events, the Food and Drug Administration in the United States has reviewed these reports and found them to be seriously flawed. Large, randomized, placebo-controlled trials are needed to provide more definitive data regarding the efficacy and safety of this treatment in middle and older men with the MetS and low TT levels.

  3. Testosterone and metabolic syndrome

    Science.gov (United States)

    Cunningham, Glenn R

    2015-01-01

    Controversies surround the usefulness of identifying patients with the metabolic syndrome (MetS). Many of the components are accepted risk factors for cardiovascular disease (CVD). Although the MetS as defined includes many men with insulin resistance, insulin resistance is not universal. The low total testosterone (TT) and sex hormone binding globulin (SHBG) levels in these men are best explained by the hyperinsulinism and increased inflammatory cytokines that accompany obesity and increased waist circumference. It is informative that low SHBG levels predict future development of the MetS. Evidence is strong relating low TT levels to CVD in men with and without the MetS; however, the relationship may not be causal. The recommendations of the International Diabetes Federation for managing the MetS include cardiovascular risk assessment, lifestyle changes in diet, exercise, weight reduction and treatment of individual components of the MetS. Unfortunately, it is uncommon to see patients with the MetS lose and maintain a 10% weight loss. Recent reports showing testosterone treatment induced dramatic changes in weight, waist circumference, insulin sensitivity, hemoglobin A1c levels and improvements in each of the components of the MetS are intriguing. While some observational studies have reported that testosterone replacement therapy increases cardiovascular events, the Food and Drug Administration in the United States has reviewed these reports and found them to be seriously flawed. Large, randomized, placebo-controlled trials are needed to provide more definitive data regarding the efficacy and safety of this treatment in middle and older men with the MetS and low TT levels. PMID:25652634

  4. Context-dependent metabolic networks

    CERN Document Server

    Beguerisse-Díaz, Mariano; Oyarzún, Diego; Picó, Jesús; Barahona, Mauricio

    2016-01-01

    Cells adapt their metabolism to survive changes in their environment. We present a framework for the construction and analysis of metabolic reaction networks that can be tailored to reflect different environmental conditions. Using context-dependent flux distributions from Flux Balance Analysis (FBA), we produce directed networks with weighted links representing the amount of metabolite flowing from a source reaction to a target reaction per unit time. Such networks are analyzed with tools from network theory to reveal salient features of metabolite flows in each biological context. We illustrate our approach with the directed network of the central carbon metabolism of Escherichia coli, and study its properties in four relevant biological scenarios. Our results show that both flow and network structure depend drastically on the environment: networks produced from the same metabolic model in different contexts have different edges, components, and flow communities, capturing the biological re-routing of metab...

  5. Metabolic control of renin secretion.

    Science.gov (United States)

    Peti-Peterdi, János; Gevorgyan, Haykanush; Lam, Lisa; Riquier-Brison, Anne

    2013-01-01

    One emerging topic in renin-angiotensin system (RAS) research is the direct local control of renin synthesis and release by endogenous metabolic intermediates. During the past few years, our laboratory has characterized the localization and signaling of the novel metabolic receptor GPR91 in the normal and diabetic kidney and established GPR91 as a new, direct link between high glucose and RAS activation in diabetes. GPR91 (also called SUCNR1) binds tricarboxylic acid (TCA) cycle intermediate succinate which can rapidly accumulate in the local tissue environment when energy supply and demand are out of balance. In a variety of physiological and pathological conditions associated with metabolic stress, succinate signaling via GPR91 appears to be an important mediator or modulator of renin secretion. This review summarizes our current knowledge on the control of renin release by molecules of endogenous metabolic pathways with the main focus on succinate/GPR91.

  6. Gait Dynamics and Locomotor Metabolism

    Science.gov (United States)

    2009-05-01

    field settings from simple technologies such as gps monitors and pedometers. 15. SUBJECT TERMS Locomotion, gait, metabolism, body size, load...a reduction in exercise intensity. REFERENCES: 1. Alexander, RM. Sprinting and endurance for runners and cyclists . American Journal of

  7. Metabolic Resistance in Bed Bugs

    Directory of Open Access Journals (Sweden)

    Omprakash Mittapalli

    2011-03-01

    Full Text Available Blood-feeding insects have evolved resistance to various insecticides (organochlorines, pyrethroids, carbamates, etc. through gene mutations and increased metabolism. Bed bugs (Cimex lectularius are hematophagous ectoparasites that are poised to become one of the major pests in households throughout the United States. Currently, C. lectularius has attained a high global impact status due to its sudden and rampant resurgence. Resistance to pesticides is one factor implicated in this phenomenon. Although much emphasis has been placed on target sensitivity, little to no knowledge is available on the role of key metabolic players (e.g., cytochrome P450s and glutathione S-transferases towards pesticide resistance in C. lectularius. In this review, we discuss different modes of resistance (target sensitivity, penetration resistance, behavioral resistance, and metabolic resistance with more emphasis on metabolic resistance.

  8. Histone variants and lipid metabolism

    NARCIS (Netherlands)

    Borghesan, Michela; Mazzoccoli, Gianluigi; Sheedfar, Fareeba; Oben, Jude; Pazienza, Valerio; Vinciguerra, Manlio

    2014-01-01

    Within nucleosomes, canonical histones package the genome, but they can be opportunely replaced with histone variants. The incorporation of histone variants into the nucleosome is a chief cellular strategy to regulate transcription and cellular metabolism. In pathological terms, cellular steatosis

  9. Metabolism and biochemistry in hypogravity

    Science.gov (United States)

    Leach, Carolyn S.

    The headward shift of body fluid and increase in stress-related hormones that occur in hypogravity bring about a number of changes in metabolism and biochemistry of the human body. Such alterations may have important effects on health during flight and during a recovery period after return to Earth. Body fluid and electrolytes are lost, and blood levels of several hormones that control metabolism are altered during space flight. Increased serum calcium may lead to an increased risk of renal stone formation during flight, and altered drug metabolism could influence the efficacy of therapeutic agents. Orthostatic intolerance and an increased risk of fracturing weakened bones are concerns at landing. It is important to understand biochemistry and metabolism in hypogravity so that clinically important developments can be anticipated and prevented or ameliorated.

  10. Metabolic syndrome and periodontal disease

    Directory of Open Access Journals (Sweden)

    Bharti Vipin

    2009-01-01

    Full Text Available It is important for a dentist to be well informed and updated on the latest research on the association of oral and systemic health. Of late, the metabolic syndrome has gained importance in dental literature, and metabolic syndrome and periodontal disease have been linked. Metabolic syndrome (MeS is a group of three or more (up to five interrelated metabolic abnormalities, which increases the risk of cardiovascular morbidity and mortality. Also, both MeS and periodontal disease may be linked through a common pathophysiological pathway. Some studies have been conducted to show such an association and additional studies are required to establish this association. A dental surgeon can play a major role in evaluating patients with MeS and thus prevent the development of overt cardiovascular disease.

  11. Metabolism and biochemistry in hypogravity

    Science.gov (United States)

    Leach, Carolyn S.

    1991-01-01

    The headward shift of body fluid and increase in stress-related hormones that occur in hypogravity bring about a number of changes in metabolism and biochemistry of the human body. Such alterations may have important effects on health during flight and during a recovery period after return to earth. Body fluid and electrolytes are lost, and blood levels of several hormones that control metabolism are altered during space flight. Increased serum calcium may lead to an increased risk of renal stone formation during flight, and altered drug metabolism could influence the efficacy of therapeutic agents. Orthostatic intolerance and an increased risk of fracturing weakened bones are concerns at landing. It is important to understand biochemistry and metabolism in hypogravity so that clinically important developments can be anticipated and prevented or ameliorated.

  12. Multidimensional optimality of microbial metabolism.

    Science.gov (United States)

    Schuetz, Robert; Zamboni, Nicola; Zampieri, Mattia; Heinemann, Matthias; Sauer, Uwe

    2012-05-04

    Although the network topology of metabolism is well known, understanding the principles that govern the distribution of fluxes through metabolism lags behind. Experimentally, these fluxes can be measured by (13)C-flux analysis, and there has been a long-standing interest in understanding this functional network operation from an evolutionary perspective. On the basis of (13)C-determined fluxes from nine bacteria and multi-objective optimization theory, we show that metabolism operates close to the Pareto-optimal surface of a three-dimensional space defined by competing objectives. Consistent with flux data from evolved Escherichia coli, we propose that flux states evolve under the trade-off between two principles: optimality under one given condition and minimal adjustment between conditions. These principles form the forces by which evolution shapes metabolic fluxes in microorganisms' environmental context.

  13. Can you boost your metabolism?

    Science.gov (United States)

    ... M, Jeukendrup A, King NA, Blundell JE. The relationship between substrate metabolism, exercise, and appetite control: Does glycogen availability influence the motivation to eat, energy intake or food choice? Sports Med . 2011;41(6):507-521. PMID: 21615191 www. ...

  14. Metabolic Resistance in Bed Bugs.

    Science.gov (United States)

    Mamidala, Praveen; Jones, Susan C; Mittapalli, Omprakash

    2011-03-18

    Blood-feeding insects have evolved resistance to various insecticides (organochlorines, pyrethroids, carbamates, etc.) through gene mutations and increased metabolism. Bed bugs (Cimex lectularius) are hematophagous ectoparasites that are poised to become one of the major pests in households throughout the United States. Currently, C. lectularius has attained a high global impact status due to its sudden and rampant resurgence. Resistance to pesticides is one factor implicated in this phenomenon. Although much emphasis has been placed on target sensitivity, little to no knowledge is available on the role of key metabolic players (e.g., cytochrome P450s and glutathione S-transferases) towards pesticide resistance in C. lectularius. In this review, we discuss different modes of resistance (target sensitivity, penetration resistance, behavioral resistance, and metabolic resistance) with more emphasis on metabolic resistance.

  15. Adipose Tissue Metabolism During Hypobaria

    Directory of Open Access Journals (Sweden)

    D. P. Chattopadhyay

    1974-10-01

    Full Text Available Possible factors affecting the metabolism of adipose tissue under hypobaric conditions have been reviewed. The hormonal changes brought into play under hypoxic stress generally stress generally increase the adipose tissue lipolysis.

  16. Metabolic-hydaulic model Data

    Data.gov (United States)

    U.S. Geological Survey, Department of the Interior — The data contained in this workbook were compiled to investigate the relationship between hydrology of the Colorado River and ecosystem metabolism parameters (i.e.,...

  17. Carbohydrate Metabolism in Submariner Personnel

    Science.gov (United States)

    1983-06-01

    metabolism the Wilkerson Point System, for glucose values, used in conjunction with patterns of insulin response described by Kraft(4) serves as the means...amount of exercise and carbohydrate metabolism characteristics occurred in both submariners and non-submariners. An inverse relationship also seems to...individuals(7). In the present study a significant negative correlation was also found between exercise vs one and two hour postprandial glucose and two hour

  18. Tailoring the metabolism against mutations

    Science.gov (United States)

    Gulbahce, Natali; Motter, Adilson E.; Almaas, Eivind; Barabasi, Albert Laszlo

    2008-03-01

    In the post-genomic era, organisms can be modelled at the whole-cell level in silico via steady state methods to describe their metabolic capabilities. We use two such methods, Flux Balance Analysis and Minimization of Metabolic Adjustment to explore the behavior of cells (of E. coli and S. cerevisiae) after severe mutations. We propose experimentally feasible ways of modifying the underlying biochemical reaction network of a mutant cell such that cell functionality, in particular growth rate, is significantly improved.

  19. Evolution of metabolic network organization

    Directory of Open Access Journals (Sweden)

    Bonchev Danail

    2010-05-01

    Full Text Available Abstract Background Comparison of metabolic networks across species is a key to understanding how evolutionary pressures shape these networks. By selecting taxa representative of different lineages or lifestyles and using a comprehensive set of descriptors of the structure and complexity of their metabolic networks, one can highlight both qualitative and quantitative differences in the metabolic organization of species subject to distinct evolutionary paths or environmental constraints. Results We used a novel representation of metabolic networks, termed network of interacting pathways or NIP, to focus on the modular, high-level organization of the metabolic capabilities of the cell. Using machine learning techniques we identified the most relevant aspects of cellular organization that change under evolutionary pressures. We considered the transitions from prokarya to eukarya (with a focus on the transitions among the archaea, bacteria and eukarya, from unicellular to multicellular eukarya, from free living to host-associated bacteria, from anaerobic to aerobic, as well as the acquisition of cell motility or growth in an environment of various levels of salinity or temperature. Intuitively, we expect organisms with more complex lifestyles to have more complex and robust metabolic networks. Here we demonstrate for the first time that such organisms are not only characterized by larger, denser networks of metabolic pathways but also have more efficiently organized cross communications, as revealed by subtle changes in network topology. These changes are unevenly distributed among metabolic pathways, with specific categories of pathways being promoted to more central locations as an answer to environmental constraints. Conclusions Combining methods from graph theory and machine learning, we have shown here that evolutionary pressures not only affects gene and protein sequences, but also specific details of the complex wiring of functional modules

  20. Metabolism of verruculogen in rats.

    OpenAIRE

    Perera, K P; Day, J. B.; Mantle, P. G.; Rodrigues, L

    1982-01-01

    Radiolabeled verruculogen was detected in a wide range of body tissues 6 min after intravenous administration, but after a further 20 min it was mainly being excreted via the biliary route. In isolated liver perfusion, [14C]verruculogen was rapidly taken up by the liver and metabolized completely, principally to the related tremorgen TR-2 but also to a desoxy derivative of verruculogen. In addition, a smaller amount of an isomer of TR-2 was detected. These metabolic products were excreted in ...

  1. Gut Microbiota and Metabolic Disorders

    OpenAIRE

    Kyu Yeon Hur; Myung-Shik Lee

    2015-01-01

    Gut microbiota plays critical physiological roles in the energy extraction and in the control of local or systemic immunity. Gut microbiota and its disturbance also appear to be involved in the pathogenesis of diverse diseases including metabolic disorders, gastrointestinal diseases, cancer, etc. In the metabolic point of view, gut microbiota can modulate lipid accumulation, lipopolysaccharide content and the production of short-chain fatty acids that affect food intake, inflammatory tone, or...

  2. Metabolic management of brain cancer.

    Science.gov (United States)

    Seyfried, Thomas N; Kiebish, Michael A; Marsh, Jeremy; Shelton, Laura M; Huysentruyt, Leanne C; Mukherjee, Purna

    2011-06-01

    Malignant brain tumors are a significant health problem in children and adults. Conventional therapeutic approaches have been largely unsuccessful in providing long-term management. As primarily a metabolic disease, malignant brain cancer can be managed through changes in metabolic environment. In contrast to normal neurons and glia, which readily transition to ketone bodies (β-hydroxybutyrate) for energy under reduced glucose, malignant brain tumors are strongly dependent on glycolysis for energy. The transition from glucose to ketone bodies as a major energy source is an evolutionary conserved adaptation to food deprivation that permits the survival of normal cells during extreme shifts in nutritional environment. Only those cells with a flexible genome and normal mitochondria can effectively transition from one energy state to another. Mutations restrict genomic and metabolic flexibility thus making tumor cells more vulnerable to energy stress than normal cells. We propose an alternative approach to brain cancer management that exploits the metabolic flexibility of normal cells at the expense of the genetically defective and metabolically challenged tumor cells. This approach to brain cancer management is supported from recent studies in mice and humans treated with calorie restriction and the ketogenic diet. Issues of implementation and use protocols are presented for the metabolic management of brain cancer.

  3. Inherited or acquired metabolic disorders.

    Science.gov (United States)

    Eichler, Florian; Ratai, Eva; Carroll, Jason J; Masdeu, Joseph C

    2016-01-01

    This chapter starts with a description of imaging of inherited metabolic disorders, followed by a discussion on imaging of acquired toxic-metabolic disorders of the adult brain. Neuroimaging is crucial for the diagnosis and management of a number of inherited metabolic disorders. Among these, inherited white-matter disorders commonly affect both the nervous system and endocrine organs. Magnetic resonance imaging (MRI) has enabled new classifications of these disorders that have greatly enhanced both our diagnostic ability and our understanding of these complex disorders. Beyond the classic leukodystrophies, we are increasingly recognizing new hereditary leukoencephalopathies such as the hypomyelinating disorders. Conventional imaging can be unrevealing in some metabolic disorders, but proton magnetic resonance spectroscopy (MRS) may be able to directly visualize the metabolic abnormality in certain disorders. Hence, neuroimaging can enhance our understanding of pathogenesis, even in the absence of a pathologic specimen. This review aims to present pathognomonic brain MRI lesion patterns, the diagnostic capacity of proton MRS, and information from clinical and laboratory testing that can aid diagnosis. We demonstrate that applying an advanced neuroimaging approach enhances current diagnostics and management. Additional information on inherited and metabolic disorders of the brain can be found in Chapter 63 in the second volume of this series.

  4. Metabolic regulation of insulin secretion.

    Science.gov (United States)

    Keane, Kevin; Newsholme, Philip

    2014-01-01

    Regulation of metabolic fuel homeostasis is a critical function of β-cells, which are located in the islets of Langerhans of the animal pancreas. Impairment of this β-cell function is a hallmark of pancreatic β-cell failure and may lead to development of type 2 diabetes mellitus. β-Cells are essentially "fuel sensors" that monitor and react to elevated nutrient load by releasing insulin. This response involves metabolic activation and generation of metabolic coupling factors (MCFs) that relay the nutrient signal throughout the cell and induce insulin biosynthesis and secretion. Glucose is the most important insulin secretagogue as it is the primary fuel source in food. Glucose metabolism is central to generation of MCFs that lead to insulin release, most notably ATP. In addition, other classes of nutrients are able to augment insulin secretion and these include members of the lipid and amino acid family of nutrients. Therefore, it is important to investigate the interplay between glucose, lipid, and amino acid metabolism, as it is this mixed nutrient sensing that generate the MCFs required for insulin exocytosis. The mechanisms by which these nutrients are metabolized to generate MCFs, and how they impact on β-cell insulin release and function, are discussed in detail in this article.

  5. Metabolic syndrome, inflammation and atherosclerosis

    Directory of Open Access Journals (Sweden)

    Rodolfo Paoletti

    2006-06-01

    Full Text Available Rodolfo Paoletti1,2, Chiara Bolego1, Andrea Poli2, Andrea Cignarella1,31Department of Pharmacological Sciences, University of Milan, Italy; 2Nutrition Foundation of Italy (NFI, Milan; 3Department of Pharmacology and Anesthesiology, University of Padova, ItalyAbstract: The inflammatory component of atherogenesis has been increasingly recognized over the last decade. Inflammation participates in all stages of atherosclerosis, not only during initiation and during evolution of lesions, but also with precipitation of acute thrombotic complications. The metabolic syndrome is associated with increased risk for development of both cardiovascular disease and type-2 diabetes in humans. Central obesity and insulin resistance are thought to represent common underlying factors of the syndrome, which features a chronic low-grade inflammatory state. Diagnosis of the metabolic syndrome occurs using defined threshold values for waist circumference, blood pressure, fasting glucose and dyslipidemia. The metabolic syndrome appears to affect a significant proportion of the population. Therapeutic approaches that reduce the levels of proinflammatory biomarkers and address traditional risk factors are particularly important in preventing cardiovascular disease and, potentially, diabetes. The primary management of metabolic syndrome involves healthy lifestyle promotion through moderate calorie restriction, moderate increase in physical activity and change in dietary composition. Treatment of individual components aims to control atherogenic dyslipidemia using fibrates and statins, elevated blood pressure, and hyperglycemia. While no single treatment for the metabolic syndrome as a whole yet exists, emerging therapies offer potential as future therapeutic approaches.Keywords: metabolic syndrome, systemic inflammation, coronary artery disease

  6. Metabolic syndrome and cardiovascular risk

    Directory of Open Access Journals (Sweden)

    Abdullah M Alshehri

    2010-11-01

    Full Text Available The constellation of dyslipidemia (hypertriglyceridemia and low levels of high-density lipoprotein cholesterol, elevated blood pressure, impaired glucose tolerance, and central obesity is now classified as metabolic syndrome, also called syndrome X. In the past few years, several expert groups have attempted to set forth simple diagnostic criteria for use in clinical practice to identify patients who manifest the multiple components of the metabolic syndrome. These criteria have varied somewhat in specific elements, but in general, they include a combination of multiple and metabolic risk factors. The most widely recognized of the metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics, commonly manifest a prothrombotic state as well as and a proinflammatory state. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated serum triglyceride and apolipoprotein B (apoB, increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C. The metabolic syndrome is often referred to as if it were a discrete entity with a single cause. Available data suggest that it truly is a syndrome, ie, a grouping of atherosclerotic cardiovascular disease (ASCVD risk factors, that probably has more than one cause. Regardless of cause, the syndrome identifies individuals at an elevated risk for ASCVD. The magnitude of the increased risk can vary according to the components of the syndrome present as well as the other, non-metabolic syndrome risk factors in a particular person.

  7. Sleep apnoea and metabolic dysfunction

    Directory of Open Access Journals (Sweden)

    Maria R. Bonsignore

    2013-09-01

    Full Text Available Obstructive sleep apnoea (OSA is a highly prevalent condition often associated with central obesity. In the past few years, several studies have analysed the potential independent contribution of OSA to the pathogenesis of metabolic abnormalities, including type 2 diabetes, the metabolic syndrome and non-alcoholic fatty liver disease. New perspectives in OSA patient care have been opened by the promotion of lifestyle interventions, such as diet and exercise programmes that could improve both OSA and the metabolic profile. The rich clinical literature on this subject, together with the growing amount of data on pathophysiological mechanisms provided by animal studies using the chronic intermittent hypoxia model, urged the organising Committee of the Sleep and Breathing meeting to organise a session on sleep apnoea and metabolic dysfunction, in collaboration with the European Association for the Study of Diabetes. This review summarises the state-of-the-art lectures presented in the session, more specifically the relationship between OSA and diabetes, the role of OSA in the metabolic consequences of obesity, and the effects of lifestyle interventions on nocturnal respiratory disturbances and the metabolic profile in OSA patients.

  8. 阿立哌唑联合奥氮平治疗老年阿尔茨海默病伴精神障碍的临床疗效及安全性评价%Clinical efficacy and safety of aripiprazole combined with olanzapine in the treatment of elderly Alzheimer’ s disease with mental disorders

    Institute of Scientific and Technical Information of China (English)

    付旭; 秦晓霞

    2016-01-01

    目的:观察阿立哌唑联合奥氮平治疗老年阿尔茨海默病伴精神障碍的临床疗效及安全性。方法将80例老年阿尔茨海默病伴精神障碍患者随机分为对照组40例和试验组40例。对照组予以口服奥氮平2.5 mg,每晚一次;试验组予以口服奥氮平2.5 mg,每晚一次联合阿立哌唑2.5 mg,每晚一次。2组患者一个疗程均为2周,共治疗4个疗程。比较2组患者的临床疗效、简易智能精神状态表(MMSE)评分、临床失智表(CDR)评分、日常生活能力表(ADL)评分、阿尔茨海默病评价表-认知分量表(ADAS-cog)评分、精神神经科问卷(NPI)评分、激动性问卷( CMAI)评分,以及不良反应发生率。结果治疗后,试验组的总有效率97.50%显著高于对照组47.50%( P<0.05)。治疗后,试验组的MMSE评分显著高于对照组( P<0.05),试验组的CDR、ADL、ADAS-cog、NPI、CMAI的评分显著低于对照组(P<0.05)。试验组的不良反应发生率7.50%显著低于对照组40.00%( P<0.05)。结论阿立哌唑联合奥氮平治疗老年阿尔茨海默病伴精神障碍的临床疗效确切,有利于患者神经功能的恢复,且不良反应较小。%Objective To evaluate the clinical efficacy and safety of aripiprazole combined with olanzapine in the treatment of elderly Alzhei-mer’s disease with mental disorders.Methods Eighty patients of elder-ly Alzheimer’ s disease with mental disorders were randomly divided into treatment group ( n=40) and control group ( n=40).Patients in control group were received olanzapine 2.5 mg, oral, qn.Patients in treatment group were given olanzapine 2.5 mg, oral, qn and aripiprazole 2.5 mg, oral, qn.The course of treatment was 2 weeks in two groups.A total of treatment was 4 courses.They were compared with clinical efficacy, easy-mental state table ( MMSE) score, clinical dementia table ( CDR) score, table of daily living ( ADL

  9. Comparative study of depressive disorder with somatic symptoms treated by duloxetine combined with aripiprazole%度洛西汀联合阿立哌唑治疗伴躯体化症状抑郁症的对照研究

    Institute of Scientific and Technical Information of China (English)

    魏宏强; 康瑞; 霍军; 曹雍华; 李淑英

    2013-01-01

    目的 探讨度洛西汀联合阿立哌唑治疗伴躯体化症状抑郁症患者的临床疗效及安全性.方法 将60例伴躯体化症状中度抑郁症患者随机分为两组,每组30例:度洛西汀(40~60 mg/d)联合阿立哌唑(2.5~7.5 mg/d)组(研究组)、度洛西汀(40~60 mg/d)组(对照组),治疗观察期均为8周.两组患者于基线及治疗后1、2、4、8周末分别评定24项汉密尔顿抑郁量表(HAMD-24)及躯体化症状自评量表(SSS)的部分单项分,并采用副反应量表(TESS)评定治疗期间的不良反应.结果 研究组、对照组分别脱落3、2例;1周末与基线比较,研究组的抑郁症状评分差异有统计学意义(P<0.05),而该组四类躯体化症状及对照组的抑郁症状评分差异均无统计学意义(P均>0.05);研究组的抑郁症状及四类躯体化症状评分差异在1、2、4、8周末时点间均有统计学意义(P均<0.05);8周末时两组间抑郁症状有效率及四类躯体化症状评分差异均有统计学意义(P均<0.05),而不良反应发生率差异均无统计学意义(P均>0.05).结论 度洛西汀联合阿立哌唑治疗伴躯体化症状中度抑郁症患者可有效、持续改善其抑郁及躯体化症状,且不良反应发生率与单一度洛西汀治疗相当.%Objective To investigate the efficacy and safety of duloxetine combined with aripiprazole in the treatment of depressive patients with somatic symptoms.Methods Total 60 moderate depressive patients with somatic symptoms were randomly divided into two groups:duloxetine(40-60 mg/d) combined with aripiprazole (2.5-7.5 mg/d) group (study group) and duloxetine (40-60 mg/d) group(control group),30 cases for each group.Each group had a 8-week treatment.The efficacy were assessed and analyzed by 24-item Hamilton Depression Scale(HAMD-24) and parts of the individual scores of Self-rating Somatization symptom Scale (SSS) at baseline and at week 1,2,4 and 8.The side effects were assessed by Treatment

  10. Treatment of Antipsychotic Drug-induced Phlegm Dampness Type Amenorrhea by Wuji Powder and a Small Dose Aripiprazole: a Clinical Study%五积散与小剂量阿立哌唑治疗抗精神病药物所致痰湿型闭经的临床研究

    Institute of Scientific and Technical Information of China (English)

    夏时炎; 张颖然; 虞洪; 孟旭; 张鹏; 刘军

    2014-01-01

    Objective To assess the efficacy and safety of Wuji Powder (WP) and a small dose aripiprazole in treatment of antipsychotic drug-induced phlegm dampness type amenorrhea.Methods Seventy female schizophrenic patients with antipsychotic drug-induced galactorrhea-amenorrhea syndrome (GAS) were recruited and randomly assigned to the treatment group and the control group,35 in each group.All patients received antipsychotic drug therapy.Patients in the treatment group additionally took WP,while those in the control group took aripiprazole (at the daily dose of 5 mg,once daily).The therapeutic course for all was 4 weeks.Prolactin levels and obesity indices [body weight、waist aircumstance、body mass index(BMI) and waist-hit ratio (WHR)] were determined before and after treatment.The efficacy was evaluated.Results The treatment course was completed in 95.71% of patients.The total effective rate of the 33 patients of the treatment group was 93.94% (31/33),while it was 91.18%(31/34) in the 34 patients of the control group.There was no difference in the total effective rate between the two groups (P >0.05).Prolactin levels in both group after treatment were significantly lower than those of the baseline (P <0.01).There was no significant difference in prolactin levels between the two groups after treatment (P >0.05).Compared with before treatment,body weight,BMI,waist circumstance,and waist-hip ratio obviously decreased after treatment,showing significant difference when compared with the control group (P <0.05).There was no significant difference in body weight,BMI,waist circumstance,and waist-hip ratio in the control group between before and after treatment (P